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1. INTRODUCTION 
       In Siddha system of medicine, siddhars mentioned 4448 diseases.
1
 Vatha disease is 
one of them. According to Saint Yugi, the Vatha diseases are classified into 80 types and 
one of them is Uthira vatha suronitham.
2
 The term ‗Uthiram‘ means blood and ‗Vatham‘ 
is a constructive humour responsible for all kinds of movements in our body. Suronitham 
is one of the physical constituents (Udal thathukkal) responsible for reproduction in 
females. The incidence of the disease has always been much higher in female population 
and hence the term suronitham.
3
 
     As mentioned by Yugi Munivar in his verses aetiology of Vatha diseases,
4
 the socio-
economical (starvation and doing hard work like lifting heavy weights), psychological 
(disrespecting elders and neglecting parents and teachers and defying vedic scriptures), 
environmental (seasonal changes), and lifestyle factors (consumption of bitter astringent, 
rancid and salty food, alcohol, day time sleep and night-time overwork) cause 
immunological modification thereby leading to infection, which is highly correlated to the 
aetiology of Rheumatoid Arthritis (RA)  as mentioned in modern science. 
    Uthira vatha suronitham indicates a systemic illness caused by the derangement of 
vatham which manifests as pain, swelling, tenderness and limitation of movements in 
major and minor joints, low grade fever, tiredness, mental depression. The signs and 
symptom of Uthira vatha suronitham is correlated to Rheumatoid Arthritis in modern 
science.  
     One of the major causes of disabilities at global level, accounting for 0.8% of total 
years lived with disabilities (YLDS), is RA.
5
 The prevalence and incidence of RA are 
higher in women when compared to men. 
6,7
The prevalence and incidence increase with 
age and peaks at the age 70 then declines. As per WHO statistics 2016, the total 
prevalence of RA and OA in India is about 5.5%.
8
 
     Rheumatoid arthritis is a chronic multi-system disease of unknown cause. 
Characteristically, RA is a chronic polyarthritis.
9
 Gradually, it begins with fatigue, 
anorexia, generalized weakness, weight loss, increase in body temperature and vague 
musculoskeletal symptoms followed by specific symptoms such as pain, swelling and 
tenderness of several joints especially those of hands, wrist, knees and feet in a symmetric 
fashion. The pain is aggravated by the movement of the affected joints, which is a well-
2 
 
established common sign of RA. Generalized stiffness is frequent and is usually greatest 
after a period of inactivity. Morning stiffness of more than one hour duration is an almost 
invariable feature of RA. Swelling, tenderness and limitation of motion are clinically 
caused by synovial inflammation. Initially, pain and inflammation impair physical 
function and disability owing to this is an early feature of aggressive RA.  
        RA is associated with reduced life expectancy. More than 50% of RA patients are 
incapable of doing full-time job within 10 years of onset of the diseases.
10
 
    The siddha science has successfully contributed many anti-vatha sastric herbo mineral 
formulations for the treatment of arthritis from time immemorial. One such formulation is 
Nandhi Mezhugu, a sastric Siddha herbo mineral preparation indicated for treating 80 
types of Vatha diseases. The long term treatment of RA with medicines of other systems 
has its own limitations. Nandhi Mezhugu is a cost effective and time tested Siddha herbo 
mineral formulation and it is well-known for its unique action against Uthira Vatha 
Suronitham (Rheumatoid Arthritis) as evidenced by several decades of its use in clinical 
practice. For global acceptance, scientific validation of Nandhi Mezhugu by safety and 
efficacy studies is the need of the hour. 
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2. AIM AND OBJECTIVE 
AIM:  
To evaluate the safety and efficacy of Siddha herbomineral formulation Nandhi 
Mezhugu for the treatment of Uthira Vatha Suronitham (Rheumatoid Arthritis). 
 
OBJECTIVE: 
Qualitative and Quantitative analysis: 
 To analyze the physico chemical parameters of Nandhi Mezhugu as per Ayush 
Guidelines. 
Safety study: 
 To establish the safety profile of Nandhi Mezhugu in Rat model by doing Acute, 
Sub acute (28-day Repeated oral toxicity studies), Sub chronic (90-day Repeated oral 
toxicity studies) studies as per OECD guidelines. 
Pharmacological Study: 
In-vivo: 
 To evaluate the Analgesic effect and Vascular permeability of Nandhi Mezhugu in 
Acetic acid-induced writhing in mice and Evans blue vascular permeability assay model. 
 To evaluate the Acute and Chronic Anti-inflammatory activity of the Nandhi 
Mezhugu in Carrageenan induced rat paw oedema and Cotton pellet granuloma method 
respectively. 
 To evaluate the Anti-rheumatoid activity of the Nandhi Mezhugu in Freund‘s 
complete adjuvant (FCA) Arthritis Model. 
 To evaluate the Gene expression effect of the Nandhi Mezhugu in RT-PCR. 
In-vitro: 
 To evaluate the cyto-toxicity and cyto-protective effect of the Nandhi Mezhugu in 
MTT Assay using RAW 264.7–Mouse macrophage cell line. 
 To evaluate the Gene expression effect of the Nandhi Mezhugu in RT-PCR. 
Clinical study: 
 To validate the safety and efficacy of Nandhi Mezhugu for the treatment of Uthira 
Vatha Suronitham by doing open labelled clinical study. 
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3. REVIEW OF LITERATURE 
3a. DISEASE REVIEW: 
3a.1.SIDDHA ASPECTS: 
3a.1.1.Definitions and descriptions of Vatham: 
        Vatham is one of the 3 humours and it consists of wind and space, two of the five 
elements, i.e. pancha boothas. It is said to occupy the region below the naval in our body. 
It is responsible for all movements in the body. It spreads throughout the body and causes 
respiration, hunger, thirst, etc., without itself undergoing any change.
2
 
       Vatham mainly refers to the Vayu(wind) and its functions. The Vayu (Wind) forms the 
vital forces of the human body and is present everywhere in the system. 
        Although it is invisible, its presence is manifest everywhere. It is known by its two 
attributes, namely sound and touch. It passes through the whole system in a rapid current. 
It is the energy or power that prevails all over the body keeping the various tissues in good 
condition. 
       Vatham(wind) is of 10 types- Praanan, Abaanan, Uthaanan, Vyaanan, Samaanan, 
Naagan, Koorman, Kirukaran, Devathathan and Thananjayan. Of these, the first five play 
an important role in the physical functions necessary for the preservation of the physical 
body.
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1. Praanan: It regulates the respiratory system and helps the digestive system. 
Unneyae melezhundhu paniraendangulam 
Uyarnthavaet tangkulanthaan meela vaangi 
Nanninalan     gulanthaan paazhir paayum 
Namaana kunamaellaam piraana vaayu 
            -------------------------------------------------------- 
                  Pappalavaam posippaellam seernamaagum 
2. Abaanan: 
      It helps in the excretions from lower organs, evacuation and generation. It controls the 
sphincteric action of anus. 
Marukkavae keezhnokki malasalan thllum; 
-------------------------------------------------- 
Arukkavae yaasanththais surukki vaikkum; 
Annasaarath thaiyaellan saera vaikkum; 
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Abaana Vatha(Vayu) is one of the 14 physiological reflex actions (vegas) of the 
body. When its expulsion is partially or completely controlled or obstructed it leads to 
diseases of the chest Vayu gunmam(characterized by dryness of the liver and chest, 
burning sensation in abdomen, gnawing pain on the sides, heaviness and aching of head, 
dizziness, acidic vomiting and intestinal colic), Uthara vatham (characterized by uni-
lateral in-drawing of the testis, scrotal swelling due to accumulation of gases, decent of 
the drawn- in testis in to scrotum due to the displacement of gases in to abdomen, and 
resultant pain), stabbing and gnawing pain all over the body, Vallai vatham ( enlargement 
of spleen), obstruction of daefecation and micturiation, leading to indigestion and loss of 
appetite. 
3. Vyaanan: 
It helps in the circulation of energy throughout the entire nervous system and helps 
in the movements of various part of the body. It is responsible for the tactile sensation. 
“Sirappana   vyaananthu thooli ninru 
Thigazhaezhupath theeraayira narambir senru 
Tharuppaana saravasaranth thanilae ninru 
Thaaneetal mudakk pannip parisa mariyum 
Aruppaana vannasaaranthan naiththaan 
Aagaangae niraippithaak kaiyaik kaakkum” 
4. Uthaanan: 
It regulates the higher functions of the brain like speech. It is responsible for the 
physiological reflex action like vomiting, hiccup, cough, etc. 
 
“Ezhilaana utharavak kiniye zhuppip 
Poomanaa mannasaarantha naiththaan 
Porunthavae samiipaththu niruththi vaikkum 
Kamanaa yaeduppiththum kalakki vaiththum 
Kalakkiyae vruththuvikkum valappa maagum” 
5. Samaanan:  
When any one of the other vayus is affected, this samaanan, also is affected. It helps 
in the proper digestion, etc. by balancing the other vayus, the six tastes, water and food. 
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“Vaamaenra vaayuvinai minjottaamal 
Madakkiyae samanseithu naruvap pannum 
Thmaenra arusuvainth thannee rannam 
Samanseithu sareeramaelaaj saarap pannum” 
6. Naagan: 
It is responcible for the intelligence of an individual. It helps learning different arts, 
singing of good songs, etc. It is responsible for winking, opening of eyes and hair-raising. 
“Seyalaana sakalakalai yaakku viththup 
Payvamaayp paaduvikkum kanvizhikkum; 
Paangkaaga vaesimizhkkum roma masaikkum;” 
7. Koorman: 
This is responsible for yawning, closure of mouth (movement of lower jaw), 
yielding strength and also winking. It helps in closing and opening of the eyes and 
shedding of tears. It is responsible for the vision. 
― Kodiyamananh thanininru nimaikot tummae; 
Nimaikotutung kottaavi thaanung kollum; 
Naeraaga vaaymoodum pala nundaakkum; 
Kamai kottumng kanvizhkkum ndap pannum; 
Kaatciyaelaang kaanpikkum vizhinee rodum 
Emai kottum;” 
8. Kirukaran: 
It is responsible for the salivation in the oral cavity and mucous secretion in the 
nasal cavities. It is responsible for good appetite. It helps in meditation. It produces cough 
and sneeze. 
“Kasinaavu naasithanir kasivundaamae; 
Kasivundaang kadumpasiyir kanmaj saellum 
Kanniyae yiruththalodu poethlaagum; 
Thusivudaayth thummalo diruma lundaam;” 
9. Devathathan: 
It is responsible for the laziness and also lassitude while waking up. It helps 
movements of the eyeball in various directions. It is responsible for begging, quarrelling, 
arguing, etc., and also for much anger. 
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“ Kudilamaays soembi murith thidutha laamae; 
Muriththiduthal vizhikkumpo thuyarchi yaagi; 
Mukulithamaayk kannaiyot tulaavu viththuth; 
Thariththiduthal sandai koelal tharkkam paesal; 
Sandaala kopaththai yundu pannal” 
10. Thananjeyan: 
It is responsible for the swelling all over the body. It produces sensation of roaring 
like the sea in the ears. It leaves the body by blowing up the cranium only on the 3
rd
 day 
after death. 
“Thadiththumae yudampaellaam veengap pannum 
Thanthiramaaik kannaththir samuththiram poel 
Thudiththumae sundaramaaik koesa maagith 
Thirandumae thujsukaa lanthaniraan; 
Vadithumae vaayuvaellaam poena pinbu; 
Valamaana thanalavaedikkum moonra naalil 
Adiththmae thalaivaediththaa lappaar paegum;” 
3a.1.2.Aetiology: 
In yugi, we cannot find any specific aetiological factors for Uthira Vatham,
4
 but 
causes for all types of vatha diseases in general have been described and they are as 
follows:- 
“Ennavae vaathnthaa naenpathaagum 
Egaththilae manitharkaluk kaeyyumvaaru 
Pinnavae ponthanaiyae soranjseithu 
Paeriyorkal piraamanaraithudaniththum 
Vannathevas soththil soranj seithu 
Maathapithaa guruvai maranhthaperkkum 
Kannavae veththai ninthai seithaal 
Kaayaththir kalanthidumae vaathanhthaanae” 
                                                                              -Yugi Chinthamani- verse 243 
i.e. Breach of trust, abusing the pious elderly people, the priests and also the holy scripts, 
exploitation of charitable properties, ingratitude towards mother, father and teacher:- 
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“Thanaenra kasappoedu thuvarppu raippu 
Saathagamaay minjsugilum samaiththa vannam 
Aanaentra vaarinathu pusiththa laalum 
Aagaayath thaeralathu kudiththa laalum 
Paanaenra pagalurarakka miraavizhippu 
Pattiniyae migavuruthal paara meithal 
Thaenaenra moezhiyaar maer sinthaiyaathal 
Seekkiramaay vaathamathu senikkun thaanae” 
                                                                              -Yugi Chinthamani- verse 244 
i.e. Excessive eating of food items of bitter, astringent and pungent taste, intake of dry and 
old cooked rice, drinking raw rain water, sleeping during day and keeping awake during 
night, undue starving, lifting or carrying of heavy loads and sexual pre-occupations. 
“Vaathavarth thanaikaala maethoe vennil 
Maruvukinra vaanigark kadaga maagum 
Aathavaip pasiyodu kaarththigai thannil 
Adarumae mattramaa thanggal thannil 
Poethavae samikkugintra kaala maagum” 
                                                                              -Yugi Chinthamani- verse 245 
i.e The disease will be precipitated in the months from Aani to Karthigai(from June to 
December). 
“Aanaana varantranaiyae mathiyaamaanhthar 
Agathi parathaesiyarkatkanna meeyaar 
Koenaana gurumoezhiyai maranhthapaergal 
Koelai kalavupoi kaamanhkuriththaperkku 
Oonaana sadanhthannil vaatham vanhthu 
Urpavikkum vaethatthin unmai thaanae”. 
                                                                              -Yugi Chinthamani- verse 253 
i.e. Disrespectful attitude towards god, refusing food for destitutes  and sanyasins, 
disregarding the advice of preceptors, engaging in murdering, stealing and lustful 
activities and lying. 
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“Pagaravae vaathamathu kopith thappoe 
Panpaagap paenpoega mathuthaan seiyil 
Nagaravae vaeguthoora vazhina dakkil 
Naliraana kaatrumae pani maerpattaal 
Migaravae kaaykal kani kizhangu thannai 
Migavarunthi meeriyae thayirthaan koendaal 
Mukaravae muthukaelumpai murukki noenhthu 
Muzhankaalum kanaikaalum kaduppundaamae” 
                                                 -Yugi Chinthamani- verse 285 
i.e. Indulging in sexual act during the abnormally increased condition of vatha, walking 
for a long distance, exposure to chillness, excessive intake of curd immediately after 
excessive intake of vegetables, fruits, and tubers will lead to twisting pain in the back and 
burning pain in the ankle and knee joints. 
Kanma as a cause: 
      In Siddha system, many diseases are said to be precipitated by Kanma which means 
the deeds good or bad committed by an individual in his previous and the present births. 
The genetic disposition of certain diseases are probably the result of kanma. Vatha 
disease, according to Agasthiyar Kanma Kandam-300, verse-56, may also be precipitated 
by Kanma.
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“Noo lentra vaatham vanhtha vagaithaanaethu 
Thunmaiyaayk kanmaththin vagaiyaik kaelu 
Kaalilae thoentriyathu kaduppa thaethu 
Kaikalil mudakkiyathu veekkamaethu 
Koelilae padugintra virutsamaana 
Kuzhanthaimaranhthanai vaetta mael thoel seeval 
Naalilae seeva saenhthu kaal muriththal 
                      Nalla koembu thazhai muriththal naliththal kaanae”. 
 i.e. cutting or denuding of green young living trees, breaking the legs of living-beings, 
cutting the branches of a living tree, etc. lead to vatha disease. These deeds are detrimental 
to fellow-beings and such psychosocial aspects  of an individual implies psychogenesis of 
the vatha disease. 
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3a.1.3.Mukkutra Pathology: 
        The primary humour affected is Vatham. Vitiation of Vatham accompanied by 
vitiation of pitham and kapham lead to the clinical condition and this is clearly indicated 
by Theraiyar as
13
 
                      “Vathamalaathu meinikaedathu”-Theraiyar saegarappa 
        Vitiation of vatham leads to the disorders of function of certain types of vayus like 
Pranan, Abaanan, Uthaanan, Vyaanan, Samaanan, Naagan, Koorman, Kirukaran and 
Devathathan.Involvement of Pranan results in anorexia and dyspnoea on exertion in mild 
and moderate anaemic patients of uthira vatha suronitham.Involvement of Vyaanan causes 
local heat, tenderness,pain in the affected joints, joint stiffness ,restricted  movements of 
the joints of upper and lower limbs. Involvement of Abaanan leads to constipation. 
Involvement of Samaanan leads to indigestion, anorexia and imbalance of functions of 
other Vayus. Involvement of Naagan leads to sluggishness and mental depression and of 
Koorman leads to diminished vision and Devathathan affects the normal sleep rhythm. 
          In uthiravathasuronitham patients, involvement of Anal pitham causes anorexia and 
involvement of Ranjaga pitham affects senneer thathu. Involvement of Saathaga pitham 
causes difficulty in doing routine day to day activities like walking,holding, 
gripping,fisting of hands and flexion,extension and rotation of the joints and Prasaka 
pitham accounts for the dryness and loss of lustre of skin.Alosaka pitham accounts for 
defective vision 
Vitiation of five types of kapam in uthira vatha suronitham patients are as follows;   
         Kilethakam affected(anorexia),Bothakam affected(tastelessness,bitter taste 
sense),Tharpagam affected(burning sensation of eyes),Santhigam affected(difficulty  in 
flexion,extension movements of the joints,crepitation),Avalambagam affected(since it 
supports other four kapams).  
          In Seven Udal thadhus, Saaram and Senneer are affected leading to anorexia, 
lethargic and depressed conditions. Senneer when affected leads to nervousness, dryness 
of skin, diminution of bodily luster. Oon is affected leading to muscle spasm, 
musclewasting. Kozhuppu is the main thathu affected and vitiation of this thathu leads to 
difficulty in movements, crepitations as a result of diminution of the pulpy semifluid 
material. Enbu thathu is affected leading to bone erosion,cartilage destruction, osteophytic 
changes. 
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3a.1.4.Classification of Vatham: 
           Based on Yugi Chinthamani and Siddha Maruthuvam text book, Vatha diseases are 
classified here. In the classification, we can find contradictory views regarding the 
number.
1,14
 
             Yugi says “Ennavae Vathamathu enbhathaagum” 
i.e. there are 80 types of Vatham but ‗Siddha Maruthuvam‘ mentions 85 types while 
describing the names and symptoms. The same Yugi while ending a verse describing the 
names of the types of Vatham reaffirms that the number of types Vatham is 80:- 
              “Thakkaana vathanthaan enbhathaagum” 
        In the concluding section of the yugi vaithiya chinthamani, the number of vatha 
diseases has been given as 84. 
“Aamappa vaatham aen baththu naalu 
Athinudaiya  gunaagungaladangalaaga” 
       In some books, vatham has been classified as 80 types based on the symptomatology 
and involvement of different parts of the body. e.g. Astanga Sangiraham and Noi Nadal 
Noi Mudhal Naadal- Part II.
14
 
 
       In Theraiyar Vagadam, 81 types of Vatha diseases
15
 have been described and in 
Thanvanthri Vaithiyam and Jeeva Rakshamirtham the number has been given as 80. 
 
       In Agasthiyar 2000
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“Enpathu vaatha maagu miruvagaip paduththuk kaanil 
Nanpuru araikku maelae naarpathu vaathamagum 
Pan  saeraraikkumk keelae paththunaankkagum maentru 
Vandu saer guzhalinaalae vaathaththin kooruthaanae” 
i.e. 40 types of Vatha are in the upper half and 40 in the lower half of the body and the 
total number is 80. 
3a.1.5.Clinical features of Vatha Diseases: 
The signs and symptoms of Vatha diseases have been given in many Siddha literatures. In 
Sathaka Naadi, the following signs and symptoms have been given:
2
 
Vatham 
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“Vaathamaenum naadiyathu thoentril 
Seetha manthamodu vayiru poerumal thiratchivaayu 
Seethamurung kiraani magotharam neeramai 
Thiralvaayu soolaivali kadupputh thirai” 
Vathapitham:  
“Porulaana vaathathil pithanj saernthu 
--------------------------------------------- 
Karuvaana thaegamathil ulaitchal sombal 
Kaikaaltharippu naakkasakkumannam” 
In Agathiyar naadi: 
―Sollavae vaathamathu meerittraanal 
Sorvadainthu vaayuvinaal thaegamaengum 
Maella kaikaalkalasathi yundaagum 
Maeimudangum nimira vonnaath thimirundaagum‖ 
 
―Vaatidum saeththumaththil vanhthidum vaathamaagil 
Naatiya kaalgal poel narambellam valiththu nirkum” 
Vatha kapham: 
―Paangaana vaathathil saeththumanaadip 
Parisiththaal thimirmaevu mulaichalaagum” 
---   Sathaka Naadi 
Kapha Vatham: 
―Kandaayoe silaerpanaththil vaathanaadi 
------------------------------------------------- 
------------------------------------------------- 
------------------------------------------------- 
Uruthiratchai vaayuvali sannithodam” 
    In the above verses, symptoms like gnawing and stabbing pain, stiffness, numbness, 
sluggishness, weakness of limbs, constipation have been described 
Theraiyar Vagadam, describes the following features: 
―Vaathaveeru annameeranggaathu kaduppundaam vannamundaam 
 Moothu kattu roegam suramundaamirumalumaa muranggaa thaentrum 
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 Oothusooriya vaathamanalaagum nadukkamundaam poerulkalaaynh Theethaenavae 
narampisiththu santhugal thorungkadukkanh thinamunhthaanae” 
 
i.e. when Vatham is increased,bodily pain, diminution of the body lustre, fever, cough and 
sleeplessness occur. 
 
In Agasthiyar 2000, the following features are given: 
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―Vaathaththin gunamae thennil mayangunhthiyangum malar sivakkum 
Paathangulirnthu saruvaangam patri nadakkumugangkadukkunj 
Seethaththudanae vayirupunnaaj sirippith thathunhtaeri mootchaam 
Poethath thanneer thaanvaangum pugazhum panja gunamaamae” 
 
“Vaathathin gunaththaik  kaenmin vayiroothum porumikkollum 
Thaathuttra udambu kaikaal santhugal kadupputh thoentrum 
Theethutra siruneer thaanunj sivanhthudal gaduththu veezhum 
Poethutrra uppusamaay poethavum pasiththidaathae” 
 
“Kaalkai kadukkunnh thimirundaang kannunh thuunggi  soebikkum 
Koelanjseriyum manhgamaellaang kulirnhtha sanhthuganang kolluj 
Seelamigunhthu seerkaanil siruneer vatrri varumigavae 
Maalath thadangan maananaiyaai maathae vaatha rogamithae” 
i.e. giddiness, redness of eyes, stabbing pain in the face, burning pain in body and limbs, 
numbness in limbs, etc., are found when vatham is increased. 
 
3a.1.6.Vatha suronitham: 
        Vatham is generated below the abdomen and spreads all over the body and is 
responsible for the movements of the body. According to Yugi Vaidhiya Chinthamani 
vatha, diseases are classified into 80 types,   which include Vatha Suronitham. Yugi 
classified Vatha Suronitham into seven types 
 Vatha suronitham 
 Uthira Vatha suronitham 
 Sithu Vatha suronitham 
 Vaigitha Vatha suronitham 
 Paithiya Vatha suronitham 
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 Slethuma Vatha suronitham 
 Uthara Vatha suronitham 
3a.1.7.Uthira Vatha Suronitham: (pothu maruthuvam p.no: 608) 
Clinical Features of Utira Vatha suronitham:
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―Vaigithamaaik  kanaikkaalu  muzhangal  thaanu 
Markadanth sandthu puravadiyum veengich 
Saeigithamaanj siruviralgal migavum nondhu 
Sinthai thadumaariyae salippundaagum 
Paigithamaam paithiyaththil vathamminjip 
Baaramaai urpaviththu azhalundaagum 
Uyikithamaai asanamathu thaanumvaenda 
Uthiravatha suronithathin unaarchchi yaamae”      
- Yugi Vaithiya Chinthamani 
 
 
 Table no: 3a.1.7.1.Correlation of Uthira vatha suronitham and Rheumatiod 
arthritis:
18,19
 
S.No 
Symptoms for Uthira 
Vathasuronitham 
Symptoms for Rheumatoid Arthritis 
1. 
―Vaigithamaaikkanaikkaalu  
muzhangal  thaanu Markadanth 
sandthu puravadiyum veengich 
Swelling of Ankle, Knee, and smaller 
joints of the Hand (flexion of Distal 
inter phalangeal joints and Extension 
of Proximal inter phalangeal joints 
looks like Apes Hand-Swan neck 
Deformity. 
2. 
Saeigithamaanj siruviralgal 
migavum nondhu 
Pain and tenderness of minor joints 
especially phalanges. 
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3. 
Sinthai thadumaariyae 
salippundaagum 
Depression and Apathetic mood. 
4. 
Paigithamaam paithiyaththil 
vathamminjip Baaramaai 
urpaviththu 
Signs of Inflammation (Elevation of 
Pitham) pain and restricted 
movements of the joints (Elevation of 
vatham). 
5. Azhalundaagum Fever 
6 
Uyikithamaai asanamathu  
thaanumvaenda 
Loss of appetite 
 
 
3a.1.8.Diagnosis:
2
 
     Diagnosis can be arrived at using the following Siddha methods:- 
1) Poriyalarithal, Pulanalarithal and Vinathal(and some of these are included in the 
―Envagai Thervu‖ also). i.e. inspection, palpation, percussion and interrogation. 
2) Envagai Thervu: 
―Naadip parisam naa niram moezhi vizhi 
Malam moothiram evai mruththuvaraayutham” 
a) Naadi: 
     By examining the pulse, the condition of humour and the features are 
understood. 
b) Sparism: 
     By palpation, the conditions of the disease are understood. 
c) Naa: 
     Examination of tongue 
d) Niram: 
     Colour of the skin and mucous membrane is examined. 
e) Mozhi: 
      Nature of Speaking 
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f) Vizhi: 
      Vision and other aspects are tested. 
g) Malam: 
       Examination of stools.  
h) Moothiram: 
       Examination of urine which includes Neerkuri and Neikuri 
Examination of urine- Neikkuri
2
 
          Neikuri is an important test to assess the predominantly affected humour. A drop of 
gingelly oil is allowed to fall on the surface of the urine kept in a kidney tray, exposed to 
bright sunlight. 
    
“Aravaena neendidin agthae vaatham” 
“Aazhi poerparavin agthae pitham” 
“Muthoththu nikkin moezhivathaena kabhamae” 
 If the drop of oil spreads like a snake, it indicates Vatha disease, if it spreads like a ring, it 
indicates Pitha disease, and if it appears like a pearl it indicates Kapha disease. 
   The final diagnosis (here as Uthara Vathasuronitham) is arrived at by summarizing all 
the clinical findings observed by the methods described above which includes 
examination of pulse and Neikkuri. 
 
3a.1.9.Differential diagnosis:
4,14
 
   Uthira Vathasuronitham is differentiated from other types of Vatha Suronitham as 
follows: 
According to the text ‗Yugi Vaithiya chinthamani’ 
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Vaatha Suronitham:  
“Arinthitta angamaellaa maelivu maagi 
Asaivaana thavvidangal veekka maagi 
Narinthitta nadaikoedaa thaani ruththal 
Naliyaagi moezhimozhiya veekka maagatch 
Sorinthitta thaegamaengu masaivu kaanal 
Sotrrinmae ninaivinrith thookka maathal 
Varinhthitta vvayathani neerthaa nooral 
Vathasuro nithanhthaanum vaguththa vaarae” 
In Vatha Suronitham, gradual weight loss, weakness, pain and swelling in the joints, loss 
of appetite, somnolence, excessive salivation are the symptoms described. 
Sithuvatha surunitham: 
“Vaarana sareeramaellaa nuzhainthu oothum 
Maasatra thoelthaanunh thirainthu poogum 
Naarana naarupoel narampu sukkum 
Naakkuththaan vazhavazhaththuk koezhai yaagum 
Thooraana naeruppuththaan pattaar poela 
Noenhthumae sadamaellaang koeppa likkum 
Veerana vurinhthupinnai vaethumpi   veenggum 
Mikkasiththu vaathasuroe nithamaamae” 
In Sithuvatha surunitham symptoms like generalized body swelling, neuralgia, blisters all 
over the body, excessive salivation have been listed. 
Paithiyavaatha suronitham: 
“Unarchchiyaay suronithanhthaan migavae thumpi 
Ookkamaayth thaekamaengu migavae noenthu 
Unarchchiyaay muzhangaalgal muzhangai yoekka 
Munaiyaana siruvralgal kannam naetri 
Thanarchchiyaaych sanhthusaru vaanga maenhgum 
Thaattiga maaykkudainthu suramu mundam 
Panarchchiyaayp paandathupoen maeni yaagum 
Payiththiyava thasuroenithathin panpu thaanae” 
In Paithiyavaatha suronitham symptoms like weakness of the body, pain in the knee, 
elbow, fingers, feverishness and paleness of the body have been listed. 
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Sethumavaatha suronitham: 
“Panpaaga udalkulirnthu vaeru veengip 
Pathaipaana vidanhthottaar pola  noevaam 
Thinpaana sirasunaetri noekkaa dundaam 
Silaettumamaayk koezhaiyoedu suvaasa maagum 
Manpaaga mayakkamoedu kanavu mundaam 
Vaayvarandu rusiyillaa varuththa maagum 
Nanpaaga naadiyumae padapa dakkum 
Narselaetma suronithamaam naadung kaalae” 
In Sethumavaatha suronitham symptoms like chillness of the body, swelling and pain on 
touch, headache, and shortness of breath, giddiness, dryness of mouth and loss of taste 
have been listed. 
Uthara Vathasuronitham: 
―Naadumae suaramvanthu nadukka lundaam 
Naavarandu thalainoenthu udam pazhundhi 
Vaadumae thaegamaellaa manichcham pooppoel 
Magaavaruththa mundaagi mayakka maagum 
Saadumae yadikkadithaan paethi thaanum 
Thavikkumae thanneerthaa naatta maagith 
Thaedumae soetrinmael ninaivu thaanum 
Saeya uthara vaathasuro nithanhthaan naennae” 
 In Uthara Vathasuronitham, symptoms like fever with rigor, dryness of tongue, 
inflammation and redness all over the body like Anicham flower, generalized tiredness 
due to pain, diarrhea, excessive thirst and hunger have been described. 
Vaigithavaatham: 
“Aamaentra veenhginathor vidaththil raththam 
Azhuththamaaith thirandumae engum paaynhthu 
Omaentru oottiyae thirandi rukkum 
Uruthiyaayth thottudanae maeththaen raagum 
Thaemaentra thaegamaen kaanuki  sikkum 
 
Paamaentra sadanhthanilae thimirun  daagum 
Paaramaay vaigithamaam vaathanhthaanae” 
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In Vaigithavaatham presence of swelling, pain, tenderness over the joints, cough, fever 
are the symptoms described.
4,14
 
3a.1.10.Treatment of Uthira vatha suronitham 
1
 
The line of treatment consists of:- 
1. Oil bath, a pre-requisite to alleviate vatha kuttram. 
2. Purgation,a pre-requiste to alleviate vatha kuttram. 
3. Internal medicine to relieve pain and stiffness of the  minor and major joints to inhibit 
the progression of the disease process. 
4. Pathiyam i.e., dietary regimen to suit the drug and the disease. 
5. Kanma neekam  
Treatment 
On day -1, patients were instructed to have oil bath with Chittra mutti thylum.  
On day-2 patients were given a purgative like Agasthiyar kulambu 100mg with hot 
               water in the early morning. 
On day-3 patients were advised to take rest and instructed not to take any medicines. 
On day-4 patients were advised to take internal medicine Nandhi mezhugu in the  
               dose of 500mg along with palm jaggery twice a day after food intake. 
               Medicine was given for 7 days followed by 7 days drug holiday likewise 
               for a period of 60 days. 
 
Pathiyam 
             Pathiyam forms an important part of treatment.Certain dietary and other 
restrictions are imposed in relation to the disease or the drug.While on treatment with 
Nandhi mezhugu,the patients were advised to avoid tamarind and salt and take plenty of 
cow‘s  butter milk,cow‘s milk,cow‘s ghee(these measures will probably neutralize the 
toxicities if any,and irritability of the internal drug). 
Siddhars‘ view on Pathiyam 
 Kadum pathiyam: 
―Kadumai entridu pathiya muvar varuththundal 
Adaivilaa maru paththiyath thuvar varuth tharunthal 
Kodumai sei pulithanei suttu cootida lantri 
Padiyil katthari chickkurup pinjineip parugal 
--Sundharananthar Ayulvedha Pothu Lakshanam. 
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In strict (diet) pathiyam, a small quantity of fried salt is added to cooked rice which is 
eaten after adding hot water.This has to be observed during the entire period of taking 
medicine and then re-dieting is prescribed in which burnt tamarind,unripe brinjal and 
drumstick are taken in the form of soup along with fried salt. 
             ‗Poerunthidathu pen poegamore marunthukkum puviyil’ 
      Refraining from sexual intercourse during drug treatment is insisted. 
According to Therer: 
―Uppinaa lappaana loottuppun pinpoema 
Vappinaa dappaanaa laampiramaet- truppinaa 
Doppiraap baratha mee thutrathai laathikalukk 
Kuppiraap pathiya meethoor” 
A strict (diet pathiyam is observed when taking mercurial drugs .i.e., salt is completely 
avoided during the days of pathiyam (during drug treatment) and also during 
redieting(maru pathiyam) for the same number of days.Fried salt is taken after redieting.A  
bath ,with application of milk, boiled with adjowan seeds over scalp, is taken 2 days after 
redieting and then tamarind and cow‘s ghee can be added in the diet.20 
Pathiyam for vatha diseases in ―Agasthiyar Vallathi 600‖ 
―Kaelunj sirupairru pasuvinpal thayirneiyaagum vasamoththuththu 
Varaiyuda paruppumaagum mainhthanae pudalangkaaya yavaraikkaayam, naesa 
Motrra murungkakaay sirukeeraiyaagum naellikkaai thoothuvalai paruppaampaarae” 
“Paararaana vaellaadu suraameenkaadai parum viraaludumpudanae 
Muyalumaagum, vaaraana karappanaera vasthvaaga manggaiyaraik 
Koodaathae milakaaymaaththu paeraana soolaipathinaettum pogum 
-------------------------------------------------------------------------------------------- 
-------------------------------------------------------------------------------------------- 
Aamaera vaathmaellaamaganru poga mappanae:‖ 
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 In Pathartha Guna Chinthaamani: 
Vaatharogaari vasthukkal: 
―Saengazhu     neer kottanh then milagu nallaennai 
Thanggu perunggaayanh thazhuthaalai- yaengngaenggum 
Kootu siru muththunaei kothilunhthivaigal 
Vaattu manilaththai mathi” 
i.e. Root of water lily (Pontederia vaginalis), Costus root( Costus speciosus), Honey 
collected on branches of trees, black pepper( Piper nigram) gingelly oil, asafoetida, leaves 
of clerodendron phlomides, castor oil, black gram, etc., cure Vatha diseases.
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3a.1.11.Siddha Medicines for Rheumatoid Arthritis: 
     3a.1.11.1.Herbo-Mineral Formulations for RA: 
In Siddha system, there are several herbo mineral formulations mentioned for Vatha 
Disease. Some major formulations are given below 
 
 Chooranam: 
1. Attathi Chooranam    -  Thanjai Vaidhiyaraja chinthamani Part 1 P.No:21-2222 
2. Elathi Chooranam - Agathiyar Vaithiya Rathina surukkam Song No:149-150.23 
3. Thalisathi Chooranam - Siddha Vaithiya Thirattu  P.No:228-229.24 
4. Seenthil Chooranam   - Agathiyar Paripooranam-400 Song No:324-32525 
Chendooram: 
1. Gantha Chendooram   -  Gunapaadam Part 2 and 3 P.No:8026 
2. Velli Chendooram      -  Gunapaadam Part 2 and 3 P.No:129-13026 
3. Ulogamandoora Chendooram - Therayar Yamaga Venbha 27 
4. Linga Chendooram      -  Gunapaadam Part 2 and 3 P.No:159 26 
5. Aya Chendooram        -  Agathiyar Paripooranam-400 Song No:261-26425 
6. Aya veera Chendooram   -  Gunapaadam Part 2 and 3 P.No:5826 
7. Kaalamega Naarayana Chendooram – Vaidiya saarasangiragam P.No:496-497.40 
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Parpam: 
1. Muthu Chippi Parpam  - Siddha Vaithiya Thirattu  P.No:128 
2. MuthuParpam               - Therayar Maha Karisal  P.No:132- Song No:50 13428 
3. Thalaga Parpam            - Agathiyar Paripooranam-400 Song No:195-201 
4. Thanga Parpam             -  Gunapaadam Part 2 and 3 P.No:109-110 
Pathangam: 
1. Linga Pathangam            - Therayar Karisal 300 Song No:2 P.No:829 
Thylam: 
1. Gandhaga Sudar Thylam - Agathiyar Paripooranam-400 SongNo:351-352 
P.No:63 
2. Gundhiriga Thylam   -  Hospital Pharmacoepia  P.No:13330 
3. Laguvisamushiti Thylam   - Therayar Thyla Vargasurukkam Song No:79 
P.No:101
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4. Mayana Thylam   - Therayar Thyla Vargasurukkam Song No:79 P.No:130 
5. Merugulli Thylam   - Therayar Thyla Vargasurukkam P.No:75 
6. Vaathakesari Thylam - Therayar Thyla Vargasurukkam Song No:9, P.No:48 
Leghium:  
1. Maha vallathi Leghiyam    - Boogar Vaithiyam 700 Song No:175-18732 
2. Thettrankottai Leghiyam -  Agathiyar Paripooranam-400 Song No:281-282 
Manappagu: 
1. Aadathodai Manappagu  -  Siddha Vaidhiya Thirattu  P.No:257 
Rasayanam: 
1. Gandhaga Rasayanam  -  Pulipaani-500 Song No:324-33033 
2. Parangipattai Rasayanam - Agathiyar Vaithiya Rathina surukkam Song No:114-
118
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Mezhugu: 
1. Mahaveera Mezhugu  - Siddha Vaithiya Thirattu  P.No:203-204 
2. Navauppu Mezhugu   - Siddha Vaithiya Thirattu  P.No:193-194 
3. Nandhi Mezhugu - Siddha Vaithiya Thirattu  P.No:187-193 
4. Panchasootha Mezhugu - Yugi Karisal-151 Song No:16-24 34 
5. Rasa Mezhugu - Agathiyar Paripooranam-400 Song No:126-129 
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Mathirai, Kuligai, Vadagam: 
1. Korosanai Mathirai - Agathiyar Vaithiya Rathina surukkam Song No:149-150 
2. Mehanaatha Kuligai  - Siddha Vaithiya Thirattu  P.No:41 
3. Pachaikarpoora Mathirai - Siddha Vaithiya Thirattu  P.No:30-31 
4. Thalisathi Vadagam  -  Therayar Paadal Thirattu P.No:2835 
5. Vatha Rakshanan  - Agathiyar Vaithiya Rathina surukkam Song No:36-38 
6. Viresana Poobathi - Bala Vaagadam P.No:79-8036 
Kulambu: 
1. Koushigar Kulambu  - Siddha vaidhiya Thirattu  P.No:204-213 
Pattru: 
1. Moosambra Pattru - Siddha Vaithiya Thirattu  P.No:305 
Karuppu: 
1. Sivanar Amirtham  - Siddha Vaithiya Thirattu  P.No:165-166 
Kattu: 
1. Poorak Kattu  - Gunapaadam Part 2 and 3 P.No:163 
Chunnam: 
1. Velvanga Chunnam    - Gunapaadam Part 2 and 3 P.No:122 
3a.1.11.2.Anti-Vatha Herbs: 
           Drugs which are prevent the Vatha Diseases in the body mentioned in 
Gunapadam Part I Mooligaivaguppu. 
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Some important herbs which prevent Vatha 
diseases are mentioned in following table  
      Table no: 3a.1.11.2.1.Herbs Prevent Vatha Diseases. 
S.No Herbs Botanical Name Part Used 
 
1. Aamanakku Ricinus communis, 
Linn. 
Leaves,roots 
 
2. Aanaipuli Adansonia digitata, 
Linn. 
Leaves 
 
3. Kadambu Anthocephalus  
cadamba Roxb 
Seed 
 
4. Chinni Acalypha fruticosa, 
Forsk 
Root 
 
5. Kattaamanakku Jatropha curcus, Linn. Leaves,root 
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6. Chevvamanakku Ricinus tanarius, Linn. Leaves,root 
 
7. Thakkolam Illicium veram, Hook.f. Seed 
 
8. PirappanKizhangu Calamus rotang Linn. Rhizome 
 
9. Mizhagu Piper nigram Linn. Seed 
 
10. Musuttai Rivea ornate 
(Roxb)W.& A 
WholePlant 
 
11. Merugu Alocasia indica, 
Schott. 
Rhizome 
 
12. 
 
Maikonrai Poinciana 
pulcherrima, Linn. 
Flower,Bark 
13. 
 
VathaNaarayanan Delonix elata, (L) 
Gamble 
Leaves 
14. Vizhuthi Cadaba trifoliate 
(Roxb)W.& A. 
Leaves and Fruit 
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3a.2. RHEUMATOID ARTHRITIS (RA) MODERN ASPECT 
3a.2.1.Definition: 
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that typically affects 
small and medium-sized joints in a symmetric fashion.The acellular synovium is invaded 
by immune cells causing the primary lesion called synovitis, leading to the formation of 
inflammatory ‗pannus‘. This hyperplastic, invasive tissue causes cartilage breakdown, 
bony erosion and ultimately, loss of function of the affected joints. Systemic involvement-
for example of the respiratory, cardiovascular and haematopoietic system- may happen.  
The risk of developing lymphoma and atherosclerosis is high in RA, with 7 years 
reduction in life expectancy. 
38
 
3a.2.2.Epidemiology: 
RA affects approximately 0.5-1% of European and North American adults, with 
considerable regional variation. Prevalence estimates for Southern European countries 
(median of 3.3 cases per 10
3
) are lower than for Northen Europe(5.0 per 10
3
), and highest 
rates are found in America (10.7 per 10
3
). Asian studies report between 2.8 and 3.5 cases 
per 10
3
. 
     Women are about three times more frequently affected than men. It has long been 
documented that RA cluster in Families: the likelihood that a first-degree relative of the 
patients will share the diagnosis is 2-10 times the population prevalence of the disease, 
and recurrence risks are highest for relatives of the most severely affected index cases. 
3a.2.3.Pathogenesis:  
Auto antibodies: RA as an autoimmune disease. 
Witebsky postulated in 1957 that a disease must fulfil three criteria to be considered 
autoimmune nature. A contemporary understanding of these postulates requires: 1) the 
presence of autoantibodies or a cell mediated immune response against an auto antigen: 2) 
that the respective auto antigen is known, and 3) that a similar disease can be initiated in 
animals based on an analogous immune response. The status of RA as an autoimmune 
entity, while generally accepted, remains somewhat controversial based on these 
requirements. For example, although an array of anti-bodies targeting ‗Self‘ antigen   
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including collagen type II, calreticulin, cathepsin, BiP, CH65, and human collagen 
glycoprotein has been described, the identity of a dominant arthrito genic auto antigen has 
remained elusive. Moreover, while inflammatory arthritis phenotypically similar to human 
RA with autoimmune aetiology, may be artificially induced in animals (as in the example 
of collagen induced arthritis (CIA), the direct relevance of such models to human disease 
has been difficult to demonstrate. 
Rheumatoid factor (RF): 
The Fc part of human Ig G is targeted by the auto antibodies (called as RF) in the 
affected patients‘ blood. Ig M – RF is the common form of RFs present in the patient 
blood. But Ig G- RF and Ig A- RF which form immune complexes, activating complement 
in the joints are detectable in the sub groups of patients. 
The mere presence of RF, however, is insufficient to initiate arthritis development, 
as RF is also found in other autoimmune diseases, infectious diseases and in15% of 
healthy elderly individuals. Thus, the sensitivity and specificity of RF are, depending on 
the population studied, 60-70% and 50-90% respectively, and their role in disease 
aetiology remains unclear. Despite this lack of specificity, presence of RF is one of seven 
diagnostic criteria for RA put forward by the American College of Rheumatology in 1987. 
Anti-citrullinated peptide antibody: 
An enzyme called peptidyl arginine deiminase(PAD) post-translationally modifies  
the arginine residues in a given protein in the presence of high calcium concentrations in a 
process called Citrullination . Citrullination plays a major role during apoptosis for 
degradation of intracellular proteins.   
     Citrulline-specific reactivities against a number of additional citrullinated proteins 
(eg fibrinogen, vimentin, and α-enolase) have since been identified. Using novel assays 
that employ synthetic cyclic citrillinated peptides(CCP) as antigens, anticitrullinated 
protein antibodies(ACPA) are found in 60-70% of RA patients, but hardly ever in other 
diseases or healthy subjects. 
     Circumstantial evidence for their role in disease induction comes from 
observations that ACPAs can be detected in sera several years before clinical onset of 
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arthritis, that their presence predicts progression from undifferentiated arthritis (UA) to 
RA, and that they are associated with a more severe course of disease. 
     Interestingly, IgM-ACPA are detectable in samples from patients with early as  
well as longstanding RA, indicating that new antibody secreting cells are continuously 
generated as a reflection of an ongoing immune response. 
Genetic risk factors: 
 HLA association 
  The strongest and most relevant genetic risk factor for the development of RA, 
contributing around 30% to the total genetic effect, is found at the HLA(Human leucocyte 
antigen) class II molecule-encoding locus(chromosomal position 6p21.3) and relates to 
experiments first performed in 1969.It is notable that a distinct amino acid sequence 
containing the aspartine (D) residue(DERAA), and encoded by several HLA-DRB1 
alleles(*0103,*0402,*1102, *1103, *1302, *1304), has been found to independently 
protect its carriers from the development of RA when present at the same DRB1 position. 
Its protective effect seemingly remains even in the presence of coexisting SE alleles, and 
it is associated with less erosive disease in both ACPA-positive and ACPA-negative 
patients. The protective mechanism of DERAA has remained elusive, however and 
remains at present no more than a tantalising hypothesis. 
     The first robust non-HLA genetic association with RA was found during 
investigation of the PTPN22 candidate gene, which encodes a lymphoid specific protein 
tyrosine phosphate, Lyp. A single nucleotide polymorphism(SNP) at position 1858(C->T) 
leads to gain-of-function mutation in Caucasian populations, whereby enhanced 
regulation of T cell receptor(TCR) signalling during thymic selection is thought to permit 
autoantigen-specific T cells to escape clonal deletion. This appears to predispose to 
autoimmunity in general, and to ACPA-positive (but not ACPA-negative) RA in 
particular. 
Several whole genome association scans have recently been performed on large RA 
cohorts and healthy controls originating from different countries. Such genome-wide 
scans test up to 500 000 SNPs distributed over the entire genome for their association with 
disease.In addition to confirmation association at HLA-DRB1 and PTPN22 loci, these 
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scans have identified polymorphism in genetic regions encoding a large number of protein 
products that may have pathophysiological relevance in RA. Initially, polymorphism at 
signal transducer and activator of transcription 4 (STAT4), 6q23 and 9q33.2 loci were 
identified as novel risk factors for ACPA-positive disease(Wellcome Trust Case Control 
Consortium 2007). STAT4(chromosome 2q32) encodes a transcription factor (STAT4) 
involved in the differentiation of both type 1 helper T cells (Th 1) and Th 17 cells 
(discussed later). Although direct evidence for specific gene disruption by risk alleles at 
the other two loci has not yet been forthcoming, the most biologically compelling 
candidate genes remain TNFAIP3 and TRAF1, respectively. TNFAIP3(tumour necrosis 
factor-α induced  protein protein 3) codes for a protein(A20) that is a negative regulator of 
NFκB and as such involved in the regulation of TNFα signalling. TRAF-1(tumour 
necrosis factor receptor associated factor-1) is involved in signalling of TNFα via TRAF-1 
and, interestingly, downstream NFκB. A potential implication of RA association with 
TNFAIP and TRAF1 is therefore the importance of the NFκB pathway in disease 
induction, and several additional risk loci containing NFκB-related genes have now been 
identified: CD40, PRKQC, and TNFRSF14. Functional studies are needed to confirm and 
further explore the mechanism of such associations. 
Additional RA-associated genetic variants have been found in regions or genes 
encoding CTLA4, KIF%A- PIP4K2C, CCL21, CDK6, CD28, PRDM!, CD2/CD58, and 
IL2RA. It is important to note that the majority of association studies performed to date 
have been in Caucasian populations, and some important racial differences exist with 
regards to risk profiles. For example, the PTPN22 risk allele is not seen in Asian 
populations, where convincing evidence conversely exists for an association of RA with 
an SNP in the PADI4 locus(chromosome 1p36.13), which encodes the enzyme PAD. 
Moreover, the non-HLA genetic variants described here invariably confer only very 
modest independent disease risk, often displaying individual odds ratios of little more than 
1. The additive effects of such minor genetic determinants are unlikely to ever describe all 
of the unaccounted heritability of RA, and it seems likely that distinct genetic risk factors 
may provide multiplicative, rather than merely additive, combined risk because of their 
compound molecular consequences, with gene-environment interactions further 
completing the picture.  
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Smoking, genes, autoantibodies, and the problem of ACPA-negative RA: 
Cigarette smoking is the most important environmental risk factor for RA. 
Importantly, and analogous to the case with SE and PTPN22 risk alleles described `above, 
smoking is seen to represent a risk factor for ACPA-positive, but not ACPA- negative, 
RA. Indeed, this risk is further increased in the presence of SE alleles(up to an estimated 
21 fold as compared to SE-negative non-smokers), illustrating the multiplicative effect of 
combined risk factors(Klareskog et al 2006, Kallberg et al 2007). PTPN22 risk alleles also 
appear to interact with SE alleles to confer multiplicative risk(Kallberg et al 2007). In the 
light of these observations, it has been proposed that cigarette smoke could be involved in 
the induction of protein citrullination. Supporting this hypothesis, citrullinated proteins 
have been detected in bronchoalveolar lavage fluids from smokers but not from non-
smokers. How and why this response eventually targets the joints, however, remains 
unknown and could require additional environmental factors. A possible genetic risk 
factor is the MCH class II gene HLA-DR3,which is part of a conserved 
haplotype(A1;B8;DRB1*03) that includes the MCH class III region, itself comprising 
many immune-related genes. In addition, polymorphisms defining several haplotypes in 
the promoter region of the gene coding for IRF-5 (interferon regulatory factor 5) were 
found to associate with ACPA-negative RA. IRF-5 is involved in signalling via Toll-like 
receptors(TLRs) 7 and 9, and the polymorphisms might influence the induction of IRF-5 
dependent type 1 interferons. 
Additional environmental risk factors: 
In a Danish cohort, however, coffee consumption did show an association with 
ACPA-positive RA after adjustment for smoking.Occupational exposure to mineral 
oils(eg, motor oils, hydraulic oils, etc) was found to be risk factor for ACPA-positive RA 
in males in a Swedish cohort, independent of the presence of shared epitope alleles. This 
finding is of interest as mineral oils are arthritogenic in certain rat strains due to an as yet 
unknown mechanism. 
     Female predominance in various autoimmune diseases including RA suggests that 
sex hormones and reproductive factors influence both RA development and severity. 
Women with lower age at menarche have a comparatively low risk for the development of 
RA. In the Danish cohort, for example, women with older age at menarche had an almost 
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twofold risk of developing RA. Pregnancy is in itself a risk factor for the development of 
RA, as around 12% of women with RA experience disease onset within 1 year after 
pregnancy. During pregnancy, most women with RA(in older studies up to 90%) 
experience a significant reduction in disease activity(including complete remissions), but 
almost all patients relapse within 6 months after delivery. Multiparity(>3 children) favours 
a more severe course of disease, but does not additionally increase the risk for developing 
RA. 
Disturbance of Immune system:  
The heritability of RA, together with the presence of autoantibodies that precede 
clinical onset in a subset of patients, support a now widely-held pathogenetic model in 
which autoimmune propensity is long established by the time joint inflammation is 
‗triggered‘. The precise nature of the trigger(s), and the tendency for ensuing 
inflammatory pathways to converge in peripheral synovial joints, remain tantalisingly 
unexplained, however, though innate immune mechanisms undoubtedly play an important 
role. Thereafter rheumatoid synovitis is characterised by the infiltration of various 
immune effector cells, typically via chemo-attractant gradients. Over-time, this process 
creates a cytokine milieu in the joint that activates synovial fibroblast(SF) and osteoclast, 
which in turn degrade cartilage and bone. Key cellular mediators ae well as important 
cytokines supporting this process are discussed here. 
T cells: 
T cells are one of the most abuntant cell types in RA synovium, comprising 30 -
50% of synovial tissue mononuclear cells. The majority are CD4+, ‗T helper‘(Th) cells, 
matured from naïve precursors, which have traditionally been divided into Th1 and Th2 
subtypes. 
In health, Th1 cells secrete interferon-ɣ  (IFNɣ ) and defend against intracellular 
bacteria; IL4-secreting Th2 cells combact extracellular parasites. Only recently have two 
novel CD4+ subsets begun to be properly characterised: Th 17 cells appear to defend 
against extracellular bacteria such as Klebsiella pneumoniae, while regulatory T cells(T-
regs) plays a vital role in immune tolerance and the modulation of established immune 
response.It now seems likely that newly described Th17 cells are significant players in 
autoimmune inflammation. The differentiation of this cell type from naïve precursors 
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requires the presence of TGFß,IL23 and pro-inflammatory cytokines such as IL6 and 
IL1ß.Lineage commitment of human TH17 cells appears to be flexible, with 
subpopulation producing IFNɣ  or IL10 in addition to IL17. Apart from these cytokines, 
Th17 cells can produce TNFα,IL6,IL22 and granulocyte- macrophage colony-stimulating 
factor (GM-CSF). Th17 cells are critical orchestrators of CIA in mice, and evidence for 
their importance in human RA comes from the observation that both IL17 and IL23 are 
found in sera, synovial fluid and synovial biopsies of patients, but are mostly absent from 
the same compartment in osteoarthritis(OA). IL17 itself is highly pleiotropic, acting on a 
variety of cell types to perpetuate local inflammation while promoting angiogenesis, 
osteoclastogenesis and, ultimately, destruction of cartilage and bone. It has therefore, 
become an interesting novel therapeutic target in RA. 
T-regs appear to be overrepresented in the synovium of RA patients, but 
controversy remains as to whether this might simply reflect ongoing methodological 
challenges in distinguishing cells of this phenotype from activated T cells in human. If the 
suggested overpresentation is real, it may suggest the functional impairment of T-regs 
within the auto immune microenvironment they are supposed to supress. A possible 
explanation is that T-reg cells express TNFR-II, which makes them susceptible to the 
deleterious effects of TNFα.Indeed, functional T-reg defects may be reversed following 
treatment with TNF antagonist, apparently through the generation of a distinct T-reg cell 
population that secretes TGFß and IL10. 
B Cells 
         During inflammation ,B cells infiltrate RA synovium although the degree of 
infiltration and local structural organisation varies significantly between 
patients.Fibroblasts- like synoviocytes and dendritic cells in synovium secrete factors 
attracting B cells and influencing their differentiation and survival,as well as orchestrating 
the formation of tertiary  lymphoid structures in some patients which  perpetuate 
autoimmunity.These include BAFF,CXCL12,and APRIL,some of which are currently 
being evaluated as therapeutic targets.B cells can also take up antigen via surface Ig and 
are very efficient APCs.Moreover, recent evidence suggests that Ig- class switching and 
somatic hyper mutation,which are classically dependent on CD-40-CD40L interactions 
with CD4+T cells, may also occur independently of T cells.This process again requires 
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BAFF,which is present in elevated amount in RA synovium and additionally prolongs B 
cell survival. 
       B cells are prolific producers of cytokines.By secreting TNFα and IL6, they 
contribute to the activation of macrophages and directly participate in inflammation .IL6 
is also an important autocrine differentiation factor for B cells themselves.RF from B 
cells form immune complexes that can induce tissue damage and efficiently activate the 
complement. System they can also be taken up by macrophages, thereby perpetuating 
inflammatory cytokine secretion. Finally, as with CD4+T cells,regulatory B cell 
phenotype has recently been described,which producesIL10 in abundance and may 
downregulate immune responses by tolerising T cells. 
Mast cells 
       Mast cells are highly granular cells best known for their role in allergy and 
anaphylaxis, and as components of the innate immune system.They may be stimulated to 
degranulate in response to direct injury,Fcε receptors cross-linking,TLR ligation or 
activated complement,releasing cytokines,proteases and biogenic amines including 
histamine.TGFβ ,complement components C3a and C5a,serum amyloid A and platelet 
activating factor are important for mast cell recruitment,and their differentiation is 
supported by stem cell factor secreted from fibroblasts,stromal cells,and epithelial 
cells.Mast cells are the producers of IL17.Indeed ,within the rheumatoid synovium they 
may be more important in this regard than Th17 cells(Huber et al 2010).In addition,a 
prominent role for mast cells in the pathogenesis of ACPA-positive RA Iin particular is 
suggested by the presence of IgE ACPA,and the observation that synovial fluid histamine 
levels are highest in sero positive disease,possibly as a result of ACPA IgE-mediated mast 
cell degranulation. 
Monocytes/macrophages 
The role of activated macrophages in RA synovium is central to driving and 
maintaining chronic inflammation.Macrophages are multipotent effector cells that very 
efficiently integrate innate and adaptive immune responses. They are abundantly present 
in the rheumatoid synovial membrane and at the cartilage/pannus junction(Fig 
3a.2.3.1).Important function include strong phagocytic activity,antigen processing and 
presentation,expression of Fc receptors responsive to (auto-) antibodies and immune 
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complexes,complement activation and regulation,TLR expression,and tissue degradation 
and remodelling.They are important producers of pro inflammatory 
cytokines(eg,TNFα,IL1,IL6),cartilage degrading enzymes(MMP9 and 12) and growth 
factors(GM-CSF), among other mediators of pathology. 
         As macrophages are tissue-resident in most organs,they are ,along with dendritic 
cells,likely to be the first to encounter pathogen-derived antigen,and are well- placed to 
present it to autoreactive T cells,providing the initial trigger necessary to start an immune 
response on the basis of genetic predisposition.In this regard,synovial macrophages have 
been shown to respond to direct cell contact with Tcells and fibroblasts.Co-culture with 
fibroblsts not only induces secretion of IL6,IL8 and GM-CSF,but also enhances cartilage 
degradation in vitro.Bacterial cellwall[eg,lipopolysaccharide(LPS)] and nuclear(eg,DNA) 
components, but also cartilage degradation products such as hyaluronic acid,are strong 
macrophage activators.Macrophages are also responsive to oestrogens,a finding that 
could explain changes in disease activity during pregnancy.Interestingly,physiological 
oestrogen levels induce IL1 expressions,where as higher levels(as occur in pregnancy) 
inhibit IL1 secretion.Macrophage function is in itself regulated by various cytokines that, 
in some cases, have autocrine effects.IL4, for example,downregulates  macrophage 
function by reducing the expression of TNFα,IL1β,and PGE2.IL10 lowers the expression 
of HLA-DR and reduces antigen processing and the expression of Fc receptors.Both IL4 
and IL10 have strong anti arthritic properties in murine models of arthritis,and some 
studies have linked polymorphisms in theIL10 gene to disease susceptibility. 
Inflammatory cytokines 
Proinflammatory cytokines represent mediators of active disease,encouraging the  
recruitment and activation of the adaptive immune system,and inducing SFs to secrete 
cartilage degrading matrix metalloproteases-but they remain non specific targets which 
may be less important  in early disease.With this in mind, it is notable that patients with 
early arthritis(symptom duration less than 3 months) who progressed to RA exhibited a 
different synovial cytokine profile than patients who went into remission or developed 
other arthritides.Patients prone to develop RA showed elevated levels of T cell-derived 
cytokines IL2,IL4,IL13, and IL17 and of stromal and macrophage related cytokines 
EGF,bFGF,IL1 and IL15.IFNγ was not detected in these samples,and IL6 seemed to be 
associated with inflammation independent of underlying disease phenotype.Interestingly,  
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this profile was absent from patients with established RA and seemed to be present only 
transiently.The absence ofTh1-cytokine IFNγ and the presence of Th2-cytokines IL4 and 
IL13 together with (presumably) Th17-derived IL17 in early RA favour an important role 
for T cells- in the initiation phase of RA. 
T cells,macrophages,and stromal cells are also the main source of cytokines in the 
established RA.Macrophage derived cytokines,however,predominate, and T cell derived 
cytokines become less abundant.Examinations of synovial biopsies indicate the disease 
subtype specific patterns might exist.Distinct cytokine profiles were found to correlate 
with subtypes of lymphocyte infiltration in active RA.Hence ,diffuse lymphocytic 
infiltrates were associated with RF-negative RA and displayed low levels of 
IFNγ,IL4,IL1β,and TNFα.Germinal centre formation ,on the other hand, correlated with 
high levels of IFNγ and IL10,and absence of IL4.Patients with extra- articular disease 
manifestations showed synovial granuloma formation associated with high levels of 
IFNγ,IL4,IL1βand TNFα. 
IL18 needs consideration as a proinflammatory cytokine, driving macrophage 
activation together with IL12and IL15.IL18 is over expressed in RA synovium,it induces 
RANKAL expression in T cells, and strongly aggravates experimental arthritis. The 
existence of a natural inhibitor,IL18 binding protein,makes IL18 an interesting 
therapeutic target.IL15 attracts T cells and IL15 activated Tcells in turn activate 
macrophages.It is expressed in the synovial membrane and by macrophages 
themselves.Finally ,TGFβ is an important regulator of tissue degradation and remodelling 
and displays pro- and anti-inflammatory properties.It is produced by macrophages in RA 
synovium, and low expression of TGFβ due to genetic polymorphisms is associated with 
disease severity.In addition,TGFβ drives development of regulatory T cells,but can also 
enhance Th17 development in the presence of IL6. 
Cartilage and bone degradation: the role of fibroblasts and osteoclasts 
While immune effector cells discussed above are responsible for initiating and 
maintaining inflammation, two cell types are of prime importance for the destruction of 
cartilage and bone. SFs adhere to cartilage and degrade extracellular matrix.Osteoclasts 
,on the other hand ,are mainly involved in bone destruction.Both cell types closely 
interact with cells of the immune system and by secreting large amounts of 
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cytokines,participate in the maintenance of inflammation.SFs in RA are characteristically 
found in the sub-lining layer of the synovium.Expression of various transcription factors 
indicates that they proliferate locally in disease,contributing to synovial hyperplasia.SF in 
RA patients  show prolonged survival,and resistance to apoptosis.Intriguingly,they have 
been shown experimentally to have the potential to migrate between joints in 
experimental models,suggesting a possible route to disease progression in 
humans.Functionally, they adhere to cartilage via attachment to fibronectin,collagen type 
VI, and cartilage oligomeric matrix protein(COMP),and display an aggressive invasive 
behaviour.SFs are an abundant source of IL15,IL16,and IL17.They aiso secrete  
CXCL12,CXCL13, and members of the IL6 family(eg,IL11).These cytokines activate T 
cells  and  influence B cell migration and survival.Large amounts of secreted PGE2 
additionally  support inflammation.In addition, degradation of cartilage by SFs is due to 
the secretion of matrix  metalloproteinases(MMPs) and cathepsins.Specifically ,SF 
produce MMP-1,-3,-13,-14 and -15 as well as cathepsins B,K and L.These enzymes 
degrade extracellular  matrix providing a rich source of potential neo- antigens for T and 
B cell polyclonal proliferation. 
Bone degradation in RA is mainly mediated by osteoclasts.Osteoclastogenesis—
that is, the differentiation of osteoclasts from precursor cells –requires M-CSF and the 
presence of an osteoclast differentiation,as it was found that ODF and osteoprotegrin 
ligand(OPG-L) are identical to  RANKL(receptor activator of NFkB ligand) and 
TRANCE(TNF-related activation induced cytokine) molecules first identified in activated 
T cells.Meanwhile,synovium,and RANKAL –deficient mice are protected from bone 
destruction in experimental arthritis despite active infiammation.RANKAL is expressed 
not only by T cells,which thereby directly drive osteoclastogenesis,but also by neutrophils 
and in large amounts by SFs.TNFα accelerates this process by inducing RANKAL 
expression and enhancing RANKAL  signalling.Interestingly,Th1- and Th2- 
cytokines(IFNγ,IL4,IL10) as well as IL12 and IL18 inhibit osteoclastogenesis.IL 17 
however induces RANKAL expression in osteoblasts and might significantly contribute 
to osteoclast formation.  
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Figure No:3a.2.3.1 Development of rheumatoid arthritis(RA) 
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Figure No: 3a.2.3.2 Mechanism of the development of the immune 
response
 
Figure No: 3a.2.3.3 Factors contributing to osteoclastogenesis. 
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3a.2.4.Clinical aspect of rheumatoid arthritis: 
Introduction 
RA is the most prevalent chronic inflammatory joint disease.RA is a heterogeneous 
condition with a variable mode of disease onset and disease course.Some patients have 
very acute disease onset with  fever,polyarthritis and extra-articular manifestations, 
whereas other patients have a more gradual and insidious onset.The latter presentation is 
more common.Typical articular signs and symptoms include pain,stiffness and 
swelling.Redness and warmth of involved joints are less common findings.Concomitant 
tenosynovitis,bursitis,and even carpal tunnel syndrome may be present.RA is a systemic 
disease as manifested by generalised weakness,weight loss or low grade fever and extra-
articular features such as sicca syndrome,nodules,and interstitial lung fibrosis. 
A special type of RA has been called palindromic rheumatism.This clinical picture 
includes variable episodes of poly arthritis which suddenly may affect one or more large 
or peripheral joints.The duration  may be hours or a few days and then  spontaneous 
improvement  with complete disappearance of all rheumatic signs between attacks.About 
one third of these palindromic cases will eventually evolve into typical RA.Both 
prevalence and incidence rates are about two-to fourfold higher in women and symptoms 
are more severe than in men.The female:male ratio decreases with age.The reasons for the 
greater prevalence of RA among women have not been firmly established.A decline in the 
incidence has been especially apparent in women possibly as a consequence of some 
environmental factor such as the introduction of oral  contraceptives in the1960s.A shift in 
the incidence towards a higher age of disease onset has been observed across several 
cohorts. The incidence rate seems to increase with age up to a plateau of around 60 years. 
Disease onset 
Articular manifestations: 
  The typical joint involvement at disease onset is swelling of the proximal 
interphalangeal (PIP) joints, the Metacarpophalangeal(MCP) joints, the wrists and the 
Metatarsophalangeal(MTP) joints. However, the disease starts gradually with involvement 
of one or a few joints and then over time, develops from undifferentiated oligo-or 
polyarthritis into a more polyarticular, and classically symmetrical, disease.Sometimes, 
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the disease also starts with monoarthritis, for example,of the knee.The differential 
diagnosis depends on the pattern of joint involvement at disease onset.Sometimes, the 
disease onset may be similar to reactive arthritis, but polyarticular inflammatory OA is a 
more common differential diagnostic consideration,especially in patients aged 50 or over. 
Extra-articular manifestation: 
The dominating feature at disease onset is usually joint involvement. However, the 
disease may start much more dramatically with fever and inflammatory manifestation of 
internal organs, for eg, with pericarditis and pleuritis. In such cases, other systemic 
diseases may be the most important differential diagnosis, for eg, Systemic lupus 
erythematoses. Other extra-articular manifestations such as Sicca syndrome, nodules and 
interstitial lung fibrosis are more commonly seen in established RA. 
Symptoms: 
1.  Tenderness and pain in the inflammed joints. 
2. Joint stiffness while moving the joints. 
3. Swelling of the joints. 
4. Morning stiffness is a typical and common symptom. 
5. Fatigue and loss of energy. 
Clinical findings: 
The typical clinical finding of inflammed joints is soft tissue swelling and 
tenderness, and frequently, limited motion.Detection of synovitis is essential for the 
diagnosis. 
Symmetrical joint swelling is noted in finger joints, wrist joints, ankle joints and in 
the forefeet. 
As extra–articular manifestations are more commonly seen in established RA 
general physical examination is included in the clinical examination. Bibasilar inspiratory 
crepitations can point to underlying interstitial lung fibrosis. 
40 
 
A general organ examination is needed to find out concomitant diseases, since the 
intake of the related medications may result in an undesired harmful effect and worsen 
existing concurrent conditions.  
3a.2.5.Laboratory investigation: 
Typical findings are elevated erythrocyte sedimentation rate (ESR) and C reactive 
protein (CRP) concentration. Thrombocytosis and leucocytosis can be seen in active 
inflammatory disease. Reduced haemoglobin is also common. Serum iron mey be lowered 
whereas ferritin concentration may be elevated as a reflection of the acute phase reaction. 
Liver and kidney function tests as well as routine urine examination are included in 
the laboratory screening to rule out liver or kidney related abnormalities.  
Most importantly, tests for RF and anti-citrullinated peptide/protein antibodies 
(ACPA such as anti-CCP antibodies) are important both for the diagnosis and for the 
staging of the disease, since the presence of RF and ACPA are associated with a more 
severe disease course. Other immunological examinations may be important for 
differential diagnosis. It is common to test for the presence of antinuclear anti body 
(ANA), but the value of this test can be questioned if there is no clinical evidence of any 
systemic connective tissue disease. The presence of ANA has not been shown to have any 
prognostic value. However, secondary Sjogren‘s syndrome (anti-SSA and anti-SSB) may 
also be present in RA 
Imaging procedures: 
Ultrasonography may be helpful at disease onset to demonstrate synovitis of 
involved joints. Subclinical synovitis can be detected with ultrasonography and Doppler, 
but the clinical utility of this for clinical decision making remains to be established. At an 
early stage of the disease, it may also be useful to detect erosions of minor joints. X-ray is 
the gold standard conventional diagnostic to assess the joint damage, but the x-ray report 
of  absence of erosions does not rule out RA.  
Scoring system have been developed and validated to assess the extent of and 
changes in radiographic damage, such as the modified Sharp-van der Heijde score which 
is commonly used in clinical trials. 
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Magnetic resonance imaging (MRI) of wrist and finger joints may be an important 
tool for early diagnosis and staging of the disease. imaging procedure with gadolinium is 
performed to detect Synovitis.   
3a.2.6.Diagnosis:  
RA Clinical diagnosis based on the signs and symptoms that are considered typical 
of RA, and by excluding other diseases. The new EULAR/ACR classification criteria for 
patients with early arthritis to tailor treatment ,taking these prognostic markers in to 
account.(table  ) (Aletaha et al 2010) 
 
The ACR/EULAR 2010 classification criteria for RA
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              To be applied to patients: (1) who have ≥ 1 joint with definite synovitis, 
excluding the DIP joints, first MTP joints, and first CMC joints, and (2) in whom the 
synovitis cannot be explained by another disease. 
             Table No: 3a.2.6.1 The ACR/EULAR 2010 classification criteria for RA 
Criteria Score 
A. Joint involvement:  
1 large joint 
 
0 
2- 10 large joints
a 
 
1 
1-3 small joints( With or without involvement of large 
joints) 
 
2 
4-10 small joints
b
( With or without involvement of large 
joints) 
 
3 
             >10 joints(at least 1 small joints) 
 
5 
B. Serology(at least 1 test result is needed for classification): 
Negative RF and negative anti-CCP antibodies 
 
0 
Low-positive RF or low-positive anti-CCP antibodies
c 
 
2 
High-positive RF or high-positive anti-CCP antibodies
d 
 
3 
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C. Acute phase reactants: 
Normal CRP level and normal ESR 
 
0 
Abnormal CRP level or abnormal ESR 
 
1 
D. Duration of symptoms: 
<6 weeks 
 
0 
≥6 weeks  
 
1 
                        BT Score:                                                          AT Score: 
ACR, American College for Rheumatology; EULAR, European League Against 
Rheumatism; RA, rheumatoid arthritis; DIP, distal interphalangeal; MTP, 
metatarsophalangeal; CMC, Carpometacarpal; MCP, metacrpophalangeal; PIP, proximal 
interphalangeal; RF, Rheumatoid factor; anti-CCP, anti-cyclic citrullinated protein; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; BT-Before Treatment; AT-After 
Treatment. 
a
Large joints= shoulder, elbow, hips, knees, ankles. 
b
Small joints= MCPs, PIPs, Second-fifth MTPs, thumb IPs, wrists. 
c
Low-positive is ≤ 3 times the upper limit of normal 
d
High-positive is > 3 times the upper limit of normal. 
3a.2.7.Differential diagnoses:
38
 
The DD to be considered, depends on the clinical feature while onset of the 
disease. RA incidence increases with age and reaches a level around 60 years of age. This 
means that hand OA/generalised OA often will be the most frequent differential diagnosis 
to be considered in patient with a typical polyarticular disease with involvement of finger 
joints. The typical clinical feature which differentiates RA from hand OA is involvement 
of the MCP and wrist joints, which are very frequently involved in hand OA(except in 
cases with haemochromatosis). 
Polymyalgia rheumatic and calcium pyrophosphate deposition disease (CPDD) are 
also important differential diagnoses in elderly patients. RA in the elderly may start with 
symptoms of polymyalgia rheumatic and it is difficult to diagnose RA of elderly onset and 
polymyalgica rheumatic with existing arthritis. RF is often negative in these cases and 
large joints are most frequently involved than the small finger joints. 
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 A differentiation between inflammatory rheumatic disease and OA of large joints 
with secondary inflammation of synovial membrane can also be considered in these cases. 
RA should be differentiated from other inflammatory rheumatic diseases in 
younger patients. Reactive arthritis frequently involving knees, ankles and MTP joints and 
infrequently involving finger joints should be differentiated. Among the connective tissue 
diseases, SLE is the most frequent differential diagnosis. 
  Psoriatic arthritis and RF negative RA can also be difficult to differentiate. It is common 
to classify polyarthritis combined with the presence of RF as RA even if the patient has 
psoriasis, whereas RF negative arthritis combined with psoriasis is classified as psoriatic 
arthritis. 
    The incidence of various inflammatory arthropathies has been examined in Southern 
Sweden (Soderlin et al 2002) and in Finland, and these results highlight that many 
inflammatory arthropathies have to be considered in patients with recent onset joint 
swelling. 
Table no: 3a.2.7.1.Differential diagnosis of RA 
Psoriatic arthritis 
Spondyloarthropathies 
Polymyalgia rheumatic with peripheral arthritis 
Reactive arthritis 
Acute sacoid arthropathy(Lofgren‘s syndrome) 
Systemic lupus erythematosus 
Other connective tissue diseases 
Calcium pyrophosphate deposition disease 
Lyme arthritis 
In Table no 3a.1.7.1 the most common inflammatory joint diseases which are to be 
considered as differential diagnoses to rheumatoid arthritis are shown.   
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3a.2.8.Disease assessment 
              The EULAR disease activity and response criteria are based on the disease 
activity score, but several other scores mentioned below have been validated and are used 
in clinical practice.Core measures of disease activity include tender and swollen joint 
counts,patient and investigator global assessments of disease activity on a visual analogue 
scale(VAS), intensity of joint pain on a VAS, a patient- reported measure of physical 
disability(usually Health Assessment Questionnaire(HAQ)), and acute phase 
reactants(ESR and CRP)  
              Functional disability is most commonly measured by the Stanford HAQ, which is 
the most widely used instrument measuring disability in RA. The shortened version, the 
Modified Health Assessment Questionnaire(MHAQ),reduces the number of items from 20 
to eight,one for each of the eight components,and does not allow upgrading of scores by 
use of technical devices or  help by another person. 
              Joint damage is usually assessed by imaging modalities,using one of the accepted 
scoring systems to assess erosions and joint space narrowing.The most widely used 
systems are the Larsen score and the Sharp score(with modifications by Genant or van der 
Heijde).Clinical scores of deformities are also available. 
3a.2.9.Identification of prognostic markers 
              Since RA can have a variable disease course, it is of particular importance and 
relevance to identify markers that may predict the disease course.In the ideal scenario,  
one would be able to tailor treatment according to such indicators – that is,to treat patients 
with predictors of severe disease course aggressively,and to protect the patients with a 
potentially mild disease from drugs that are associated with severe adverse reactions.  
 Three different outcomes can be considered to be of particular relevance; radiograhic 
damage, functional disability, and mortality. Table no 3a.9.1 shows known predictors for 
these long term outcomes 
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Table no: 3a.2.9.1.Prediction of outcome in rheumatoid arthritis
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ACPA,anticitrullinated protein antibodies;HAQ,Health Assessment Questionnaire. 
 
 
 
Prediction of future physical 
disability(HAQ score) 
Prediction of structural 
damage 
Prediction of increased 
mortality 
HAQ score 
Age 
Acutephasereactants(?)        
Female gender(?) 
Level of education(?) 
Jointcounts(?) 
Rheumatoid factor(?) 
Erosive disease(?) 
                                              
Erosive disease 
Acutephasereactants 
Rheumatoid factor 
ACPA 
Jointcounts(?) 
Geneticmarkers(shared 
epitope) 
Female gender(?) 
Present HAQ score(?) 
Age 
Levelofeducation/coping 
Physical status 
Rheumatoid factor 
Comorbidities 
Extra-articular manifestations 
Gender(?) 
Jointcounts(?) 
Acute phase reactants(?) 
Structural damage(?) 
Use of corticosteroids(?) 
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3a.2.10.Recent onset arthritis 
  Patient should be monitored frequently,especially during the first year of the 
disease.Tight control of disease activity in this period is important to induce remission or 
achieve a low disease activity and to prevent future damage and disability,because of the 
relationship between level of inflammatory activity and future damage.This concept has 
been supported by several studies –for example,the TICORA study(Grigor et al 
2004).Patients who were followed by tight control of disease activity had less 
radiographic progression than patients followed by a regular follow-up regimen. 
3a.2.11.Established disease 
The clinical challenge in patients with established disease is different from recent 
onset or early RA. The joint involvement can be dominated by deformities as a 
consequence of longstanding inflammation and radiographic damage. It is also 
particularly important to be aware of the possibility of involvement of internal organs due 
to RA. 
3a.2.12. Involvement of hands: 
MCP and PIP joints are frequently involved. Deformities of the PIP joints usually 
result from lack of ligament support. 
Boutonnier’s deformity (Fig 3a.2.12.1): It describes a finger with flexion of the PIP joint 
and hyperextension of the DIP joint.  
Z-deformity (Fig 3a.2.12.3): The similar deformity of the thumb is also called the 90-90 
thumb because both the flexion of the MCP and the hyperextension of the IP joint may be 
90˚ which is otherwise called as Z deformity. 
Swan-neck deformity (Fig 3a.2.12.2): of the finger describes a hyperextension of PIP 
joint and a flexion of the DIP joints. 
Deformities of the MCP joints include volar sub luxation, which may be seen as a 
step, ulnar drift (often in combination with radial deviation of the wrist), and flexion 
deformities. 
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Wrist deformities include volar subluxation with a visible step opposite the 
radiocarpal joint and radial deviation of the carpus from the axis of the wrist and hand. 
Arthritis of the distal radioulnar joint results in instability and dorsal subluxation of 
the ulnar head with a ‗piano key‘ movement on downward pressure. A dorsally sub-
luxated ulnar head with erosive abnormalities will often mechanically lead to rupture of 
neighbouring tendons. 
 
Figure no: 3a.2.12.1.Boutonnier’s deformity 
   
Figure No 3a.2.12.2.Swan neck deformity 
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Figure No: 3a.2.12.3 Z deformity 
Elbow and shoulder 
The elbow joint   is frequently involved in established RA.Loss of extension is a 
typical early sign.Functionally, loss of supination is disabling when eating and performing 
daily activities.The other disabling limited motion is reduced flexion. This may lead to 
inability to reach hair, face, etc. 
Shoulder involvement in RA is not very frequent, but most patient with severe 
disabling RA also have shoulder involvement.Shoulder symptoms will usually appear 
when joint destruction has become advanced and will limit daily self-care 
activities.Synovitis leads to erosion and damage of both the humeral head and glenoid 
fossa. 
The long head of the biceps muscle may rupture.This can be detected by biceps 
bulge when the patient flexes the elbow against resistance.The rotator cuff can also 
frequently be involved with inflammation and destruction.Involvement of  the 
acromioclavicular joint is infrequent.The shoulder pain is infrequent.The shoulder pain is 
typically localised in the C4 region,whereas pain developing from the humerogleoidal 
joint or from the rotator cuff is typically perceived in the C5 region,including upper arm. 
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3a.2.13.Cervical spine 
Involment of the cervical spine is relatively rare but potentially life- threatening.The 
space between the odontoid process from C2 and the arch of the atlas normally measures 
3mmor less.If this space exceeds 5mm the condition is defined as atlantoaxial subluxation. 
Synovial involvement may also affect the apophyseal joints in the occiput atlantal 
area.The consequence of the synovitis in this area may be an atlanto-axial subluxation 
with neurological symptoms due to myelomyopathy. 
This deformity is important and should be detected before general anaesthesia. 
When a patient with RA requires surgery the presence of cervical subluxation presents a 
general anaesthetic risk.Routine cervical radiographs with the head in flexed positions is 
recommended before surgical procedures.Special precautions are required preoperatively 
to prevent cervical cord damage when atlantoaxial subluxation is detected. 
3a.2.14.Joints of the lower limbs 
Knee involvement is much more common in RA (3a.2.12.3). Synovial effusion is 
the typical sign of inflammatory activity of the knee.Patients with knee swelling have a 
tendency to assume a more comfortable position with the knee flexed, and if this becomes 
a habit ,a loss of full knee extension eventually results. 
Reduction of knee extension may be associated with a cyst of the popliteal region 
called Baker‘s cyst.This cyst can extend from its location in the gastrocnemius bursa 
down into the medial aspects of the calf.This is best seen when patients are standing. The 
baker‘s popliteal cyst arises as an extension from the joint cavity.Rupture of this cyst can 
give a general swelling of the calf and a clinical picture which mimics deep vein 
thrombosis.Destruction of the knee may lead to instability due to laxity of the collateral 
and cruciate ligaments.This laxity is detected by stressing the knee joint for lateral and 
medial collateral stability.A special problem arises in women with physiological 
valgus.This valgus increases the load on the lateral compartment and as the valgus 
increases due to arthritis the loading will also increase so that a vicious cycle is 
produced.Varus position is more common in OA than RA. 
         Within the foot ,the subtalar and mid-tarsal joints are more frequently involved than 
the ankle joint.The ankle is usually quite stable,but reduced dorsal flexion may interfere 
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with walking ability.The subtalar and talonavicular joints are commonly affected in 
RA.Synovitis causes pain and stiffness and will sometimes lead to subtalar dislocation.As 
cartilage loss and bone erosion develop,valgus deformity increases with progressive 
flattening of the longitudinal arch.Involvement of the MTP joints is common in RA 
causing pain and disability.Forefoot deformity starts with synovitis of the MTP joints and 
involvement of the flexor tendons,which can result in clawing of the toes and dorsal 
dislocation of the MTP  joints.The metatarsal heads can be destroyed due to the synovitis 
and can lead to extreme pain. 
3a.2.15.Other joint areas 
The temporomandibular joint may be involved with tenderness and painful 
limitation of mouth opening.Occasionally the cricoarytenoid joint may be involved and 
associated with hoarseness. The ossicles of the ear may also be involved with hearing loss 
independent of medication-induced effects.  
3a.2.16.Nodules, tenosynovitis, and bursitis:  
Subcutaneous nodules overlying the extensor aspects of the proximal ulna are 
present in about one quarter of the patients with RA.Subcutaneous nodules may form over 
other pressure locations such as the occiput, palms of the hands,and Achilles tendon. 
Flexor tenosynovitis can lead to loss of active flexion.A trigger finger is a frequent 
feature of flexor tenosynovitis.The pathology is a thickening of the tendon or may be 
stenosis of the tendon sheet.Flexor tenosynovitis is often also accompanied by a 
tenosynovitis of the carpal tunnel, which may lead to entrapment of median nerve and 
development of carpal tunnel syndrome. 
The synovial membrane lining the bursa  secretes synovial fluid and will develop 
rheumatoid synovitis.  Typical example of bursitis by RA is olecranon bursitis. 
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3a.2.17.Extra-articular manifestations and RA-related comorbidities 
Because of the systemic and chronic nature of the disease, patients with established 
RA are at risk of developing extra-articular manifestations such as subcutaeneous nodules, 
vasculitis, pericarditis, pulmonary nodules or interstitial fibrosis, mononeuritis multiplex, 
episcleritis or scleritis, and specific comorbidities including osteoporosis, premature 
atherosclerosis, muscle weakness, infections and cancer. 
3a.2.18.Secondary osteoporosis 
RA is associated with an increased generalised bone loss, as diagnosed by a reduced 
bone mineral density(BMD).RA in itself is directly associated with the increased 
occurrence of vertebral fractures.There is two-fold increase in the occurrence of 
osteoporosis both in RA males and females.It is generally assumed that osteoporosis is 
due to inflammation(eg,cytokine release with osteoclast activation),but use of 
glucocorticoids and immobility can also be risk factors in some patients. 
3a.2.19.Muscles 
Muscle weakness and atrophy is common in RA, often due to either neuropathy, use 
of steroids or less use due to joint involvement.  
3a.2.20.Secondary Sjogren’s syndrome 
Secondary Sjogren‘s syndrome is a typical manifestation of RA with sicca 
symptoms from eyes and also dryness of the mouth. 
3a.2.21.Other eye complications 
Scleritis, episcleritis or both occur in some patients with RA,but are rather 
infrequent.In episcleritis the eye becomes red within minutes.Unlike other inflammatory 
conditions of the eye,episcleritis results in no discharge other than tearing in response to 
great discomfort.Loss of vision does not occur as a direct result of episcleritis,but cataracts 
may develop secondarily and cause visual loss.Scleritis causes severe ocular pain and a 
dark red discolouration 
 
 
52 
 
3a.2.22.Infections 
The incidence of bacterial infections is increased in RA patients partly due to the 
disease itself, and partly due to the use of glucocorticoids and other drugs with 
immunosuppressive actions; in particular, the new anti-TNF drugs.It is important to be 
aware that RA in itself also increases the risk for septic arthritis.It can be extremely 
challenging to differentiate between an acute flare of arthritis or a septic arthritis.The most 
important examination is to culture the synovial fluid. 
3a.2.23.Cancer 
There is a slight increased risk of malignancy in RA patients, especially lymphoma 
in certain patient subsets. 
3a.2.24.Haematological abnormalities: 
Mild normocytic hypochromic anaemia is associated with raised ESR and the 
disease activity.A few of these patients respond to iron therapy.Folate and B12 deficiency 
may also be a cause of anaemia in RA. Similarly thrombocytosis is also frequent in RA 
and is related to disease activity. 
3a.2.25.Vascular complications 
Initial pathological changes in RA includes inflammatory changes in the small 
blood vessels.However, when talking about vasculitis as a complication, the focus is more 
on the arteries or arterioles  that lead to cutaneous ulceration or peripheral neuropathy or 
involvement of internal organs.Vasculitis is fortunately uncommon, but the presence of 
vasculitis is associated with disease severity and activity. 
3a.2.26.Renal complication: 
The kidney is rarely directly involved in RA but may be compromised by therapy. 
Both analgesics and non-steroidal anti-inflammatory drug(NSAIDs), as well as some 
DMARDs(eg,gold,ciclosporin), can affect renal function,resulting in elevated serum 
creatinine and/or proteinuria. 
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3a.2.27.Lung disease: 
There are several forms of lung disease in RA. Pleuritis can be seen both at 
disease onset and during the disease course and may be seen together with 
pericarditis.Interstitial pneumonitis and fibrosis is rather common in longstanding 
RA.Nodular lung disease can be seen but usually in patients who also have rheumatic 
nodules in other parts of the body and in smokers.Pulmonary hypertension is rare.  
3a.2.28.Heart disease 
As part of the inflammatory activity, pericarditis can be seen with RA and  often 
Co-existing with pleuritis.Myocardial and endocardial inflammations may also be present. 
3a.2.29.Arteriosclerosis 
Several studies have shown that patients with RA have an increased risk of clinical 
coronary heart disease(CHD) compared with age-and sex-matched non-RA subjects,and 
that this risk is maintained after accounting for traditional CHD risk factors(diabetes 
mellitus,hypertension,dyslipidaemia,body mass index,smoking). 
Some studies support the view that atherosclerosis is correlated to the level of 
systemic inflammatory activity over time and that the inflammatory process impacts on 
cardiovascular morbidity and mortality and accelerated coronary and extra-coronary 
atherosclerosis.The therapeutic consequence is that anti-inflammatory therapy would 
therefore reduce the risk, and some studies have shown that therapy with methotrexate and 
anti-TNF drugs may reduce cardiovascular morbidity and mortality. 
3a.2.30.Gastrointestinal complication 
RA does not affect the gastrointestinal tract directly.Gastroduodenal ulcers 
are,however,rather frequent due to use of NSAIDs,which is why proton pump inhibitors 
are routinely prescribed to RA patients on chronic NSAID therapy.Liver disease may also 
be secondary to drugs commonly used in RA—for example,methotrexate,diclofenac,and 
other NSAIDs as well as paracetamol. 
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3a.2.31.Secondary amyloidosis 
Secondary amyloidosis is an increasingly uncommon complication of RA.This is 
thought to be related to the implementation of more effective treatment strategies in 
RA.Amyloidosis results from the deposition in various organs of autologous protein in an 
insoluble fibrillar form,especially in kidneys.In patients with RA,excess serum amyloid A 
protein production is stimulated by the cytokines of the inflammatory 
response.Previously, renal amyloidosis was a rather frequent complication leading to 
Renal failure,dialysis and renal transplantation,and this should now primarily be regarded 
as treatment failure of RA itself. 
3a.2.32.Functional disability and its consequences 
  Important correlates of functional disability in RA patients include female sex, 
age, disease duration,and disease activity measures such as the Ritchie articular index and 
ESR,which can be considered predictors of a poorer functional status. 
          In addition to indicating a requirement for more aggressive treatment,high levels of 
disability have a negative impact on the psychological and social functioning of the 
patient,the consequences of which include mental distress,depression,and fatigue. 
Fatigue is also a significant and frequently debilitating problem for people with 
RA,as it contributes to work difficulties,personal injury,reduced ability to participate in 
rehabilitation programmes,and strained relationships. 
3a.2.33.Mortality 
Disease severity,activity and disability are strongly linked to mortality in RA 
sufferers, and other independent predictors include age,level of education,male 
sex,comorbidity,and usage of prednisone.The major contributing causes of death among 
RA patients are cardiovascular and cerebrovascular diseases.Some studies have indicated 
that RA currently is a milder disease than some years ago and also that the disease on 
average starts later than before.It is also assumed that the advances in treatment strategies 
and access to new therapies improves the health of patients with RA.However,it is still 
important to consider RA as a severe disease with a potential reduction in life expectancy. 
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3a.2.34.Rheumatoid Arthritis: Treatment 
DMARDs : Disease Modifying Anti-Rheumatoid Drugs: 
DMARDs constitute the backbone of RA pharmacological treatment and all patients 
with RA are candidates for DMARD therapy. The qualification, disease-modifying, is 
given to any antirheumatic drug that has a positive impact on radiological outcome of 
joint damage (erosion and joint space narrowing), which is considered the final common 
pathway of the different pathogenic mechanism that underlie RA.  
The synthetic DMARDs most commonly used include methotrexate (MTX), 
sulfasalazine (SSZ), leflunomide, hydroxylchloroquine(HCQ), and glucocorticoids. Those 
now rarely used, due to their unfavourable risk/benefit ratios, include azathioprine(AZA), 
gold, minocycline, ciclosporin and D-penicillamine.  
Table No: 3a.2.34.1.Rheumatoid Arthritis: Treatment 
Common Name Drugs Adverse reaction 
 
 
Synthetic 
DMARDs 
 
 
Methotrexate 
Probably safe to continue at least in low dose. 
Adverse reaction to MTX occur in half of 
treated patients, mainly comprise 
gastrointestinal complaints and mild 
transaminase elevation. 
 
 
 
 
Sulfasalazine 
Patients withdrew because of intolerable side 
effect of gastro intestinal symptoms or central 
nervous system toxicity(headache, dizziness) 
,4-5% of rash. Contra-indication with 
impaired renal or hepatic functions or blood 
dyscrasias. 
 
 
 
 
Leflunomide 
Teratogenic effect. Contra-indication to the 
use of leflunomide include liver disease, 
severe renal impairment, severe immune 
deficiency, and rifampicin therapy. Elevated 
liver enzymes, diarrhea, alopecia, high blood 
pressure, rash , penumonitis. 
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Glucocorticoids 
Osteoporosis, hyper- glycaemia, hypertension, 
skin fragility, peptic ulcer disease, premature 
atherosclerosis, cataracts, myopathy, 
osteonecrosis, infection, mood changes, sleep 
disturbances and weight gain. 
 
 
Hydroxychloroqui
ne/ chloroquine 
Retinopathy, impaired renal and hepatic 
functions, rash, abdominal cramps and 
diarrhea. 
Biological 
DMARDs 
 
Infliximab 
Contra-indication with systemic tuberculosis, 
allergic granulomatosis of the lung, or mild 
leucopenia. 
 
 
 
Adalimumab 
Upper respiratorytract infection, headache, 
sinusitis flu-like symptoms, pain and  reaction 
at injection site, skin rash, antibody 
development urinarytractinfection abdominal 
pain. 
 
 
Etanercept 
 
Redness, itching, pain, or swelling at the 
injection site may occur. 
 Certolizumab 
Shortness of breath, swelling ankles/feet, 
severe/unusual tiredness, 
easy bruising/bleeding,swollen joints, 
numbness/tingling of arms/legs, rash on nose 
and cheeks, eye pain, vision changes, 
dizziness, seizures. 
 Golimumab 
Cold symptoms like sore throat or redness,   
sneezing, stuffy nose,  itching, pain or 
swelling at the injection site,   dizziness. 
 Tocilizumab 
Runny or stuffy nose,sinus  pain, sore throat, 
headache, dizziness, itching, mild stomach 
cramps, or urinary tract infection (UTI). 
 Abatacept 
Nausea, diarrhea, stomach pain, indigestion; 
or headache, dizziness; cold symptoms such 
as stuffy nose, sneezing, sore throat, cough; 
back pain. 
 Rituximab 
Headache, fever, chills, stomach pain, nausea, 
diarrhea, heartburn, flushing. 
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3b. DRUG REVIEW: 
1. Seraankottai: 41 
Botanical Name: Semecarpus anacardium L.f  
Taxonomical classification: 
Kingdom: Plantae 
Subkingdom: Tracheobionta 
Super division: Spermatophyta 
Division: Magnoliophyta 
Class: Magnoliopsida 
Sub class: Rosidae 
Order: Sapindales 
Family: Anacardiaceae 
Genus: Semecarpus 
Species: Anacardium                    
Vernacular Names: 
Sans: Bhallaka ; Hindi&Beng: Bhela ;Tam: Shenkottai;  Eng:Marking-nut tree
42,43
 
It is katu, tikta, kashaya& ushna, anthelmintic,helpful in deranged kapha vata, 
intestinal affections, epistasis, polyuria &piles. 
Occurrence & Distribution: 
It occurs throughout the hotter parts of India including tropical outer Himalayas. 
Description: 
A Moderate-sized, dioecious, deciduous tree, exuding a dark juice, young branches, 
inflorescence, petioles and underside a leaves clothed with a fine pale pubescence, Leaves 
oblong-obovate, large, rounded at apex, cartilaginous at margin, very coriaceous, Flowers 
fasiculate, arranged in erect compound, terminal panicles, greenish yellow, Drupes 
obliquely oval or oblong, smoth, shining, purplish-black when ripe cup orange –red. 
Flowering at different times of the year, mostly during May-June. The Fruit ripens from 
November to February. 
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Part used: Fruits and bark 
Therapeutic uses: 
Fruits: in asthma, ascites, epilepsy, neuralgia, psoriasis and rheumatism, as 
abortifacient and vermifuge, decoction mixed with milk and butter, asthma, gout, 
hemiplegia, neuritis, piles, rheumatism, sciatica and syphilitic complaints, kernel is 
anthelmintic.Cardiotonic, carminative and digestive, oil used externally in gout, leprosy 
and leucoderma. 
Bark: 
Brownish gum exudates found useful in nervous debility and in leprous, scrofulous 
and venereal affections. 
Chemical constituents: 
Nicotinic acid, riboflavin,thiamine and the essential amino acids,arginine, 
histidine,isoleucine, leucine,lysine,methionine, phenylalanine,threonine,tryptophan and 
valine (fruits);nacardic acid ,aromatic amines,bhilawanols(1-pentadeca-
8
-enyl-2,3-
dihydroxy benzene) and 1-pentadeca-
7,10 –dienyl-2,3-di dihydroxy benzene,being the 
major components of more than sevenclosely related aromatic carboxylic acids(also from 
nut shell);biflavanoids A,B, and C,latter two characterized as 3,8-binaringenin and 3-8-
biliquisitigenin;tetrahydrobustaflavanone, tetrahydroamentoflavanone, nallaflavone 
(nuts); galluflavanone, jeediflavanone(nutshell);linolenic,myristic,oleic palmitic and 
stearic acids(kernel oil); amentoflavone (leaves)biflavones A&A also reported. 
Semecarpus anacardium Linn. (Family: Anacardiaceae), commonly known 
‗Ballataka‘ or ‗Bhilwa‘, has been used in various traditional system of medicines for 
various ailments since ancient times. Its nuts contain a variety of biologically active 
compounds such as biflavonoids, phenolic compounds, bhilawanols, minerals, vitamins 
and amino acids, which show various medicinal properties. The fruit and nut extract 
shows various activities like antiatherogenic, antinflammatory, antioxidant, antimicrobial, 
anti-reproductive, CNS stimulant, hypoglycemic, anticarcinogenic and hair growth 
promoter. The article reviews the various activities of the plant.
42
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Semecarpus anacardium is used for various medicinal properties. The fruit and nut 
extract shows various activities like antiatherogenic, antiinflammatory, antioxidant, 
antimicrobial, anti-reproductive, CNS stimulant, hypoglycemic, anticarcinogenic and hair 
growth promoter.  
Bhallataka should be used with caution since it is extremely hot and sharp in its 
attributes,. Individuals showing allergic reactions to it should stop and avoid the usage of 
Bhallataka. It should not be used in small children, very old persons, pregnant women and 
individuals of predominant pitta constitution. The use of the same should be restricted in 
summer season. For its allergic reactions like itching rash and swelling, the antidotes used 
externally are coconut oil, rala ointment, ghee, coriander leaves pulp or butter mixed with 
musta (Cyperus rotundus). The salt and spices should be strictly restricted and during 
Bhallataka treatment, exposure to sun, heat and excessive sex is to be avoided. The oily 
part of the nut is toxic and its degree of removal is proportional to its safety margin. 
Ramprasathet et al. investigated the antiinflammatory effects of SA nut extract on 
developing and developed adjuvant arthritis. Semecarpus anacardium significantly 
decreased the carrageenan-induced paw edema and cotton pellet granuloma. These results 
indicate the potent antiinflammatory effect and therapeutic efficacy of SA Linn. Nut 
extract against all phases of inflammation is comparable to that of indomethacin. 
Salvem et al. investigated that ethyl acetate extract of SA led to the isolation of  the 
major active principle, tetrahydroamentoflavone (THA), a biflavonoid. The in 
vitro cyclooxygenase (COX-1)-catalyzed prostaglandin biosynthesis assay of THA gave 
an IC50 value of 29.5 μM (COX-1) and 40.5% inhibition at 100 g/mL (COX-2). The in 
vivo carrageenan-induced paw edema assay resulted in dose-dependent antiinflammatory 
effect of THA and the activity was comparable to that of ibuprofen. 
Bhitre et al. prepared the methanolic, ethanolic, chloroform, ethyl acetate and 
petroleum ether extracts of fruits of SA and tested to study the anti-inflammatory activity 
using the technique of carrageenan-induced paw edema in albino rats. The extract showed 
significant antiinflammatory activity comparable to the reference standard 
aspirin.Satayavati et al. and Bajpai et al, reported the antiinflammatory activity of SA for 
both immunological and non-immunological origin. 
Singh et al. evaluated that SA extract can inhibit proinflammatory cytokine 
production. Crude ethanolic extract of SA nuts was studied for its antiinflammatory 
activities in vitro using peripheral blood and synovial fluid mononuclear cells of healthy 
individuals and rheumatoid arthritis (RA) patients. Semecarpus anacardium extract 
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inhibited the spontaneous and LPS-induced production of proinflammatory cytokines IL-
1beta and IL-12p40 but had no effect on TNF-alpha and IL-6 production, both at protein 
and mRNA level. The crude fruit extract ,also suppressed LPS-induced nuclear 
translocation of transcription factors, AP-1 and NF-kappaB; through the inhibition of I 
kappa Bα phosphorylation, the inhibition of NF-kappa B was attained. In mouse 
macrophage cell line, RAW 264.7, the extract also suppressed LPS-activated nitric oxide 
production .Premlatha et al. have been reported for immunomodulatory potency, 
antioxidative, membrane stabilizing, tumors marker regulative, glucose level restoring 
and mineral regulation properties of the nut extract in hepatocellular carcinoma and found 
to detoxify a potent hepatocarcinogen aflatoxin B1 and causes its metabolites to be 
excreted in urine. 
In the other case, they explained the therapeutic effects of extract on the changes 
associated with collagen and glycosaminoglycan metabolism in adjuvant arthritic Wistar 
rats. Decreased levels of glycosaminoglycans (GAGS) and collagen components 
(hyaluronic acid ,chondroitin sulfate, heparan sulfate,) and increase in the levels of 
connective tissue degrading lysosomal glycohydrolases such as beta-N-acetyl 
glucosaminidase, beta-glucuronidase, acid phosphatase and cathepsin-D observed in 
arthritic animals were reverted back to near normal levels upon treatment with SA. 
Ramprasath et al. found that nut milk extract modulates reactive oxygen/nitrogen 
species levels and antioxidative system in adjuvant arthritic rats. A significant increase in 
the levels of lipid peroxides (LPOs), ROS (superoxide radical, hydroxyl radical, H2O2 and 
myeloperoxidase) and RNS (nitrate + nitrite) observed in adjuvant arthritic animals were 
found to be significantly decreased on administration of the drug at 150 mg/kg body 
weight/day. Treatment with Semecarpus anacardium recovered the reformed antioxidant 
defense components to near normal levels. These evidences suggest that the SA 
preparations are mainly used for abnormalities produced during arthritis and to cure 
arthritis. 
Kalphaamrutha is a siddha medicine which has been reported for its potent 
antioxidant, antipyretic, analgesic properties. Mythilypriya et al. studied in adjuvant-
induced arthritic rat (AIA) model, the antiinflammatory activity of SA with reference to 
mediators of inflammation (lysosomal enzymes) and its effect on proteoglycans. The 
levels of plasma protein bound carbohydrate components of glycoproteins and activities 
of various enzymes were measured and their elevation in arthritic rats when compared to 
control animals was observed. 
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Krishnamurthy et al. developed Kalpaamruthaa (KA), a modified Siddha 
preparation, which contains SA Linn., EO and honey, and studied for the variations in 
lipids, lipid-metabolizing enzymes and lipoproteins in cancerous animals and the effect of 
KA on lipid metabolism. The increased levels of total cholesterol, free cholesterol, 
phospholipids, triglycerides and free fatty acids and decreased levels of ester cholesterol 
in plasma, liver and kidney found in cancer-suffering animals were reverted back to near 
normal levels on treatment with KA and SA. The effects of KA were found to be more 
effective than SA. 
Immunomodulatory effects
43
 of Semecarpus anacardium LINN. nut milk extract 
(SA) were investigated in adjuvant induced arthritis by studying the alterations in 
humoral and cell mediated immune responses and also the anti-inflammatory effects by 
evaluating the changes in paw edema, tumour necrosis factor (TNF-alpha), nitric oxide 
and myeloperoxidase activities. Pharmacological studies were also conducted with SA 
and indomethacin on experimental animals for evaluating the anti-inflammatory, 
analgesic, antipyretic and ulcerogenic activities. The alterations in humoral and cell 
mediated immunity were significantly reverted back to near normal levels on treatment 
with SA. The drug significantly reduced the elevation in the paw edema, TNF-alpha, 
nitric oxide and myeloperoxidase levels when compared with adjuvant induced arthritic 
animals, which shows the anti-inflammatory activity of the drug. SA showed strong anti-
inflammatory effects in xylene-induced ear edema and formalin-induced inflammation. In 
analgesic test, the extract elicited a potential activity on both acetic acid-induced writhing 
response as well as hot plate test showing its central and peripheral mediated action. The 
drug also elicited antipyretic action in yeast-induced hyperemia in rats. In addition, the 
extract did not produce any ulceration on gastric mucosa during ulcerogenic test and did 
not produce any serious adverse effects. All these effects are nearly similar to the 
activities of indomethacin except the ulceration where indomethacin produced significant 
ulceration. From this study, the protective immunological and pharmacological role of SA 
is demonstrated. 
Confirmation of Structure of Semecarpus biflavanone B by chemical studies ,a new 
biflavonoid Jeediflavanone-isolated from nut shells and characterized; galluflavanone 
isolated from nut shells and its structure determined; isolation and structure elucidation of 
semecarpus flavanone from nut shells.
43
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Plant extract showed direct depressant effect on isolated frog heart & rabbit 
intestine and antagonized spasmogenic effects of carbachol, histamine, barium chloride 
and pitocin, Trypan blue capillary permeability test was found to be positive. It produced 
delayed hypotension in dogs which remained unaltered after prior atropinisation. 
Bhilawanol from fruits was shown to be a mixture of cis and trans isomers of 
ursubenol.
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2. Etti    : 45,46 
Botanical name: Strychnos nux-vomica 
Taxonomical classification: 
Kingdom: Plantae 
Sub kingdom: Tracheobionta 
Super division: Spermatophyta  
Division: Magnoliophyta 
Class: Magnoliopsida 
Sub class: Asteridae 
Order: Gentianales 
Family: Loganiaceae  
Genus: Strychnos  
Species:  nux-vomica               
  It is used in bronchitis, diabetes, intermittent fever, dyspepsia, chronic 
constipation from atony of the bowels, chronic dysentery, atonic diarrhea, prolapses of 
the rectum, gouty, rheumatic, paralytic and neuralgic affections, worms, tobacco-
amaurosis, insomnia from over-fatigue, hydrophobia, bronchitis, emphysema, phthisis, 
impotency, spasmodic diseases, spermatorrhoea, excessive venery, alcoholism, opium 
and lead poisioning, nocturnal incontinence, retention of urine and externally headaches, 
swollen glands, odema of the hands feet and abdomen, rat bites and bites of venomous 
reptiles, muscular and chronic rheumatism, palsy and hypodermically in narcotic 
poisioning, chronic alcoholism and snakes-bites. 
Vernacular names: 
Sans: Kupilu, Kulaka, Vishamushti, Vishtindu: Eng: Nux-vomica or strychnine tree; 
Poison-Nut; Quaker button. Fr: - Noix Vomique. Ger: Gemeiner Brechnussbaum, Hindi: -
Jahar; Kuchla, Bom& Mah: Kajra, Kuchala, Tel: Mushti-vittulu Tam: Yetti; Yetti kottai 
Mal: Kanjiram, Can: Kasarkana mara, Kon: Karya-ruku Burm: Khaboung 
Habitat: This tree is wild and plentiful throughout tropical India, commonly in the jungles 
about Manbhoom, in the Madras presidency, Malabar and Coromandal coast, Cochin, 
Travancore, Southern India, Orissa and Ceylon. 
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Parts used: Stem-bark, dried ripe seeds called nux-vomica. 
Constituents: Indian nux-vomica seeds contain 2.6 to 3 % total alkaloids approximately, 
of which 1.25 to 1.5 p.c is strychnine. (Chopra); brucine is 1.7% and vomicine; Igasurine 
or impure brucine in combination with igasuric or strychnic acid; loganin, a glucoside 
(which is present also in pulp of the fruit); proteids 11 p.c., yellow colouring matter, a 
concrete oil or fat, gum, starch, sugar 6 p.c., wax, earthly phosphate and ash 2 p.c. Wood, 
bark and leaves contain the largest percentage of brucine, i.e. 3.1 p.c. Leaves contain 1/3 
rd p.c. Though the alkaloids occur in numerous species of Strychnos, they are not present 
in suffient amounts to serve as commercial sources.  
(Chopra). N.B:- Investigation shows that the alkaloidal content is not altered by 
long storage in a moist condition. Adulteration of the seeds with S.blanda, a non-
strychnine bearing seed, appears to be the real cause of the reported variation. 
3. Chukku  
Botanical name: Zingiber officinale, Roscoe  
Family: Scitaminae  
Part used: Scraped and Dried Rhizome  
Chemical constituents:  
Aromatic volatile oil having a characteristic odour and containing camphene, 
phellandrene, zingiberine, cineol and borneol; gingerol a yellow pungent body; an oleo-
resin-gingerin the active principle, other resins and starch; K-oxalate.  
Actions:  
Aromatic, carminative, stimulant to the gastro-intestinal tract and stomachic also 
sialagogue and digestive. Externally it acts as a local stimulant and rubefacient.  
 
Uses:  
Ginger is extremely valuable in dyspepsia, flatulence, colic, vomiting, spasms and 
other painful affections of the stomach and the bowels unattended by fever; for cold, 
cough, asthma, dyspepsia and indigestion. 
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4. Milagu: P.no:96945 
Botanical name: Piper nigrum, Linn  
Family: Piperaceae 
Part used: Dried unripe fruit   
Chemical constituents:  
A volatile alkaloid Piperine or pipirine ,Piperidine or piperidin, a balsamic volatile 
essential oil, fat, mesocarp contains chavicin, a balsamic volatile oil, starch, lignin, gum, 
fat ,proteids and ash containing organic matter .Chavicin is a soluble pungent concrete 
resin; It contains very little piperine and no volatile oil. Piperine crystallizes in flat, four-
sided glassy prisms insoluble in water. 
Actions:  
Acrid, pungent, hot, carminative also used as antiperiodic. Externally it is 
rubefacient and stimulant to the skin and resolvent. On the mucous membrane of the 
urethra it acts like cubebs; Piperine is a mild antipyretic and antiperiodic 
Uses:  
It is used in cholera, dyspepsia, flatulence, diarrhoea and various gastric ailments. It 
is used in constipation, piles, colic, gastric troubles, ascites, anaemia, worms, asthma, etc. 
5. Thippili: 45 
Botanical name: Piper longum, Linn. 
Family: Piperaceae 
Part used: Immature berries dried in sun.(dried unripe fruits or fruiting spikes) 
Chemical constituents: Resin, volatile oil, Starch, Gum, Fatty acid, In organic matter and 
an alkaloid, Piperine  
Actions: Stimulant, carminative, alterative, tonic, aphrodisiac, diuretic, vermifuge and 
emmenagogue. 
Uses: It relieves cough cold, asthma, hoarseness and hiccup.  
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6. Ellam: 45 
Botanical name: Elettaria cardamomum, Maton 
Family: Scitaminaceae  
Part used: Dried riped seed  
Chemical constituents: Fixed oil, essential oil, volatile oil of the seeds. It contains 
considerable amount of terpinyl acetate, cineole, free terpineol, limonene , potassium 
salts, starch, nitrogenous mucilage, yellow colouring matter, Ligneous fibre and ash 
containing manganese. 
Actions: Powerful aromatic, stimulant, carminative, stomachic and diuretic. 
Uses: It is used to treat nausea, vomiting, head ache, refrigerant, liquefies matter, 
resolvent, cardiac stimulant, absorbs moisture, expels wind, helps digestion, relieves 
hepatic colic. 
7. Cittrathai: 45 
Botanical name: Alpinia officinaram, Hance   
Family: Scitaminaceae 
Part used: Dried Rhizome 
Chemical constituents: Flavonoids Galangin, 3-O-methyl galangin, essential oil, 1, 8-
cineole, methyl cinnamate, ∞-cadinene, kaempferide, alpinin, galangol.  
Actions: Stomachic, stimulant, carminative. 
Uses: It is used to cure indigestion, vomiting sensation and gastric problems 
(sankarnarayanan 2009) 
8. Sadamanjil:  
Botanical name: Nardostachys jatamansi, DC 
Family: Valeriancaceae 
Part used: Rhizome 
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Chemical constituents: A volatile essential oil, resin, sugar, starch, bitter extractive matter 
and gum. 
Actions: Bitter taste, aromatic, anti-spasmodic, diuretic, emmenagogue, nerve sedative, 
nerve stimulant, tonic, carminative, deobstruent, sedative to the spinal cord, promotes 
appetite and digestion. 
Uses: Tonic for heart, liver, brain. It removes obstruction, diuretic and emmenagogue, 
jaundice and to treat stone in kidney. 
9. Akkiragaram: 
Botanical name: Anacylus pyrethrum, DC 
Family: Compositae  
Part used: Root  
Chemical constituents: It contains essential volatile oil and an alkaloid pellitorin or 
pyrethrin. 
Actions: Cordial, stimulant and sialagogue. 
Uses: Root is a valuable sialagogue and is regarded as a tonic to the nervous system. It is 
powerful irritant. A decoction of the root is useful as a gargle in sore throat, tonsillitis, 
carious teeth and toothache,. It has been given in paralysis, hemiplegia, epilepsy, chorea 
and rheumatism and a host of other diseases. An infusion of this drug is useful in cases of 
rheumatism.  
10.   Amukkura:  
Botanical name: Withania somnifera, Dunal. 
Family: Solanaceae 
Part used: Roots 
Chemical constituents: Plant growing in southern Europe is found to contain a bitter 
alkaloid somniferin having hypnotic property, also has resin, fat and colouring matters. 
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Actions: tonic, alterative, astringent, aphrodisiac and nervine sedative. Root is also 
diuretic and deobstruent. 
Uses: Root is used as an application in obstinate ulcers and rheumatic swellings. Root is 
used to treat all cases of general debility, senile debility, emaciation of children, 
rheumatism, brain-fag, loss of memory, nervous exhaustion, loss of muscular energy and 
spermatorrhoea. It infuses fresh energy and vigour in a system worn out owing to any 
constitutional disease like rheumatic fever etc. 
11.   Avuri: 47 
Botanical name: Indigofera tinctoria, Linn. 
Family: Papilionaceae  
Part used: Leave 
Chemical constituents: Indican(a glucoside) the oxidized form of Indigo-white, the 
product obtained by the fermentation of the fresh green plant. 
Actions: The plant is stimulant, alterative, deobstruent and purgative. Indigo is anti-septic 
and astringent. 
Uses: It is used for enlargement of liver and spleen, epilepsy and other nervous infection.  
It is used for haemostatic sedative, piles, healers of ulcers, diuretic, dropsy. 
12.   Thalisapathri: 45 
Botanical name: Taxus baccata, Linn 
Family: Coniferae 
Part used: Leaves 
Chemical constituents: Alkaloid (taxine), Volatile oil, tannic acid, gallic acid  
Actions: Carminative, expectorant, stomachic, tonic, anti –spasmodic. 
Uses: Asthma, haemoptysis, epilepsy and other spasmodic affections. 
13. Siruthekku: 
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Botanical name: Premna herbacea, Roxb 
Family: Verbenaceae 
Part used: Root 
Chemical constituents: Root contains an orange brown acid resin, trace of alkaloid, 
starch.   
Actions: Stimulant, alterative, bitter stomachic  
Uses: Cough, asthma, fever, dropsy and rheumatism. 
14.   Kurosani omam: 
Botanical name: Hyoscyamus niger Linn. 
Family: Solanaceaea 
Part used: Seeds 
Chemical constituents: Hyoscyamine, empyreumatic oil. 
Actions: Narcotic, anodyne, digestive, astringent and anthelmintic 
Uses: A paste of seed in brandy or in wine is applied to gouty enlargements, inflamed 
breasts and swollen testicles. Internally is used for cough, asthma, gout along with 
henbane seeds and poppy seeds. 
15.   Vaaividangam:  
Botanical name: Embelia ribes Burm. 
Family: Myrsinaceae 
Part used: Fruits or dried berries 
Chemical constituents: Embelic acid, volatile and fixed oil, colouring matter, tannin, a 
resinoid body and alkaloid called Christembine. 
Actions: Carminative, anthelmintic, stimulant, and alterative. 
Uses: It is used to expel intestinal worms especially tape-worms. 
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16.   Athividayam:  
Botanical name: Aconitum heterophyllum, Wall 
Family: Ranunculaceae 
 Part used: Dried tuberous roots 
Chemical constituents: Amorphous intensely bitter alkaloid, atisine which is non-toxic, 
aconitinic acid, tannic acid, starch, fat, mixture of oleic, palmitic, stearic glycerides.  
Actions: Bitter, tonic, astringent, stomachic, antiperiodic and aphrodisiac. 
Uses: Very efficacious in diarrhoea, dysentery, acute inflammatory affections. 
17.   Jathikkai: 
Botanical name: Myristica fragrans, Houtt   
Family: Myristicaceae 
Part used: Dried seed nut meg 
Chemical constituents: Kernel(nut meg) contains a volatile oil, fixed oil(myristin,myristic 
acid), proteoids, fat, starch, mucilage, and ash  
Actions: aromatic, stimulant, carminative in large dose narcotic. anti-inflammation 
Uses: Concrete oil of nut meg is used as a good liniment for chronic rheumatism,paralysis 
and sprains.    
18.   Jathipathiri: 
Botanical name: Myristica fragrans, Houtt   
Family: Myristicaceae 
Part used: Arill 
Chemical constituents:  It contains Volatile oil, fixed oil, essential 
oil(myristicene,myristicol), resin, fat, sugar, destrin and mucilage. 
Actions: Rubefacient, stimulant, aperient and carminative. 
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 Uses: The medicated oil of this drug is useful in relieving painful cramps in cholera. 
19.   Karunjeeragam: 
Botanical name: Nigella sativa, Linn. 
Family: Ranunculaceae  
Part used: seeds  
Chemical constituents: Seeds contains yellowish volatile oil and fixed oil, essential oil, 
albumen, sugar, mucilage, organic acids, metarbin, toxic glucoside, carvone, terpene or d-
limonene (carvene), Cymene.  
Actions: aromatic, diuretic, diaphoretic, anti-bilious, stomachic, stimulant, carminative, 
digestive, anthelmintic and emmenagogue. Oil is locally anaesthetic. 
Uses: Seeds form a very useful remedy in worms, external application for skin diseases. 
20.   Jeerakam: 
Botanical name: Cuminum cyminum Linn 
Family: Umbelliferae  
Part used: seeds 
Chemical constituents:  It contains fatty oil, resin, mucilage, gum, protein compound 
malates, essential oil (thymine, carvone, cuminol, cumic aldehyde,cymene, cymol,terpene 
etc 
Actions: Carminative, aromatic, stomachic, stimulant and astringent 
Uses: It is used for hoarseness of voice, dyspepsia, chronic diarrhoea. 
21.   Ilavangam:  
Botanical name: Eugenia caryophyllata.  
Family: Myrtaceae 
Part used: Flower bud  
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Chemical constituents: Eugenol, acetyl eugenol, beta-caryophylline, vanillin, crategolic 
acid, tannins, gallotannic acid, metyl salicylate, flavonoids eugenin, kaempferol, 
rhamnetin, eugenitin, triterpenoids, oleanolic acid, stigmasterol, campesterol, 
sesquiterpenes and metyl- amyl-ketone. 
Actions: Local anesthetic, anti-spasmodic. It also has carminative, stomachic, anti-septic.    
Uses: It is used to cure head ache, tooth ache and gum problems. It cures flatulence and 
improves digestion.  
22.   Chevviyam:45 
Botanical name: Piper nigram, Linn 
Family: Piperaceae 
Part used: root 
Chemical constituents: 
It contains volatile alkaloid piperine, piperidine, piperidin, volatile oil, chavicin, starch, 
lignin.   
Actions: Acrid, pungent, hot, carminative, anti-periodic. Piperine is a mild anti-pyretic 
and anti-periodic. 
Uses: cholera, flatulence, diarrhoea and various gastric ailments. 
23.   Kattu milagu: 48 
Botanical name: Piper attenuatum Buch.-Ham  
Family: Piperaceae 
Part used: Dried fruit berries  
Chemical constituents: Pipoxide chlorohydrin, galbelgin, 8-hentriacontanol, several 
aristolactams and 4, 5-dioxaporphines. 
Actions: Anti-cancer, Antioxidant, aromatic, stimulant, stomachic, carminative. 
Uses: It is effective for head ache and muscular pains. 
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Tyagi and Kanaya Lal Dhar. Estimation of crotepoxide in the fruit of Piper attenuatum 
Buch.-Ham. Using HPTLC and APLC. Current Pharmaceutical Analysis, 12(4):343-348. 
24.   Chithramoolam: 
Botanical name: Plumbago zeylanica, Linn. 
Family: Plumbaginaceae 
Part used: root 
Chemical constituents: 
Roots contains an acrid crystalline Plumbagin 
Actions: Alterative, gastric stimulant, appetiser in large doses, it is acro-narcotic poison. 
It has a specific action on the uterus. 
Uses: It is used as a rubefacient, application in rheumatism, paralytic affection and in 
enlarged glands.  
25.   Thippli Kattai:  
Botanical name: Piper longum, Linn 
Family: Piperaceae 
Part used: stem 
Chemical constituents: Roots contains resin, volatile oil, starch, gum, fatty oil, inorganic 
matter and an alkaloid piperine. 
Actions: Stimulant, carminative, alterative, tonic, aphrodisiac, diuretic, vermifuge and 
emmenagogue.  
Uses:  Immunomodulatory and antitumor activity 
 
26.   Kasakasa:  
Botanical name: Papaver somniferum, Linn 
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Family: Papaveraceae 
Part used: seeds 
Chemical constituents: linoleic acid, oleic, and palmitic acid 1-Pentanol, 1-hexanal, 1-
hexanol 2-pentylfuran and caproic acid could be identified as the main volatile 
compounds in all examined poppy seed oil. 
Actions: Hypnotic, tonic to brain. 
Uses: It is used to treat urinary diseases. 
 
27.    Shombu: 
Botanical name: Foeniculum vulgare, Gaertn. 
Family: Umbelliferae 
Part used: seeds 
Chemical constituents: Essential oil. 
Actions: Stimulant, aromatic, carminative, diuretic, emmenagogue and purgative. 
Uses: It is used to cure amenorrhoea, vomiting and indigestion. 
28.    Naervaalam: 
Botanical name: Croton tiglium, Linn 
Family: Euphorbiaceae 
Part used: Seeds 
Chemical constituents: Fatty fixed oil, tiglinic acid,  crotonic or quartenylic acid and 
croton oil; fats present in croton oil are glycerides of stearic,palmitic,myristic,lauric acids. 
Actions: purgative, vermifuge, stimulant. 
Uses: It is used in dropsy, cerebral affections like apoplexy, convulsions. 
29.    Palm jaggery: 49 
Botanical name: Borassus flabellifer L. 
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Family: Arecaceae 
Part used: Palm jaggery 
Chemical constituents: good source of vitamin B complex and contains ascorbic acid  
Actions: Liver tonic, Digestive, Blood purifier, Anti-oxidant, Muscle relaxant, 
Aphrodisiac 
Uses: It prevents diseases like anaemia. It contains essential nutrients like magnesium and 
potassium which are vital for proper functioning of the nervous system and regulate blood 
pressure and heart functions respectively.   
30.    Kungumapoo: 50 
Botanical name: Crocus sativus L.  
Family: Iridaceae 
Part used:  Dried styles and stigma  
Chemical constituents: Saffron contains more than 150 volatile and aroma-yielding 
compounds mainly terpenes, terpene alcohol, and their esters, crocin, picrocrocin and 
safranal.  
Actions: Anti-hypertensive, anti-convulsant, anti-tussive, anti-genototoxic, anti-oxidant, 
anti-depressant, anti-nociceptive, anti-inflammatory, relaxant.   
Uses: It is used for various kinds of mental illnesses. The crude extract of pistils of 
saffron increases regaining in ischemia, reperfusion injury, memory and learning in rats.   
31.   Padikaram:51 
Common Name: Alumen 
Source: Chiefly found with peroxide of iron in silajit or in alum earths of Nepal or 
prepared from the alum shales in the Punjab, Rajputana, Bihar. Alum is a common term 
for a class of double sulphates holding aluminium and such metals as ammonium, 
potassium , iron etc.. 
Characters: Colourless, transparent crystals, with acid, sweetish astringent taste. 
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Action: astringent, caustic, haemostatic, anti-spasmodic and anti septic, irritant and 
purgative in large doses. 
Uses: It is useful in leucorrhoea, haematuria, haemoptysis, menorrhagia, gastric and 
intestinal catarrh and other haemarrhages. 
32.   Vellaiphasanam:  
Common Name: Arsenum; Acidum arseniosum  
Source: Found in arsenical ores such as arsenates of iron, nickel or cobalt; commercial 
arsenious acid is obtained by roasting the native ores in the form of a sublimate. The 
metal, arsenic is widely distributed in nature but in small quantities. 
Characters: Solid, heavy white powder or stratified masses or minute transparent and 
glass-like crystals, tasteless, soluble in water, in boiling water, in glycerine, very slightly 
in alcohol, in alkalies and their carbonates and in hydrochloric acid.  
Action: It is stomachic, nervine tonic, alterative and anti-periodic and cardiac, respiratory, 
intestinal and sexual stimulant. 
Uses: It is used in variety of disease; but chiefly in fever, either alone or combined with 
other substances. 
33.    Gowriphasanam: 52 
Common Name: Arsenic penta sulphide 
Source: vaippu sarraku ; obtained by isolation from yellow arsenic trisulphide 
Characters: It is classified into three types –red, yellow and white arsenic penta sulphide 
Action: Anti-pyretic, anti-periodic and anti-vata 
Uses: The golden coloured padaana cures Kapha, delirum, vatha diseases, scabies, 
poisonous bites, disorders of three humors, various toxicity, haemorrhage and eight types 
of throbbing pains. 
34.    Kuthiraipal pashanam:51 
Common Name: Orthoclase feldspar; Potassium aluminium silicate 
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Source: It is natural padaana. In zoological department it is categorized under silicate 
group.   
Characters: Greenish, greyish, yellowish, white pink colour. It can be an hedral and 
euhedral. Grains are commonly elongated with a tubular appearance. Hardness 6-6.5; 
vitreous;diaphenity- Transparent to translucent. 
35.   Kalmatham: 
Common Name: Erythrite; Hydrous cobalt arsenate 
Source: It is a natural ore categorised under uprasam. Erythrite is a mineral of secondary 
origin, found commonly in the upper portion of cobalt mineral deposits. 
Characters: In zoological department it is categorised under Arsenate group. crimson and 
peach red sometimes grey in colour. hardness-1.5-2.5: crystals prismatic and vertically 
striated, also in globular and reniform shapes having a drusy surface and a columnar 
structure. 
Uses: It is used to cure diseases in neck region, urogenital diseases, venereal diseases and 
urolisthisis.  
36.    Thalagam: 52 
Common Name: Orpiment; Arsenii trisulphidum  
Source: It is native to China and Persia. 
Characters: It occurs in two forms viz., in smooth shining, gold-coloured scales called 
Vansapatri haritala and in fine lemon yellow opaque masses called pinda haritala.  
Action: Alterative, febrifuge, emmenagogue, anti-periodic.  
Uses: It is given as a cure for fevers and skin diseases. It is used for asthma, paraplegia, 
hemiplegia, monoplegia and facial paralysis, in cough, chronic fever, gonorrhoea, 
epilepsy, dropsy etc. 
37.    Manoislai: 
Common Name: Red orpiment; Arsenic Disulphidum-Bisulphuret of arsenic realgar  
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Source: vaippu sarakku  
Characters: Short prismatic small from druses also found is granular and earthy 
aggregates and powdery coatings; Aurora red to orange red; Resinous; varying from 
Orange-red to aurora red Transparent-translucent. 
Uses: It is effective in the treatment of skin leprosy, fever with chills, asthma, eye 
diseases, urinary tract infection, kapha diseases, cervical adenitis etc. 
38.    Rasam: 
Source: Mercury is sometimes found in nature in its free form of small, shining, silvery 
globules called as quick silver. But it is mostly found as sulphide or native cinnabar. It is 
scattered through different kinds of stones, clay or ores. 
Characters: It is a shining ,sliver-white metal liquid at ordinary temperature divisible in to 
spherical globules, mobile, without any odour and taste, slowly volatilizing at ordinary 
temperature; insoluble in water, hydrochloric acid and hot sulphuric acid. 
Action: It is used as a tonic, alterative, purgative, indirect cholagogue, anti-
phlogistic,anti-septic and sialagogue. 
Uses: Syphilis, small amount of mercury diminish the amount of oxidation of the tissue. 
39.    Rasa sindooram: 
Common name: Red sulphide of mercury 
Source: Red sulphide of mercury is commercially prepared by combination of mercury 
and sulphur. 
Characters: Its properties and actions are more or less similar to cinnabar  
Uses: It is used to cure scabies.  
40.    Lingam:52 
Common name: Cinnabar; Red sulphide of mercury,  
Formula: Hgs; Sulphur -13.8, Mercury-86.2  
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Source: It occurs in nature as a mineral ore, in many parts of the world, particularly in 
California, China and Spain. Cinnabar is the only common mineral of mercury. It is 
usually associated with antimony, pyrite, the sulphide of copper, stibnite, realgar and gold 
Characters: Bright dark red; hardness-2-2.5;  
Action: Tonic. It has the properties of curing diseases caused by the earth and the water 
elements. 
Uses: It is used to cure skin diseases, arthritic pain, peptic ulcer, fever, anaemia and 
bronchial asthma.  
41.    Pooram: 
Common name: Rasa karpooram; Calomel; Hydrargyrum subchloride;  
Source: It is prepared by the combination of rasam and salt. 
Characters: It has hot potency and salty taste. 
Action: Laxative, tonic, anti-septic, diuretic properties. 
Uses: It cures throbbing pain in the lumbar region, burning sensation, ulcer due to 
disorder of vatha humour, hepatomegaly, pyrexia, jaundice, basillary dysentery, dropsy, 
chronic ulcers, venereal diseases, indigestion, vomiting, diarrhoea, worm infestation, 
rheumatism, itching, constipation, scabies etc. 
 
42. Gandhagam: 
Common name: Sulphur 
Source: A non-metallic element found free in the bed of gypsum and in state of 
sublimation in region of extinct volcanoes; also in combination with several ores called 
pyrites, as sulphates and sulphides of iron, copper, lead, zinc, mercury etc .In India it 
occurs naturally in some parts, in Nepal, Kashmir, Afghanistan and in Burma. 
Characters: It is bitter and has an astringent taste. It is yellow, straw and honey yellow, 
yellowish brown, greenish, reddish to yellowish grey in colour. Its hardness is 1.5-2.5.   
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Action: Laxative, tonic, anti-septic. It increases various secretions of the body including 
that of the skin.  
Uses: It is used to treat 18 types of skin diseases, liver enlargement, abdominal distension, 
eye diseases, chronic venereal diseases, chronic diarrhoeas, gastric ulcers, poisonous 
bites, fever due to vatha, chronic dysentery etc. 
43.   Pooneeru: 
Common name: Fuller‘s earth -Impure sodium carbonate-Hydrated carbonate of sodium 
and calcium. 
Formula: Na2CaCo32H2O 
Source: It is present in brackish soil. It is collected from brackish soil during winter 
season and in early the morning before sunrise. It is collected from Sivaganga, Kalasthiri 
and Mosur from the earth in the dew season, before sunrise. 
Characters: orthorhombic, White colourless, Conchoidal, Easily fusible 
Uses: It is used to purify the tortoise shell, egg shell, pearl oyster, Asbestos, fosil of crab 
and conch shell. Arsenic compound may be purified with solution prepared from 
pooneeru. Chunnam form of pooneeru promotes the action of the medicine. It is used to 
cure arthritis. 
It is the one of the main ingredients in Muppu and Saint Bogar suggested that purified 
pooneeru considered as muppu as per text Bogar muthallayiram.     
44.   Mayilthutham: 
Common name: Blue vitriol: Copper sulphate 
Source: Copper sulphate is available in nature and is also synthesized chemically.  
Action: Powerful astringent, emetic and anti-septic. 
Uses: It is used to cures ulcers, eye diseases, disorders of three humors,fever and mouth 
diseases . 
45.   Paalthutham: 
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Common name: White vitriol, Zinc sulphate 
Action: It has got body strengthening, astringent and emetic properties. 
Uses: It is used for douching white discharge, eye diseases, piles.To induce vomiting in 
case of poisoning.   
46.   Pachaikarpooram: 
Common name: Borneo camphor  
Source: Natural source. 
Characters: It is soluble in atmospheric air. It has pleasant odour. Cooling agent.  
Action: This has astringent and salty taste. Its potency is cold, and has expectorant tonic, 
and demulcent properties. 
Uses:  It is effective in eight types of gastric ulcer, vatha diseases and joint pains and 
kapha. 
47.   Kalnar: 
Common name: Asbestos 
Source: It is available in nature. In India, it is available in plenty in Karnataka state. It is 
also available in plenty in Japan and is taken out from the earth.  
Characters: Its look like a stone and when crushed it becomes a fibre like material. 
Action: Diuretic and bitter properties. 
Uses: It is used to treat rheumatism, disease of teeth, gingivitis, urethritis, urinary 
retention, bilious vomiting, dysuria, spermatorrhoea, indigestion, hernia, thirst due to 
bilious etc. 
48.   Ponnimilai: 
Common name: Gold Bismuth; Chalcopyrite 
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Source: Bismath is formed as kalimbu paste when the metals like gold, silver, copper and 
lead are melted. Chalcopyrite, the most important Cu ore mineral, is widespread and 
common. It is present in most sulphide deposits. Hardness is 3.5  
Characters: Brass yellow, Honey yellow 
Action: Astringent, tonic, sedative and alterative properties. 
Uses: It improves spermatogenesis and controls excess pitha and apoplexy. It is given 
internally for gunmam, diarrhoea and dysentery. It is applied externally for skin diseases 
and on the fissures of lips and nipples. 
49.   Nandukkal: 
Common name: Fossil Stone Crab; Fossilo ferrus limestone  
Source: It is present in nature in sea shores. Limestones are mainly of the biogenic origin. 
They are formed at the expense of calcareous skeletons and remnants of shell of 
organisms. Shell and skeletons of organisms may either be fully preserved or may appear 
to have been crushed, disintegrated and recrystallized. 
Characters: Crinoidal limestone consist of particles of calcareous skeleton of marine 
crinoids. 
Action: diuretic 
Uses:  It is used in the treatment of stranguary, urinary calculus, chronic ascites, 
gonorrhoea, leucorrhoea and phlegm. 
 
50.   Gorosanam: 
Common name: Ox-Bile 
Source: The bile of Cow. 
Action: The bile has got bitter, laxative, mucolytic and hypothermic properties. 
Uses: It is used for the treatment of Reddish syphilis with the breast milk or leaf juice of 
anisochilus carnosus(Karpooravalli). It is given in cow‘s milk, twice a day for small pox. 
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51.   Then:  
Common name: Honey 
Source:  Honeybees absorb the sweet substance from flower and store in the honey- sac 
present in their body. The sweet substance undergoes some changes in the honeybees to 
form the honey. 
Characters: Sweet and appears as a clear yellow liquid. 
Action: Anti-inflammatory, Laxative, bitter, Mucolytic, Appetite stimulant, nutritious and 
sedative properties.  
When given to children, it acts as a mild diuretic and reduces flatulence. 
Uses:  It is useful for preparation of various medicaments such as leghium, syrup, 
mezhugu, kattu and collyrium. 
It is also the best adjuvant for parpam, chendooram, chooranam, pills and decoction. As 
an ambrosia it maintain the body health, besides curing the diseases caused by vatha, 
pitha, Kapha 
52.   Pasunei:  
Common name: Cow‘s ghee  
Source: Milk product from cow‘s milk. 
Action: It controls thirst, vomiting, excessive pitha, burning sensation of the stomach, 
pitha hiccup, abdominal pain, dryness, prickly heat, cough, hyper motility of the gut, 
weakness of bones, piles ect. 
Uses: If ghee is added to the usual diet, it helps in proper digestion and utilisation of the 
diet and gives strength and vigour to the body. 
53.   Pasunchanam: 
Common name: Cow‘s dung  
Source: Excretory product of the cow. 
Characters: greenish paste consistency material. 
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Action: It reduces the swelling controls haemorrhage, worm infestations, Kapha 
associated fever and excessive thrist. It keeps the body purified and it is equivalent to 
coconut milk. 
Uses: The liquefied cow dung is used as an antidote for paadanas and the dung of young 
cow, which has not given birth to a calf, can be given internally to counteract poisioning 
due to scorpion bite. It is also used for the purification of croton tiglium and semecarpus 
anacardium and is also useful for making kavasam and dung puda. 
 Prepared Rasa Chendooram: Impcops Vaidhiya yoga ratnavali P.no: 402-403 
Drug Required: 
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1. Rasa Sunddhi  -Mercury purified    -    Part 1 
2. Gandhaka suddhi  - Sulphur Purified    - Part 1 
3. Karpasa puspa Rasa  -   Red Cotton plant flower juice  - Q.S 
4. Kumari svarasa   -   Aloe juice   -Q.S 
Preparation: 
 Mercury and sulphur were ground to prepare the black sulphide of fine consistency.  To 
this, drug 3 was added and ground with drug 4. The product was dried and powdered. The 
process of sublimation had been spread over 3 days. 
Action and uses: Vitaliser and appetiser; Gives for fevers. Used in weakness and cough in 
children with the powder of three pungents and withania roots with milk. 
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MATERIALS AND METHODS 
 
STANDARD OPERATING PROCEDURE FOR NANDHI MEZHUGU:
54,55
 
 
Preparation of the drug Nandhi Mezhugu: 
5.1 Collection of Raw Drugs: 
The required raw drugs for the preparation of Nandhi Mezhugu were procured 
from the ―Indian Medical Practitioner‘s Co-operative Society Pharmacy and Stores‖ 
(IMPCOPS) Chennai 41 
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5.2 Raw drugs Identification and authentication: 
Herbal raw drugs were authenticated by Pharmacognosist, the metals and mineral 
raw drugs were identified and authenticated by Chemist, Siddha Central research 
Institute, Arumbakkam, Chennai-106.  
5.3 Purification processes of ingredients of NM: 
56,57,58
 
The ingredients were purified as per the technique stated in the Siddha literature. 
The raw drugs were purified at the Indian Medical Practitioner‘s Cooperative Pharmacy. 
1. Purification of Pooram: 
    The poultice made of betel leaf and pepper i.e betel leaf -4 parts, pepper-4 parts 
were dissolved in 1.3 litre of water.  Pooram(Calomel) -1 part was    tied in a cloth and 
immersed in the liquid from the cross bar and heated. After the water was reduced to ¾ of 
its volume, the calomel was taken out, washed with water and dried to get it its purified 
form. 
2. Purification of Seemai Kalnar: 
Asbestos was soaked in cow‗s urine for 10 days and then washed and dried  
3. Purification of Gandhagam : 
Sulphur was placed in an iron spoon. A small quantity of cow‘s butter was added 
and the spoon was treated to heat till the butter melted; this mixture was immersed in 
cow‘s milk. This procedure was repeated  30 times to get purified sulphur. Each time, 
fresh milk was used. 
4. Purification of Gowri pashanam: 
  It was kept soaked for 3 days each in leaf juice of Indian indigo plant and bitter 
gourd plant juice individually. 
5. Purification of Vellai pashanam:  
  Vellai pashanam was powdered and triturated with lemon juice(1:3 Ratio) and 
made into  small cakes and dried. This process was repeated  7 times. 
             Ref:Siddha Materia Medica(Mineral and Animal Kingdom) Page No:295 
93 
 
 
5. Purification of Padikaram: 
  Padikaaram was dissolved in water, filtered, boiled till it attained the consistency 
of jelly and then it was cooled to get the purified form. 
6. Purification of Thalagam: 
  Small pieces of Thalagam were bundled in a double layer cloth. They were kept 
immersed in cow‗s urine and heated for 3 days. The same process was repeated with  rice 
water and vinegar individually to get purified form. 
7. Purification of Ligam: 
  Lime juice, cow‘s milk and the Indian acalypha juice were mixed in equal 
proportions and allowed to fuse with cinnabar so as to get it in a consolidated potency 
state. 
8. Purification of Rasa chendooram: 
  It was kept soaked in lemon juice for 24 hours. It was then washed and dried to 
get purified form. 
9. Purification of Ponnimilai: 
Nimilai was soaked in Cow‘s milk and washed. 
                 
10. Purification of Pooneeru: 
Fuller‘s earth was dissolved in lemon juice and filtered. The filtrate was boiled till 
the water completely evaporated.       
              
11. Purification of Manosilai: 
Manosilai was triturated with lemon juice for 3 hours and then allowed to dry. 
              
12. Purification of Palthutham: 
The copper sulphate was fried, till it turned to whitish. 
               
13. Purification of Mayilthutham: 
Copper sulphate was fried, till it turned whitish.               
14. Purification of Karpoora silajath: 
The Silasaththu was boiled in cow‘s milk and washed. 
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15. Purification of Pachai karpooram: 
It was soaked in red Indian water Lily flower juice(Nymphae odorata) for 24 
minutes and isolated. 
              
16. Purification of Nandukkal: 
Limestone and Fuller‘s earth were mixed in water and allowed to settle for 
sometime. The clear solution was then taken out. Fossil stone crab was then placed 
in this solution and heated for three hours. The fossil stone crab was taken out and 
washed in water to get its purified form. 
              
17. Purification of Rasam: 
  Rasam was ground with red Indian water Lily plant juice. 
              
18. Purification of Akkirakaram: 
The outer skin of the rhizome was removed and dried in the shade. 
              
19. Purification of Nattu Amukkura: 
The drug was powdered and boiled in milk for 3 hours and then dried well.  
                
20. Purification of Ativitayam: 
  The outer skin of the rhizome was removed and dried in shade. 
               
21. Purification of Avuri elai: 
  The leaf was taken and washed with water   
22. Purification of Catamancil: 
  The drug was cleaned and dried in shade. 
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Purification of Catikkai: 
  The drug was cleaned and dried 
              
23. Purification of Catipattiri: 
  The drug was cleaned and dried 
            
24. Purification of Cerankottai: 
The nose like projection of the marking nuts were removed and nuts were tied in 
the white cloth and immersed in earthen pot containing cow dung solution and 
boiled till the  cow dung solution was completely reduced. 
                  
25. Purification of Chevviyam: 
The outer skin of pepper root was scraped and cut into small pieces and dried. 
               
26. Purification of Chukku: 
The outer skin of dry Ginger was scraped and soaked in lime stone water.  
         
27. Purification of Cirakam: 
The drug was cleaned and dried in sunlight for 6 hours and fried. 
              
28. Purification of Cirutekku: 
   The outer skin was removed, sliced and then dried. 
                  
29. Purification of Cittarathai: 
   The outer skin was removed, and sliced and then dried. 
                  
30. Purification of Elam: 
   The drug was cleaned and fried till it attained brown colour. 
                 
31. Purification of Kumkumappoo: 
The drug was spread over the paper and subjected to indirect heat till  the drug 
attained fragile quality. 
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32. Purification of Etti vittu: 
The drug was steamed with paddy and soaked in Amaranthus tricolor juice for 1 
hour and cleaned. 
                 Purification of Ilavankam: 
The drug was cleaned and dried in the shade. 
                  
33. Purification of Kacakaca vitai: 
The drug was cleaned and dried in the shade 
34. Purification of Kattu milaaku: 
  The drug was soaked in betel leaf juice for 12 minutes and dried in the shade. 
                    
35. Purification of Kodiveli ver: 
  Root bark was powdered and steamed in milk for three hours.  
                    
36. Purification of Kurocani omam: 
The omam was mildly roasted until the aroma rose.  
                     
37. Purification of Milaku: 
  The fruits were soaked in sour butter milk for three hours then dried in the 
sunlight.  
                     
38. Purification of Nervalam: 
The seed was opened and the  cotyledons were collected discarding the embryonic 
plant. The cotyledons were suspended in cloth bag and immersed in earthen pot 
containing cow dung solution and boiled till the complete reduction of cow dung 
solution. 
                    
39. Purification of Perumcirakam: 
  The drug was cleaned and dried in the shade. 
40.  Purification of Talica pattiri: 
   Long stalks of the drug were removed and dried in the shade. 
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41. Purification of Tippili: 
The drug was soaked in plumbago decoction for 3 hours 
                    
42. Purification of Thipilik kattai: 
  The nodes of the roots were removed and dried. 
                    
43. Purification of Vaividankam: 
The drug was cleaned and dried in the shade. 
                    
44. Purification of Korojanam: 
  A needle was heated and inserted into the ox- bile and taken out, appearance of 
yellow colour on the needle and yellow colour smoke confirmed its purity. 
                   
45. Purification of Karunjeeragam: 
The drug was cleaned and dried in sunlight for 6 hours and fried. 
                
 
4.4 Preparation of Nandhi Mezhugu: (Siddha Vaidhiya Thirattu)
54,55,59
 
The medicine Nandhi Mezhugu was prepared at The Indian Medical Practitioner‘s 
Cooperative Pharmacy (IMPCOPS). 
 INGREDIENTS: 
1. Purified Marking Nut (Serankottai)                                           - 1Kg 
2. Purified Nux Vomica (Ettikkottai) seeds                                        - 315 gms 
3. Cow‘s Ghee (Nei)                                                                       -1400 gms 
4. Common Alum (Padikaram)                                                      -1120 gms 
5. Palm Jaggery (Panai Vellam)                                                      -2240 gms  
6. Honey (Then)                                                                              -1400 gms 
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The following drugs were added in equal ratio as 53 gms each: 
7. Calx of Copper pyrites (Ponnimilai parpam)                                                                                      
8. Calx of Asbestos (Kalnar Parpam)                                               
9. Calx of white asphaltum (Kalmatha Parpam)                           
10. Calx of Nandukkal (Crab‘s fossil)-Nandukkal Parpam                       
11. Borneol (Pachai karpooram)                                                                          
12. Gorochan (Korochanam)      
                                                        
13. Prepared Rasa Chenduram(IMPCOPS)   -140 gms 
The following drugs were added in equal ratio as 35 gms each: 
14. Three Pungents - (Thirikadugu) each                                          
15. Cardamom Seeds (Elarisi)                                                           
16. Beetle killer roots (Siruthekku)                                                   
17. Yew leaves (Thalisa Pathiri)                                                       
18. Henbane niger (Kurosani Omam)                                                
19. Embelia (Vaividangam)                                                               
20. Atis (Athividayam)                                                                     
21. Nutmeg (Jathikkai)                                                                        
22. Mace (Jathipathiri)                                                                            
23. Cumin seeds (Seeragam)                                                                    
24. Cloves (Lavangam)                                                                                                                                                                     
25. Black pepper root (Sevviyam)                                                             
26. Wild black pepper (Kattu Milagu)                                                     
27. Lead wort root (Kodiveli ver)                                                           
28. Long pepper stem (Thippili Kattai)                                                   
29. Poppy seeds (Kasa Kasa vidhai)                                                        
30. Fennel (Perunjeeragam)                                                                     
31. Purified Croton cotyledon (Nervalam)                                              
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32. Lesser galangal (Sitrathai)                                                                 
33. Indian spike nard (Jadamanchil)                                                       
34. Pelllitory roots (Akrakaram)                                                                     
35. Withania roots (Nattu Amukkara)                                                     
The following drugs were added in equal ratio as 25 gms each: 
36. Rasa Sinduram (Market quality)                                                        
37. Pooneeru Uppu (alkaline earth salt)                                                  
38. Purified Mayil thutham (Blue vitreol)                                               
39. Purified Pal thutham (White vitriol)                                                  
40. Purified Rasam (Mercury)                                                                 
41. Purified Kandhagam (Sulphur)                                                        
42. Purified Pooram (Calomel)                                                              
43. Purified Lingam (Cinnabar)                                                             
44. Purified Manosilai (Red Orpiment)                                                  
45. Purified thalagam (Yellow Orpiment)                                              
46. Purified Gowri  Pashanam (Arsenic pentasulphide)                         
47. Purified Vellai Pashanam (White Arsenic)                                    
48. Neeli Ilai charu and karkam(Indigo Juice and Paste) (Q.S) Quantity sufficient         
Preparation:  
(a) 1,2,3  ingredients were mixed and subjected to heat and fried. Ghee and seeds were 
separated.  The seeds were ground into a fine paste. 
(b)  14-36 were ground to fine powder and the drug number-4 was also powdered.                                                                                                                                                                                                                                                                                                       
(c)  37-47 were ground in to a paste with juices of drug no 48 for 6 hours and were made 
into cakes and dried.  The cakes were covered with the paste of drug no 48 and also 
covered by cow dung and subjected to calcination process, then the product was taken 
and powdered.  
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(d) Syrup of palm jaggery was prepared and the ingredients a, b and c and the calxes were 
added followed by ghee and honey. To this mixture powders of camphor and 
Korochanam were added and thoroughly mixed.  
5.5 Physico chemical characterization of Nandhi Mezhugu:
60,61
 
Physico chemical analysis as per AYUSH Guidelines:
60
 
Qualitative analysis of Nandhi Mezhugu: 
5.5.1 Organoleptic properties 
The organoleptic characters such as colour, odour, taste and consistency were 
recorded. 
5.5.2 Physico Chemical Parameters: 
Loss on drying at 105°C, total ash, water soluble ash, acid-insoluble ash, water 
soluble extractive, alcohol soluble extractive, rancidity, acid value, saponification value, 
iodine value, pH, total solid, fat content , reducing sugar and total sugar were carried out 
as per the procedures mentioned in standard references (Protocol for testing(AYUSH)) 
1 .Determination of Loss on Drying of drug sample
 
10 g of the drug (without preliminary drying) was placed in a tarred evaporating 
dish after having been weighed accurately. It was then dried at 105
◦
C for 5 hours. The 
procedure was repeated till the weight difference between two consecutive readings were 
less than 0.25 percentages. When two consecutive weighing after drying and cooling each 
for 30 minutes in a desiccator showed not more than 0.01 g difference, the constant 
weight was reached 
2.  Total Ash  
2g of the drug was taken in a tarred silica dish and was incinerated at 450ºC until        
free from carbon, cooled and weighed.  The percentage of ash was determined with  
respect to the air-dried drug. 
3.     Water Soluble Ash determination 
     For 5 minutes, the ash which was obtained from the above test was boiled with 25 
ml of distilled water repeatedly; collected the insoluble matter on an ashless filter paper 
and ignited to constant weight.Calculated the percentage of water soluble ash with 
reference to the air dried drug. 
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4.     Acid Insoluble Ash   
         For 5 minutes the ash, obtained( from the above test) was boiled with 25 ml of 
dilute hydrochloric acid repeatedly; collected the insoluble matter on an ash-less filter 
paper, washed with hot water and ignited to constant weight. Calculated the percentage of 
acid-insoluble ash with reference to the air dried drug. 
5.    Alcohol Soluble Extractive of drug sample 
          5 gms of the study drug was dissolved in 100 ml of alcohol of the specified strength 
(90%) in a closed flask for twenty-four hours, shaken frequently during six hours and 
allowed to stand for eighteen hours. Filtered rapidly, taking safety measures against loss 
of solvent, evaporated 25 ml of the filtrate to dryness in a tared flat bottomed shallow dish 
and dried up at 105º, to constant weight and weighed. Calculated the percentage of 
alcohol-soluble extractive with reference to the air-dried drug. 
6.     Water Soluble Extractive determination 
The procedure for the determination of alcohol soluble extractive was followed 
using distilled water instead of ethanol. 
7. Determination of pH 
Taken 10g of sample, added 100 ml of distilled water, stirred well and filtered.  
Used the filtrate for the experiment. Switched on the instrument.Given 30 minutes time 
for warming the pH meter.  Introduced the pH 4 solution first and adjusted the pH meter 
by using the knob to 4.00 for room temperature 20°C, 4.01 for room temperature 25°C, 
4.02 for room temperature 30°C.  Introduced the pH 7 solution and adjusted the pH meter 
to 7 by using the knob.After   Introducing the pH 9.2 solution, without adjusting the knob, 
the pH reading was checked . Then introduced the sample solution and noted the reading. 
Repeated the test four times and took the average reading as result. 
8. Acid Value of drug sample 
10 g of drug sample was placed in a 250ml flask and mixed with 50 ml of a mixture 
of equal volumes of alcohol and solvent ether, which was neutralized after the addition of 
1 ml of solution of phenolphthalein.  Gently heated  on a water-bath, after which titration 
was done  with 0.1 N potassium hydroxide,was shaken constantly until a pink colour  was 
obtained which lasted for 15 seconds.. Noted the number of ml required. Calculated the 
acid value from the following formula:  
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Where ‗a‘ is the number of ml. of 0.1 N potassium hydroxide required and ‗w‘ is the 
weight in g of the substance taken. 
9. Determination of Saponification value 
The fatty acids, produced from the complete hydrolysis of 1 g of the oil or fat is 
neutralised by number of mg of potassium hydroxide this number was called 
saponification value.  
35 to 40 g of potassium hydroxide was dissolved in 20 ml of water and added sufficient 
alcohol to make 1,000 ml. Allowed it to stand overnight and poured off the clear liquor. 
 
Weighed accurately about 2 g of the substance in a tared 250 ml flask, added 25 ml 
of the alcoholic solution of potassium hydroxide, attached a reflux condenser and boiled 
on a water-bath for one hour, frequently rotating the contents of the flask cool and added 
1 ml of solution of phenolphthalein and titrated the excess of alkali with 0.5 N 
Hydrochloric acid. Noted the number of ml required (a) Repeated the experiment with the 
same quantities of the same reagents in the manner omitting the substance. Noted the 
number of ml required (b). 
Calculated the saponification value from the following formula:— 
                                                (b–a) × 0.02805 × 1.000 
Saponification Value =           —————————— 
                                                                 W 
   Where ‗W‘ is the weight in g of the substance taken. 
10. Determination of Iodine Value 
Iodine value:  
Iodine value is usually expressed as the number of parts by weight of Iodine 
absorbed by 100 parts by weight of an oil or fat. 
 
 
                          a × 0.00561 × 1000 
Acid Value =    ———————— 
                                       W  
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Procedure 
Preparation of Iodine monobromide solution (Hanus method) 
Dissolved 13.2 g of Iodine in 1 litre of Glacial acetic acid using a Mortar and pestle. 
Filtered through cotton and transfered all the iodine with Glacial acetic acid.  Added 3 ml 
of liquid bromine and shaken well.  
Preparation of 0.1M Sodium thiosulphate solution 
Dissolved 25g of Sodium thiosulphate AR in 1000ml of water in a volumetric flask 
Preparation of 0.1N Potassium dichromate solution 
Dissolved 4.904g of Potassium dichromate AR in 1 litre volumetric flask and made 
up to the mark with distilled water  
Preparation of Starch solution  
Dissolved 1g of Starch in 100 ml of distilled water. Heated till it becomes 
colourless. 
Standardization of Sodium thiosulphate solution  
Taken 10ml of 0.1N Potassium dichromate solution, added 150 ml of distilled 
water, 2g of potassium iodide and 6 ml of Conc. Hydrochloric acid. Stirred well. Allowed 
to stand for 10 minutes. Titrated with sodium thiosulphate solution using starch as 
indicator. End point was the disappearance of blue colour. 
Determination of Iodine Value 
Weighed about 0.2 gm of oil/fat in an Iodine flask. Added 15 ml of Chloroform and 
dissolve. Added 25 ml of Iodine monobromide from a burette. Moistened the stopper with 
a few drops of potassium iodide solution. Kept the flask in dark for half an hour. Added 
10 ml of potassium Iodide and 100 ml of distilled water. Titrated the mixture with 
standard 0.1M Sodium thiosulphate with starch as indicator. Added starch solution only 
when the solution in the flask was pale yellow in colour. The end point was disappearance 
of blue colour. Noted the number of ml required (a). Did the blank determination without 
the oil using exactly the same quantity of chloroform and the same burette for delivering 
the Hanus reagent (b).Repeated the experiment twice for concordant values. 
Calculation: 
Iodine value = 1.269 x Strength of thiosulphatex Difference in titre (b-a)  
0.1 x Weight of oil 
11. Rancidity test (Kreis Test) 
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The test depends upon the formation of a red colour when oxidized fat is treated 
with conc. HCl and a phloroglucinol in ether solution. Epihydrin aldehyde is the 
compound present in rancid fats is account able for the colour reaction. The response 
obtained from all oxidized fats to the kries test and the quality of the colour. 
Procedure 
Mixed 1 ml of melted fat and 1 ml of conc. HCl in a test tube. Added 1 ml of a 1 % 
solution of phloroglucinol in diethyl ether and mixed thoroughly with the fat-acid  
mixture. Formation of pink colour was the indication of slight oxidation of fat; red colour 
was the indication definite oxidation of the fat. 
 
12. Determination of the Fat content 
 Weighed 3-4g of the sample in a thimble and placed it in a soxhlet fitted with a 
condenser. Taken 100 ml of petroleum ether (B.P. 40-60°C) in the RB flask and boiled 
for 4 hours.  Taken the extract in a pre-weighed conical flask and evaporated petroleum 
ether on a water bath.  Removed the traces of petroleum ether in vacuum pump. Taken the 
weight of fat to constant weight. 
 
 
Calculation  
Percentage of Fat content = Weight of petroleumether extract x 100 
       Weight of the sample taken 
13. Determination of Sugar content  (Lane&Eynon’s method) 
Preparation of Fehling’s solution: 
Solution A : 
34.639 g of pure crystallized CuSO4 .5 H2O in 500 ml water. 
Solution B : 
173 g of Rochelle salt (Potassium Sodium tartrate and 50 g of Sodium hydroxide in 
500 ml distilled water. 
Mixed equal volumes of solutions A and B. 
Methyleneblue indicator:  1g of Methylene blue in 100 ml of distilled water. 
Sample preparation 
Taken 10 g of sample in a 250 ml volumetric flask.Added 200 ml water.Added 
slightly excess solid basic lead acetate to remove tannins.Made up to the mark without 
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disturbing the solution. Shaken and filtered. Added slightly excess of solid Sodium 
oxalate to remove excess of basic lead acetate.Shaken and filtered. Used this filtrate for 
the estimation of reducing sugar. 
Reducing sugar: Take the sugar solution in a 50 ml burette 
Preliminary titration 
Pipetted 10 ml of Fehling‘s solution into a 250 ml conical flask, added from the 
burette, 15 ml of the sugar solution. Boiled the liquid on asbestos-covered gauze and 
added further quantities of the sugar solution (One ml at a time) at 10 to 15 second 
intervals to the boiling liquid until the blue colour is nearly discharged. Added 3-5 drops 
of aqueous methylene blue solution (1%) and continued the titration until the indicator 
was completely decolorized. 
Accurate titration  
The titration was repeated, adding before heating, almost all of the sugar solution 
required to effect reduction of copper. Boiled gently for two minutes.Added 3-5 drops of 
Methylene blue indicator and completed the titration within a total boiling time of three 
minutes. At the end point all the blue colour has discharged and the liquid was red.The 
proportions of the sugars, equivalent to 10 ml of Fehling‘s solution was taken from the 
table. 
Total Sugar  
Taken 20ml of reducing sugar solution, and added 10ml of Concentrated 
Hydrochloric acid and kept it aside overnight. Neutralised with approximately 1M 
Sodium hydroxide solution or with solid sodium carbonate and made up to 100 ml in a 
volumetric flask. The total sugar content was determined by the titrimetric method as 
described above.The experiment was repeated twice and the average value was taken. 
Calculation 
mg of sugar in 100 ml =Total reducing sugar from table x 100 
     Titre value 
Reducing sugar % = mg of sugar in 100 ml x 250 x 100 
      1000 x 100 x 10 
Total sugar % = mg of sugar in 100 ml x 250 x 100 x 100 
1000 x 100 x 20 x 10 
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Qualitative Phytochemical Analysis: 
62
 
Various tests for different types of secondary metabolites, viz., Steroids, terpinoids, 
alkaloids, flavonoids etc. were carried out as per the procedures quoted in standard 
organic book.  
1. Test for Steroids (Lieberman Burchard Test) 
   To few mg of the extract 2 ml of chloroform was added in a dry test tube. Few 
drops of acetic acid were added, heated and few drops of acetic anhydride and 2 drops of 
concentrated sulphuric acid were added. The green colour indicated the presence of 
steroid. 
2. Triterpenoids (Noller’s Test) 
To few mg of extract, added tin and thionyl chloride and heated in a water bath. 
Purple colour indicated the presence of tritepenoids. 
3. Test for Flavonoids (Shinoda test): 
Magnesium bits and Conc. HCl were added to the substance which was dissolved in 
alcohol. The presence of flavonoid was assessed by the appearance of magenta colour on 
heating over water bath confirmed the presence of flavonoid. 
4. Test for Alkaloids (Dragendorff’sTest): 
Few mg of extract in a separate test tube were warmed with 2% Sulphuric acid for 2 
minutes; it was filtered in a separate test tube and a few drops of Dragendorff‘s reagent 
were added.  The presence of orange red precipitate indicated the presence of alkaloids. 
5.Test for Phenol: 
Substance in water was added to 5 % alcoholic ferric chloride. Dark blue or green 
colour showed presence of phenol. 
6. Test for Tannin: 
Substance was shaken with water and added to lead acetate solution. White precipitate 
showed the presence of tannin. 
7. Test for  presence of Saponins: 
      Foam formation after shaking the mixture of distilled water with few mg of extract 
confirmed the presence of Saponins.  
8. Test for  presence of Coumarin: 
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      Extract was shaken with 10% sodium hydroxide. Yellow colour showed the presence 
of coumarin.Upon adding concentrated sulphuric acid, original extract colour was 
regenerated. 
9. Test for presence of Glycosides:  
Concentrated sulphuric acid and anthrone were treated with the substance and heated 
in the water bath; showed green colour confirmed the presence of glycoside.  
10. Test for Quinones: 
To asss few mg of extract, added few drops of concentrated sulphuric acid. 
Appearance of red colour showed the presence of quinone. 
5.5.4 Qualitative Inorganic Analysis:  
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1. Test for Aluminium: 
      To the sample solution, ammonium chloride and aqueous ammonia were added. 
White precipitate was obtained. This precipitate was dissolved in drops of  1N 
hydrochloric acid and added 2 drops of aluminon reagent (0.1% aqueous solution of 
ammonium salt of aurinetricarboxylic acid), shaken, allowed to stand for 5 minutes and 
then added excess of ammoniacal ammonium carbonate solution.  Formation of  bright 
red precipitate indicated the presence of aluminium. 
2. Test for Calcium: 
      To a drop of the neutral sample solution, added a drop of saturated aqueous solution 
of picrolonic acid. Rectangular crystallization showed the presence of calcium. 
3. Test for Cobalt: 
      To a drop of the sample solution, added two drops of the saturated solution of 
ammonium thiocyanate. Blue colour development showed the presence of cobalt. 
4. Test for Copper: 
      To a drop of sample solution, added a drop of  ammonium mercuri thiocyanate 
solution.  A violet precipitate indicated the presence of copper. 
5. Test for Iron: 
To a drop of sample solution, added a drop of 5% solution of potassiumferrocyanide. 
A blue colouration indicated the presence of iron. 
6. Test for Potassium: 
To a drop of sample solution, added a drop of dipicrylamine (1 % in 0.1 N sodium 
carbonate) 
Orange-red coloration showed the presence of potassium. 
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7. Test for Magnesium: 
To a drop of sample solution, added a drop of magneson reagent ((0.01% 
paranitrobenzeazoresinol in 1 N NaOH).  A blue precipitate  formation inferred the 
presence of magnesium. 
8. Test for Mercury: 
To a drop of sample solution, added crystals of ammonium thiocyanate and a little of 
solid cobalt acetate. Blue colour development indicated the presence of mercury. 
9. Test for Zinc: 
To a drop of sample solution, added a drop of 0.0 2% cobalt sulphate and a drop of 
the ammonium mercurithiocyanate solution. Blue precipitate was obtained indicating the 
presence of zinc. 
10. Test for Sodium: 
To a drop of sample solution, added eight drops of the zinc uranyl acetate. An yellow 
precipitate showed the presence of sodium. 
11. Test for Arsenate: 
The sample gave a white precipitate with magnesia mixture showing the presence of 
arsenate. Further it was confirmed by the liberation of iodine on addition of ammonium 
iodide and dil.HCl. 
12. Test for Chloride: 
The sample solution gave white precipitate when added with silver nitrate. 
13. Test for Silicate: 
The sample was heated with microcosmic salt (NaNH4 HPO4. 4H2O). A white speck 
was floating on the bead without dissolving in it which showed the presence of silicate. 
14. Test for Nitrate: 
The sample was mixed with saturated solution of ferrous sulphate and shaken con. 
H2SO4 was added along the side of  the test tube. A brown ring was formed showing the 
presence of nitrate. 
15. Test for Acetate: 
When heated with ethanol and H2SO4 gave fruity odour. 
16. Test for Carbonate: 
The sample was mixed well with potassium dichromate and few drops of dil.HCl 
were added. Effervescence showed the presence of carbonate. 
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17. Test for Sulphide:  
To the solution freshly prepared cadmium carbonate was added and shaken well. 
Yellow precipitate showed the presence of sulphide. 
18. Test for Sulphate:  
The above precipitate was removed by centrifugation and to the supernatant dil. acetic 
acid was added to remove excess carbonate, barium chloride solution was added white 
precipitate showed the presence of sulphate. 
Quantitative assay 
5.5.5 Assays: 
Quantitative assays for Calcium, Magnesium, Potassium, Aluminium, Copper, Iron 
and Zinc, were observed in ICP-OES using standards. Sulphur (as SO2) was estimated by 
following AOAC 990.28 method and Chloride (as NaCl) was calculated by following 
AOAC 950.52 method. 
Calcium (as Ca)  SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Magnesium(as Mg) SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Potassium (as K)  SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Aluminum (as Al)  SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Copper (as Cu) SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Iron (as Fe)  SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Zinc (as Zn)  SO-CHML-CTS-C-01 -QU-063-by ICPOES  
Sulphite (as S02)  AOAC 990.28  
Chloride(as Nacl) AOAC 950.52  
 
5.5.6 Heavy metal Analysis: 
  Tests for heavy metals, viz., lead, cadmium, arsenic and mercury were carried out 
in ICP-OES instrument (Perkin Elmer Optima 3000 DV).  
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Lead (as Pb) 
SO-IN-MUL-TE-063 by ICP-MS 
Cadmium (as Cd) SO-IN-MUL-TE-063 by ICP-MS 
Arsenic (as As) SO-IN-MUL-TE-063 by ICP-MS 
Mercury (as Hg) SO-IN-MUL-TE-063 by ICP-MS  
 
5.5.7 Microbial contamination: 
        Tests for total bacterial /fungal counts E. coli, Salmonella spp., Staphylococcus 
aureus and Entero bacteriacea were done. 
5.5.8 Pesticide residues: 
Various pesticide residues of organo chlorine and organo phosphorous viz., 
alphaBHC,  betaBHC, gam BHC(Lindane), deltaBHC, Aldrin, Dieldrin, trans Chlordane, 
cis Chlordane, Endrin, Endrinaldehyde, Endrinketone, Endosulfan-I, Endosulfan-II, 
Endosulfansulfate, Heptachlor, Heptachlorepoxide, Dicofol, Chlorthalonil, 
Hexachlorobenzene, o,p"DDT, P,P"DDT, o,p"DDD, p,p"DDD, o,p"DDE, P,P"DDE, 4-
Bromo,2-Chlorophenol, Acephate, Chlorfenvinphos, Chlorpyrifos, Phorate sulphone, 
Chlorpyrifos methyl, Malathion, Diazinon, Dichlorvos, Dimethoate, Ethion, 
Monocrotophos, Etrimfos, Fenitrothion, Iprobenphos, Methamidophos, , Omethoate, 
Oxydemeton-methyl, Quinalphos, Parathion ethyl, Parathion methyl, Phorate, Phosalone, 
Phosphamidon, Profenophos, , Triazophos, , Phorate sulphoxide were tested by following 
AOAC 2007.01 methods. 
5.5.9 Tests for Aflatoxins: 
  Aflatoxins such as B1, B2, G1 and G2 were checked using AOAC 2008.02 
methods. 
5.5.10 TLC Photodocumentation/HPTLC Finger prints profiling:
64,65
 
Sample preparation 
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Four gm of the drug was extracted successively by hexane, chloroform and ethanol using  
Soxhlet apparatus. The extracts were filtered freed from solvents  and made upto 10 ml in 
standard flasks using the respective solvents.  
TLC plate 
Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness (Merck) was used 
for the TLC/HPTLC analysis.  
Developing chamber 
Camag‘s twin trough chamber was used for the development.  
Solvent system 
Many solvent systems were tried for a better separation and the same was achieved in 
Toluene: Ethyl acetate (10 : 0.5, v/v) for hexane extract; Toluene : Ethyl acetate (5:1.5, 
v/v) for chloroform extract  and ethanol extract. 
Derivatization reagent 
For derivatization vanillin-sulphuric acid reagent was used (1 gram vanillin dissolved in a 
mixture of ethanol and sulphuric acid  with the composition 95 ml : 5 ml).  
Instrument 
Linomat 5 automatic applicator, CAMAG‘s visualizer, CAMAG‘s scanner 030618 
attached with WINCATS software were the instruments used for photo documentation 
and HPTLC finger printing. CAMAG‘s plate heater was used for derivatization.  
Procedure 
5 µl, 10 µl and 15 µl of the hexane, chloroform and ethanol extracts were applied on three 
different plates as 10 mm bands with 8 mm distance in between and developed up to 8 cm 
in the above mentioned solvent systems. The air dried developed plates were visualized 
under UV 254 and 366 nm for documenting TLC chromatograms. The plates were 
scanned in UV 254 nm (all extracts) & 366 nm (hexane and chloroform) and the finger 
print profiles were recorded. Until the development of coloured spots the vanillin-
sulphuric acid reagent plates were heated in an oven at 105˚C. After derivatization the 
TLC photo documentation in white light and 575 nm (hexane and chloroform) finger 
print profiles were recorded.  
 
5.6 Toxicity studies of Nandhi Mezhugu in Animal model: 
5.6.1 Animal Care and Husbandry: 
112 
 
The study protocol involving animals was reviewed and approved by Institutional 
Animal Ethical Committee (IAEC), National Institute of Siddha,  Chennai-600047, with 
the experimental protocol number IAEC approved Number: 1248/AC/09/CPCSEA-
4/June2011/10 for Acute toxicity study and  IAEC approved Number: 
1248/AC/09/CPCSEA-9/Dec2013/5 for Sub-acute and Sub-chronic toxicity studies. 
Experiments were performed as per the guidelines prescribed by the CPCSEA, Ministry 
of E & F, Govt of India. Male and female Wistar albino rats, (160–200  g) obtained from 
LAM, CAHS, Madhavaram, Chennai-600051 and housed in Animal house of National 
Institute of Siddha. Each group of rats was separately housed in polypropylene cages in a 
well-ventilated room under an ambient temperature of 22±3°C and 30-70% relative 
humidity, with a 12-h light/dark artificial light cycle. They were provided with rodent 
chow from VRK Nutritional Solutions, Sangli, Maharastra and Reverse Osmosis purified 
water ad libitum. All the animals were acclimatized to the laboratory conditions at least 
for 7 days prior to experimentation. 
5.6.2 Acute toxicity studies:
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The acute oral toxicity study was performed in accordance with Organization for 
Economic Cooperation and Development (OECD) test guideline 423 [Newbould 1963]. 
The limit test dose of 2000 mg/kg was used as stipulated in Organization for Economic 
Cooperation Development (OECD) guidelines. 
 
Dose Preparation: 
Palm jaggery 400mg per dose  was added in 7.5 ml of distilled water and dissolved 
well. Administratered through oral route to  Group I Animals.   
NM 50mgs per dose and Palm jaggery 400mg were added in 7.5ml of distilled water and 
dissolved well. Administratered through oral route to Group II Animals.  
NM 300mgs per dose  and Palm jaggery 2.4gms were added in 7.5ml of distilled water 
and dissolved well. Administratered through oral route to  Group III Animals.. 
NM 2000mgs per dose and Palm jaggery 16gms were added in 7.5ml of distilled water 
and dissolved well Administratered through oral route. to  Group IV Animals.  
    The dose was determined for a required concentration before administration by 
dissolving Nandhi Mezhugu and palmjaggery in distilled water. It was mixed well. The 
preparations for different doses vary in concentrations to allow a constant dosage volume.  
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In the experiments the commonly observed parameters were body weight, clinical 
signs and gross pathology and were as follows; 
a. Mortality or morbidity was noted.  
b. Following test item administration weekly body weight was recorded.  
c. Clinical signs such as lethality, convulsion, tremor, straub tail, sedation, 
excitation, abnormal gait (rolling), abnormal gait (tiptoe), jumps, motor coordination, loss 
of balance, fore paw treading, writhes, piloerection, stereotypies  (chewing), stereotypies 
(Head movements), loss of grasping, akinesia, head twitches, scratching, respiration, 
aggressiveness, fear, reactivity to touch, muscle tone, loss of righting reflex, analgesia, 
ptosis, exophthalmos, catalepsy, loss of traction, loss of corneal reflex, defecation, 
salivation, lacrimation, others were observed at approximately 30 mins, 1hr, 2hr and 4hr 
on day 1 and daily thereafter for 14 days. 
At the end of 14 days, the experimental animals were necropsied and investigated 
for gross pathological examination. 
 
5.6.3 Sub-acute Toxicity Study of Nandhi mezhugu
67
 
On the basis of these results i.e., acute toxicity study of Nandhi mezhugu and the 
therapeutic dose level as mentioned in Siddha literature , extrapolated to rat body surface 
area, the following doses of 9 mg/kg, 45 mg/kg and 90 mg/kg body weight were selected 
for the sub-acute toxicity study and administered orally  twice daily (7 days drug dosing 
followed by 7 days drug holidays).  
Preparation and administration of dose: Repeated-dose (28 days) oral toxicity study 
was carried out according to the OECD guideline 407.  
Dose Preparation:  
Palm Jaggery 72 mg per dose was added to distilled water and dissolved well. 
Administered through oral route to Group I(Vehicle control) . 
Nandhi Mezhugu 9mg per dose and 72mg palm jaggery were dissolved well in distilled 
water and administered through oral route to Group II(Low Dose)  . 
Nandhi Mezhugu 45mg per dose and 360mg palm jaggery were added to distilled water 
and dissolved well. Administered through oral route to Group III(Mid Dose) . 
Nandhi Mezhugu 90mg per dose and 720mg palm jaggery were added to distilled water 
and dissolved well. Administered through oral route to Group IV(High Dose) . 
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Palm Jaggery 72 mg per dose was added to distilled water and dissolved well. 
Administered through oral route to Group V(Recovery control)  . 
Nandhi Mezhugu 90mg per dose and 720mg palm jaggery were added to distilled 
water and dissolved well. . Administered through oral route to Group VI(High Dose 
Recovery). 
The NM was administered by oral gavage for 28 days (4 weeks) twice daily at 
regular intervals as per the protocol mentioned in the Siddha literature where 7 days of 
test drug administration followed by 7 days of drug holiday alternatively for four cycles 
of dosing to match 28 days of dosing period. Recovery groups were scheduled for follow-
up observations for the next 14 days without NM administration. High dose recovery and 
Recovery control were included in the study to determine the delayed occurrence, or 
persistence of, or recovery from toxic effects, if any. All groups were observed twice 
daily for morbidity and mortality, clinical signs once daily. Bodyweight and food intake 
of the animals were evaluated at weekly intervals. Any change in the water consumption 
was observed and recorded. 
On the 57
th
 day, after an overnight fast, the rats were anaesthetized with 
Thiopentone sodium and blood samples were collected from retro-orbital plexus under 
light ether anaesthesia by the trained personnel. The blood samples for haematological 
and biochemical analyses were collected in tubes with and without EDTA, respectively. 
Total WBC, Differential Counts, RBC, Haemoglobin, HCT, MCV, MCH, MCHC, RDW, 
PLT, MPV, PDW and PCT. Biochemical analysis was performed on serum obtained after 
centrifugation of total blood (without anticoagulant) at 2500 rpm for 15 min. Blood 
Glucose, Urea, Creatinine, Cholesterol, Triglyceride, HDL, LDL, Total serum protein , 
ALT or SGPT, AST or SGOT were analysed. 
Pathology 
Necropsy was done in all animals in Group I to Group IV on 57
th
 day and Group V 
and Group VI (recovery groups) on 70
th
 day. Blood samples were collected from 
abdominal aorta following which all the animals were euthanized by excess dose of 
Thiopentone Sodium administered by intra-peritoneal route. The carcasses were observed 
for gross lesions in all major internal organs. The organs such as brain, heart, lungs, liver, 
kidneys, and spleen were weighed and relative organ weights were calculated. The 
relative organ weight of each animal was then calculated as follows: 
71
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                Absolute organ weight (g) 
Relative Organ Weight =                     X 100  
                                                              Body weight on the day of euthanasia  
The organs were fixed in 10% neutral buffered formalin, trimmed and a 5μ thickness of 
tissue sections were stained with hematoxylin and eosin for histopathological 
investigation. 
5.6.4 Sub-chronic Toxicity Study:
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Justification for Dose Selection: As stated in results of acute toxicity studies in Wistar 
rats, NM was nontoxic up to the maximum dose level of 2000 mg/kg body weight. On the 
basis of these results and the therapeutic dose level as mentioned in Siddha literature 
extrapolated to rat body surface area, the following doses of 9 mg/kg, 45 mg/kg and 110 
mg/kg body weight were selected for the study and administered orally  twice daily. 90 
days Repeated-dose oral toxicity study was carried out according to OECD test guideline 
408. 
Dose Preparation:  
Group I: Palm Jaggery 72 mg per dose was added to distilled water and dissolved well. 
Administered through oral route to Group I (Vehicle control). 
Group II: Nandhi Mezhugu 9mg per dose and 72mg palm jaggery were added to distilled 
water and dissolved well. Administered through oral route to Group II (Low Dose).   
Group III: Nandhi Mezhugu 45mg per dose and 360mg palm jaggery were added to 
distilled water and dissolved well. Administered through oral route to Group III (Mid 
Dose). 
Group IV: Nandhi Mezhugu 110mg per dose and 880mg palm jaggery were added to 
distilled water and dissolved well. Administered through oral route to Group IV (High 
Dose) .Since 90mg dose level did not show any toxic signs the sub chronic toxicity high 
dose level was increased  from 90mg to 110mg. 
Group V: Palm Jaggery 72 mg per dose was added to distilled water and dissolved well. 
Administered through oral route to Group V (Recovery control) . 
Group VI: Nandhi Mezhugu 110mg per dose and 880mg palm jaggery were added to 
distilled water and dissolved well. Administered through oral route to Group VI (High 
Dose Recovery). 
NM was administered twice daily by oral gavage for 7 days, followed by 7 days 
drug holiday, alternatively for 180 days (90 days drug dosing and 90 days drug holiday). 
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This protocol was followed to mimic the treatment protocol in humans as mentioned in 
the traditional Siddha literature. 
Recovery groups were scheduled for follow-up observations for the next 14 days 
without NM administration.  High dose recovery and recovery control were included in 
the recovery study to define the late occurrence, or persistence of, or recovery from toxic 
effects.   All group of animals were observed, twice daily, for morbidity and mortality; 
and clinical signs daily.The bodyweights and food intake of the animals were evaluated 
on a weekly basis. Any change in the water consumption was observed and recorded. 
On the 181
st
 day, after an overnight fast, the rats were anaesthetized with Thiopentone 
sodium and blood sample for haematological and biochemical analysis were collected 
into tubes with and without EDTA, respectively. Total WBC, differential Counts, RBC, 
haemoglobin, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, PDW and PCT,Blood 
Glucose, Urea, Creatinine, Cholesterol, Triglyceride, HDL, LDL, Total serum protein, 
ALT or SGPT, AST or SGOT were screened. 
 
Histopathology 
Necropsy was done on all animals in Group I through IV on  the181
st
 day and  for 
Group V and Group VI (recovery groups)  on the 195
th
 day. Blood samples were collected 
from abdominal aorta following which all the animals were euthanized by excess dose of 
Thiopentone sodium administered by intra-peritoneal route. The gross pathological 
examination of all major internal organs  performed. The organs such as brain, heart, 
lungs, liver, kidneys, and spleen were weighed and relative organ weights were calculated 
as mentioned in the sub-acute toxicity study. The cropped organs were secured in 10% 
neutral buffered formalin,and the 5μ size  tissue sections were stained with haematoxylin 
and eosin for histopathological observation. 
 
Statistical Analysis 
All the data were expressed as Mean ± Standard Error Mean. The data were 
statistically analysed by using one-way ANOVA if the number of groups to be compared 
is more than two followed by Post-hoc test and Dunnet-t test. If only two groups are to be 
compared as in the case of recovery groups, students‘t‘ test was used. It was assumed that 
the data were normally distributed and there was homogeneity of variance.Statistically 
significant valueof P is less than 0.05 
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5.6.5 ICP-OES – Detection of Heavy metal traces in animal tissue samples (Brain, 
Liver, Kidney) in Sub-chronic toxicity studies (High dose group) of Nandhi Mezhugu: 
In sub chronic repeated oral 90 days (  7 days drug dosing and 7 days drug 
holidays) toxicity study of Nandhi Mezhugu in Wistar rats (OECD 408) the tissues of 
brain, kidney, liver of high dose group were subjected to ICP-OES study to screen heavy 
metal content and it was found that there was absence of traces of heavy metal such as 
lead, cadmium, mercury and arsenic. 
5.7 Pharmacological studies of Nandhi Mezhugu in Animal model: 
5.7.1 Analgesic activity:
72,73,74
 
Experiment animal’s husbandry: 
The study protocol involving animals was reviewed and approved by Institutional 
Animal Ethical Committee (IAEC), National Institute of Siddha, Chennai-600047, with 
the experimental protocol number IAEC approved Number: 1248/AC/09/CPCSEA-
4/June2011/10 for Analgesic and Acute Anti–inflammatory study. Experiments were 
performed as per the guidelines prescribed by the Committee for the Purpose of conduct 
and Supervisions of Experiments on Animals (CPCSEA), Ministry of Environment and 
Forest, Government of India. Male and female Wistar albino rats(160–200  g) and Swiss 
albino mice(25-35g) obtained from Laboratory Animal Medicine, Centre for Animal 
Health Studies, Madhavaram Milk Colony, Chennai-600051 were housed in Animal 
House of National Institute of Siddha. Each group of rats was separately housed in 
polypropylene cages in a well-ventilated, with room temperature of 22±3°C under an 
ambient temperature and 30-70% relative humidity, with a 12-h light/dark artificial light 
cycle maintained room.. The rodents were fed with chow from VRKNS(VRK Nutritional 
Solutions), Sangli, Maharastra and Reverse Osmosis purified water ad libitum. All the 
animals were acclimatized to the laboratory conditions for at least for 7 days prior to 
experimentation. 
Acetic acid induced writhing in mice: 
         This study was done by the method of Koster et al., 1959. There was no mortality in 
the acute oral toxicity test up to a dose of 2000mg/Kg. One tenth of the maximum 
tolerable was considered for further pharmacological activities. Acetic acid induced 
writhing method was preferred to evaluate the analgesic efficacy of the drugs/compound 
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in mice. Abdominal constractions in mice were caused by the intra-peritoneal injection of 
acetic acid. Animals were divided into five groups such as Vehicle control (0.1 ml glacial 
acetic acid + Palm jaggery solution), Positive control(0.1 ml glacial acetic acid + Disprin 
(50mg), Low Dose(0.1 ml glacial acetic acid +NM 25mg +PJ solution), Mid Dose(0.1 ml 
glacial acetic acid +NM 40mg +PJ solution), High Dose(0.1 ml glacial acetic acid +NM  
50mg + PJ solution). 
Wistar albino mice of either sex were divided into five different groups each 
containing six animals and the animals were separately marked. Food was withdrawn 12 
hours prior to drug administration till the finishing point of experiment. The animals were 
weighed and numbered correctly. The test and standard drugs were given orally. After 60 
minutes writhing was induced by intra-peritoneal injection of 1% acetic acid in volume of 
0.1 ml/10g body weight. The writhing episodes were recorded for 30 minutes; stretching 
movements consisting of elongation of body, arching of the back and extension of hind 
limbs were counted. Percentage of inhibition was estimated using following formula. The 
results of acetic acid induced writhing method in mice were tabulated. 
Mean of writhing test (control) – Mean writhing test (test) X 100     
% Inhibition =            --------------------------------------------------------------------------- 
                                                    Mean number of writhing test (control) 
5.7.2 Acute anti-inflammatory activity: 
Carrageenan induced rat paw oedema:
75,76,77
 
The Method of Winter et al was used to evaluate the Anti-inflammatory activity 
with some minor modifications .The rats were divided in to four groups containing six 
rats in each group. In each group the left paw volume at 0 hr was treated as control. In 
each group (GII, GIII, GIV) the test drug (Nandhi Mezhugu) was administered with palm 
jaggery in1:8 ratio (1 hr prior to carrageenan injection) at three dose levels which were as 
follows: Group II (low dose group) -90mg/kg b.w, Group III (Mid dose group) -
450mg/kg b.w, Group IV (High dose group) -900mg/kg b.w. The carrageenan treated Left 
paw volume was measured in all three dose levels at 1
st
 hr, 2
nd
 hr, 4
th
 hr and 6
th
 hr 
respectively. The same procedure was repeated with standard drug (Diclofenac sodium 
25mg/kg b.w) (Group 1) also.  
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The percentage of inhibition was calculated by the formula  
     Pre drug reading -- post drug reading       ×   100 
                 % Inhibition =          
     Pre drug reading 
5.7.3 Chronic anti-inflammatory activity: 
Experiment animal’s husbandry:78,79,80,81 
The study was conducted in LIVEON BIOLABS PVT. LTD. Karnataka, INDIA 
with the experimental protocol number: LBPL-EF-047/15 for chronic anti–inflammatory 
study. IAEC No: LBPL-IAEC-114-06/15. Experiments were performed as per the 
guidelines prescribed by the Committee for the Purpose of conduct and Supervisions of 
Experiments on Animals (CPCSEA), Ministry of Environment and Forest, Government 
of India. Male and female Wistar albino rats (7-8 weeks) Males: 170.63 – 200 g   
Females: 170.14 – 198.57g. Each group of rats was separately housed in polypropylene 
cages with Animal husbandry conditions: Temperature   – 20.1-23.8oC ,Humidity         – 
45-68 %, Air changes    – 12-16 changes per hour, Light cycle      – 12 hours light and 12 
hours dark (as per CPCSEA guidelines). They were provided with fed ad libitum with 
AMRUT Laboratory Animal Feed manufactured by Pranav Agro Industries Limited, 
Sangli, Maharashtra and Reverse Osmosis purified water ad libitum. 7 days prior to 
experimentation, Animals were acclimatized to the laboratory conditions. 
Cotton pellet granuloma method: 
On day 1, cotton Pellets (10±1 mg each) were sterilized and impregnated with an 
aqueous solution of Ampicillin. Two cotton pellets were implanted subcutaneously in the 
groin region of rats, one on each side under anaesthesia. G3, G4 and G5 group animals 
were treated with test item(Nandhi mezhugu) and palm Jaggery in the ratio of  at  50 
mg/kg b.wt, 150 mg/kg b.wt and 500 mg/kg b.wt respectively once a day, for 7 
consecutive days. G2 group animals were treated with Dexamethasone sodium @ 0.5 
mg/kg and it was treated as a positive control. G1 group animals were treated as vehicle 
control(palm jiggery solution) and it was treated with vehicle alone. On day 8 the animals 
were humanely sacrificed using CO2 exposure method, subjected to the gross necropsy 
and cotton pellets were collected  (Specified organs were collected and preserved in 10% 
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NBF for histopathological evaluations). Collected cotton pellets (wet and dried) were 
weighed and recorded. Obtained data were subjected to statistical analysis. 
Observations: 
a) Clinical signs of toxicity. 
b) Morbidity and mortality. 
c) Individual animal, initial, weekly and final body weights were measured and 
recorded. 
d) Gross Necropsy Cotton pellets (wet and dried) weights were recorded. 
 
5.7.4 Anti-arthritic activity: 
Experiment animal’s husbandry:82,83,84 
The study was conducted in LIVEON BIOLABS PVT. LTD. Karnataka, INDIA 
with the experimental protocol number: LBPL-EF-046/15for Anti-arthritic study. IAEC 
No: LBPL-IAEC-110-06/15. Experiments were performed as per the guidelines 
prescribed by the Committee for the Purpose of conduct and Supervisions of Experiments 
on Animals (CPCSEA), Ministry of Environment and Forest, Government of India. Male 
Sprague Dawley (7-8 weeks) 150 -170 gram. Each group of rats was separately housed in 
polypropylene cages with Animal husbandry conditions: Temperature -20.1-
23.8
o
C,Humidity - 45-69 %, Air changes - 12-16 changes per hour, Light cycle – 12 
hours light and 12 hours dark (as per CPCSEA guidelines). They were provided with fed 
ad libitum with AMRUT Laboratory Animal Feed manufactured by Pranav Agro 
Industries Limited, Sangli, Maharashtra and Reverse Osmosis purified water ad libitum. 
All the animals were acclimatized to the laboratory conditions for at least 7 days prior to 
experimentation. 
Freund’s complete adjuvant (FCA) Arthritis Model: 
After acclimatization period the animals were equally distributed into 5 groups 
with. six animals in each group.  On day 1, 0.1 ml of Freund‘s complete adjuvant (FCA) 
was injected into the sub plantar region of the left hind paw of all animals across all the 
groups (1.0 ml FCA consisted of 1 mg heat killed and dried mycobacterium tuberculosis, 
0.85 ml paraffin oil and 0.15 ml mannide mono oleate concentration of 6mg/ml). Before 
administration of the vehicle, standard and test item, size of the left and right hind paw of 
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all the animals were measured using vernier caliper. After paw measurement, G3, G4 and 
G5 group animals were treated daily with test item(Nandhi mezhugu) and palm Jaggery 
in the ratio of  1:8  at 50 mg/kg b.wt, 150 mg/kg b.wt and 500 mg/kg b.wt respectively up 
to 12 days. G1 group animals were treated as Arthritis Control and it was treated with 
vehicle alone as similar to G3 to G5 group animals, G2 group animals were treated with 
the known drug Indomethacin 0.3 mg/kg, PO up to 12 days. From day 13 - day 21 the 
animals were not treated with vehicle, standard drug or test item. On day 22
nd 
approximately 24 hours after the last test item administration all animals were 
anesthetized using CO2, blood was collected in tubes with and without anti-coagulant (2% 
K2EDTA). Blood samples without anticoagulant were centrifuged at 3000 rpm for 10 
minutes. Serum samples separated and used for estimation of clinical 
chemistry/biochemical parameters (albumin and total protein). Blood samples with 
anticoagulant were used for estimation of haematology parameters (Leukocyte count, 
ESR and Haemoglobin). After blood collection the animals were humanely sacrificed 
using CO2 asphyxiation method, subjected to the gross necropsy and knee joints or other 
specified organs were collected and preserved in 10% NBF for histopathological 
evaluations. The joints were decalcified and processed, stained with H & E stain and 
examined for cartilage integrity/arthritic parameters: inflammation, 
erosions/degeneration, fibrosis etc., and FCA administered paws were preserved in -80 
o
C 
and transferred to the monitoring scientist for the biochemical evaluation. 
Body weight, paw volume measurement and evaluation of primary and secondary 
lesions 
Body weights of the animals were measured on day 1 before the FCA 
administration and weekly once thereafter during the study period. Paw volume 
measurement for evaluation of primary and secondary lesions. For primary lesions 
adjuvant injected hind paw for secondary lesions non injected hind paw were measured 
using vernear caliper. On day 1, before and after administration FCA, both hind paws 
(limbs) of the all animals were assessed. On day 5, FCA administered hind paw of all the 
animals were assessed for primary lesions and influence of therapeutic agents on this 
phase. On day 12 and day 21, FCA administered hind paw and non-administered hind 
paw of all the animals were measured for primary lesions and secondary lesions. On day 
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21, the body weights were determined and the severity of the secondary lesions was 
evaluated visually and graded according to the following scheme: 
Scoring Scheme 
Organ Lesions Score 
Nose 
 
no swelling of connective tissue 0 
intensive swelling of connective tissue 1 
Ears 
absence of nodules and redness 0 
presence of nodules and redness 1 
Fore paws 
absence of inflammation 0 
inflammation of at least 1 joint 1 
Hind paws 
absence of inflammation 0 
slight inflammation 1 
moderate inflammation 2 
marked inflammation 3 
Tail absence of nodules 0 
 presence of nodules 1 
 
 
EVALUATION: 
a) For primary lesions: The % of inhibition of paw volume of the injected left paw 
over vehicle control was measured at day 5. 
b) For secondary lesions: The percentage inhibition of paw volume of the non-
injected right paw over controls was measured at 21
st
 Day. 
c) Calculation of an arthritic index was done by summation of the scores as indicated 
above for each animal. The average of treated animals was compared with the control 
group. 
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The total percentage change was calculated by addition of percentage inhibition of 
the injected paw on day 5 + percentage inhibition of the non-injected paw on day 21 + 
percentage change of the arthritic index. 
VASCULAR PERMEABILITY EFFECT: 
Experiment animal’s husbandry:85,86,87 
The study was conducted in LIVEON BIOLABS PVT. LTD. Karnataka, INDIA 
with the experimental protocol number: LBPL-EF-048/15 for vascular permeability 
study. IAEC number LBPL-IAEC-115-06/15 Experiments were performed as per the 
guidelines prescribed by the CPCSEA, Ministry of E and F, Govt. of India. Sprague 
Dawley (7-8 weeks) Males: 167.8 -190.6 grams   Female: 172.0 – 197.0 grams. Each 
group of rats was separately housed in polypropylene cages with Animal husbandry 
conditions: Temperature -21.8-24.2
o
C,Humidity - 46-66%, Air changes - 12-16 changes 
per hour, Light cycle – 12 hours light and 12 hours dark (as per CPCSEA guidelines). 
They were provided with fed ad libitum with AMRUT Laboratory Animal Feed 
manufactured by Pranav Agro Industries Limited, Sangli, Maharashtra and Reverse 
Osmosis purified water ad libitum. All the animals were acclimatized to the laboratory 
conditions at least for 7 days prior to experimentation. 
Evans blue vascular permeability model:
85,86,87,88
 
Test procedure: After acclimatization period the animals were equally distributed into 4 
groups. Each group had 10 animals (5 Males and 5 Females) 
Administration of 1% Evans blue dye solution:  
60 minutes before the test item administration, 1% Evans blue dye solution@ 5ml/kg 
body weight was administered to all group animals through tail vein.  
Administration of Vehicle and test item:  
One hour after administration of 1% Evans blue dye solution, the G1 group animals 
were administered with vehicle alone at 10 ml per kg body weight and G2, G3 & G4 
group animals were administered with test item(Nandhi mezhugu) and palm Jaggery in 
the ratio of 1:8  at 50 mg/kg b.wt, 150 mg/kg b.wt and 500 mg/kg b.wt respectively 
through oral route by gavage as a single dose. 
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Administration of acetic acid (0.6%):  
30 minutes after the test item or vehicle administration acetic acid (0.6%) was 
administered to the all animals at 10 ml/kg b.wt through intra-peritoneal route.  
The animals were sacrificed 30 minutes after acetic acid administration and their 
peritoneal cavity was washed with normal saline (Administered 5 ml/animal through 
intraperitoneal route) and the fluid was collected and centrifuged at 2000 rpm for 10 
minutes.
89,90
 
The absorbance of supernatant was measured at 620 nm using ELISA reader. 
Observations:  
a) Clinical signs. 
b) Morbidity and mortality. 
c) Individual animal, body weights were measured and recorded. 
d) Gross Necropsy. 
e) Measurement of dye content in peritoneal fluid using ELISA reader. 
 
5.7.6 MTT Assay for Cell Protective and Cell Toxicity Effect: 
5.7.6.1 Cyto-toxicity effect of NM:
91,92,93
 
Objective 
To determine the cytotoxicity effect of NM extract and LPS. 
Principle 
 Determination of cell proliferation and cytotoxicity were measured by MTT assay 
which is a colorimetric assay, based on reduction of the yellow colored water soluble 
tetrazolium dye MTT to formazan crystals. The live cells  which   produce mitochondrial 
lactate dehydrogenase which reduces MTT to insoluble formazan crystals, which upon 
dissolution into an appropriate solvent exhibits purple color, the intensity of which is 
proportional to the number of viable cells and can be measured spectrophotometrically at 
570nm. 
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Materials 
 Cell line: RAW 264.7–Mouse macrophage cell line (From NCCS Pune)  
 Cell culture medium:  RPMI 1640: (#AL199A, Himedia) 
 Adjustable multichannel pipettes and a pipettor (Benchtop, USA) 
 Fetal Bovine Serum (#RM10432, Himedia)   
 MTT Reagent (5 mg/ml) (# 4060 Himedia) 
 DMSO (#PHR1309, Sigma) 
  Oxaliplatin (80µM) (#O9512 SIGMA) 
 D-PBS (#TL1006, Himedia) 
 LPS (#L3012, Sigma) 
 96-well plate for culturing the cells (From Corning,USA) 
 T25 flask (# 12556009, Biolite - Thermo) 
 50 ml centrifuge tubes (# 546043 TORSON) 
 1.5 ml centrifuge tubes (TORSON) 
 10 ml serological pipettes (TORSON) 
 10 to 1000 ul tips (TORSON) 
 96-well ELISA plate reader or spectrophotometer capable of measuring the        
absorbance (ELX-800 Biotek) 
 Inverted microscope (Biolink) 
 37°C incubator with humidified atmosphere of 5% CO2  (Healforce, China) 
Assay controls: 
 
(i) Medium control (without cells) 
(ii) Negative control (Medium without the experimental medicine/compound, 
 with cells)  
(iii) Positive control (medium with cells and with 80 uM of Oxaliplatin) 
 Note: Extracellular reducing components such as ascorbic acid, cholesterol, alpha-
tocopherol, dithiothreitol present in the culture media may reduce the MTT to formazan. 
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To account for this reduction, it is important to use the same medium in control as well as 
test wells. 
Procedure for Determining Cell Cytotoxicity 
Cell Seeding 
1. Seed 200μl cell suspension in a 96-well plate at required cell density (20,000 cells per 
well), without the test agent. Allow the cells to grow for about 12 hours.  
2. Add appropriate concentrations of the test agents (Mentioned in the results - Excel 
sheet). 
3. Incubate the plate for 24 hrs at 37°C in a 5% CO2 atmosphere. 
4. After the incubation period, takeout the plates from incubator, and remove spent media 
and add MTT reagent to a final concentration of 0.5mg/mL of total volume.   
5. Wrap the plate with aluminium foil to avoid exposure to light. 
6. Return the plates to the incubator and incubate for 3 hours. 
7. (Note: Incubation time varies for different cell lines. Within one experiment, incubation 
time should be kept constant while making comparisons.) 
8. Remove the MTT reagent and then add 100 µl of solubilisation solution (DMSO). 
9. Gentle stirring in a gyratory shaker will enhance dissolution.  
10. Read the absorbance on a spectrophotometer or an ELISA reader at 570nm and 
630nm used as reference wavelength. 
 
MTT assay readings and viability calculations:    
11. The Ic50 value was determined by using linear regression equation i.e. Y =Mx+C.  
Here, Y = 50, M and C values were derived from the viability graph.  
5.7.6.2 Cytoprotective studies by using MTT Assay 
Objective 
To determine the cytoprotective nature of NM extract. 
Principle 
MTT assay is a colorimetric assay based on reduction of the yellow colored water 
soluble tetrazolium dye MTT to formazan crystals, used for the determination of 
cytotoxicity and cell proliferation. MTT is reduced to insoluble formazan crystals, which 
upon dissolution into an appropriate solvent exhibit purple color, the intensity of which is 
proportional to the number of viable cells and can be measured spectrophotometrically at 
570nm by the mitochondrial lactate dehydrogenase, which is produced by live cells. 
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 Materials 
 Cell line: RAW 264.7–Mouse macrophage cell line (From NCCS Pune)  
 Cell culture medium:  
1. RPMI 1640: (#AL199A, Himedia) 
 Adjustable multichannel pipettes and a pipettor (Benchtop, USA) 
 Fetal Bovine Serum (#RM10432, Himedia)   
 MTT Reagent (5 mg/ml) (# 4060 Himedia) 
 DMSO (#PHR1309, Sigma) 
 LPS (#L3012, Sigma) 
 D-PBS (#TL1006, Himedia) 
 96-well plate for culturing the cells (From Corning,USA) 
 T25 flask (# 12556009, Biolite - Thermo) 
 50 ml centrifuge tubes (# 546043 TORSON) 
 1.5 ml centrifuge tubes (TORSON) 
 10 ml serological pipettes (TORSON) 
 10 to 1000 ul tips (TORSON) 
 96-well ELISA plate reader or spectrophotometer capable of measuring the 
absorbance        (ELX-800 Biotek) 
 Inverted microscope (Biolink) 
     37°C incubator with humidified atmosphere of 5% CO2  (Healforce, China) 
    Assay controls: 
 (i) Medium control (medium without cells) 
 (ii) Toxicity control (medium with cells treated with 25nG/mL of LPS)  
      Note: The reduction of MTT to formazan was carried out by extracellular reducing          
components such as ascorbic acid, cholesterol, alpha-tocopherol, dithiothreitol present in 
the culture media. In control as well as test wells it is essential to use the same medium to 
account for this reduction. 
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Procedure for Determining Cytoprotective nature of plant extract  
Cell Seeding for post treatment studies  
1.  Seed 200μl cell suspension in a 96-well plate at required cell density (20,000 cells 
per well), without the test agent. Allow the cells to grow for about 12 hours.  
2.  Add appropriate concentrations of LPS (Mentioned in the results - Excel sheet). 
3.  Incubate the plate for 24 hrs at 37°C in a 5% CO2 atmosphere. 
4.  After the incubation period, takeout the plates from incubator, and remove spent 
media and add appropriate concentrations of the plant extract (Mentioned in the results - 
Excel sheet). 
5.  Incubate the plate for 24 hrs at 37°C in a 5% CO2 atmosphere. 
6.  After the incubation period, takeout the plates from incubator, and remove spent 
media and add MTT reagent to a final concentration of 0.5mg/mL of total volume.   
7.  Plate should not be exposed to light. 
8.  Return the plates to the incubator and incubate for 3 hours. 
9.  (Note: Incubation time varies for different cell lines. Within one experiment, 
incubation time should be kept constant while making comparisons.) 
10. Remove the MTT reagent and then add 100 µl of solubilisation solution (DMSO). 
11. Gentle stirring needed for dissolution. Occasionally, pipetting up and down may 
be required to completely dissolve the MTT formazan crystals especially in dense 
cultures. 
12. Read the absorbance on a spectrophotometer or an ELISA reader at 570nm and 
630nm used as reference wavelength. 
MTT assay readings and viability calculations:    
13. The viability values were determined based on the OD values.   
5.7.7 Gene Expression Study: 
Sample Collection in In-Vitro: 
Control (Untreated cells) 
LPS (100nG/mL) alone Treated cells 
NM extract alone (100uG/mL) treated cells 
LPS (100nG/mL) for 24 hrs+ NM extract treated cells (100uG/mL) 
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Procedure: 
Cell Seeding for post treatment studies  
1. Seed 0.1 x 106 cell suspension in a 6-well plate having 2 ml of culture medium without 
the test agent. Allow the cells to grow for about 12 hours.  
2. Add appropriate concentrations of LPS.  
3. Incubate the plate for 24 hrs at 37°C in a 5% CO2 atmosphere. 
4. After the incubation period, takeout the plates from incubator, and remove spent media 
and add appropriate concentrations of the plant extract. 
5. Incubate the plate for 24 hrs at 37°C in a 5% CO2 atmosphere. 
6. After incubation, the spent media is removed and the cells are washed with 1 ml of D-
PBS and cells are treated with 0.5uL of trypsin-EDTA solution, Incubate the plate for 2 to 
4 min at 37°C in a 5% CO2 atmosphere. 
7. The trypsin action is neutralised by adding 1.5mL of cell culture medium and the  cells 
are allowed for centrifugation at 2000 RPM for 5 min.  
8. The supernatant is discarded and the cells are washed with D-PBS by centrifugation at 
2000 RPM for 5 min. 
9. Now the cells are used for RNA isolation.  
Sample Collection for In-Vivo model: 
Rat Paw tissues: 
a) Control group  
b) Standard drug treated group  
Test drug (High dose) treated group 
 
Extraction of RNA
94,95
 
All the plastic wares and glass wares used for this experiment were made RNase 
free by treating with DEPC for overnight and autoclaving twice at 121
o
C until the traces 
of DEPC removed. These were then dried in Hot Air Oven at 90
o
C before use.  The 
samples stored at -80
o
C were ground to powder in liquid N2 using sterile mortar and 
pestle. To the powdered sample 1ml of Trizol Reagent (Takara Bio Inc, Japan) was added 
mixed by grinding, transferred to a 2ml microfuge tube and incubated at room 
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temperature for 15 – 20 mins. It was then centrifuged at 10,000 rpm (Sigma) for 5 min 
and the supernatant was transferred to a fresh sterile microfuge tube. Equal volume of 
Chloroform :Isoamyl alcohol (24:1) was added, mixed gently and incubated in ice for 2 
minutes. After centrifuging the above at 12,000 rpm for 5 minutes the supernatant was 
transferred to a fresh vial then incubated in ice for 2 minutes after adding 500 µl of 
isopropanol. The RNA was pelleted down by centrifuging the above for 10 minutes at 
10,000 rpm and the pellet was vortexed gently with 300 µl of 70% of ethanol. 
Centrifugation at 10,000 rpm was repeated for 10 minutes and the pellet was air dried. 
20µl of RNase free water was added to the pellet and heated gently (60
o
C) to dissolve the 
pellet in water.  
DNase treatment 
The extracted RNA was treated with DNase enzyme to remove any traces of DNA 
contamination. One micro liter of DNase was added to above isolated RNA and incubated 
for 1hr at 37
o
C and after the temperature was raised to 70
o
C for 5 minutes to inactivate 
the enzyme. The RNA was stored at -20
o
C for later use.  
RNA Quanitifcation 
 The concentration and purity of RNA was assessed using a spectrophotometer 
(Sartorius). A 1µL aliquot of RNA was pipetted onto the apparatus pedestal. RNA with 
an absorbance ratio at 260 and 280 nm (A260/A280) between 1.8 and 2.2 is indicative of 
pure RNA. The concentrations of the respective samples were as mentioned below.  
cDNA synthesis 
After quantification, RNA was reverse transcribed using oligodT (Sigma Aldrich). 
Hundred nanogram of RNA was aliquot to a fresh sterile microfuge tube and 2µl of 
oligodT was added and incubated at 70
o
C for 5 minutes and immediately transferred to 
ice. To this 2µl of dNTPs, 1µl of Reverse Transcriptase enzyme (Biolabs, New England) 
and 2 µl of 10x Reverse transcriptase buffer was added and made up the volume to 25µl 
using RNase free water. This mixture was incubated at 42
o
C for 90 minutes and reaction 
was terminated by incubating at 70
o
C for 15 minutes.   
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Primersynthesis and validation : 
The primers in In-Vitro Study were designed as below and were synthesized and 
purified.  
 
Oligo name 
No of 
bases 
Sequences (5'-3') GC content % Tm (
o
C) 
Ann
ealin
g 
Tem
p 
(
o
C) 
TNF-alpha Accession No. L19123.1 Rattus norvegicus tumor necrosis factor-alpha gene, 5' end Product 
length – 713 
FP 20 GATCGGTCCCAACAAGGAGG 60 60 
57 
RP 20 CAAAGGCGGAGATGAGACCC 60 60.4 
Cox2  Accession No. NM_011198.4 Musmusculus prostaglandin-endoperoxide synthase 2 (Ptgs2), mRNA, 
complete cds Product length – 374 
FP 20 CAAGGGAGTCTGGAACATTG 50 56.03 
55 
RP 20 ACCCAGGTCCTCGCTTATGA 55 60.33 
 
The primers in In-VivoStudy were designed as below and were synthesized and purified.  
Oligo name 
No of 
bases 
Sequences (5'-3') 
GC 
content 
% 
Tm 
(
o
C) 
Annealing 
Temp 
(
o
C) 
Beta-galacturonidase  Product length 685bp 
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FP 17 AAATCTGCAAAATTCCA 29.5 43.7 
40 
RP 21 TCATTATCCTTATGCAGAAGA 33.3 48.5 
Acid phosphatase, Accession No. M27893.1 Rat acid phosphatase mRNA, complete 
cds - Product length 515 
FP 20 CGCATGACACTACCCTGGTT 55 60 
 
RP 20 AGGCTAAACCTGTCCCTCTG 55 58.7 
Cathepsin-D Accession No. NM_134334.2 Rattus norvegicus cathepsin D (Ctsd), 
mRNA - Product length 668 
FP 20 CCGTCGGACTATGACGGAAG 60 59.9 
 
RP 20 ACAGCTCCCCGTGGTAGTAT 55 60.3 
Myeloperoxidase level Accession No. AY494708.1 Musmusculus strain DBA/2 
myeloperoxidase (Mpo) gene, promoter region and partial cds Product length – 766 
FP 20 GGCATGGGACTGTTCCTGAT 55 59.74 
 
RP 21 CAGTCCCCAAGAGCTCAACTT 52.3 55.9 
C-reactive protein Accession No. NM_017096.3 Rattus norvegicus C-reactive protein 
(Crp), mRNA Product length – 425 
FP 20 GCCTTCGTATTTCCCGGAGT 55 59.8 
 
RP 20 GACTGATTCGCGTCAAAGCC 55 59.9 
TNF-alpha Accession No. L19123.1 Rattusnorvegicus tumor necrosis factor-alpha 
gene, 5' end Product length – 713 
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FP 20 GATCGGTCCCAACAAGGAGG 60 60 
 
RP 20 CAAAGGCGGAGATGAGACCC 60 60.4 
Interferon – gamma Accession No. AH002184.2 Rattus norvegicus interferon-gamma 
(IFN-G) gene, complete cds Product length – 738 
FP 20 CATGAGCATCGCCAAGTTCG 55 59.7 
 
RP 25 AGAAAGAATGATTGGTCAAAGAGGA 36 58.4 
 
A gradient PCR was performed to standardize the optimum annealing temperature of the 
designed primer using 50 ng of synthesized cDNA keeping the temperature range of 50 – 
60
o
C and found the above mentioned annealing temperatures as optimum.   
Semi quantitative Polymerase Chain Reaction 
 The PCR was done by optimizing the concentration of cDNA to 50ng across the 
sample. Each PCR reaction consisted of 1X reaction buffer (with 1.5mM MgCl2), Taq 
DNA polymerase (1Unit),  dNTP mix (2.5mM) 10pico moles of respective forward and 
reverse primers, 50ng of cDNA and the volume was made up to 20µL with PCR grade 
water. The β-Actin was used as a housekeeping gene for normalization.   
 The PCR cycle started with an initial denaturation of 94
o
C for 5 min followed by 
35 cycles of 94
o
C for 45 sec, respective annealing temperature for 30 sec and 72
o
C for 60 
sec. Post 35 cycles a final elongation at 72
o
C for 10 min was given to complete the 
reaction and was kept for holding at 4
o
C until removed.  
Agarose Gel Electrophoresis 
 To visualize the gene expression levels in terms of the band intensity, the PCR 
product was analyzed in 1.5% Agarose gel casted adding ethidium bromide as a staining 
agent. The PCR product was added to the wells in gel by mixing with 6x gel loading dye 
and 50 volts was applied until the dye front has reached more than half of the gel. The 
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bands were illuminated under UV light and the same was captured in a Gel 
documentation Unit.  
 The captured image was analyzed and the intensity of the bands was calculated 
using the GelAnalyzer software.  
Gel imaging and semi quantitative analysis 
The Agarose gel after electrophoresis was transferred to a Gel Documentation unit 
(BioBee, India) and the image was captured under UV light. The band intensity was 
measured using the software GelAnalyzer2010a.  
Quantification: 
The calculations are as follows 
Step 1. 
Normalizing GAPDH= GAPDH Sample - GAPDH Control  
Step 2. Normalizing Samples=(Sample value - Normalized GAPDH value) - Control 
value 
Step 3. Fold Change=(Normalized value/Control value)x100;  
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6. PATIENTS AND CLINICAL METHODS 
 
6.1 Clinical study: 
6.1.1 Aim 
To evaluate the therapeutic efficacy of Nandhi Mezhugu (NM) for Uthiravatha 
Suronitham(Rheumatoid Arthritis) at different point of time (15
th
 ,29
th
 , 43
th
 , 60
th
 day) by 
observing the clinical findings. 
6.1.2 Secondary objective:  
    To study the clinical laboratory parameters related to RA (RA Factor, Anti CCP, 
CRP, ESR, etc.,) 
6.1.3 Study Design: 
Phase II:  
An open clinical study with coded Siddha Herbo Mineral Sasthric formulation NM 
was conducted in 40 Uthira Vatha Suronitham (Rheumatoid Arhritis) patients. 
Dosage of NM: 500 mg with Palm Jaggery twice a day after food. 
Duration of drug administration: 60 days (7 days medicine followed by 7 days drug 
holiday). 
6.1.4 Study period: 
  Main study-2 years 
Method of drug administration:  
The medicine was given by the following fashion – 7 days medicine –followed by a 
break of 7 days again 7 days medicine followed by a break of 7 days likewise the 
medicine was repeated for 60 days. 
Rationale behind Marupathiyam (i.e re-dieting): NM being a mercurial preparation re-
dieting must be observed during administration of these drugs. 
Dietary Regimen: 
The patients were instructed not to take non-vegetarian diet and also reduce 
tamarind and salt (salt used must be roasted before consumption)as per siddha text. 
6.1.5 Study place: 
 OPD & IPD of Ayothidoss Pandithar Hospital, 
 National Institute of Siddha, 
 Tambaram Sanitorium, Chennai-47. 
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6.1.6 Population and Sample: 
18-60 years age group fulfilling all the inclusion criteria and passing the exclusion criteria 
mentioned below. 
The sample consists of patients attending the OPD & IPD of  Ayothidoss Pandithar 
Hospital, National Institute of Siddha. 
Sample Size: 
Phase II- 40 Uthira Vathasuronitham (Rheumatoid arthritis) patients 
6.1.7 SELECTION CRITERIA: 
Inclusion Criteria: 
  Age : 18-60 years 
  Sex : Both Male and Female  
  Pain and swelling in smaller and larger joints. 
  Symmetrical joints involvement. 
  More than 3 joints involvement. 
  Fever 
  Morning stiffness. 
  Serum positive Anti CCP 
Exclusion Criteria: 
  Diabetes Mellitus 
  Hypo & Hyperthyroidism. 
  Hypertension. 
  Cardiac diseases. 
  Renal diseases. 
  Liver disorders 
  Neurological disorder 
  Pregnancy and lactation 
  Alcoholism 
  Recent treatment with steroids 
 
Withdrawal criteria: 
  Not coming for regular follow up/check up 
  Intolerance to the drug, and development of adverse reaction during the drug trial. 
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  Severe abdominal pain. 
  Any other acute illness. 
  Poor patient compliance and defaulters 
  Patients who were unwilling to continue in the course of clinical study. 
  Any other unforeseen circumstances rendering the patients unable to continue with the 
study. 
6.1.8 Specification of tests: 
 Anti-CCP 
 Acute phase protein: C-reactive protein 
 Rheumatoid factor 
 Pain score (The National Initiative on Pain Control™ 
(NIPC™),  
 Restricted movement assessment scale (BearingPoint, Atos 
Healthcare &amp; DSP Copyright EBM Rheumatoid Arthritis 
Version 5.0 final) 
 (Modified Health Assessment Questionnaire- MHAQ, 
Disability index) Source: Pincus T, Yazici Y, Bergman M. 
Development of a modified health assessment questionnaire 
(MHAQ) for the infrastructure of standard clinical care. Clin Exp 
Rheumatol. 2005;23(Suppl 39):S19-S28. 
Routine Laboratory investigation: 
Blood  
   Hb gms% 
   TC cells/cumm 
   DC –P% L% E% M% B% 
   ESR at 30 minutes –mm at 60 minutes-mm 
   Blood sugar- Fasting mgs% 
   Blood sugar- PP mgs% 
   Serum cholesterol mgs% 
   HDL mgs% 
   LDL mgs% 
   Triglycerides mgs% 
   LFT, RFT 
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   Urine Examination 
   Sugar  
   Fasting  
   PP 
   Albumin 
   Deposits 
   X-Ray –Joints (if needed) 
6.2 Siddha Diagnostic tool: 
Patients were screened by siddha diagnostic method that is Envagai thervu ,was 
carried out in all the enrolled patients .Siddha clinical assessment was also carried out in 
all the enrolled cases. 
6.3 Outcome: 
Primary outcome: 
    Reduction of pain and swelling of the joints (Universal pain assessment scale-The 
National Initiative on Pain Control™ (NIPC™),96 
  Improvement in the movement of the affected joints 
97
(Restricted movement 
assessment scale, ref -BearingPoint, Atos Healthcare &amp; DSP Copyright EBM 
Rheumatoid Arthritis Version 5.0 final) 
Reduction of disability(Ref: Modified Health Assessment Questionnaire- MHAQ, 
Disability index) 
98
 
Secondary outcome: 
  Reduction of other clinical symptoms 
  Reduction of ESR and CRP 
  Reduction in Anti-CCP and RA Factor 
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7. OBSERVATION AND RESULTS 
7.1. Organoleptic properties of study drug Nandhi Mezhugu 
Colour: Dark brown colour; Odour: Resinous odour; Taste: Metallic taste; 
Consistency: Semisolid. 
7.2. Physico-chemical analysis of Nandi mezhugu: 
 
 
      Table No:7.2.1. Physico-chemical analysis of Nandi mezhugu 
 
 
S.No 
 
Parameter 
 
Mean 
 
1. 
 
Loss on drying at 105° C  
19.156 % 
2. 
 
Total Ash 6.607 % 
3. 
 
Water soluble ash  
2.95 % 
4. 
 
Acid-insoluble ash  
0.93 % 
5. 
 
Water soluble extractive  
39.056 % 
6.  pH   
3.35 
7. 
 
Rancidity Nil 
8. 
 
Acid value 10.592 
9. 
 
Saponification value 262.62 
10. 
 
Iodine value 
 
16.864 
11. 
 
Fat content 20.683 % 
12. 
 
 
Reducing Sugar 
 
3.69 % 
13. 
 
 
Total Sugar 
 
7.54 % 
14 Alcohol Soluble Extractive 23.558% 
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7.3. PRELIMINARY PHYTOCHEMICAL ANALYSIS OF NANDHI MEZHUGU 
Table No: 7.3.1.Preliminary phytochemical analysis of Nandhi mezhugu 
 
Sl. No 
Phytochemicals Inference 
1. 
 
Steroid Present 
2. 
 
Triterpene Present 
3. 
 
Flavonoids Present 
4. 
 
Alkaloids Present 
5. Phenol Present 
6. 
 
Tannin Present 
7. 
 
Saponin Present 
8. 
 
Coumarin Present 
9. 
 
Glycoside Present 
10. 
 
Quinone Present 
  
Result of Qualitative Inorganic Analysis 
The qualitative inorganic analysis of the drug revealed the presence of mercury, 
magnesium, aluminium, calcium, sodium, potassium, copper, zinc, iron, cobalt, chloride, 
carbonate, nitrate, sulphate, sulphide, arsenate, acetate, silicate which are all biologically 
important radicles. 
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7.4. QUALITATIVE INORGANIC ANALYSIS OF NANDI MEZHUGU 
       Table No: 7.4.1. Qualitative inorganic analysis of Nandhi mezhugu 
S.No Cation/Anion Inference 
1 Mercury Present 
2 Magnesium Present 
3 Aluminium Present 
4 Calcium Present 
5 Sodium Present 
6 Potassium Present 
7 Copper Present 
8 Zinc Present 
9 Iron Present 
10 Cobalt Present 
11 Chloride Present 
12 Carbonate Present 
13 Nitrate Present 
14 Sulphate Present 
15 Sulphide Present 
16 Arsenate Present 
17 Acetate Present 
18 Silicate Present 
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 7.5. Heavy metal analysis  
   Table No: 7.5.1. Heavy metals present in Nandhi mezhugu 
 
 
Heavy metal 
 
Quantity (in ppm) 
 
Lead (as Pb) 
 
2.95 
                                              
Arsenic (as As)   
 
7233.42 
 
Cadmium (as Cd) 
 
0.01 
 
Mercury (as Hg) 
 
9336.61 
7.6. Microbial contamination  
In the microbial study, the drug was found free from E. coli, Salmonella spp., 
Staphlococcus aureus and Enterobacteriacea.  
Table No: 7.6.1.Microbial contamination results of Nandhi mezhugu 
S. No Parameter Detection of 
Microbes 
WHO Limit (CFU/g) 
1.  E. coli Absent 10 
2.  Salmonella spp. Absent None 
3.  Staphylococcus aureus Absent Absent 
4.  Enterobacteriacea Absent 103 
5.  Total Bacterial count 2x103CFU/gm 105 
6.  Total Fungal count Less than 10 
CFU/gram 
10
3
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7.7. Pesticide residue: 
Table No: 7.7.1. Pesticide residue 
Pesticide residue Level in mg/kg 
alphaBHC BLQ (LOQ : 0.01) 
BetaBHC BLQ (LOQ: 0.01) 
gam BHC (Lindane) BLQ (LOQ : 0.01) 
DeltaBHC BLQ (LOQ : 0.01) 
Aldrin BLQ (LOQ : 0.01) 
Dieldrin BLQ (LOQ : 0.01) 
trans Chlordane BLQ (LOQ : 0.01) 
cis Chlordane BLQ (LOQ : 0.01) 
Endrin BLQ (LOQ : 0.01) 
Endrinaldehyde BLQ (LOQ : 0.01) 
Endrinketone BLQ (LOQ : 0.01) 
Endosulfan-I BLQ (LOQ : 0.01) 
Endosulfan-II BLQ (LOQ : 0.01) 
Endosulfansulfate BLQ (LOQ : 0.01) 
Heptachlor BLQ (LOQ : 0.01) 
Heptachlorepoxide BLQ (LOQ : 0.01) 
Dicofol BLQ (LOQ : 0.01) 
Chlorthalonil BLQ (LOQ : 0.01) 
Hexachlorobenzene BLQ (LOQ : 0.01) 
o,p"DDT BLQ (LOQ : 0.01) 
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P,P"DDT BLQ (LOQ : 0.01) 
o,p"DDD BLQ (LOQ : 0.01) 
p,p"DDD BLQ (LOQ : 0.01) 
o,p"DDE BLQ (LOQ : 0.01) 
P,P"DDE BLQ (LOQ : 0.01) 
4-Bromo,2-Chlorophenol BLQ (LOQ : 0.01) 
Acephate BLQ (LOQ : 0.01) 
Chlorfenvinphos BLQ (LOQ : 0.01) 
Chlorpyrifos BLQ (LOQ : 0.01) 
Chlorpyrifos methyl BLQ (LOQ : 0.01) 
Diazinon BLQ (LOQ : 0.01) 
Dichlorvos BLQ (LOQ : 0.01) 
Dimethoate BLQ (LOQ : 0.01) 
Ethion BLQ (LOQ : 0.01) 
Etrimfos BLQ (LOQ : 0.01) 
Fenitrothion BLQ (LOQ : 0.01) 
Iprobenphos BLQ (LOQ : 0.01) 
Malathion BLQ (LOQ : 0.01) 
Methamidophos BLQ (LOQ : 0.01) 
Monocrotophos BLQ (LOQ : 0.01) 
Omethoate BLQ (LOQ : 0.01) 
Oxydemeton-methyl BLQ (LOQ : 0.01) 
Parathion ethyl BLQ (LOQ : 0.01) 
Parathion methyl BLQ (LOQ : 0.01) 
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 BLQ: Below limit of Quantification /LOQ- Limit of quantification 
7.8. Quantitative Assays results of Nandhi mezhugu 
                  Table No:7.8.1. Assays results of Nandhi mezhugu 
Inorganic Compounds Value in mg/kg 
 
Calcium (as Ca) 
 
3165.72 
 
Magnesium(as Mg) 
 
358.72 
 
Potassium (as K) 
 
1950.25 
 
Aluminum (as Al) 
 
4943.37 
 
Copper (as Cu) 
 
501.35 
 
Iron (as Fe) 
 
497.30 
 
Zinc (as Zn) 
 
26.290 
 
Sulphur (as SO2) 
 
BLQ (LOQ : 10.0) 
 
Chloride (as NaCl) 
 
0.03 
      
   BLQ: Below limit of Quantification /LOQ- Limit of quantification 
Phorate BLQ (LOQ : 0.01) 
Phosalone BLQ (LOQ : 0.01) 
Phosphamidon BLQ (LOQ : 0.01) 
Profenophos BLQ (LOQ : 0.01) 
Quinalphos BLQ (LOQ : 0.01) 
Triazophos BLQ (LOQ : 0.01) 
Phorate sulphone BLQ (LOQ : 0.01) 
Phorate sulphoxide BLQ (LOQ : 0.01) 
146 
 
 
7.9. Test for Aflatoxins (B1,B2,G1,G2): 
All the four aflatoxin were not detected in the drug.  
Table No:7.9.1. Test for Aflatoxins (B1,B2,G1,G2): 
 
Test 
 
Observed Result 
 
Aflatoxins B1 
 
BLQ(LOQ:0.5) µg/kg 
 
Aflatoxins B2 
 
BLQ(LOQ:0.5) µg/kg 
 
Aflatoxins G1 
 
BLQ(LOQ:0.5) µg/kg 
 
Aflatoxins G2 
 
BLQ(LOQ:0.5) µg/kg 
  
      BLQ: Below limit of Quantification /LOQ- Limit of quantification 
 
7.10. Results and Discussion of TLC and HPTLC 
         The TLC photodocumentation of hexane extract of Nandi mezhugu under UV 254 
nm showed 5 visible spots at Rf value 0.25, 0.30, 0.38, 0.50 and 0.71 (all green); under 
UV 366 nm showed three visible spots at Rf value 0.30 (blue), 0.38 (fluorescent blue) and 
0.71 (pale blue). After derivatization with vanillin-sulphuric acid, showed 8 spots at 0.20, 
0.25, 0.30, 0.35 (all purple), 0.38 (brown), 0.46, 0.57 and 0.71 (all purple).  
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Table No: 7.10.1.TLC spots of hexane extract of Nandhi mezhugu 
Under UV 254 nm Under UV 366 nm 
White light after 
derivatization 
 
Rf Colour Rf Colour Rf Colour 
- 
 
All green 
- - 0.20 Purple 
0.25 - - 0.25 Purple 
0.30 0.30 Blue 0.30 Purple 
0.38 - - 0.35 Purple 
- 0.38 
Fluorescent 
blue 
0.38 Brown 
0.50 - - 0.46 Purple 
- - - 0.57 Purple 
0.71 0.71 Pale blue 0.71 Purple 
 
 
   
UV 254 nm UV 366 nm White light after dipping in 
vanillin-sulphuric acid 
Figure 7.10.1.TLC photodocumentation of hexane extract of Nandi mezhugu 
Solvent system - Toluene : Ethyl acetate (10:0.5, v/v) 
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Figure: 
7.10.2.HPTLC finger print profile of hexane extract of Nandi mezhugu at 254 nm 
 
Figure.7.10.3.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of hexane extract of Nandi mezhugu at 254 nm 
 
 
The HPTLC finger print profile of hexane extract at UV 254 nm showed 12 peaks 
in which the peak at Rf 0.84 was the major peak with an area of 54.90 % followed by a 
peak at Rf 0.29 with an area of 11.66 %. All other peaks are minor with an individual area 
less than 10 %. 
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Figure.7.10.4.3D chromatogram of hexane extract of Nandi mezhugu at 254 nm 
 
 
Figure.7.10.5. HPTLC finger print profile of hexane extract of Nandi mezhugu at 
366 nm 
 
 
Figure.7.10.6.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of hexane extract of Nandi mezhugu at 366 nm 
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          The HPTLC finger print profile of hexane extract at UV 366 nm showed 8 peaks in 
which the peak at Rf 0.85 was the major peak with an area of 39.57 % followed by a peak 
at Rf 0.29 (19.43 %), 0.09 (13.40 %) and 0.37 (11.59 %). All other peaks are minor with 
an individual area less than 10 %. 
 
 
Figure.7.10.7.3D chromatogram of hexane extract of Nandi mezhugu at 366 nm 
 
 
Figure.6.10.8.HPTLC finger print profile of hexane extract of Nandi mezhugu at 575 
nm 
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Figure.7.10.9.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of hexane extract of Nandi mezhugu at 575 nm 
 
         The HPTLC finger print profile of hexane extract at 575 nm showed 10 peaks in 
which the peak at Rf  0.73 was the major peak with an area of 59.17 % followed by a peak 
at Rf 0.59 (14.35 %), 0.22 (8.02 %) and 0.47 (6.25 %). All other peaks are minor with an 
individual area less than 10 %. 
 
   
 
Figure.7.10.10.3D chromatogram of hexane extract of Nandi mezhugu at 575 nm 
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UV 254 nm UV 366 nm White light after dipping in 
vanillin-sulphuric acid 
Figure.7.10.11.TLC photodocumentation of chloroform extract of Nandi mezhugu 
Solvent system - Toluene : Ethyl acetate (5:1.5, v/v) 
 
 
 
 
Table .7.10.2.TLC spot of chloroform extract of Nandi mezhugu 
 
Under UV 254 nm Under UV 366 nm White light after 
derivatization 
 
Rf Colour Rf Colour Rf Colour 
0.16 Green - - 0.17 Peacock blue 
- - 0.47 Fluorescent blue 0.22 Brown 
- - - - 0.36 Purple 
- - - - 0.53 Purple 
0.71 Green 0.70 Fluorescent blue - - 
0.75 Pale blue 0.76 Fluorescent blue 0.74 Purple 
0.82 Pale blue 0.83 Fluorescent blue - - 
0.85 Green 0.94 Fluorescent blue - - 
- - - - 0.91 Purple 
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Figure.7.10.12.HPTLC finger print profile of chloroform extract of Nandi mezhugu 
at UV 254 nm 
 
 
 
Figure.7.10.13.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of chloroform extract of Nandi mezhugu at UV 254 nm 
  
 
154 
 
         
 
Figure.7.10.14.3D chromatogram of chloroform extract of Nandi mezhugu at UV 
254 nm 
 
 
        The HPTLC finger print profile of chloroform extract at UV 254 nm showed 9 peaks 
in which the peak at Rf 0.12 was the major peak with an area of 56.90 %. All other peaks 
are minor appearing at Rf 0.17, 0.29, 0.56, 0.61, 0.73, 0.78, 0.85 and 0.89 with an 
individual area less than 10 %. 
 
 
155 
 
Figure.7.10.15.HPTLC finger print profile of chloroform extract of Nandi mezhugu 
at UV 366 nm 
 
 
Figure.7.10.16.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of chloroform extract of Nandi mezhugu at UV 366 nm 
 
 
         The HPTLC finger print profile of chloroform extract at UV 366 nm showed 9 
peaks in which the peak at Rf 0.77 was the major peak with an area of 53.15 % followed 
by a peak at Rf 0.84 (23.00 %). Other peaks appeared at Rf 0.13, 0.28, 0.33, 0.38, 0.47, 
0.57 and 0.61 with an individual area contribution of less than 10 %. 
 
 
 
 
Figure.7.10.17.3D chromatogram of chloroform extract of Nandi mezhugu at UV 
366 nm 
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Figure.7.10.18.HPTLC finger print profile of chloroform extract of Nandi mezhugu 
at 575 nm 
 
 
 
Figure.7.10.19.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of chloroform extract of Nandi mezhugu at 575 nm 
 
         The HPTLC finger print profile of chloroform extract at 575 nm showed 10 peaks in 
which the peak at Rf 0.12 was the major peak with an area of 36.74 % followed by a peak 
at Rf  0.72 (12.76%), 0.36 (9.84%), 0.51 (8.16%), 0.91 (7.33%), 0.29 (6.82%) and all 
other peaks are minor with an individual area less than 5 %. 
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Figure.7.10.20.3D chromatogram of chloroform extract of Nandi mezhugu at 575 
nm 
 
 
  
  
UV 254 nm UV 366 nm White light after dipping in 
vanillin-sulphuric acid 
Figure.7.10.21.TLC photodocumentation of ethanol extract of Nandi mezhugu 
Solvent system - Toluene : Ethyl acetate (5:1.5, v/v) 
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Figure.7.10.22.HPTLC finger print profile of ethanol extract of Nandi mezhugu at 
UV 254 nm 
 
Figure.7.10.23.Rf value of peaks with percentage peak area of HPTLC finger print 
profile of ethanol extract of Nandi mezhugu at UV 254 nm 
  
 
          The HPTLC finger print profile of ethanol extract at UV 254 nm showed 9 peaks in 
which the peak at Rf 0.19 was the major peak with an area of 41.80 % followed by a peak 
at Rf  0.65 (15.14%), 0.32 (14.32%), 0.54 (11.93%), 0.99 (8.20%)  and all other peaks are 
minor with an individual area less than 5 %. 
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Figure.7.10.24.3D chromatogram of ethanol extract of Nandi mezhugu at UV 254 
nm 
 
      Figure 7.10.25 HPTLC finger print profile of ethanol extract of Nandi 
mezhugu at UV 366 nm 
 
Figure 7.10.26. Rf value of peaks with percentage peak area of HPTLC finger print 
profile of ethanol extract of Nandi mezhugu at UV 366 nm 
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        The HPTLC finger print profile of ethanol extract at UV 366 nm showed 9 peaks in 
which the peak at Rf 0.65 was the major peak with an area of 32.83 % followed by a peak 
at Rf  0.37 (22.64%), 0.31 (13.26%), 0.99 (8.06%), 0.58 (6.89%), 0.28 (6.57%) and other 
peaks at Rf  0.52, 0.22 and 0.09 are minor with an individual area less than 5 %. 
 
 
 
Figure.7.10.27.3D chromatogram of ethanol extract of Nandi mezhugu at UV 366 nm 
 
 
Figure 7.10.28 HPTLC finger print profile of ethanol extract of Nandi mezhugu at 
UV 575 nm 
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Figure 7.10.29. Rf value of peaks with percentage peak area of HPTLC finger print 
profile of ethanol extract of Nandi mezhugu at UV 575 nm 
   
        The HPTLC finger print profile of ethanol extract at 575 nm showed 9 peaks in 
which the peaks at Rf 0.62 (18.86%), 0.67(17.52 %), 0.19 (14.40 %), 0.49 (14.32%), 0.55 
(13.55 %) and 0.30 (8.89 %) were the major peaks. The other peaks at Rf  0.73 (2.92 %) 
and 0.96 (3.38 %) were minor. The peak at Rf 0.01 was not µconsidered as it is very close 
to the spotting position. 
 
Figure.7.10.30.3D chromatogram of ethanol extract of Nandi mezhugu at UV 575nm 
Any changes due to various concentrations of extract (eg- 5,10,15 micro liter) can be 
inferred from 3D chromatogram of the extract at UV254nm,UV 366nm,UV 575nm. 
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Figure.7.11.Results and Discussion: 
Acute toxicity studies Table 7.11.1.Behaviour changes in acute toxicity study 
(+ indicates that the particular behaviour is present and – indicates absence of the 
behaviour in animals)  
Note:1.Alertness 2. Aggressiveness 3. Piloerection 4. Grooming 5.Gripping 6. Touch 
Response 7. Decreased Motor Activity 8.Tremors 9.Convulsions 10. Muscle Spasm 11. 
Catatonia 12. Muscle relaxant 13. Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhoea 18.Writhing 19. Abnormal Respiration 20. Mortality. 
The limit dose of 2000 mg/kg Nandhi mezhugu (NM) did not cause mortality or any sign 
of acute toxicity, in the three rats on single dosing by oral route, for a short period (48 h) 
and long period (14 days). No behavioural changes and death were observed at the end of 
the treatment Table 7.11.1. Similarly, subsequent study with 50, 300 and 2000 mg/kg did 
not show any significant differences in bodyweight between control and treated groups 
during this period (Table 7.11.2). 
Dose mg/kg Behavioural Change 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Control (Palm 
jaggery 
solution) 
+ - - + + + - - - - - - - - - - - - - - 
NM 
(50mg/kg) 
+ - - + + + - - - - - - - - - - - - - - 
NM 
(300mg/kg) 
+ - - + + + - - - - - - - - - - - - - - 
NM 
(2000mg/kg) 
+ - - + + + - - - - - - - - - - - - - - 
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    Table 7.11.2. Feed intake chart  
Days Vehicle control 
(Palm jaggery 
solution) 
Low dose NM 
(50mg/kgb.wt) 
Mid Dose NM 
(300mg/ kg b.wt) 
High dose NM 
(2000mg/kg 
b.wt) 
1 78.4 78.6 79.1 80.0 
2 74.5 74.7 75.1 76.3 
3 75.4 75.3 75.5 76.1 
4 73.8 73.5 74.1 77.3 
5 74.8 74.9 75.3 76.3 
6 73.7 73.6 74.1 76.5 
7 76.2 76.1 77.2 78.4 
8 77.3 78.1 76.9 77.5 
9 78.1 78.3 78.9 78.1 
10 72.9 73.1 74.2 76.1 
11 73.4 73.5 74.2 75.2 
12 75.2 75.1 76.1 77.2 
13 74.1 74.3 75.3 76.7 
14 75.2 75.5 76.1 76.9 
   There was no treatment related changes in the feed intake by all the dose groups during 
the observation period of 14 days. 
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7.12. Sub-acute toxicity study: 
Table No:7.12.1:Effect of Nandhi Mezhugu on Body weight of experimental Wistar 
rats in Sub-acute toxicity study 
Groups Days and Body Weight in Mean and SE 
D-0 D- 8 D- 14 D-27 D- 41 Day 56 
(Wt. gain Vs 
Day 0) 
Vehicle control (Palm 
jaggery solution) gm/bwt 
237.6 
± 
31 
241.3 
± 
31 
244.1 
± 
32 
259.6 
± 
39 
275.8 
± 
42 
279.6 
± 
44 (42.0 g) 
Low dose (NM) 9mg/kg 
b.wt. 
232.0 
± 
17 
255.4 
± 
21 
258.4 
± 
22 
272.6 
± 
25 
285.2 
± 
27 
292.8 
± 
29 (60.8 g) 
Mid Dose(NM) 45mg/kg 
b.wt. 
204.1 
± 
8 
225.6 
± 
13 
228.4 
± 
13 
240.4 
± 
17 
253.3 
± 
19 
262.2 
± 
21 (58.1g) 
High dose(NM) 90mg/kg 
b.wt. 
217.3 
± 
9 
244.5 
± 
12 
248.4 
± 
13 
259.5 
± 
17 
274.3 
± 
20 
282.9 
± 
22 (65.6g) 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.005 is considered as significant  .In the above 
table all are non –significant. 
 
Recovery Groups 
Groups Day 0 Day 8 Day 14 Day 27 Day 41 Day 56 (Wt. 
gain Vs Day 
0) 
Day 69 
(wt.gainVs 
Day56) 
p-value 
Recovery control 
(Palm jaggery 
solution) 
246.1 
± 
30 
251.8 
± 
31 
256.0 
± 
31 
267.5 
± 
37 
281.6 
± 
41 
289.8 
± 
42(43.7 g) 
299.6 
± 
44 (9.8g) 
>0.05 
 
High dose 
recovery(NM) 
90mg/kg b.wt 
205 
± 
16 
227.1 
± 
20 
231.3 
± 
21 
240.8 
± 
23 
253 
± 
27 
261.8 
± 
30(56.8 g) 
270.3 
± 
31(8.5g) 
>0.05 
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All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.005 is considered as significant. While comparing 
the above two , it was found non-significant. 
Table No:7.12.2 Feed intake of animals in Sub-acute toxicity study 
Weeks Vehicle 
control 
Low 
dose 
Mid 
Dose 
High 
dose 
Control  
Recover
y 
High Dose 
Recovery 
1 78.2 78 78.7 78.6 78.4 78.9 
2 76.5 76.3 77.1 77.9 76.2 78.1 
3 77.9 77.7 77.5 78.2 78.1 78.7 
4 76.9 76.7 78.2 77.9 76.2 78.2 
5 77.2 77.5 78.7 78.9 77.5 79.2 
6 78.1 78.7 79.2 79.7 78.2 80.1 
7 76.5 76.8 78.1 78.7 76.4 78.9 
8 76.4 77.1 78.6 79.1 76.2 80.4 
9 - - - - 77.6 79.7 
10 - - - - 76.5 80.9 
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Effect of NM on Histopathalogical changes in Rat organs Sub 
acute Toxicity study 
SPECIMEN 
Study no: LBPL-HP-004/15 
Liver: Normal, H&Ex10  Kidney : Normal, H&Ex10 
Lungs:  Normal, H&Ex10 Spleen : Normal, H&Ex10 
 
 
 
 
 
 
 
 Brain : Normal, H&Ex10 
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Study no: LBPL-HP-004/15 (Sub acute Toxicity study) 
 
NHRF(1),Liver: Mononuclear cell 
infiltration, H&E X10 
RCF(1), Liver : Mononuclear cell 
infiltration, H&E X10 
 
RCF(1), Lungs: Perivascular Mononuclear 
cell infiltration, H&E X10 
 
RCF(1), Spleen: Cyst, H&E X10 
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Study no: LBPL-HP-004/15 (Sub acute Toxicity study) 
NHRF -2, Lungs: Perivascular 
Mononuclear cell infiltration, H&E X10 
NCF-1, Brain: Mononuclear cell 
infiltration, H&E X10 
 
NHRF (3), Brain: Mononuclear 
cell infiltration, H&E X10 
 
NHM (5), Kidney: Cysts H&E X4 
 
RCM (2), Liver: Mononuclear cell 
infiltration, H&E X10 
 
RCM (2), Lungs: Perivascular 
Mononuclear cell infiltration, H&E X10 
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Study no: LBPL-HP-004/15 (Sub acute Toxicity study) 
 
NHF(5), Liver: Mononuclear cell 
infiltration, H&E X10 
 
NHF(5), Heart: Mononuclear cell 
infiltration, H&E X10 
 
NHRM (2), Liver: Mononuclear cell 
infiltration, H&E X10 
 
NHF(1), Lungs: Lungs: Perivascular 
Mononuclear cell infiltration, H&E X10 
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HISTOPATHOLOGY REPORT 
In-house ref no: LBPL-HP-004/15 (Sub acute Toxicity study) 
Species and strain: Rats 
Tissue for histopathology: Liver, Kidneys, Lungs, Heart, Spleen, Stomach, Brain, skin, 
femur bone 
The tissue samples from the study were preserved in 10% Neutral Buffered Formalin 
were processed by paraffin embedding method, sectioned and stained with Heamatoxylin 
& eosin stain. The stained tissue sections (Liver, Kidneys, Lungs, Heart, Spleen, 
Stomach, Brain, skin and femur bone) from different groups were examined 
microscopically for histopathological changes.   
RESULTS:  
The various histopathological or microscopic changes in the organs/ tissues are recorded 
in their respective ‗Individual Animal Histopathology Report‘ formats.  
There were no treatment related changes in the organs/tissues examined at different dose 
level at differnent groups. The changes noticed were considered as incidental and 
spontaneous in nature to this particular species and strain of animal (Refer Table 1A): 
Table 1A: INDIVDUAL ANIMAL HISTOPATHOLOGY FINDINGS 
Sample no. Tissue/Organ Histopathology 
findings/Observations 
NHRF(1) 
Nandhimezhugu High dose recovery Female 
Liver Mononuclear cell 
infiltration- minimal 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHRM (1) 
Nandhimezhugu High dose Recovery Female 
Liver NAD 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
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Brain NAD 
Skin NAD 
Femur bone NAD 
RCF (1) 
Recovery control Female 
Liver Mononuclear cell 
infiltration- minimal 
Kidneys NAD 
Lungs Preivascular 
Mononuclear cell 
infiltration- minimal 
Heart NAD 
Spleen Capsule-cyst, focal 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHRF -2 
Nandhimezhugu High dose recovery Female 
Liver NAD 
Kidneys NAD 
Lungs Preivascular 
Mononuclear cell 
infiltration- minimal 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
Note: NAD-No Abnormalities Detected, Degree of severity=1-minimal, 2-mild, 3-moderate, 
4- marked/severe. 
Table 1A (Cont..): INDIVDUAL ANIMAL HISTOPATHOLOGY FINDINGS 
Sample no. Tissue/Organ Histopathology 
findings/Observations 
NCF-1 
Nandhimezhugu Control Female 
Liver NAD 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain Mononuclear cell infiltration- minimal, 
focal 
Skin NAD 
Femur bone NAD 
NHM (1) 
Nandhi mezhugu High Dose Male 
Liver NAD 
Kidneys NAD 
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Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHRF (3) 
Nandhi Mezhugu High Dose 
Recovery Female 
Liver NAD 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain Mononuclear cell infiltration- minimal, 
focal 
Skin NAD 
Femur bone NAD 
NCM (1) 
Nandhi Mezhugu Control Male 
Liver NAD 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
Note: NAD-No Abnormalities Detected, Degree of severity=1-minimal, 2-mild, 3-moderate, 
4- marked/severe. 
 
Table 1A (Cont..): INDIVDUAL ANIMAL HISTOPATHOLOGY FINDINGS 
Sample no. Tissue/Organ Histopathology 
findings/Observations 
NHM (5) 
Nandhi Mezhugu High dose Male 
Liver NAD 
Kidneys Cortex-Cysts, multiple 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
RCM (2) 
Nandhi Mezhugu  Recovery Control Male 
Liver Mononuclear cell infiltration- 
minimal, focal 
Kidneys NAD 
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Lungs Preivascular Mononuclear cell 
infiltration- minimal 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHRM (3) 
Nandhi Mezhugu High dose recovery 
Control Male-3 
Liver NAD 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHF(5) 
Nandhi Mezhugu  High dose Female 
Liver Mononuclear cell infiltration- 
minimal 
Kidneys NAD 
Lungs NAD 
Heart Mononuclear cell infiltration- 
minimal, focal-pericardium 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
 
Note: NAD-No Abnormalities Detected, Degree of severity=1-minimal, 2-mild, 3-moderate, 
4- marked/severe. 
 
Table 1A (Cont..): INDIVDUAL ANIMAL HISTOPATHOLOGY FINDINGS 
Sample no. Tissue/Organ Histopathology 
findings/Observations 
NHRM (2) 
Nandhi Mezhugu  High dose recovery Male 
Liver Mononuclear cell 
infiltration- minimal, 
focal 
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Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHF (4) 
Nandhi Mezhugu  High dose Female 
Liver NAD 
Kidneys NAD 
Lungs NAD 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
NHF(1) 
Nandhi Mezhugu  High dose Female 
Liver NAD 
Kidneys NAD 
Lungs Preivascular 
Mononuclear cell 
infiltration- minimal 
Heart NAD 
Spleen NAD 
Stomach NAD 
Brain NAD 
Skin NAD 
Femur bone NAD 
 
Note: NAD-No Abnormalities Detected, Degree of severity=1-minimal, 2-mild, 3-moderate, 
4- marked/severe. 
 
Table No: 7.12.3.Effect of Nandhi Mezhugu on Hematological Parameters of 
experimental Wistar rats in Sub-acute toxicity study 
 
Groups WBC × 
10
9
/L 
Lymp
h  × 
10
9
/L 
Mon × 
10
9
/L 
Gran 
× 
10
9
/L 
Lymp
h % 
Mono 
% 
Gran 
% 
RBC 
× 
10
12
/L 
HGB 
g/dL 
Vehicle 
control (Palm 
jaggery 
solution) 
3.51 
± 
1.1 
2.56 
± 
0.9 
0.1 
± 
0.03 
0.8 
± 
0.3 
61.6 
± 
12 
2.95 
± 
0.8 
18.83 
± 
4 
5.34 
± 
1.4 
8.63 
± 
2.9 
Low dose 
(NM)9mg/kg 
b.w 
8.23 
± 
1.3**
 
5.55 
± 
0.8 
0.4 
± 
0.07**
 
2.3 
± 
0.4 
61.9 
± 
7 
3.91 
± 
0.4 
24.19 
± 
3 
7.35 
± 
1.3 
14.56 
± 
1.7** 
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Mid 
dose(NM) 
45mg/kg b.w 
12.02 
± 
1.5**
 
8.91 
± 
1.3**
 
0.5 
± 
0.06**
 
2.7 
± 
0.32** 
71.9 
± 
3.5 
4.25 
± 
0.6 
23.83 
± 
3 
9.83 
± 
0.7* 
15.80 
± 
1.2** 
High 
dose(NM) 
90mg/kg b.w 
3 
± 
0.5 
2.15 
± 
0.3 
0.1 
± 
0.02 
0.8 
± 
0.13 
71.4 
± 
2 
3.63 
± 
0.2 
24.93 
± 
2 
6.66 
± 
0.8 
10.76 
± 
1.4 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05. **p < 0.01. 
Recovery Groups 
Groups WBC× 
10
9
/L 
Lymph  
× 10
9
/L 
Mon × 
10
9
/L 
Gran× 
10
9
/L 
Lymph 
% 
Mono 
% 
Gran 
% 
RBC× 
10
12
/L 
HgB 
g/dL 
Recovery 
Control (Palm 
jaggery solution) 
4.4 
± 
1.6 
3.1 
± 
1.2 
0.16 
± 
0.1 
1.2 
± 
0.4 
68.3 
± 
1 
3.66 
± 
0.3 
28.1 
± 
1.5 
8.42 
± 
1.2 
12.33 
± 
2.4 
High dose 
recovery(NM) 
90mg/kg b.w 
3.7 
± 
1.1 
2.5 
± 
0.8 
0.16 
± 
0.2 
1.0 
± 
0.2 
66.9 
± 
3 
4.26 
± 
0.3 
28.7 
± 
2.7 
6.14 
± 
1.4 
9.95 
± 
2.4 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
 
Groups HCT 
% 
MCV fL MCH pg MCHC 
g/dL 
RDW 
% 
PLT × 
10
9
/L 
MPV fL PDW PCT % 
Vehicle 
control 
(Palm 
jaggery 
solution) 
27.4 
± 
7.4 
51.09 
± 
0.39 
15.13 
± 
0.0 
29.78 
± 
1.3 
12.03 
± 
0.3 
185.1 
± 
96 
6.76 
± 
0.2 
15.45 
± 
0.2 
0.12 
± 
0.06 
Low 
dose(NM) 
9mg/kg 
b.w 
38.8 
± 
5.8 
51.38 
± 
6.7 
22.04 
± 
4.5* 
36.71 
± 
5.6 
18.20 
± 
4* 
530.5 
± 
66* 
5.89 
± 
0.7 
13.43 
± 
1.5 
0.35 
± 
0.04 
Mid 49.59 50.25 16.07 32.05 12.51 529.4 6.57 14.9 0.35 
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  All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05. **p < 0.01 
 Recovery Groups 
Groups HCT 
% 
MCV 
fL 
MCH 
pg 
MCHC 
g/dL 
RDW 
% 
PLT × 
10
9
/L 
MPV 
fL 
PDW PCT 
% 
Recovery 
Control (Palm 
jaggery 
solution) 
42.5 
± 
6.2 
50.6 
± 
1.2 
14.23 
± 
1.5 
28.31 
± 
3.1 
12.16 
± 
0.4 
319.6 
± 
78.5 
6.4 
± 
0.1 
15.03 
± 
0.09 
0.2 
± 
0.04 
High dose(NM) 
recovery 
90mg/kg b.w 
31.15 
± 
7.1 
50.71 
± 
0.85 
15.75 
± 
0.46 
31.18 
± 
0.7 
12.43 
± 
0.44 
349.16 
± 
115 
6.58 
± 
0.1 
15.2 
± 
0.19 
0.22 
± 
0.07 
   All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.**p < 0.01 
Table No:7.12.4.Effect of Nandhi Mezhugu on biochemical parameters of 
experimental Wistar rats in Sub-acute toxicity study  
Groups Glucose 
mg/dl 
Urea 
mg/dl 
Creatinine 
mg/dl 
Cholestrol 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
Vechicle control 
(Palm jaggery 
solution) 
85.0 
± 
3.6 
37.0 
± 
2.2 
0.9 
± 
0.03 
78.6 
± 
0.3 
137.5 
± 
8.5 
21.0 
± 
0.0  
26.5 
± 
1.5 
Low dose (NM) 
9mg/kg b.w 
53.6 
± 
6.1 
39.5 
± 
1.8 
0.7 
± 
0.1 
82.1 
± 
4.6 
105.2 
± 
25.5 
24.6 
± 
4.1 
36.6 
± 
6.9 
Mid dose(NM) 
45mg/kg b.w 
92.3 
± 
38.7 
± 
0.8 
± 
78.6 
± 
111.7 
± 
24.0 
± 
32.8 
± 
dose(NM) 
45mg/kg 
b.w 
± 
3.9* 
± 
0.69 
± 
0.2 
± 
0.2 
± 
0.4 
± 
87* 
± 
0.1 
± 
0.1 
± 
0.05 
High 
dose(NM) 
90mg/kg 
b.w 
33.25 
± 
4.2 
49.83 
± 
0.83 
15.93 
± 
0.3 
32.09 
± 
0.3 
11.45 
± 
0.3 
219.7 
± 
67 
6.34 
± 
0.1 
15.02 
± 
0.1 
0.13 
± 
0.04 
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13.6 1 0.1 1.8 10.4 0.78 1.8 
High dose(NM) 
90mg/kg b.w 
137.3 
± 
8.5** 
42.2 
± 
1.1* 
0.7 
± 
0.03 
74.7 
± 
3.8 
84.9 
± 
5.4* 
25.6 
± 
1.9 
31.3 
± 
2 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Recovery Groups 
Groups Glucose 
mg/dl 
Urea 
mg/dl 
Creatinine 
mg/dl 
Cholestrol 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
Recovery Control 
(Palm jaggery 
solution) 
124.0 
± 
5.3 
38.6 
± 
1.8 
0.55 
± 
0.03 
82.83 
± 
5.3 
134.3 
± 
13.4 
25.25 
± 
2.7 
30.83 
± 
7.2 
High dose 
Recovery(NM) 
90mg/kg b.w 
103.8 
± 
9.6 
36.6 
± 
2 
0.49 
± 
0.03 
79.16 
± 
6.2 
168.16 
± 
20.6 
27.48 
± 
4 
32.5 
± 
10.8 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
 
Groups TRP 
g/dl 
ALB 
g/dl 
SBIL 
mg/dl 
SGOT 
IU/L 
SGPT 
IU/L 
SAP 
IU/L 
Vechicle control 
(Palm jaggery 
solution) 
7 
± 
0.1 
3.4 
± 
0.4 
0.25 
± 
0.00 
159.3 
± 
19.6 
55.4 
± 
5.2 
179.3 
± 
21.2 
Low dose (NM) 
9mg/kg b.w 
7.5 
± 
0.3 
3.3 
± 
0.2 
0.20 
± 
0.00 
138.0 
± 
7.4 
65.4 
± 
25.7 
131.6 
± 
25.3 
Mid dose (NM) 
45mg/kg b.w 
7.8 
± 
0.2 
3.3 
± 
0.16 
0.25 
± 
0.02 
156.1 
± 
15.6 
61.1 
± 
2.9 
133.3 
± 
3.2 
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High dose(NM) 
90mg/kg b.w 
6.8 
± 
0.3 
3.1 
± 
0.24 
0.23 
± 
0.03 
215.6 
± 
15.6* 
55.5 
± 
2.6 
116.0 
± 
6.3 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
 
Recovery Groups 
Groups TRP 
g/dl 
ALB 
g/dl 
SBIL 
mg/dl 
SGOT 
IU/L 
SGPT 
IU/L 
SAP 
IU/L 
 Recovery Control  
(Palm jaggery 
solution) 
7.53 
± 
0.52 
2.9 
± 
0.3 
0.3 
± 
0.1 
193.1 
± 
18 
50 
± 
4 
111 
± 
13.4 
High dose 
Recovery(NM) 
90mg/kg b.w 
7.11 
± 
0.19 
2.8 
± 
0.1 
0.2 
± 
1.2 
211.1 
± 
34 
59 
± 
4 
109 
± 
21.8 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
 
Table No 7.12.5: Effect of Nandhi Mezhugu on relative organ weight of experimental 
Wistar rats in Sub-acute toxicity study 
Groups Brain Heart Lungs Liver Spleen Kidney 
Vehicle control 
(Palm jaggery 
solution) 
1.32 
± 
0.03 
0.413 
± 
0.02 
0.851 
± 
0.03 
2.86 
± 
0.27 
0.265 
± 
0.01 
0.906 
± 
0.01 
Low dose (NM) 
9mg/kg b.w 
1.32 
± 
0.03 
0.406 
± 
0.01 
0.885 
± 
0.04 
2.53 
± 
0.18 
0.257 
± 
0.01 
0.933 
± 
0.03 
Mid dose(NM) 1.29 0.385 0.831 2.66 0.269 0.848 
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45mg/kg b.w ± 
0.03 
± 
0.01 
± 
0.03 
± 
0.15 
± 
0.01 
± 
0.02 
High dose(NM) 
90mg/kg b.w 
1.28 
± 
0.02 
0.366 
± 
0.01 
0.689 
± 
0.01 
2.50 
± 
0.13 
0.253 
± 
0.01 
0.841 
± 
0.03 
   
Recovery Groups 
Groups Brain Heart Lungs Liver Spleen Kidney 
Recovery control (Palm 
jaggery solution) 
1.35 
± 
0.06 
0.426 
± 
0.04 
0.811 
± 
0.01 
2.511 
± 
0.25 
0.280 
± 
0.02 
0.857 
± 
0.04 
High dose recovery(NM) 
90mg/kg b.w 
1.36 
± 
0.05 
0.460 
± 
0.04 
0.883 
± 
0.04 
2.617 
± 
0.21 
0.286 
± 
0.01 
0.999 
± 
0.03 
    All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Results of sub-acute toxicity study: 
There were no treatment-related toxicity signs and mortality observed in both sexes 
of rats treated Nandhi mezhugu(NM) at a dose of 9, 45 and 90 mg/kg b.w orally for 
a dosing period of 28 days(7 days drug dosing followed by 7 days drug holiday) and 
in the Recovery group of rats. No significant difference in body weight gain was 
observed between control and treated groups during the study (Table 7.12.1). Feed 
consumption of NM treated groups was found to be non-significant in both the 
sexes when compared to control (Table 7.12.2). Haematological parameters such as 
haemoglobin, red blood cells, white blood cells, mean corpuscular haemoglobin, 
though found to be statistically significant at low and mid doses as compared to the 
control, they were found to be well within the normal range in the rats of  
experimental groups (Table 7.12.3), hence the changes observed were not treatment 
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related effects. All the biochemical profile such as glucose, total cholesterol, 
triglycerides, total protein, alkaline phosphatase, creatinine, blood urea were within 
the normal range (Table 7.12.4) observed between control and treated groups. The 
levels of liver marker enzymes like SGOT and SGPT were found to be well within 
the normal range in rats of NM treated groups (Table 7.12.4). There were no 
significant differences in organ weight of brain, heart, liver, lungs, kidneys recorded 
between the control and NM groups (Table 7.12.5). In our study, histopathological 
examinations in control and high dose group revealed no abnormalities. There were 
no haematological, biochemical and histopathological alterations observed with NM 
administration even at 90 mg/kg b.w twice daily in rats for a period of 28 days 
compared to control. The No Observed Adverse Effect Level (NOAEL) of NM was 
estimated to be greater than 90 mg/kg b.w /day in rats. Hence, it is concluded that 
NM is safe for oral administration in rats up to 90 mg/kg b.w/day. 
7.13. Sub-chronic toxicity study: 
Table No:7.13.1.Effect of Nandhi Mezhugu on Body weight of experimental Wistar 
rats in Sub-chronic toxicity study 
Groups On day 
1  7  14  28  35  42  49  56 63  70  77  84  91 
Vehicle control 
(Palm jaggery 
solution) 
235 
± 
19 
257 
± 
40 
259 
± 
47 
262 
± 
49 
273 
± 
59 
271 
± 
58 
276 
± 
63 
281 
± 
65 
288 
± 
69 
293 
± 
73 
299 
± 
76 
304 
± 
79 
309 
± 
81 
Low 
dose(NM) 
9mg/kg b.w 
187 
± 
6 
229 
± 
18 
230 
± 
14 
240 
± 
17 
244 
± 
18 
250 
± 
20 
254 
± 
22 
260 
± 
23 
266 
± 
24 
271 
± 
25 
278 
± 
26 
283 
± 
26 
290 
± 
28 
Middose 
(NM)45mg/kg 
b.w 
230 
± 
11 
258 
± 
15 
261 
± 
16 
268 
± 
17 
273 
± 
18 
279 
± 
19 
282 
± 
19 
285 
± 
19 
290 
± 
20 
294 
± 
21 
298 
± 
22 
303 
± 
22 
308 
± 
23 
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High 
dose(NM) 
110mg/kg b.w 
254 
± 
13.3 
282 
± 
21 
288 
± 
21 
297 
± 
22 
302 
± 
24 
308 
± 
25 
311 
± 
26 
316 
± 
27 
321 
± 
28 
327 
± 
29 
332 
± 
30 
336 
± 
31 
342 
± 
32 
 
Groups On day 
 98 105 112  19 126 133 140 147  154  161  168  172  179 
Vehicle 
control (Palm 
jaggery 
solution) 
311 
± 
83 
310 
± 
88 
311 
± 
91 
331 
± 
92 
333 
± 
94 
334 
± 
94 
335 
± 
87 
330 
± 
94 
329 
± 
93 
331 
± 
90 
334 
± 
88 
345 
± 
84 
 
352 
± 
98 
Low dose 
9mg/kg b.w 
295 
± 
28 
298 
± 
29 
301 
± 
30 
302 
± 
31 
306 
± 
32 
305 
± 
32 
300 
± 
32 
297 
± 
31 
299 
± 
30 
300 
± 
29 
302 
± 
29 
308 
± 
33 
319 
± 
33 
Mid dose 
45mg/kg b.w 
310 
± 
24 
313 
± 
24 
316 
± 
25 
320 
± 
26 
323 
± 
26 
323 
± 
27 
318 
± 
26 
314 
± 
26 
312 
± 
25 
313 
± 
23 
316 
± 
23 
324 
± 
25 
338 
± 
26 
High dose 
110mg/kg b.w 
344 
± 
33 
346 
± 
34 
349 
± 
33 
351 
± 
34 
355 
± 
34 
355 
± 
35 
350 
± 
34 
345 
± 
33 
342 
± 
32 
341 
± 
31 
344 
± 
32 
354 
± 
33 
362 
± 
34 
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Groups On day 
1  7 14 28 35  42  49  56  63  70 77 84  91 
Recovery 
control 
(Palm 
jaggery 
solution) 
226 
± 
33 
262 
± 
69 
251 
± 
51 
255 
± 
52 
259 
± 
55 
265 
± 
58 
269 
± 
61 
272 
± 
63 
276 
± 
68 
282 
± 
72.3 
285 
± 
74 
288 
± 
75.2 
293 
± 
77 
High dose 
Recovery(N
M) 
110mg/kg 
b.w 
224 
± 
19 
251 
± 
40 
255 
± 
45 
263 
± 
49 
267 
± 
50 
271 
± 
53 
275 
± 
58 
278 
± 
58 
282 
± 
63 
286 
± 
65 
292 
± 
69 
297 
± 
72 
302 
± 
76 
Groups On day 
 98 105  112  119 126  133  140  147  154  161  168  175 182  193 
Recovery 
control(Palm 
jaggery 
solution) 
295 
± 
14 
298 
± 
12 
301 
± 
12 
302 
± 
11 
306 
± 
11 
305 
± 
10 
300 
± 
9 
297 
± 
8 
299 
± 
10 
300 
± 
13 
302 
± 
16 
310 
± 
15 
315 
± 
14 
319 
± 
33 
Highdose 
Recovery 
110mg/kg b.w 
311 
± 
36 
310 
± 
39 
311 
± 
39 
315 
± 
47 
317 
± 
48 
318 
± 
48 
321 
± 
46 
315 
± 
54 
314 
± 
49 
317 
± 
51 
320 
± 
51 
338 
± 
50 
345 
± 
53 
353 
± 
98 
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 Table No:7.13.2.Feed intake of animals in Sub chronic toxicity study 
Weeks Vehicle control Low dose Mid Dose High dose Recovery 
control 
High Dose 
Recovery 
1 78.9 78.8 79.2 80.2 78.7 80.1 
2 77.4 77.2 77.4 79.5 77.5 79.5 
3 78.5 78.9 79.4 80.1 79.1 80.2 
4 76.4 77.4 78.6 79.2 78.4 79.4 
5 77.9 78.2 79.8 79.9 77.2 80.4 
6 76.3 77.7 78.6 078.4 76.9 79.1 
7 78.2 78.9 79.7 80.4 78.2 80.2 
8 77.4 77.9 78.7 79.2 77.9 79.7 
9 78.7 79.2 79.4 79.9 78.2 80.4 
10 78.2 78.4 78.2 78.6 77.5 79.5 
11 78.9 79.1 79.7 80.3 78.7 80.1 
12 77.4 78.2 78.1 79.2 77.9 79.2 
13 78.2 79.2 79.8 80.5 77.5 79.9 
14 77.8 78.3 78.4 79.1 78.5 78.4 
15 78.7 79.4 79.6 80.7 77.7 80.2 
16 77.2 78.4 78.5 79.4 76.5 79.2 
17 77.6 79.3 79.9 80.4 77.9 80.3 
18 77.1 78.5 78.4 79.5 76.8 79.6 
19 77.8 79.7 79.6 80.3 77.7 79.9 
20 77.5 78.6 78.9 79.4 76.5 79.2 
21 77.9 79.4 79.4 80.2 77.5 80.1 
22 77.3 78.7 78.7 79.8 77.1 79.6 
23 78.2 79.7 79.6 80.5 77.8 80.5 
24 77.5 78.5 78.6 79.5 77.2 79.8 
25 78.0 79.5 79.5 80.4 77.9 80.4 
26     77.5 79.7 
27     77.8 80.5 
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Effect of NM on Histopathalogical changes in Rat organs Sub 
chronic Toxicity study 
SPECIMEN 
Study no: LBPL-HP-014/16 (Sub chronic Toxicity study) 
Liver : Normal, H&Ex10 Lung : Normal, H&Ex10 
Spleen : Normal, H&Ex10 Brain : Normal, H&Ex10 
 
 
 
 
 
 
Kidney : Normal, H&Ex4 
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Study no: LBPL-HP-014/16 (Sub chronic Toxicity study 
 
 
HRM-B-I: NAD, H&E X4 
 
 
HRM-B-I: NAD, H&E X4 
 
HRM-B-III: MNC infiltration, H&E X10 
 
HRM-T-I: MNC infiltration, H&E X10 
 
HRM-T-III: MNC infiltration, H&E X10 
 
HRF-B-III: MNC infiltration, H&E X10 
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Study no: LBPL-HP-014/16 (Sub chronic Toxicity study 
 
 
HRF-B+T-III: MNC infiltration, H&E X10 
 
 
HDM-H -III: MNC infiltration, H&E X10 
 
 
HDM-H +B-III: MNC infiltration, H&E X4 
 
 
HDF-H +B-III: MNC infiltration, H&E X4 
 
 
HDF-B+T-I: MNC infiltration, H&E X10 
 
 
HDF-B+T-III: MNC infiltration, H&E X10 
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Study no: LBPL-HP-014/16 (Sub chronic Toxicity study 
 
RCM-T-I: MNC infiltration, H&E X40 
 
RCM-T-II: Basophilic tubule, H&E X10 
 
RCM-T-III:MNC infiltration, H&E X10 
 
VCM-T-I: MNC infiltration, H&E X10 
 
  VCM-T-III: MNC infiltration, H&E X10 
 
VCF-T-III: MNC infiltration, H&E X10 
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HISTOPATHOLOGY REPORT 
Ref Study no: LBPL-HP-014/16 (Sub chronic Toxicity study) 
Organ/tissue: Liver, Kidney, Lung, Heart, Spleen, Stomach, Skin, Brain 
 
The tissue samples were collected and preserved in neutral buffered formalin. The fixed 
tissues were processed, sectioned and stained with Heamatoxylin & eosin stain. The 
stained tissue sections from the different groups were examined microscopically for 
histopathological changes.  The various histopathological or microscopic changes noticed 
in above mentioned organs/tissues from all the groups were recorded. Details of 
individual histopathological findings are presented in Table 1.  
RESULTS:  
There were no treatment related histopathological abnormalities in the organs examined 
microscopically. Histopathological changes noticed were within the normal histological 
limits for this particular species and strain.  
TABLE 1B: INDIVIDUAL HISTOPATHOLOGICAL FINDINGS 
Group Slide no. Tissue Histopathology 
observations 
HRM-B 
High dose recovery Male 
HRM-B-I Liver  NAD 
HRM-B-II Kidney  NAD 
HRM-B-
III 
Lung  MNC infiltration 
<1> 
HRM-B-
IV 
Heart  NAD 
HRM-B-V Spleen  NAD 
HRM-B-
VI 
Stomach  NAD 
HRM-B-
VII 
Skin  NAD 
HRM-B-
VIII 
Brain  NAD 
HRM-T HRM-T-I Liver  MNC infiltration 
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High dose recovery Male <1> 
HRM-T-II Kidney  NAD 
HRM-T-
III 
Lung  MNC infiltration 
<2> 
HRM-T-
IV 
Heart  NAD 
HRM-T-V Spleen  NAD 
HRM-T-
VI 
Stomach  NAD 
HRM-T-
VII 
Skin  NAD 
HRM-T-
VIII 
Brain  NAD 
HRF-B 
High dose recovery female 
HRF-B-I Liver  NAD 
HRF-B-II Kidney  MNC infiltration 
<1> 
HRF-B-III Lung  MNC infiltration 
<1> 
HRF-B-IV Heart  NAD 
HRF-B-V Spleen  NAD 
HRF-B-VI Stomach  NAD 
HRF-B-
VII 
Skin  NAD 
HRF-B-
VIII 
Brain  NAD 
HRF-B+T 
High dose recovery female 
HRF-
B+T-I 
Liver  NAD 
HRF-
B+T-II 
Kidney  NAD 
HRF- Lung  MNC infiltration 
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B+T-III <1> 
HRF-
B+T-IV 
Heart  NAD 
HRF-
B+T-V 
Spleen  NAD 
HRF-
B+T-VI 
Stomach  NAD 
HRF-
B+T-VII 
Skin  NAD 
HRF-
B+T-VIII 
Brain  NAD 
HDM-H 
High dose  male 
HDM-H-I Liver  NAD 
HDM-H-II Kidney  NAD 
HDM-H-
III 
Lung  MNC infiltration 
<1> 
HDM-H-
IV 
Heart  NAD 
HDM-H-
V 
Spleen  NAD 
HDM-H-
VI 
Stomach  NAD 
HDM-H-
VII 
Skin  NAD 
HDM-H-
VIII 
Brain  NAD 
HDM-H+B 
High dose male 
HDM-
H+B-I 
Liver  NAD 
HDM-
H+B-II 
Kidney  NAD 
HDM-
H+B-III 
Lung  MNC infiltration 
<2> 
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HDM-
H+B-IV 
Heart  NAD 
HDM-
H+B-V 
Spleen  NAD 
HDM-
H+B-VI 
Stomach  NAD 
HDM-
H+B-VII 
Skin  NAD 
HDM-
H+B-VIII 
Brain  NAD 
HDF-H+B 
High dose  female 
HDF-
H+B-I 
Liver  NAD 
HDF-
H+B-II 
Kidney  NAD 
HDF-
H+B-III 
Lung  MNC infiltration 
<2> 
HDF-
H+B-IV 
Heart  NAD 
HDF-
H+B-V 
Spleen  NAD 
HDF-
H+B-VI 
Stomach  NAD 
HDF-
H+B-VII 
Skin  NAD 
HDF-
H+B-VIII 
Brain  NAD 
HDF-B+T 
High dose female 
HDF-
B+T-I 
Liver  MNC infiltration 
<1> 
HDF-
B+T-II 
Kidney  NAD 
HDF-
B+T-III 
Lung  MNC infiltration 
<1> 
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HDF-
B+T-IV 
Heart  NAD 
HDF-
B+T-V 
Spleen  NAD 
HDF-
B+T-VI 
Stomach  NAD 
HDF-
B+T-VII 
Skin  NAD 
HDF-
B+T-VIII 
Brain  NAD 
RCM-T 
          Recovery control male 
RCM-T-I Liver  MNC Infiltration 
<1> 
RCM-T-II Kidney  Dilated tubules with 
eosinophilic material 
<1>, Basophilic 
tubules <1>  
RCM-T-
III 
Lung  MNC infiltration 
<1> 
RCM-T-
IV 
Heart  NAD 
RCM-T-V Spleen  NAD 
RCM-T-
VI 
Stomach  NAD 
RCM-T-
VII 
Skin  NAD 
RCM-T-
VIII 
Brain  NAD 
RCF-H 
Recovery control Female 
RCF-H-I Liver  NAD 
RCF-H-II Kidney  NAD 
RCF-H-III Lung  NAD 
RCF-H-IV Heart  NAD 
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RCF-H-V Spleen  NAD 
RCF-H-VI Stomach  NAD 
RCF-H-
VII 
Skin  NAD 
RCF-H-
VIII 
Brain  NAD 
VCM-T 
Vechicle control Male 
VCM-T-I Liver  MNC infiltration (1) 
VCM-T-II Kidney  NAD 
VCM-T-
III 
Lung  MNC infiltration 
<1> 
VCM-T-
IV 
Heart  NAD 
VCM-T-V Spleen  NAD 
VCM-T-
VI 
Stomach  NAD 
VCM-T-
VII 
Skin  NAD 
VCM-T-
VIII 
Brain  NAD 
VCF-T 
Vechicle control Female 
VCF-T-I Liver  NAD 
VCF-T-II Kidney  NAD 
VCF-T-III Lung  MNC infiltration 
<1> 
VCF-T-IV Heart  NAD 
VCF-T-V Spleen  NAD 
VCF-T-VI Stomach  NAD 
VCF-T-
VII 
Skin  NAD 
VCF-T-
VIII 
Brain  NAD 
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Note: Severity grading: 1-minimal, 2-mild, 3-moderate, 4-marked, Distribution of 
lesions: [ ]: diffuse, <>-multifocal, ( )-focal, NAD-No Abnormalities Detected, 
MNC-Mononuclear cell infiltration 
 
Table No:7.13.3.Effect of Nandhi Mezhugu on Hematological Parameters of 
experimental Wistar rats in sub-chronic oral toxicity study 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
 
 
 
Groups WBC × 
10
9
/L 
Lymph  
× 10
9
/L 
Mon × 
10
9
/L 
Gran × 
10
9
/L 
Lymph 
% 
Mono 
% 
Gran 
% 
RBC × 
10
12
/L 
HGB 
g/dL 
Vechicle 
control(Palm 
jaggery 
solution) 
6.24 
± 
3.5 
3.96 
± 
2.8 
0.24 
± 
0.05 
2.04 
± 
0.8 
60.2 
± 
11.3 
4.7 
± 
1.4 
35.14 
± 
10 
10.42 
± 
3.6 
16.98 
± 
6 
Low dose 
9mg/kg b.w 
5.71 
± 
1.23 
3.78 
± 
0.8 
0.25 
± 
0.06 
1.68 
± 
0.39**** 
66.53 
± 
1.3 
4.05 
± 
0.18 
29.4 
± 
1.3 
7.7 
± 
0.9 
12.26 
± 
1.4 
Mid dose 
45mg/kg b.w 
6.62 
± 
1.54 
4.53 
± 
1.03 
0.27 
± 
0.07 
2.31 
± 
0.57*** 
61.15 
± 
6.8 
4 
± 
0.17 
26.79 
± 
1.63 
8.54 
± 
1.15 
14.07 
± 
1.9 
High dose 
110mg/kg 
b.w 
6.36 
± 
0.4 
4.22 
± 
1.03 
0.29 
± 
0.06 
1.85 
± 
0.2*** 
66.88 
± 
2.7 
4.28 
± 
0.83 
28.82 
± 
1.63 
9.05 
± 
0.66 
15.07 
± 
1.4 
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Recovery Group 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05. **p < 0.01 
Groups HCT 
% 
MCV 
fL 
MCH 
pg 
MCHC 
g/dL 
RDW 
% 
PLT × 
10
9
/L 
MPV 
fL 
PDW PCT 
% 
Vehicle 
control(Palm 
jaggery 
solution) 
51.9 
± 
18 
49.6 
± 
2.5 
16.2 
± 
0.66 
32.8 
± 
0.8 
12.4 
± 
0.9 
408.2 
± 
198 
6.92 
± 
0.4 
15.3 
± 
0.3 
0.28 
± 
0.13 
Low dose 
9mg/kg b.w 
37.5 
± 
4.1 
49.2 
± 
1 
15.9 
± 
0.3 
32.5 
± 
0.33 
12.24 
± 
0.24 
301.6 
± 
55.2 
6 
± 
0.088 
15.05 
± 
0.09 
0.19 
± 
0.03 
Mid dose 
45mg/kg b.w 
41.9 
± 
5.7 
48.9 
± 
0.7 
16.3 
± 
0.2 
33.6 
± 
0.17 
11.6 
± 
0.35 
319.2 
± 
62.2 
6.64 
± 
0.15 
15.09 
± 
0.15 
0.2 
± 
0.03 
High dose 
110mg/kg b.w 
45.4 
± 
3.7 
50.0 
± 
0.9 
16.5 
± 
0.33 
33.1 
± 
0.4 
12 
± 
0.64 
242.66 
± 
37.5 
6.88 
± 
0.12 
15.37 
± 
0.11 
0.16 
± 
0.02 
Groups WBC 
× 
10
9
/L 
Lymph  
× 10
9
/L 
Mon × 
10
9
/L 
Gran × 
10
9
/L 
Lymph 
% 
Mono 
 % 
Gran  
% 
RBC × 
10
12
/L 
HGB 
g/dL 
Recovery 
Control(Palm 
jaggery 
solution) 
5.05 
± 
1.4 
3.16 
± 
0.9 
0.2 
± 
0.07 
1.66 
± 
0.4 
61.45 
± 
1.7 
4.65 
± 
0.3 
33.9 
± 
1.6 
5.9 
± 
0.53 
9.56 
± 
0.9 
High dose 
recovery 
110mg/kg 
b.w 
 
3.43 
± 
1.7 
2.18 
± 
1.14 
0.1 
± 
0.06 
1.15 
± 
0.52 
55.6 
± 
5 
4.5 
± 
0.7 
39.8 
± 
4.5 
4.2 
± 
1.3 
6.91 
± 
2.2 
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All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Recovery Group: 
Groups HCT 
% 
MCV 
fL 
MCH 
pg 
MCHC 
g/dL 
RDW 
% 
PLT × 
10
9
/L 
MPV 
fl 
PDW PCT 
% 
Recovery 
Control(Palm 
jaggery 
solution) 
28.95 
± 
2.6 
48.7 
± 
0.9 
16.0 
± 
0.3 
33.0 
± 
0.3 
10.91 
± 
0.5 
338.3 
± 
180 
6.66 
± 
0.1 
15.36 
± 
0.2 
0.090 
± 
0.03 
High dose 
recovery 
110mg/kg 
b.w 
20.56 
± 
6.4 
48.5 
± 
0.8 
15.8 
± 
0.4 
32.7 
± 
0.6 
10.48 
± 
0.2 
170.5 
± 
61 
6.75 
± 
0.2 
15.76 
± 
0.2 
0.108 
± 
0.03 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p< 0.05.  **p< 0.01 
Table No:7.13.4.Effect of Nandhi Mezhugu on serum biochemical parameters of 
experimental Wistar rats sub-chronic oral toxicity study 
Groups Glucose 
mg/dl 
Urea 
mg/dl 
Creatinine 
mg/dl 
Cholestrol 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
Vechicle 
control(Palm 
jaggery solution) 
172.4 
± 
3.5 
34.0 
± 
2.4 
0.7 
± 
0.02 
100.6 
± 
5.3 
131.4 
± 
17 
26.0 
± 
2 
48.4 
± 
3.5 
Low dose 9mg/kg 
b.w 
149.2 
± 
5.7 
32.1 
± 
3 
0.7 
± 
0.05 
91.0 
± 
7.5 
100.5 
± 
13 
22.5 
± 
1 
48.5 
± 
6.7 
Mid dose 
45mg/kg b.w 
132.5 
± 
11.3* 
26.6 
± 
2.7 
0.7 
± 
0.04 
81.4 
± 
3.2* 
146.4 
± 
13 
22.2 
± 
1 
29.8 
± 
3.0* 
High dose 
110mg/kg b.w 
160.7 
± 
6.6 
27.3 
± 
1.5 
0.6 
± 
0.02 
85.7 
± 
3.3 
141 
± 
18 
20.79 
± 
1* 
36.7 
± 
3.6 
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All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Recovery control 
 
Groups Glucose 
mg/dl 
Urea 
mg/dl 
Creatinine 
mg/dl 
Cholestrol 
mg/dl 
TGL 
mg/dl 
HDL 
mg/dl 
LDL 
mg/dl 
Recovery 
Control(Palm 
jaggery 
solution) 
139 
± 
5.9 
35 
± 
0.9 
0.41 
± 
0.01 
75 
± 
4 
118 
± 
15 
24.8 
± 
1.19 
31 
± 
1.88 
High dose 
Recovery 
110mg/kg b.w 
146 
± 
9.6 
37 
± 
0.73 
0.31 
± 
0.03 
76 
± 
3.9 
131 
± 
22 
26.6 
± 
1.9 
31 
± 
4.9 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Groups TRP g/dl ALB g/dl SBIL mg/dl SGOT 
IU/L 
SGPT 
IU/L 
SAP IU/L 
Vechicle 
control(Palm 
jaggery 
solution) 
7.04 
± 
0.25 
2.82 
± 
0.19 
0.12 
± 
0.02 
312.4 
± 
30.7 
96.0 
± 
2.9 
198.2 
± 
18.3 
Low dose 
9mg/kg b.w 
6.88 
± 
0.28 
2.83 
± 
0.22 
0.13 
± 
0.02 
236.3 
± 
57.3 
80.8 
± 
10 
170.7 
± 
13.7 
Mid dose 
45mg/kg b.w 
6.67 
± 
0.11 
2.84 
± 
0.19 
0.10 
± 
0.0 
238.8 
± 
16.0 
69.3 
± 
3.2** 
146.1 
± 
16.2 
High dose 
110mg/kg 
b.w 
6.89 
± 
0.06 
2.82 
± 
0.09 
0.11 
± 
0.01 
216.3 
± 
13.5 
67.6 
± 
3.2** 
114.4 
± 
9.0** 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
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Groups TRP g/dl ALB g/dl SBIL 
mg/dl 
SGOT 
IU/L 
SGPT 
IU/L 
SAP IU/L 
Recovery 
Control(Palm 
jaggery 
solution) 
6.8 
± 
0.22 
2.3 
± 
0.18 
0.1 
± 
0.02 
191.5 
± 
13.3 
66 
± 
7.6 
181.16 
± 
18.4 
High dose 
Recovery 
110mg/kg 
b.w 
6.3 
± 
0.18 
2.3 
± 
0.14 
0.1 
± 
0.02 
192.33 
± 
23.2 
67 
± 
5.2 
178.66 
± 
12.3 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05. **p< 0.01 
Table No: 7.13.5.Effect of Nandhi Mezhugu on relative Organ weight of 
experimental Wistar rats in Sub-chronic oral toxicity study 
Groups Brain Heart Lungs Liver Spleen  Kidney 
Vehicle control(Palm jaggery 
solution) 
1.31 
± 
0.03 
0.338 
± 
0.02 
0.728 
± 
0.04 
2.359 
± 
0.18 
0.231 
± 
0.01 
0.837 
± 
0.05 
Low dose 9mg/kg b.w 1.30 
± 
0.02 
0.373 
± 
0.02 
0.803 
± 
0.03 
2.585 
± 
0.22 
0.244 
± 
0.01 
0.900 
± 
0.02 
Mid dose 45mg/kg b.w 1.36 
 ± 
0.02 
0.329 
± 
0.01 
0.712 
± 
0.03 
2.398 
± 
0.15 
0.227 
± 
0.01 
0.852 
± 
0.05 
High dose 110mg/kg b.w 1.34 
± 
0.02 
0.320 
± 
0.01 
0.754 
± 
0.02 
2.283 
± 
0.18 
0.211 
± 
0.01 
0.813 
± 
0.03 
201 
 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Recovery control 
Recovery 
control(Palm 
jaggery 
solution) 
1.33 
± 
0.03 
0.368 
± 
0.01 
0.797 
± 
0.03 
2.546 
± 
0.24 
0.241 
± 
0.01 
0.900 
± 
0.05 
High dose 
recovery 
110mg/kg 
b.w 
1.32 
± 
0.03 
0.351 
± 
0.01 
0.786 
± 
0.02 
2.392 
± 
0.19 
0.223 
± 
0.01 
0.824 
± 
0.04 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison. *p < 0.05.  **p < 0.01 
Results of Sub chronic toxicity 
There were no treatment-related toxicity signs and mortality observed in both sexes 
of rats treated with Nandhi mezhugu at a dose of 9, 45 and 110 mg/kg b.w orally for a 
period of 90 days ( 7 days drug dosing followed by 7 days drug holidays) and in the 
recovery group of rats. No significant difference in body weight gain was observed 
between control and treated groups during the study (Table 7.13.1). Feed consumption of 
NM treated groups were found to be non-significant in both the sexes when compared to 
control study (Table 7.13.2). Haematological parameters such as haemoglobin, red blood 
cells, white blood cells, mean corpuscular haemoglobin, were found to be well within the 
normal range in rats of experimental groups (Table 7.13.3). All the parameters in serum 
biochemical profiles such as glucose, total cholesterol, triglycerides, total protein, alkaline 
phosphatase, creatinine, blood urea were within the normal range (Table 7.13.4). The 
levels of liver marker enzymes like SGOT and SGPT were found to be well within the 
clinical range in rats of NM treated groups (Table 7.13.4). There were no significant 
differences in absolute/relative organ weight of brain, heart, liver, lungs, kidneys recorded 
between the control and NM groups (Table 7.13.5). In my study, histopathological 
examinations in control and high dose group revealed no abnormalities. There were no 
haematological, biochemical and histopathological alterations observed with NM 
administration even at 110 mg/kg b.w twice daily in rats for a period of 90 days compared 
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to control. The No Observed Adverse Effect Level (NOAEL) of NM was estimated to be 
greater than 110 mg/kg/day in rats. Hence, it can be concluded that NM is safe for oral 
administration. 
7.14. Pharmacological activity: 
7.14.1. Analgesic activity: 
     Acetic acid induced writhing method: 
Groups onset of 
Writhing (sec) 
No of 
writhing 
Control(0.1ml glacial acetic acid+Palm 
jaggery solution) 
4.3±0.3 17±3.3 
Standard((0.1ml glacial acetic acid +Disprin 
50mg) 
3.8±1.1 3±0.9**** 
Low dose(0.1ml glacial acetic acid+Palm 
jaggery solution+NM 25mg) 
2.3±2.5 8.2±0.6** 
Mid dose(0.1ml glacial acetic acid+Palm 
jaggery solution+NM 40mg) 
6.8±1.6 4.7±0.2*** 
High dose(0.1ml glacial acetic acid+Palm 
jaggery solution+NM 50mg) 
11.8±2.5 2.3±0.6**** 
All values are mean ± SE. Statistical analysis by one-way ANOVA followed by 
Dunnett‘s Multiple Comparison.  **p < 0.01, ***p < 0.001,****p < 0.0001 
 
Result: The high dose group (NM 50mg) showed significant analgesic activity when 
compared to standard drug.It was inferred by the delayed onset of writhing and the 
reduction in the number of writhing. 
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7.15. Acute anti-inflammatory activity Model 
Carrageenan induced paw odema method:  
Table no: 7.15.1.Effect of Nandhi mezhugu on Carrageenan induced paw odema 
method 
Groups 0 hour Paw Volume  Left paw volume 
 Left Paw Right 
Paw 
After 
Administrating 
Carrageenan 
0.01ml Lt Paw 
Volume 
1 hr 2 hr 4 hr 6 hr 
Standard 
(Diclofenac 
sodium 
25mg/kg 
b.w) 
1.022 
± 
0.081 
1.022 
± 
0.081 
1.392 
± 
0.156 
1.415 
± 
0.081 
1.267 
± 
0.125 
1.103 
± 
0.172 
0.950 
± 
0.095 
Low 
dose(NM)  
90mg/kg 
b.w 
1.332 
± 
0.137 
1.223 
± 
0.140 
1.485 
± 
0.108 
1.435 
± 
0.120 
1.385 
± 
0.223 
1.413 
± 
0.179 
1.085 
± 
0.106 
Mid 
dose(NM) 
450 mg/kg 
b.w 
1.263 
± 
0.092 
1.193 
± 
0.106 
1.572 
± 
0.230 
1.3 
± 
0.161 
1.382 
± 
0.192 
1.333 
± 
0.119 
0.955 
± 
0.09 
High 
dose(NM) 
900mg/kg 
b.w 
1.15 
± 
0.147 
1.027 
± 
0.136 
1.537 
± 
0.230 
1.322 
± 
0.173 
1.268 
± 
0.161 
1.118 
± 
0.173 
0.908 
± 
0.034 
Values are Mean± SD 
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Table no: 7.15.2.Percentage of Inhibition in Carrageenan induced paw odema 
method 
Groups % Inhibition 
1 Hr 2Hr 4Hr 6Hr 
Standard 
Standard 
(Diclofenac 
sodium 25mg/kg 
b.w) 
-2.3 8.08 19.07 31.48 
Low 
dose(NM)  
90mg/kg b.w 
3.24 7.09 4.73 26.69 
Mid 
dose(NM) 
450 mg/kg 
b.w 
15.4 10.7 13.63 37.86 
High 
dose(NM) 
900mg/kg 
b.w 
11.35 15.51 26.04 39.95 
 
Paw volume was reduced significantly in high dose group with that of standard. 
Percentage of inhibition in high dose group was comparatively high when compared to 
that of standard. 
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7.16. Chronic anti-inflammatory activity: 
Cotton pellet granuloma method: 
Results: 
a) Body weight (g) and Body weight gain (%): 
Summary of male and female animals body weight (g) and body weight gain 
(%) are presented in Table-7.16.1 and Table-7.16.2  
There were no biologically significant changes observed in body weight (g) and 
body weight gain (%) in all group animals. 
b) Clinical signs observation: 
All the animals were found to be normal in their health condition during entire 
experimental duration.  
c) Weights of dry and wet weights of cotton pellets and Percentage inhibition 
of Granuloma tissue formation : 
Summary of dry & wet (initial and final) weights of the cotton pellets of males 
and females are presented in table 7.16.3 & 7.16.4 respectively. 
Percentage inhibition of granuloma tissue formation of males and females are 
presented in Table-7.16.5. 
Dose dependent inhibition of granuloma tissue formation was observed in 
dexamethasone treated group animals and test item treated group animals when 
compared with the control group animals. 
d) Haematology parameters: 
Summary of haematology parameters are presented in Table-7.16.6 and Table-
7.16.7.    
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Table 7.16.1 
SUMMARY OF WEEKLY ANIMALS BODY WEIGHT (g) AND BODY 
WEIGHT GAIN (%) OF MALES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
n=5; Values are Mean, ±Standard Deviation;  p value 
 
 
 
 
Group 
 
Treatment and 
Dose(mg/kg) 
 DAYS (Body wt in mean and SE) 
1  7   1-7 
G1 Vehicle Control 
(Palm jaggery solution) 
203.35 
± 
12.99 
214.7
9± 
5.13 
5.88 
±s 
5.19 
G2 Positive Control 
(Dexamethasone ) – 0.5 
203.77 
± 
10.56 
215.6
0± 
11.91 
5.82 
± 
2.51 
G3 Nandhi mezhugu – 50 195.38 
± 
19.22 
204.5
6± 
14.33 
5.00 
± 
5.73 
G4 Nandhi mezhugu-150 207.67 
± 
20.04 
218.7
7± 
17.33 
5.54 
± 
4.13 
G5 Nandhi mezhugu -500 202.23 
± 
11.52 
213.8
6± 
16.80 
5.65 
± 
2.85 
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Table 7.16.2.WEEKLY ANIMALS BODY WEIGHT (g) AND BODY 
WEIGHT GAIN (%) OF FEMALES 
Group Treatment and 
Dose(mg/kg) 
                               DAYS 
1  7  1-7 
G1 Vehicle 
Control(Palm 
jaggery solution) 
 
    182.71 
        ± 
     12.76 
  195.49 
      ± 
    12.26 
      7.08 
      ± 
     3.76 
G2 Positive Control 
(Dexamethasone ) – 
0.5 
    184.00 
      ± 
    10.48 
    194.20 
      ± 
   12.27 
      5.60 
       ± 
     4.67 
G3  Nandhi mezhugu  -
50 
    182.07 
      ± 
     5.25 
    195.08 
     ± 
    13.22 
     7.06 
      ± 
     4.27 
G4 Nandhi mezhugu-
150 
    186.82 
     ± 
    12.13 
   203.43 
    ± 
  23.84 
    8.77 
     ± 
    9.06 
G5 Nandhi mezhugu-
500 
   193.97 
     ± 
   13.56 
   206.85 
      ± 
    9.69 
    6.82 
     ± 
    4.41 
n=5; Values are Mean, ±Standard Deviation;  
        TABLE – 7.16.3 SUMMARY OF DRY AND WET COTTON PELLET WEIGHTS 
(mg) OF MALES 
Group Treatment and 
Dose(mg/kg) 
INITIAL FINAL 
Right groin Left groin Right groin Left groin 
Dry Wet  Dry Wet  Dry Wet  Dry Wet  
G1 Vehicle 
Control 
(Palm jaggery 
solution) 
10.22 
±0.56 
68.72 
±10.50 
10.26 
±0.43 
65.38 
±10.82 
36.64 
±3.49 
181.24 
±13.18 
35.66 
±2.04 
1  14.90 
±  16.20 
G2 Positive 
Control 
(Dexamethason
e ) – 0.5 
10.46 
±0.44 
63.12 
±4.99 
10.18 
±0.61 
54.56 
±18.01 
20.86*** 
±2.01 
111.86*** 
±14.95 
21.18*** 
±2.17 
5   0.32*** 
±  21.39 
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G3 Nandhi 
mezhugu -50 
10.12 
±0.50 
52.90 
±13.50 
10.24 
±0.32 
46.88 
±4.38 
29.50* 
±6.64 
133.26*** 
±11.70 
28.26*** 
±3.61 
     83.72*** 
± 11.73 
G4 Nandhi 
mezhugu -150 
10.18 
±0.61 
50.46 
±12.62 
10.00 
±0.34 
43.90 
±13.37 
27.34** 
±2.08 
122.08*** 
±16.62 
26.28*** 
±4.33 
8  3.96*** 
± 27.35 
G5 Nandhi 
mezhugu-500 
10.50 
±0.25 
75.18 
±11.04 
10.44 
±0.61 
76.28 
±14.71 
23.80*** 
±4.21 
124.84*** 
±12.54 
24.88*** 
±1.05 
4  2.04*** 
    13.10 
n=5; Values are Mean, ±Standard Deviation; p-value 
 
 
TABLE – 7.16.4 SUMMARY OF DRY AND WET COTTON PELLET 
WEIGHTS (mg) OF FEMALES 
 
Group Treatment and 
Dose(mg/
kg) 
INITIAL FINAL 
Right groin Left groin Right groin Left groin 
Dry Wet  Dry Wet  Dry Wet  Dry Wet  
G1 Vehicle Control 
(Palm jaggery 
solution) 
9.90 
±1.04 
48.56 
±7.28 
10.34 
±0.57 
43.38 
±5.24 
35.36 
±1.73 
179.92 
±12.38 
33.80 
±3.87 
131.74 
±12.32 
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n=5; Values are Mean, ±Standard Deviation; 
TABLE – 7.16.5 PERCENTAGE INHIBITION OF GRANULOMA TISSUE 
FORMATION OF MALES & FEMALES 
Grou
p 
Treatment and 
Dose(mg/kg) 
   MALES FEMALES 
Right groin Left groin Right groin Left groin 
Dry Wet  Dry Wet  Dry Wet  Dry Wet  
G1 Vehicle Control 
(Palm jaggery 
solution) 
- - - - - - - - 
G2 Positive 
Control 
(Dexamet
hasone ) – 
0.5 
10.34 
±0.91 
44.14 
±8.29 
10.82 
±0.94 
48.20 
±8.50 
20.84*** 
±1.81 
120.96*** 
±9.90 
20.30*** 
±1.12 
68.98*** 
±18.10 
G3  Nandhi 
mezhugu -
50 
10.76 
±0.89 
45.54 
±2.81 
9.40 
±0.96 
46.56 
±5.92 
27.46*** 
±3.12 
131.42*** 
±7.67 
26.74* 
±4.68 
86.08*** 
±7.78 
G4  Nandhi 
mezhugu-
150 
10.44 
±0.85 
47.68 
±7.94 
10.28 
±0.18 
46.18 
±6.36 
24.52*** 
±2.09 
128.40*** 
±12.05 
25.76** 
±3.47 
83.08*** 
±13.42 
G5 Nandhi 
mezhugu -
500 
9.92 
±0.85 
40.94 
±6.49 
10.74 
±0.90 
40.64 
±5.36 
23.10*** 
±4.80 
127.16*** 
±13.34 
24.10** 
±3.53 
86.90*** 
±13.67 
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G2 Positive 
Control 
(Dexamethason
e )  
– 0.5 
43.07 38.28 40.61 41.82 41.06 32.77 39.94 33.09 
G3  Nandhi 
mezhugu-50 
19.49 26.47 20.75 27.56 22.34 26.96 20.89 24.26 
G4  Nandhi 
mezhugu -150 
25.38 32.64 26.30 29.08 30.66 28.63 23.79 26.19 
G5  Nandhi 
mezhugu-500 
35.04 31.12 30.23 34.37 34.67 29.32 28.70 27.17 
n=5; Values are in percentage. 
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TABLE –7.16.6 SUMMARY OF HEAMATOLOGY PARAMETERS OF 
MALES 
 
 
n=5; Values are Mean, ±Standard Deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups 
Treatment 
(mg/kg) 
 WBC              
(10
3 
cells/µl) 
RBC                
(10
6 
cells/µl) 
 
HgB 
(g/dl) 
 
 HCT 
(%) 
 
MCV 
(fL) 
 
MCH    
(pg) 
 
MCHC 
(g/dl) 
 
PLT (10
3 
cells/µl) 
 
G1 
 Vehicle 
Control 
       (Palm 
jaggery 
solution) 
18.90 
±6.73 
7.13 
±0.42 
12.68 
±0.72 
41.86 
±2.29 
58.74 
±1.06 
17.80 
±0.66 
30.30 
±0.77 
779.00 
±45.59 
 
G2 
Positive 
Control 
(Dexamethas
one) – 0.5 
16.86 
±2.46 
7.72 
±0.92 
13.60 
±0.58 
45.40* 
±1.91 
59.30 
±4.97 
17.78 
±1.51 
29.94 
±0.15 
745.80 
±325.69 
 
G3 
 Nandhi 
mezhugu-50 
17.24 
±5.79 
7.79 
±0.31 
13.48 
±0.49 
45.04* 
±1.28 
57.82 
±1.04 
17.30 
±0.60 
29.92 
±0.60 
835.40 
±226.66 
 
G4 
Nandhi 
mezhugu-150 
17.82 
±7.29 
7.38 
±0.37 
13.10 
±0.44 
43.02 
±1.58 
58.30 
±1.80 
17.74 
±0.54 
30.46 
±0.29 
876.80 
±174.26 
 
G5 
 Nandhi 
mezhugu -
500 
20.06 
±4.90 
7.40 
±0.35 
13.46 
±0.62 
43.78 
±1.96 
59.22 
±2.48 
18.20 
±0.95 
30.78 
±0.44 
900.80 
±194.52 
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TABLE – 7.16.7.SUMMARY OF HEMATOLOGY PARAMETERS OF 
FEMALES 
n=5; Values are Mean, ±Standard Deviation; 
 
 
 
 
 
Group Treatment 
(mg/kg) 
 WBC               
(10
3 
cells/µl) 
RBC                
(10
6 
cells/µ
l) 
HGB 
(g/dl) 
 HCT 
(%) 
MCV 
(fL) 
MCH     
(pg) 
MCH
C 
(g/dl) 
 PLT  
(10
3 
cells/µl) 
G1 Vehicle Control 
(Palm jaggery 
solution) 
17.38 
±3.18 
7.16 
±0.45 
12.92 
±0.56 
41.28 
±2.01 
57.68 
±1.25 
18.06 
± 
0.58 
31.28 
±0.55 
816.60 
±130.96 
G2 Positive Control 
(Dexamethasone) 
– 0.5 
13.92 
±3.44 
7.23 
±0.34 
13.18 
±0.52 
42.40 
±1.56 
58.76 
±2.53 
18.2 
± 
0.92 
31.08 
±0.26 
854.60 
±123.84 
G3 Nandhi mezhugu-
50 
15.34 
±2.60 
6.79 
±0.87 
12.70 
±0.87 
40.32 
±2.67 
59.80 
±3.75 
18.4 
± 
1.5 
31.50 
±0.78 
939.20 
±162.34 
G4 Nandhi mezhugu -
150 
12.28 
±2.14 
6.78 
±0.71 
12.58 
±1.31 
39.88 
±3.34 
58.94 
±2.99 
18.56 
± 
0.69 
31.54 
±1.44 
916.40 
±279.90 
G5 Nandhi mezhugu -
500 
19.00 
±7.10 
6.83 
±0.69 
12.83 
±0.64 
39.67 
±3.74 
58.10 
±0.66 
18.7 
± 
1.07 
32.47 
±1.51 
986.67 
±103.37 
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7.17 Vascular permeability: 
Results:  
Body Weight & Clinical Signs: 
The summary of body weight measurements (Before treatment) and clinical signs 
of male and female animals is presented in Table-7.17.1.  
There were no clinical signs were observed during the study period. 
Gross Necropsy: 
The summary of external and internal gross pathological observations of male and 
female animals is presented in Table-7.17.2. 
There were no external and internal gross pathological changes were observed during 
necropsy except. 
Measurement of dye content in peritoneal fluid: 
The summary of dye content in peritoneal fluid of male and female animals is 
presented in Table-7.17.3. 
Graphical representation is presented in (Figure-7.17.1) 
Percentage Inhibition: 
Percentage inhibition of dye migration was calculated using Following formula: 
 
                          (Mean OD of Control group – Mean OD of Treatment group) 
% Inhibition = ---------------------------------------------------------------------------------X100 
                                               Mean OD of Control group 
 
Group Males Females 
G2 49.33 24.53 
G3 64.97 53.00 
G4 55.92 72.72 
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TABLE No.: 7.17.1 SUMMARY OF BODY WEIGHT (g) AND CLINICAL SIGNS 
RECORD 
N: Normal 
TABLE No.: 7.17.2. SUMMARY OF GROSS NECROPSY  
NAD: No abnormalities detected 
 
Group 
Treatment Dose 
(mg/kg) 
No. of 
Animals 
Body weight (g) and Clinical signs 
Male Female 
G1 Control 
(Palm 
jaggery 
solution) 
0 5+5 178.1 
±4.6 
N 190.3 
±5.9 
N 
G2 Nandhi 
Mezhugu 
50 5+5 183.7 
±6.8 
N 191.5 
±7.1 
N 
G3 150 5+5 183.7 
±6.8 
N 189.9 
±8.4 
N 
G4 500 5+5 176.6 
±4.8 
N 177.6 
±7.6 
N 
 
Group 
Treatment Dose 
(mg/kg) 
No. of 
Animals 
GROSS PATHOLOGICAL CHANGES 
Male Female 
External Internal External Internal 
G1 Control 
(Palm 
jaggery 
solution) 
0 5+5 NAD NAD NAD NAD 
G2 Nandhi 
Mezhugu 
50 5+5 NAD NAD NAD NAD 
G3 150 5+5 NAD NAD NAD NAD 
G4 500 5+5 NAD NAD NAD NAD 
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TABLE No.: 7.17.3 SUMMARY OF ABSORBANCE OF DYE CONTENT IN 
PERITONEAL FLUID 
 
Group 
Treatment Dose 
(mg/kg) 
No. of 
Animals 
COLOUR ABSORBANCE 
Male Female 
G1 Control 
(Palm 
jaggery 
solution) 
0 5+5 1.55 1.67 
±0.53 ±0.77 
G2 Nandhi 
Mezhugu 
50 5+5 0.79*     1.26 
±0.33 ±0.98 
G3 150 5+5 0.54** 0.79** 
±0.46 ±1.05 
G4 500 5+5 0.68* 0.46** 
±0.32 ±0.28 
Level of Significance: ** = p<0.01, * = p<0.05 
Figure 7.17.1 GRAPHICAL REPRESENTATION OF ABSORBANCE OF DYE 
CONTENT IN PERITONEAL FLUID 
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  Figure 7.17.4.FORMULATION DETAILS 
Group & 
Treatment 
1.0% Evans 
blue dye 
solution 
Vehicle / Test 
item (Dose mg/kg 
body weight) 
Acetic 
acid 
(0.6%) 
No. of 
Animals 
Test Item 
(mg) 
Vehicle 
(ml/group/
day) 
Total 
Volume 
(ml/group/
day) 
G1 – Control 
(Palm 
jaggery 
solution) 
5.0 ml/kg 
Bwt 
- 10 ml/kg 
Bwt 
10 - 25 25 
G2 – Nandhi 
Mezhugu  
50 10 125 25 25 
G3 – Nandhi 
Mezhugu  
150 10 375 25 25 
G4 – Nandhi 
Mezhugu   
500 10 1250 25 25 
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 7.18.Freund’s Complete adjuvant (FCA) Arthritis Model Results: 
7.18.1.Body Weight & Body weight gain 
The summary of weekly body weight and body weight gain measurements of 
animals are presented in Table-7.18.1.  
There were no treatment related statistical significance observed in all treatment 
groups when compared with the control group animals. 
7.18.2.Clinical signs and Mortality observations 
The summary of clinical signs and mortality observations of animals are presented 
in Table-7.18.2.  
There were  no treatment related abnormal clinical signs  were observed across all 
the treatment group animals during the experiment period except swelling of paw oedema 
due to administration of FCA. 
7.18.3.Paw measurements and scoring system  
Paw measurements (mm) on day-1, 5 & day 21 and percentage of inhibition on day-
5 & day 21 
The summary of paw measurements and percentage inhibition of all group animals 
are presented in Table-7.18.3.  
7.18.4 Arthritis index 
The summary of Arthritis index of all group animals is presented in Table-7.18.4.  
7.18.5 Total percentage change 
The summary of Total percentage change of treated group animals is presented in 
Table-7.18.5. Dose dependent related changes were observed in treatment group animals. 
7.18.6 Clinical pathology 
Hematology 
The summary of haematology parameters of all group animals is presented in 
Table-7.18.6. There were no significant changes across all the groups when compared 
with the G1 group animals. 
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7.18.7 Clinical chemistry 
The summary of clinical chemistry parameters of all group animals is presented in 
Table-7.18.7. There were no statistical significant changes observed in clinical chemistry 
parameters in treatment group animals when compared with the control animals. 
7.18.8 Pathology 
 
 
 
Group Treatment and 
Dose(mg/kg) 
DAYS 
Treatment period 
       Body Weight (g)                                    Body gain (%) 
Day 1 Day 8 Day 15 Day 1-
8 
Day 8-15 
G1 Arthritis Control 
(Palm jaggery 
solution) 
159.27 
±9.07 
180.8 
±17.0 
212.0 
±14.9 
13.4 
±5.5 
17.6 
±6.4 
G2 Reference drug 
(Indomethacin) – 0.3 
157.27 
±5.66 
175.0 
±6.6 
197.4 
±7.6 
11.3 
±3.1 
12.9 
±4.7 
G3 Nandhi Mezhugu – 
50 
160.98 
±9.03 
183.0 
±11.4 
202.0 
±10.0 
13.7 
±4.2 
10.7 
±7.2 
G4 Nandhi Mezhugu -
150 
158.83 
±7.84 
169.2 
±11.0 
199.8 
±15.0 
6.7 
±8.1 
18.5 
±12.4 
G5 Nandhi Mezhugu – 
500 
159.83 
±8.21 
181 
±14.0 
205 
±19.0 
13.7 
±10.8 
13.0 
±1.8 
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Gross pathology 
The summary of gross pathological observations of all group animals is presented 
in Table-7.18.8.There were no external and internal gross pathological changes noticed 
during the necropsy except for the swelling of paws.  
Histopathology 
The summary of histo-pathological observations of all group animals is presented 
in Table-7.18.9.There was a moderate degree of arthritis induction at G1 group. There 
was mild degree of improvement in the arthritis condition at G2 when compared to the 
G1 group. There was a marginal degree of reduction in the arthritis score at G3, G4 and 
G5 groups.  
TABLE –7.18.1 SUMMARY OF ANIMALS WEEKLY BODY WEIGHT (g) AND 
BODY WEIGHT GAIN (%) 
    n=6; Values are Mean±Standard Deviation;  
 
TABLE –7.18. 2 SUMMARY OF CLINICAL SIGNS AND MORTALITY 
OBSERVATIONS 
Group Treatment and 
Dose(mg/kg) 
DAYS 
Day 
1-10 
Day 
10-20 
Mortality 
G1 Arthritis Control 
(Palm jaggery 
solution)  
N N 0/6 
G2 Reference drug 
(Indomethacin) – 0.3 
N N 0/6 
G3  Nandhi Mezhugu – 
50 
N N 0/6 
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G4 Nandhi Mezhugu - 150 N N 0/6 
G5  Nandhi Mezhugu – 
500 
N N 0/6 
    N-Normal 
TABLE – 7.18.3 SUMMARY OF PAW MEASUREMENTS (mm) ON DAY-1, DAY-
5 & DAY-21 AND PERCENTAGE OF INHIBITION ON DAY-5 & DAY-21  
Gro
up 
Treatmen
t (mg/kg) 
PAW MEAUSREMTS (mm) PERCENTAGE OF 
INHIBITION (%) 
Day-1 Day-5 Day-21 
Left 
hind 
paw  
Right 
hind 
paw 
Left 
hind 
paw  
Right 
hind 
paw 
Left 
hind 
paw  
Right 
hind 
paw 
Percentage 
inhibition 
of injected 
paw on day 
5 
Percentage 
inhibition of 
non - 
injected paw 
on day 21 
G1 Arthritis 
Control 
(Palm 
jaggery 
solution) 
8.63 
±0.39 
4.55 
±0.24 
8.11 
±0.31 
4.52 
±0.31 
6.24 
±0.2
6 
4.44 
±0.28 
- - 
G2 Referenc
edrug 
(Indomet
hacin) – 
0.3  
8.61 
±0.81 
4.74 
±0.13 
6.80 
±0.62 
4.44 
±0.15 
5.73 
±0.2
5 
4.42 
±0.16 
16.25 7.01 
G3 Nandhi 
Mezhugu  
-50 
8.71 
±0.91 
4.28 
±0.11 
7.34 
±0.62 
4.12 
±0.07 
6.15 
±0.2
5 
4.64 
±0.16 
9.59 3.89 
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n=6;Values are Mean±Standard Deviation; 
TABLE – 7.18.4 ARTHRITIS INDEX 
n=6;Values are Mean±Standard Deviation; 
G4 Nandhi 
Mezhugu  
- 150 
9.06 
±0.77 
4.44 
±0.12 
7.29 
±0.66 
4.27 
±0.12 
5.63 
±0.3
2 
4.52 
±0.19 
10.17 2.66 
G5 Nandhi 
Mezhugu 
- 500 
9.07 
±0.80 
4.48 
±0.21 
7.11 
±0.57 
4.25 
±0.11 
5.51 
±0.2
5 
4.51 
±0.25 
12.33 5.70 
Group Treatment 
(mg/kg) 
Arthritis index 
Ear Nose Tail Fore 
paws 
Hind Paws 
(Only Left 
Hind paw) 
Sum 
G1 Arthritis 
Control(Palm 
jaggery 
solution) 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
3.0 
±0.0 
3.0 
±0.0 
G2 Reference drug 
(Indomethacin) 
– 0.3 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
2.0 
±0.0 
2.0 
±0.0 
G3 Nandhi 
Mezhugu  -50 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
2.6 
±0.5 
2.6 
±0.5 
G4 Nandhi 
Mezhugu  - 
150 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
2.0 
±0.0 
2.0 
±0.0 
G5 Nandhi 
Mezhugu  - 
500 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
0.0 
±0.0 
2.0 
±0.0 
2.0 
±0.0 
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TABLE – 7.18.5 TOTAL PERCENTAGE CHANGE 
n=6;Values are Mean±Standard Deviation;
Group Treatment 
(mg/kg) 
TOTAL PERCENTAGE CHANGE 
(Percentage inhibition of injected paw on day 5+ Percentage 
inhibition of non - injected paw on day 21+  Percentage 
change of the arthritis index) 
Percentage 
inhibition of 
injected paw 
on day 5 (%) 
Percentage 
inhibition of non 
- injected paw 
on day 21  (%) 
Percentage 
of 
Inhibition 
Arthritis 
index  (%) 
Total 
Percentage 
Change 
(%) 
G1 Arthritis 
Control (Palm 
jaggery 
solution) 
- - - - 
G2 Reference drug 
(Indomethacin) 
– 0.3  
16.25 7.01 33.33 56.60 
G3  Nandhi 
Mezhugu  -50 
9.59 3.89 14.29 27.77 
G4  Nandhi 
Mezhugu  - 
150 
10.17 2.66 33.33 46.16 
G5  Nandhi 
Mezhugu  - 
500 
12.33 5.70 33.33 51.36 
223 
 
TABLE –7.18 6 SUMMARY OF HAEMATOLOGY PARAMETERS 
n=6;Values are Mean±Standard Deviation; P<0.05*; 
 
Gr Treatment 
(mg/kg) 
Total 
(WBC)               
(10
3 
cells/µl) 
Total 
(RBC)                
(10
6 
cells/µl) 
 HGB 
(g/dl) 
 
HCT 
(%) 
MCV 
(fL) 
 
MCH    
(pg) 
 
MCHC 
(g/dl) 
 
 PLT 
(10
3 
cells/µl
) 
ESR 
(mm/ho
ur) 
G1 Arthritis 
Control 
(Palm 
jaggery 
solution) 
12.23 
± 
1.66 
7.87 
± 
0.31 
13.80 
± 
0.25 
44.43 
± 
1.41 
56.43 
± 
1.22 
17.55 
± 
0.63 
31.08 
± 
0.90 
752.67 
± 
153.17 
0.27 
± 
0.16 
G2 Reference 
drug 
(Indometha
cin) – 0.3  
13.80 
± 
2.59 
7.93 
± 
0.23 
13.88 
± 
0.38 
43.93 
± 
1.00 
55.47 
± 
1.56 
17.53 
± 
0.63 
31.60 
± 
0.41 
627.17 
± 
236.86 
0.22 
± 
0.15 
G3  Nandhi 
Mezhugu  -
50 
14.05 
± 
3.67 
7.38 
± 
0.61 
13.12 
± 
1.02 
43.17 
± 
3.41 
58.52 
± 
2.00 
17.80 
± 
0.87 
30.42 
± 
1.35 
668.67 
± 
113.99 
0.17 
± 
0.08 
G4  Nandhi 
Mezhugu  – 
150 
11.37 
± 
1.46 
7.57 
± 
0.54 
13.50 
± 
0.77 
43.12 
± 
1.91 
57.03 
± 
1.75 
17.87 
± 
0.61 
31.30 
± 
0.60 
682.33 
± 
160.39 
0.18 
± 
0.13 
G5  Nandhi 
Mezhugu  – 
500 
12.95 
± 
2.89 
7.09 
± 
0.70 
13.27* 
± 
0.69 
41.83 
± 
2.35 
59.25 
± 
3.41 
18.78
* 
± 
0.98 
31.72 
± 
0.48 
634.83 
± 
209.50 
0.17 
± 
0.08 
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TABLE – 7.18.7 SUMMARY OF CLINICAL CHEMISTRY PARAMETER 
     n=6;Values are Mean±Standard Deviation 
 
 
 
 
 
 
 
 
Group Treatment  
(mg/kg) 
TOTAL 
PROTEIN  
(g/dl) 
ALBUMIN  
(g/dl) 
G1 Arthritis Control (Palm jaggery 
solution) 
6.58 
±0.71 
3.60 
±0.27 
G2 Reference drug  
(Indomethacin) – 0.3 
7.69 
±1.62 
3.43 
±0.40 
G3  Nandhi Mezhugu  – 50 8.19 
±1.08 
3.49 
±0.15 
G4  Nandhi Mezhugu  – 150 7.56 
±0.84 
3.76 
±0.20 
G5  Nandhi Mezhugu  – 500 7.30 
±0.98 
3.75 
±0.62 
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Study No.: LBPL-EF-046/15  FCA HISTOPATHALOGY SPECIMEN 
 
GI,A.No.03-I, H&E x10 
 
GI,A.No.03-II, H&E x10 
 
GI,A.No.03-III, H&E x10 
 
GI,A.No.06-III, H&E x10 
 
GII,A.No.07-II, H&E x10 
 
GII,A.No.07-III, H&E x10 
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Study No.: LBPL-EF-046/15  FCA HISTOPATHALOGY SPECIMEN 
 
GII,A.No.08-II, H&E x10 
 
GII,A.No.08-III, H&E x10 
 
GIII,A.No.13-III, H&E x4 
 
GIV,A.No.21-III, H&E x10 
 
GIV,A.No.24-II, H&E x4 
 
GV,A.No.27-I, H&E x4 
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Study No.: LBPL-EF-046/15  FCA HISTOPATHALOGY SPECIMEN 
 
 
GV,A.No.29-III, H&E x4 
 
GV,A.No.30-II, H&E x4 
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TABLE – 7.18.8 SUMMARY OF GROSS PATHOLOGICAL OBSERVATIONS 
 
      n=6;NAD – No abnormalities detected 
TABLE –7.18.9 SUMMARY OF HISTOPATHOLOGICAL OBSERVATIONS 
 
 
Group Treatment  (mg/kg) External Internal 
G1 
Arthritis Control (Palm jaggery 
solution) 
NAD NAD 
G2 
Reference drug  
(Indomethacin) – 0.3 
NAD NAD 
G3  Nandhi Mezhugu  – 50 NAD NAD 
G4  Nandhi Mezhugu  – 150 NAD NAD 
G5  Nandhi Mezhugu  – 500 NAD NAD 
Group Treatment (mg/kg) Mean Arthritic score 
G1 
Arthritis Control (Palm jaggery 
solution) 
3.0 
G2 
Reference drug  
(Indomethacin) – 0.3 
1.8 
G3   Nandhi Mezhugu - 50 2.0 
G4 
                                                                         
Nandhi Mezhugu  - 150 
1.5 
G5 
                                                                            
Nandhi Mezhugu  - 500 
1.5 
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7.19.MTT Assay: 
7.19.1 Cytoprotective effect of Nandhi mezhugu: 
Table No:7.19.1.1Cytoprotective effect of Nandhi mezhugu extract vs 25nG/mL of 
LPS  
 
Table No:7.19.1.2 Cytoprotective effect of Nandhi mezhugu extract vs 50 nG/mL of 
LPS
 Blank Untreated LPS 25 ng/ml Concentration Unit: µg/ml 
    50 100 150 
Reading 1 0.024 1.795 1.75 1.748 1.777 1.553 
Reading 2 0.008 1.793 1.761 1.736 1.716 1.505 
Mean 0.016 1.794 1.7555 1.742 1.7465 1.529 
Mean OD-
Mean B 
NA 1.778 1.7395 1.726 1.7305 1.513 
SD  0.001414214 0.007778175 0.008485 0.043134 0.033941 
SEM  0.001000151 0.005500831 0.006001 0.030505 0.024004 
Viability% NA 100 97.83464567 97.07537 97.32846 85.09561 
 Blank Untreated 
LPS 50 
ng/ml 
Concentration Unit: µg/ml 
    50 100 150 
Reading 1 0.024 1.795 1.743 1.748 1.767 1.565 
Reading 2 0.008 1.793 1.749 1.736 1.767 1.445 
Mean 0.016 1.794 1.746 1.742 1.767 1.505 
Mean OD-Mean 
B 
NA 1.778 1.73 1.726 1.751 1.489 
SD  0.001414214 0.004232641 0.004242641 0 0.084852814 
SEM  0.001000151 0.005500831 0.003000453 0 0.060009062 
Viability% NA 100 97.83464567 97.35658043 98.48143982 83.74578178 
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Figure No:7.19.1.1Cytoprotective effect of Nandhi mezhugu extract vs 25nG/mL of 
LPS  
 
 
Figure No:7.19.1.2 Cytoprotective effect of Nandhi mezhugu extract vs 50 nG/mL of 
LPS 
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Table No:7.19.1.3 Cytoprotective effect of Nandhi mezhugu extract vs 100 nG/mL of 
LPS 
 
 
 
Figure No:7.19.1.3 Cytoprotective effect of Nandhi mezhugu extract vs 100 nG/mL 
of LPS 
7.19.2. Cytotoxicity Effect of Nandhi mezhugu compared with LPS: 
7.19.2.1 Cytotoxicity Effect of LPS: 
Table No:7.19.2.1 Cytotoxicity Effect of LPS: 
 Blank Untreated 
LPS 100 
ng/ml 
Concentration Unit: µg/ml 
    50 100 150 
Reading 1 0.024 1.795 1.72 1.802 1.832 1.687 
Reading 2 0.008 1.793 1.722 1.758 1.798 1.632 
Mean 0.016 1.794 1.721 1.78 1.815 1.6595 
Mean OD-
Mean B 
NA 1.778 1.705 1.764 1.799 1.6435 
SD  0.001414214 0.001414214 0.031112698 0.024041631 0.038890873 
SEM  0.001000151 0.001000151 0.022003323 0.017002568 0.027504153 
Viability% NA 100 95.89426322 99.21259843 98.48143982 92.43532058 
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Figure No: 7.19.2.1 Cytotoxicity Effect of LPS: 
Table No: 7.19.2.2 Cytotoxicity Effect of Nandhi mezhugu  
 
 Blank Untreated 
Oxaliplati
n 
(80µM) 
Concentration unit: ng/ml 
    62.5 125 250 500 1000 
Reading 1 0.011 0.655 0.344 0.657 0.633 0.627 0.613 0.355 
Reading 2 0.004 0.669 0.357 0.644 0.638 0.623 0.616 0.339 
Mean 0.0075 0.66175 0.3505 0.6505 
0.635
5 
0.625 0.61 0.347 
Mean OD-
Mean B 
NA 0.65425 0.343 0.643 0.628 
0.617
5 
0.607 0.3395 
SD  0.010253048 
0.0091922
388 
0.00919
2 
0.006
364 
0.009
192 
0.0077
78 
0.0113
14 
SEM  0.007251095 
0.0065009
82 
0.00650
1 
0.004
501 
0.006
501 
0.0055
01 
0.0080
01 
Viability% NA 100 
52.426442
49 
98.2804
7 
97.82
193 
96.29
347 
82.690
1 
51.891
48 
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Figure No: 7.19.2.2 Cytotoxicity Effect of Nandhi mezhugu  
 
7.20. Gene expression study: 
7.20.1.Gene expression study of Nandhi melugu in-vivo model : 
Results 
 
 
Figure 7.20.1.1 Gel analyzer view in in vivo gene expression study 
 
Here, the sample refers to Treated/Positive control treated  
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  Table No: 7.20.1.1 Gene Expression effect of Nandhi mezhugu 
 
Gene Control Treated 
Fold 
change Positive 
Fold 
Change 
GAPDH 638 841   542   
Beta-galacturonidase 2191 2635 11.00 3241 52.30 
Acid phosphatase 731 1075 19.29 1324 94.25 
Cathepsin-D 1951 2272 6.05 2572 36.75 
Myeloperoxidase level 0 0 0.00 0   
C-reactive protein 1812 982 -57.01 1120 -32.89 
TNF-alpha 522 896 32.76 987 107.47 
Interferon – gamma 704 716 -27.13 525 -11.79 
 
M  C   T   P  C   T  P  M  C    T   P   C   T    P   M  
C   T  P 
M  C  T   P  C   T   P  M  C   T    P 
GAPD
H 
B-
Gal 
Acid 
Phos 
Cathe
-D 
Mye
lo 
C-
Reac 
TNF-
α 
Inter
-ϒ 
1000bp 
1000bp 
500bp 
100b
p 
100bp 
500bp 
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            Figure No: 7.20.1.2 Gene Expression effect of Nandhi mezhugu 
 
7.20.2.Gene expression study of Nandhi melugu in-vitro model : 
Results: 
 
 
 
 
 
 
 
 
Figure 7.20.2.1.Gel analyzer view in in vitro gene expression study 
 
 
 
GAP
DH 
Cox 
2 
T
N
F 
  C        L         LT       T        M       C        L         LT       T        C         
L      LT      T   
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Here, the sample refers to LPS/LPS test/Test treated 
Table No: 7.20.2.1.Effect of Nandhi mezhugu in in -vitro gene expression study: 
 
 
 
Figure No: 7.20.2.2.Effect of Nandhi mezhugu in in -vitro gene expression study: 
 
In vitro cell line assay: 
 In cytotoxicity assay in a LPS induced inflammation in the RAW 264.7–Mouse 
macrophage cell line study .Nandhi Mezhugu showed a cytotoxicity at 500 µg/ml and 
above, which is too high concentration to correlate to the in vivo studies. The 
concentrations less than 250 µg/ml were considered for the cytoprotective cell line assay 
where the expression of the inflammatory biochemical markers such as COX-2 and TNF-
alpha were studied. Nandhi Mezhugu at 100 µg/ml showed a decrease in inflammatory 
markers to the extent of 14% and 10% of COX-2 and TNF-alpha respectively. This result 
suggests that the Nandhi Mezhugu preparation can be used as an alternative treatment for 
the inflammatory conditions. 
 
 
Sample CONTROL 
Flod 
change 
LPS 
Fold 
Change 
LPS 
TEST 
Fold 
Change 
TEST 
Fold 
Change 
GAPDH 2432  2416  2540  2504  
Cox2 3552 1 4354 23.03 4168 14.30 3710 2.42 
TNF 2396 1 2767 16.15 3375 10.18 2501 1.38 
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In Vivo –Rat Paw oedema assay: 
 In rat paw oedema bio-assay, there was a dose dependent decrease in the inflammation 
was observed. The highest dose studied in this bio-assay was 500 mg/kg which is almost 
equivalent to the standard drug indomethacin. The pro-inflammatory and anti-
inflammatory gene expression studies were performed in the rat paw treated with Nandhi 
Mezhugu. A slight increase in the gene expression of Beta-galacturonidase, Acid 
phosphatase, and Cathepsin-D at 11,19, and 6% respectively which is biologically non-
significant, whereas there was a decrease in C-reactive protein and Interferon-gamma 
gene expression at 57 and 27% respectively considered due to anti-inflammatory effect of 
Nandhi Mezhugu. An increase in TNF-alpha which is a pro-inflammatory marker which 
is expected to reduce with the treatment, however the increase in the level could not be 
explained. Further studies are required to understand the pathway of anti-inflammatory 
effect of Nandhi mezhugu. 
 
7a.CLINICAL STUDY  
Clinical Study of Nandhi mezhugu: 
Subject enrolment 
215 patients were screened for Rheumatoid arthritis, among them 80 patients were 
included in the study .Out of them 60 patients were enrolled. Among 60 patients 5 
patients were withdrawn their consent and 15 patients failed to come for follow up. The 
remaining 40 patients were completed the full duration of study in OPD and IPD of 
Ayothidoss pandithar hospital, National Institute of Siddha, Tambaram sanatorium, 
Chennai-47. 40 patients were observed in the present study. The observations were made 
and tabulated with regards to the following features: 
 
 Gender distribution(Sex distribution) 
 Age distribution 
 Kaalam distribution 
 Food habits  
 Socio economic status 
 Occupational status   
 Distribution of thinai(Land) 
 Paruvakaalam(Seasons) 
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 Imporigal 
 Impulangal 
 Kanmendrium 
 Kanmavidayam 
 Kosangal 
 Seven udal thathukkal 
 Distribution of mukkutram 
 Deranged vatham 
 Deranged pitham 
 Deranged kabam 
 Envagaithervugal 
 Neerkuri, Neikuri 
 Clinical features 
 Clinical signs 
 Clinical symptoms 
 Pain score 
 Grade for Restricted movements 
 MHAQ 
 EULAR Score 
 Haematological parameters 
 Biochemical parameters 
 LFT 
 RFT 
 Hb, ESR 
 Anti CCP,RA,CRP 
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Outline of the Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chart: Flow chart of patient recruitment for clinical study 
 
215 patients screened 
80 patients under inclusion 
criteria 
60 patients enrolled 
20 patients withdrawan  40 patients completed 
Pt-15 – Lost to follow up 
Pt-5- Withdrawn their consent 
Male - 4 Female -36 
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Demograpic characteristics 
7a.1 Gender distribution: 
 
Figure:7a.1 shows that among 40 cases, 4(10%) cases were male and 36(90%) cases were 
females.  
 
7a.2 Age distribution: 
 
Figure 7a.2 shows that among 40 patients 35% of cases in 31-40 years of age, 35% of 
cases in 41-50 years of age, 17.5% of cases between 20-30 years of age and 12.5% of 
cases in 51-60 years of age. 
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7a.3 Distribution of Thinai(Land): 
 
 
 
Figure 7a.3 shows among 40 cases 70% of cases from Neithal, 15% of cases from 
Marutham, 7.5% of cases from Mullai and 7.5% of cases from Kurinji. 
 
7a.4 Kaalam(Age) distribution: 
 
Figure 7a.4 shows among 40 patients 30% of patients comes under Vatha kaalam (1-33 
years of age) and 70% of patients comes under Pitha kaalam (34-66 years of age). 
 
 
 
KAALM (AGE ) DISTRIBUTION 
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7a.5 Noiutrakaalam: 
 
Figure 7a.5 shows among 40 patients 60% of patients reported in Ilavaenil (April 15- 
June 14), 32.5% patients affected in Muthuvaenil kaalam (June15-August 14), 5% of 
patients affected in Kaarkaalam (August 15-October 14) and 2.5% of patients affected in 
Pinpanikaalam (February 15- April 14). 
7a.6 Distribution of Food Habits: 
 
Figure 7a.6 shows 97.5% of patients were non-vegetarian and 2.5% of patients were 
vegetarian. 
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7a.7.Duration of illness: 
 
Figure 7a.7 shows that 7.5% of patients having symptoms more than 10 years, 10% of 
cases having symptoms more than 5 years, 55% of patients having symptoms more than 1 
year, 12.5% of patients having symptoms with 7-12 months and 15 % of patients having 
symptoms with 2 weeks-6 months.  
7a.8 Body constitution: 
 
 
Figure 7a.8 shows that 30% of cases had Vathapitha thegam, 22.5% of cases had Vatha 
thegam, 17.5% of cases had Vathakabha thegam, 12.5% of cases had Pitha thegam, 10% 
of patients had Kabha thegam and 7.5% of cases had Kabhavaatha thegam.  
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7a.9Distribution of Socio Economic Status: 
 
Figure 7a.9 shows that 50% of cases coming under Middle class , 22.5% of cases coming 
under Upper middle class, 22.5% of cases coming under Lower middle class and 5% of 
cases coming under Poor class. 
 
7a.10 Distribution of Occupational status: 
 
 
Figure 7a.10 shows that 60% of cases were Housewives.7.5% of cases were in Field work 
with intellectual job category, 7.5% of cases working as a Teacher, 25% of patients were 
in Field work with physical exertion category.  
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7a.11Gunam Distribution: 
 
 
Figure 7a.11 shows that  85% had Rajo gunam(courage,honesty,perseverance), 12.5% of 
patients had Sathuva gunam(patience,selfcontrol,humility), and 2.5% of patients had 
Thamo  gunam(excessive sleep,laziness,anger). 
 
7a.12 Imporigal (5 Sense Organs): 
 
Figure 7a.12 shows, percentage of affected Mei(Skin), Vai(mouth) , Kann(Eye) before 
treatment(BT) and after treatment (AT) 
Vai(mouth) tongue  was affected (coated, sore, pallor, dryness) in BT- 45% and  AT-
12.5% of cases,  
Mei(Skin) was affected( dryness, pallor) in BT- 15% and AT -15% of cases.  
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Kann(Eye) was affected (pale conjunctiva, redness, squint)  in BT- 27.5% and AT -
22.45% of cases.  
7a.13 Impulangal (5 Senses): 
 
Figure 7a.13 shows % of affected Sparisam(Touch), Rasam(Taste), Roopam(Vision) 
before treatment(BT) and after treatment (AT) 
Sparism(Touch sense) was affected (Thoduvali-tenderness, Veppam-local heat, Neru 
neruthal-Crepitation) in BT- 100%  and AT-25% of cases, BT- 100%  and AT-7.5% of 
cases, BT- 30%  and AT-30% of cases respectively. 
Rasam(Taste sense) was affected (Suvai inmai-Tastelessness, Vai kasathal-Bitter taste, 
Vai pulithal-sour taste, Naa erichal-burning sensation)  in BT-37.5 % and AT -0% of 
cases.  
Kann(Visual sense) was affected (Maaru kan(squint)  in BT- 7.5% and AT -7.5% of 
cases. 
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7a.14.Kanmenthiriyangal (Organs of Action): 
 
Figure 7a.14 shows percentage of affected Kai(upper limb), Kaal(Lower limb) before 
treatment(BT) and after treatment (AT) 
Kai(Upper limb) was affected( swollen joints and muscle spasm of Upper limb) in BT-
97.5 % and AT -17.5% of cases.  
Kaal(Lower limb) was affected( swollen joints and muscle spasm of lower limb)  in BT 
100 % and AT -17.5% of cases.  
7a.15 Kanmavidayam(Motor Action): 
 
KANMENDIRIYAM (ORGANS OF ACTION) 
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Figure 7a.15 shows percentage of affected Kamanam(actions of lower limb), 
Thaanam(actions of Upper limb), Visarkam(Defecation) before treatment(BT) and after 
treatment (AT) 
Kamanam(actions of lower limb) was affected(Abduction, adduction, flexion, extension, 
standing, walking, running etc.,) in BT-77.5 % and AT -17.5% of cases.  
Thanam(actions of Upper limb) was affected(Abduction, adduction, flexion, extension, 
rotation, gripping, fisting etc.,)  in BT 95 % and AT -17.5% of cases.  
Visarkam(Defecation) was affected(constipation)  in BT 12.5% and AT -0% of cases. 
7a.16 Kosangal(Sheaths or Coverings of Aathma(soul): 
 
Figure 7a.16 shows percentage of affected Annamayakosam (Sheath of food-It is the 
body constituted by  the 7 physical constituents.This food  of sheath helps in the digestion 
of food which is separated into essence and excrement and nourishes the 7 physical 
constituents), Pranamayakosam (Sheath of breath/praanan-It is the body constituted by 
the combination of Praanan and Kanmenthiriyam. This helps to take in the vital air from 
outside and spreads it all over the body,collects the vayu(i.e.CO2)produced as a result of 
metabolic function from all over the body  and expels it from the body)., 
Manomayakosam(Sheath of mind-It is the body constituted by the Manam(mind) and 
Gnanenthiriyam.The heart is said to be the seat of the mind. The heart, with the help of 
the vascular system, circulates the blood throughout the body. So the mind is said to have 
control or influence over the cardio-vascular system (N.B: According to some yogis, the 
mind has no specific seat and it pervades all the tissues.) Vignanamaya kosam(Sheath of 
249 
 
Knowledge- It is the body constituted by the Buddhi and Gnanenthiriyam. Seated in the 
brain knowledge, with the support of Kanmenthiriyam and Gnanenthiriyam, rules over 
the other kosams), Aanandhamayakosam (Sheath of bliss-It is constituted by the Praana 
vayu and Suzhuthi(a sleep like state).It indicates the maintaining of a blissful state with 
the application of knowledge. 
 Before treatment (BT) / After treatment (AT) 
Annamayakosam was affected (Anorexia) in BT-45% and AT-0% 
Praanamayakosam was affected (Dyspnoea) in BT-10% and AT-10% 
Manomayakosam was affected (Stress) in BT-100% and AT-32.5% 
Vignanamayakosam was affected (Depression) in BT-100% and AT-32.5% 
Aanandhamayakosam was affected (Sleep disturbances) – in BT- 45% and AT - 20% 
Note: Kosam- It implies coverings of the aathma which experiences the different levels of 
consciousness ranging from the gross physical body to subtle levels of mind which 
includes emotional and spiritual aspects. It is the experience leading from individual 
consciousness to cosmic consciousness. 
7a.17.1.Uyirthatukkal–Vatham 
 
Figure 7a.17 shows percentage of affected Praanan(It helps in inspiration, expiration and 
digestion), Abaanan(It helps in the act of urination, defecation, discharge of semen during 
sexual act), Udhaanan(It responsible for the reflexes like cough, sneeze, hiccup and 
vomiting, Viyaanan(It performs movements of both movable and immovable parts of the 
body, Samaanan(controls all the other vayus, balance the six tastes, water and foodstuffs 
during the process of digestion and reaches them to their sites of action, Naagan( It acts as 
an instrument for Anthakaranam(Manam, Puthi, Sitham, Agankaaram),responsible for 
one‘s intelligence. It activates the brain to learn all kinds of arts and to sing good songs), 
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Koorman(It emanates from manam(mind) acts on the eye and  produces blinking and 
good vision. It responsible for the act of yawning and closing of the mouth), Kirukaran(It 
acts on the tongue to produce salivary secretion and on the nose to produce nasal(mucous) 
secretion. It produces much hunger. Devathathan (It emanates the form of circle it 
produces laziness and tiredness on waking up from bed),  
Before treatment -BT/After treatment-AT. 
Praanan was affected (Dyspnoea on exertion) in BT-10% and AT-10% due to moderate 
iron deficiency anaemia (Hb level 8-9.5 gm/dL). 
Abaanan was affected (Constipation) in BT-12.5% and AT-0%. 
 Samaanan was affected (Anorexia, controlling other vaayus was affected- Praanan, 
Abaanan, Vyanan, Naagan, Koorman, Kirukaran, Devathaththan) in BT-100% and AT-
25%. 
Vyaanan was affected (Tenderness and Restricted movements of the minor and major 
joints of upper and lower limbs) in BT-100% and AT- 25%. 
Koorman was affected (defective vision) in BT- 7.5% and AT-7.5%. 
Kirukaran was affected (Anorexia and dryness of the tongue) in BT-50% and AT-0%. 
Devathathan was affected (Tiredness ) in BT-37.5% and AT-15%. 
 
7a.17.2 Pitham: 
 
Figure 7a.17.2 shows affected Anal pitham (Located in the digestive organ , helps in the 
process of digestion.), Ranjaka pitham( It has the characteristic of increasing the blood 
volume. Located in the stomach and intestine, it gives the juice, which is separated from 
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the digested food, the typical red colour.), Saathaka pitham(It has the characteristic of 
performing or executing an act.), Praasakam(Located on the skin, it gives lustre to the 
skin.), Alosakam( It has the characteristic of enabling the eyes to perceive the objects.) 
Anal pitham was affected (Anorexia) in BT-45% and AT-0% 
Ranjaka pitham was affected (Anemia) in BT-52.5% and AT-50% 
Saathaka pitham was affected (difficult to perform routine works) in BT-100% and AT-
30% 
Praasakapitham was affected  (loss of luster and dryness of skin) in BT-40% and AT-40% 
Alosakapitham was affected (Myopia, squint) in BT-7.5% and AT-7.5%. 
 
7a.17.3 Iyyam: 
 
 
Figure 7a.17.3 shows affected Avalambagam(It supports the other 4 Kabams),  
Kilethagam(located in the stomach, it wets the food and water ingested and renders them 
softness), Pothagam(located in the tongue, it perceives the sense of taste of foods and 
liquids taken in by mouth), Tharpakam(Located in the head, it cools the eyes), 
Santhikam(Located in the joints, it gives lubrication and helps in extension, flexion and 
rotation). 
Avalambagam was affected (It supports other kabams-Tharpagam, Santhikam, etc) in BT-
100% and AT-100% 
Kilethagam was affected (Anorexia) in BT-45% and AT-0% 
Pothagam was affected (Tastelessness , Bittertaste sense) in BT-32.5% and AT-0% 
Tharpagam was affected (Burning sensation of eyes) in BT-7.50% and AT-0% 
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Santhikam was affected (Tenderness and restricted movement) in BT-100% and AT-
100%. 
 
7a.18.Seven Udalthadhukkal: 
 
Figure 7a.18 shows In Seven Udal thathus, Saaram was affected leading to lethargic and 
depressed conditions. Senneer was affected  leading to nervousness, dryness of skin, 
diminution of bodily luster. Oon was affected(muscle spasm) ,resulting in difficulty to 
perform routine duties. Kozhuppu was the main thathu affected , lead to cause 
crepitations( due to diminution of the pulpy semifluid material) and difficulty in 
movements of the joints.. Enbu thathu was affected, leading to restricted movements of 
the joints and joint stiffness. Moolai thath(bone marrow) was affected,  leading to 
Anaemia. 
Saaram, Senneer, Oon, Kozhuppu, Enbu  were affected in 40 cases and Moolai was 
affected in 21 cases. 
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7a.19 EnvagaiThervu (Eight Fold Examination): 
7a.19.1 NaadiNadai (Pulse Play): 
 
Figure 7a.19.1 Among the 40 cases, 80% of cases had Vatha pitha naadi, 20% of cases 
had Pithavatha naadi. 
7a.19.2 Sparism(Mei kuri -Physical signs): 
 
Figure 7a.19.2 shows Thoduvali (Tenderness) Among 40 cases, 70% cases had 
tenderness till 29
th
 day of treatment and further 14 days treatment, only 25% of cases had 
tenderness. 
 Veppam (Warmth) 
Among 40 cases, initially 100% of cases had veppam, 72.5% of cases had veppam 
(warmth) at 29
th
 day of treatment and further 14 days of treatment only 7.5% of cases had 
veppam. 
Neruneruthal (Crepitation): 
From Day 1 –Day 60 only 30% of cases had Neruneruthal(Crepitation). 
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7a.19.3 Naa (Tongue): 
 
Figure 7a.19.3 shows out of 40 patients 22.5% of patients had Maa padinthiruthal (coated 
tongue), 20% of patients had Suvai inmai(tastelessness), 12.5% of patients had Naa 
Vaeluppu( Pallor tongue), 10% of patients had Naa Kaippu( Bitter taste), 7.5% of patients 
had Naa Varatchi(Dryness of tongue), 7.5% of patients had Karu naakku(Pigmented 
tougue), 2.5% of patients had Naa pun.   
 
7a.19.4 Niram(Complexion) 
 
 
Figure 7a.19.4 Among 40 cases 27.5% of cases had Vathaniram, 55 % of cases had 
Pithaniram and 17.5% of cases had Kabhaniram. 
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7a.19.5 Mozhi: 
 
 
Voice (mozhi) 
Figure shows 7a.19.5 Among 40 cases, 65% cases had Samaoli (medium pitched voice), 
12.5% cases had Ennathoni (low pitched voice) and 22.5% cases had Uratthaoli (high 
pitched voice). 
7a.19.6 Vizhi (Eyes): 
 
Figure shows 7a.19.6 Among 40 cases, 65% of cases had normal eyes, 20% of cases had 
Imai inaipaadala vaeluppu( pale conjunctivae), 7% cases had Kann eritchal (burning of 
eyes), 5% of cases had Kittap parvai (myopia) and 3% of cases had Paarvai kuraipaadu 
(diminished vision). 
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7a.19.7 Malam (Stools) 
 
 
Figure shows 7a.19.7 Among 40 cases, 100% cases had Yellow (Manjal) coloured stools 
throughout the treatment period 
 Among 40 cases, 12.5 % cases had constipation in first 3 visits and became normal in 
further course of treatment. 
  Among 40 cases, 87.5 % cases had normal bowel habits and became 100% normal at the   
end of the treatment. 
7a.19.8.1 Neerkuri  (Urine-Physical characteristics): 
 
Figure shows 7a.19.8.1 
Colour of the urine  
Among 40 cases, 40% cases had pale yellow coloured urine, 20% cases had 
colourless urine, 7.5 % cases had straw coloured urine, 20% cases had yellow coloured 
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urine, 10% cases had dark yellow coloured urine and 2.5% cases had amber coloured 
urine in before treatment. 52.5% cases had pale yellow coloured urine, 27.5% cases had 
colourless urine, 7.5 % cases had straw coloured urine, 7.5% cases had yellow coloured 
urine and 5% cases had dark yellow coloured urine in after treatment. 
         Smell of the urine  
Among 40 cases, 100% of cases had normal odour(ammonical odour) in before and 
after treatment. 
Volume (Alavu) of urine 
Among 40cases, 100% of cases had normal volume of urine in before and after treatment. 
Turbidity (Nurai) of urine  
Among 40cases, 100% of cases had clear urine in before and after treatment.   
 
Deposits (Enjal) in urine:  
Among 40cases, 100% of cases reported normal in  before and after treatment.   
 
7a.19.8.2 Neikkuri (Oil on Urine sign): 
 
Figure 7a.19.8.2                
In before treatment 
Spreading pattern 
    Among 40cases, 95% of cases had slow spreading pattern in before treatment and 5% 
of cases had fast spreading pattern. 
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Shape 
   5% had snake pattern, 22.5% of cases had pearl shaped, 2.5% of cases had mountain 
shaped, 30% of cases had sieve pattern, 27.5% cases had ring shaped, 2.5% of cases had 
trigon shaped, 2.5% cases had half-moon shaped, 2.5% cases had  irregular shaped, 2.5% 
cases had oval shaped and 2.5% cases had coin shaped and 0%  of cases had drumstick 
pattern. 
In after treatment 
Spreading pattern 
   90% cases had slow spreading, 10% cases had fast spreading. 
Shape 
   2.5% of case had Snake pattern, 27.5% of cases had Pearl shaped, 0% of cases had 
Mountain shaped, 10% of cases had Sieve pattern, 42.5% cases had Ring shaped, 0% of 
cases had Trigone shape, 0% cases had half-moon, 7.5% cases had irregular, 2.5% cases 
had Oval shape and 2.5% cases had coin shaped and 2.5% of cases had Drumstick 
pattern. 
              7a.20. Physical functions assessment 
7a.20.1Clinical Features: 
7a.20.1.1Arthritis of more than 3 joints: 
 
At the baseline period, 100 % of patients had pain and inflammation in more than three 
joints. At the end of treatment with NM i.e., 60
th
 day (7 days dosing followed by 7 days 
drug holiday) only 15% of patients had the pain and inflammation in more than three 
joints. 
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7a.20.1.2 Arthritis of hand joints  
 
 
At the baseline period, 100 % of patients had pain and inflammation of hand joints. 
During the treatment period, in all the patients, pain and inflammation of hand joints were 
reduced gradually. Only 12.5% of patients had pain and inflammation of hand joints at 
the end of NM treatment. 
 
7a.20.1.3 Morning stiffness> 1 hr: 
 
 
 
MORNING STIFFNESS MORE THAN 1 HR 
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At the baseline period, 100 % of patients had morning stiffness in the joints. 
During the treatment with NM for 60 days, only 17.5%.of patients had the morning 
stiffness at the end of the treatment..  
7a.20.1.4 Symmetrical arthritis: 
 
At the baseline period, 97.5 % of patients had involvement of arthritis in the 
symmetrical joints. During the treatment with NM for 60 days, the involvement of 
arthritis in symmetrical joints was reduced into 30% of patients at 43
rd 
day. Only 17.5% 
of patients had symmetrical joints involvement after the end of 60 days treatment. 
7a.20.1.5 Restricted movements: 
 
At the baseline period, 100 % of patients had restricted movements of the joints. During 
the treatment with NM for 6o days, only 27.5% of patients had restricted movements in 
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the joints at 43
rd 
day of treatment and at the end of the treatment period, only 17.5% of 
patients had restricted movements. 
 
7a.20.1.6Spindled appearance of fingers: 
 
 
At the baseline period, 20 patients had spindled appearance of fingers. No change was 
observed in all the 20 patients even after the treatment period of 60 days.  
 7a.20.1.7Low grade fever  
 
At the baseline period, 90 % of patients had intermittent low grade fever. After 60 days of 
treatment with NM, none of the patients had reported of having low grade fever. 
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7a.20.1.8 Tenderness  
 
At the baseline period, 100 % of patients had tenderness in the joints. But at the end of 60 
days treatment with NM, only 25% of the patients had tenderness in the joints.  
 
7a.20.1.9 Muscle spasm  
 
At the baseline period, 100 % of patients had muscle spasm in the affected joints. During 
the treatment with NM for 60 days, only17.5% of patients  had muscle spasm in the 
affected joints.  
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7a.20.1.10 Local heat  
 
At the baseline period, 100 % of patients had local heat. During the treatment with NM 
for 60 days, only 7.5%.of patients had local heat over the affected joints. 
 
 
7a.20.1.11Joint stiffness  
 
 
At the baseline period, 100 % of patients had joint stiffness. During 60 days of 
treatment with NM, only 25% of patient had stiffness of the joints at 43
rd 
dayand
.
 at the 
end of 60
th
 day ,only17.5% of patients had  jsoint stiffness.  
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7a.21 MHAQ:(Modified health assessment questionnaire (MHAQ)) score 
Before treatment: 
 
Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8- the mean of 40 patients  
 
 
 
 
Are you able to without ANY 
difficulty 
<0> 
with SOME 
difficulty 
<1> 
with MUCH 
difficulty 
<2> 
unable 
TO DO 
<3> 
Q1 Dress yourself, including tying 
shoelaces and doing buttons? 
   2.425 
Q2 Get in and out of bed?   1.975  
Q3 Lift a full cup or glass to your 
mouth? 
   2.025 
Q4 Walk outdoors on flat 
ground? 
  1.275  
Q5 Wash and dry your entire 
body? 
  1.7  
Q6 Bend down to pick up clothing 
from the floor? 
  1.65  
Q7 Turn regular faucets on and 
off? 
  1.325  
Q8 Get in and out of a bus, car, 
train, or airplane? 
  1.65  
Sub-total   9.575 4.450 
Total     14.025 
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After treatment 
  
 
 
 
 
 
 
Are you able to without 
ANY 
difficulty 
<0> 
with 
SOME 
difficulty 
<1> 
with 
MUCH 
difficulty 
<2> 
unable 
TO DO 
<3> 
Q1 Dress yourself, including tying 
shoelaces and doing buttons?  
 0.325   
Q2 Get in and out of bed?   0.375   
Q3 Lift a full cup or glass to your 
mouth?  
 0.333   
Q4 Walk outdoors on flat ground?   0.4   
Q5 Wash and dry your entire body?  0.475   
Q6 Bend down to pick up clothing 
from the floor? 
 0.525   
Q7 Turn regular faucets on and off?  0.4   
Q8 Get in and out of a bus, car, train, 
or airplane? 
 0.425   
Sub-total  3.25   
Total  3.25 
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Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8- the mean of 40 patients 
Table No:7a.21.1 Modified health assessment questionnaire(MHAQ) 
MHAQ Before treatment After treatment p-value 
Q1 2.425 0.325 p<0.0001 
Q2 1.975 0.375 p<0.0001 
Q3 2.025 0.333 p<0.0001 
Q4 1.275 0.4 p<0.0001 
Q5 1.7 0.475 p<0.0001 
Q6 1.65 0.525 p<0.0001 
Q7 1.325 0.4 p<0.0001 
Q8 1.65 0.425 p<0.0001 
Total 14.025 3.25 p<0.0001 
Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8- each value denotes the mean of 40 patients  
 
 
 
 
 
 
 
 MHAQ score less than 0.3 is considered normal. 
 
 
 
 
MHAQ Total  
Total/8 (mean of 8 
questions) 
Before treatment 14.025 1.75 
After treatment 3.25 0.406 
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Figure 7a.21.1.Modified health assessment questionnaire(MHAQ) 
 
              The mean MHAQ score was recorded after treatment(0.406) and compared with 
the score of before treatment(1.75). The mean score was significantly reduced from the 
base line after treatment with NM 500 mg/kg, orally with Palm Jaggery, twice daily for 
60 days( 7 days drug dosing followed by 7 days drug holiday). In this study the mean of 
MHAQ after treatment for 40 patients was 0.406. So it was inferred that after treatment, 
the patients were improved in their disability index. 
7a.22 Disease Activity - EULAR Score 
 
Before Treatment 8.125 
After Treatment 4.775 
 
Figure 7a.22.1 EULAR score 
 
****P value   <  0.0001 
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The mean EULAR score was recorded after treatment and compared with the score of 
before treatment.for 40 patients.The mean score was reduced from 8.125 to 4.775 after 
treatment with NM 500 mg/kg, orally with Palm Jaggery, twice daily for 60 days( 7 days 
drug dosing followed by 7 days drug holiday).The reduction in EULAR score could be 
attributed to treatement effect. 
7a.23.Pain Score:(UNIVERSAL PAIN ASSESSMENT SCALE-The National Initiative 
on Pain Control™ (NIPC™)), 
 
Table no: 7a.23.1 Pain score 
Pain score Day 1 Day 15 Day 29 Day 43 Day 60 
0: No Pain 0 0 0 6 30 
1-3: Mild Pain 0 0 14 30 7 
4-6: Moderate Pain 2 25 26 4 3 
7-9: Severe Pain 34 15 0 0 0 
10: Worst Pain 4 0 0 0 0 
Total no.of. patients 40 40 40 40 40 
 
          Figure no:7a.23.1 P ain score             
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  Table 7a.23.2 Pain score before and after treatment  
Pain score 
Before 
treatment 
D1 
After 
treatment 
D60 
 
Inference 
0: No Pain -- 30 
 2 from  moderate pain and 28 from 
severe pain 
1-3: Mild Pain -- 7 
1 from worst pain and 6 from 
severe pain 
4-6: Moderate Pain 2 3 3 from worst pain 
7-9: Severe Pain 34 -- Nil 
10: Worst Pain 4 -- Nil 
T. no .of. patients 40 40  
After treatment pain score status of forty patients: 
In after treatment, out of four patients who had worst pain, reported moderate pain (3 
patients) and mild pain (1 patient) 
Out of thirty four patients, who had severe pain, twenty eight patients reported no pain 
and six patients reported mild pain.   
Out of two patients, who had moderate pain, reported no pain.  
 
7a.24 Restricted Movement Assessment Scale:      (Ref:BearingPoint, Atos Healthcare 
&amp; DSP Copyright EBM Rheumatoid Arthritis Version 5.0 final) 
Grade I   - Able to perform normal duties. 
Grade II - Moderate Restriction- Self-care is possible. 
Grade III – Marked restriction – Limited self-care/ some assistance required. 
Grade IV – Confined to bed or wheel chair. 
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Table 7a.24.1.Restricted Movement Assessment Scale 
Grade Day 1 Day 15 Day 29 Day 43 Day 60 % patients 
Grade I 
-- -- 4 29 33 82.5 
Grade II 
4 13 32 9 6 15 
Grade III 
32 24 4 2 1 2.5 
Grade IV 
4 3 -- -- -- -- 
Total no. 
of. Patients 
40 40 40 40 40 
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Figure 7a.24.2.Restricted Movement Assessment Scale 
 
As per the restricted movement assessment scale,in before treatment,four patients (10%) 
were in GradeII(moderate restriction-self care is possible), thirty two patients(80%) were 
in Grade III(marked restriction-limitted self care-some assistance required) and four 
patients(10%) were in GradeIV(confined to bed/wheel chair). After treatment thirty three 
patients (82.5%,) were found to perform normal duties(GradeI) ,six patients(15%) were 
able to care themselves(GradeII) and one patient(2.5%) needed some assistance(Grade 
III). 
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7a.25.1Haematological parameters: 
   Table 7a.25.1Haematological parameters: 
  
S.No Variables/ Units Measurements Before n=40 After n=40 p Value 
1 Hb g/dl 
Mean 
Median 
Range 
SD 
SEM 
11.56 
12 
8.5-14.5 
1.56 
0.25 
11.58 
12 
8.48-14.3 
1.51 
0.24 
0.82 
2 TC Cells/cumm 
Mean 
Median 
Range 
SD 
SEM 
8050 
7750 
4600-4900 
1736 
274.5 
7502 
7300 
4900 
11300 
1600 
252.9 
*0.0346 
3 
DC- Polymorphs 
% 
Mean 
Median 
Range 
SD 
SEM 
66.2 
66 
40-86 
7.81 
1.23 
65.4 
65 
44-78 
6.23 
0.99 
0.3315 
4 Lymphocytes % 
Mean 
Median 
Range 
SD 
SEM 
28.2 
28 
12-55 
7.8 
1.23 
29.02 
30 
15-54 
6.9 
1.08 
0.4518 
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5 Eosinophils % 
Mean 
Median 
Range 
SD 
SEM 
3.55 
4 
0-5 
1.18 
0.19 
3.85 
4 
1.5-7 
1.20 
0.19 
0.4171 
6 Monocyte % 
Mean 
Median 
Range 
SD 
SEM 
1.95 
2 
0-7 
1.50 
0.24 
1.55 
1 
0-7.3 
1.54 
0.24 
0.1218 
7 
 
Total RBC 
Cells/cumm 
 
 
 
Mean 
Median 
Range 
SD 
SEM 
3.8 
4.5 
3.8-5.3 
0.45 
0.07 
3.3 
4.03 
3.3-5.3 
0.50 
0.08 
*0.0490 
8 PCV % 
Mean 
Median 
Range 
SD 
SEM 
37.05 
36.95 
29.5-27.2 
3.98 
0.63 
36.41 
37.3 
27.2-44.4 
3.99 
0.63 
0.0593 
9 MCV fL/red cell 
Mean 
Median 
Range 
SD 
SEM 
81.3 
80.9 
64.8-90.27 
6.19 
0.98 
82.28 
82.6 
66.7-99.2 
5.99 
0.95 
*0.0363 
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*p value <0.05, **p value <0.01, ****p Value<0.0001 are considered as significant 
 
10 MCH pg/cell 
Mean 
Median 
Range 
SD 
SEM 
25.32 
25.05 
18.1-18.8 
2.83 
0.45 
25.89 
26 
18.8-30.4 
2.68 
0.42 
**0.002 
11 MCHC g/dL 
Mean 
Median 
Range 
SD 
SEM 
31.6 
31.3 
27.1-33.4 
1.52 
0.24 
31.5 
31.6 
27.8-36.3 
1.64 
0.26 
*0.04 
12 PLT cells/cumm 
Mean 
Median 
Range 
SD 
SEM 
3.604 
3.3 
2.1-6.7 
1.12 
0.18 
3.785 
3.5 
2.23-6.5 
1.16 
0.18 
*0.02 
13 AEC cells 
Mean 
Median 
Range 
SD 
SEM 
295.7 
299 
98-440 
92.99 
14.7 
300.1 
94.6 
110-520 
14.87 
14.9 
0.77 
14 ESR mm/hr 
Mean 
Median 
Range 
SD 
SEM 
48.1 
44.5 
10-100 
26.01 
4.113 
33.78 
32 
10-85 
19.67 
3.11 
****0.0001 
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Figure 7a.25.1 ESR 
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In Haematology significant reduction was observed in TC, TRBC, MCH, MCHC, PLT, 
ESR and their respective p values are 0.03, 0.046, 0.002, 0.04, 0.02, 0.0001. 
275 
 
7a.26.1Biochemical parameters: 
Table 7a.26.1Biochemical parameters: 
S.No Variables Measurements Before n=40 After n=40 P 
Value 
1 FBS mg/dl Mean 
Median 
Range 
SD 
SEM 
92.18 
92 
80-108 
8.45 
1.34 
93.95 
93.5 
79-109 
8.317 
1.32 
0.25 
2 PPBS mg/dl Mean 
Median 
116.7 
118.5 
113.5 
112.5 
0.18 
     
  Range 
SD 
SEM 
91-135 
12.51 
1.98 
89-135 
11.89 
1.88 
 
3 T. Cholesterol 
mg/dl 
Mean 
Median 
Range 
SD 
SEM 
175.2 
171 
99-272 
42.35 
6.697 
159.4 
151.5 
109-250 
36.82 
5.82 
**0.006 
4 HDL mg/dl Mean 
Median 
Range 
SD 
SEM 
40.88 
39 
25-60 
8.23 
1.30 
37.67 
9.03 
1.43 
9.03 
1.43 
0.06 
5 LDL mg/dl Mean 
Median 
99.42 
94 
89.32 
89.5 
*0.02 
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Range 
SD 
SEM 
48-150 
24.46 
3.87 
44-129 
22.7 
3.589 
6 VLDL mg/dl Mean 
Median 
Range 
SD 
SEM 
23.56 
22 
10-45 
8.19 
1.30 
23.76 
22.3 
12-45 
8.05 
1.28 
0.87 
7 TGL mg/dl Mean 
Median 
Range 
SD 
SEM 
120.6 
110.5 
55-224 
41.31 
6.53 
116.8 
112.1 
59-200 
34.91 
5.52 
0.50 
           *p value <0.05, **p value <0.01, ****p Value<0.0001 are considered as 
significant. 
Discussion:  While comparing the Total cholesterol level before and after treatment, there 
was significant reduction was observed (p Value 0.006), and LDL also significantly 
reduced (p value  0.02). 
7a.27.Liver function test (LFT): 
S.No Variables Measurements Before n=40 After n=40 p Value 
1 T.Bilirubin mg/dl Mean 
Median 
Range 
SD 
SEM 
0.56 
0.5 
0.24-1 
0.17 
0.03 
0.59 
0.6 
0.3-1 
0.18 
0.03 
0.22 
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2 D.Bilirubin mg/dl Mean 
Median 
Range 
SD 
SEM 
0.21 
0.2 
0.09-0.4 
0.08 
0.01 
0.22 
0.2 
0.1-0.5 
0.09 
0.01 
0.58 
3 I.Bilirubin mg/dl 
 
 
Mean 
Median 
Range 
SD 
SEM 
0.35 
0.3 
0.1-0.7 
0.13 
0.02 
0.37 
0.3 
0.2-0.71 
0.12 
0.02 
0.38 
4 SGOT U/L Mean 
Median 
Range 
SD 
SEM 
19.38 
18.5 
10-37 
6.71 
1.06 
17.03 
15 
6-37 
6.14 
0.97 
0.06 
5 SGPT U/L Mean 
Median 
Range 
SD 
SEM 
18.53 
18 
7-32 
6.14 
0.97 
15.44 
14.5 
7-30 
6.89 
1.09 
*0.01 
6 ALP U/L Mean 
Median 
Range 
SD 
SEM 
82.6 
80.5 
40-148 
22.88 
3.61 
84.38 
80 
43-140 
19.34 
3.06 
0.63 
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Table 7a.28 Renal function test (RFT) 
S.No Variables Measurements Before n=40 After n=40 p Value 
1 
 
 
 
Total  
Protein 
g/dl 
 
 
Mean 
Median 
Range 
SD 
SEM 
7.093 
7 
6-8.7 
0.78 
0.12 
7.095 
7.05 
6-9.1 
0.72 
0.11 
 
0.99 
 
2 Albumin 
g/dl 
Mean 
Median 
Range 
SD 
SEM 
3.99 
3.73 
3.1-
4.8 
0.39 
0.06 
4.02 
3.93 
2.9-
4.6 
0.30 
0.05 
 
 
0.40 
3 Globulin 
g/dl 
Mean 
Median 
Range 
SD 
SEM 
3.11 
3 
2-4.9 
0.81 
0.13 
3.05 
3 
1.8-5 
0.79 
0.12 
 
 
0.62 
4 Urea mg/dl 
Mean 
Median 
Range 
SD 
SEM 
17.58 
17.5 
9-25 
3.69 
0.58 
15.24 
15.5 
7-22 
3.79 
0.56 
 
 
***0.0003 
5 Creatinine 
mg/dl 
 
Mean 
Median 
Range 
SD 
SEM 
0.76 
0.8 
0.6-1 
0.10 
0.01 
0.73 
0.7 
0.48-
1 
0.14 
0.02 
 
 
0.29 
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*p value <0.05 is considered as significant. 
Others: 
1 Calcium 
mg/dl 
Mean 
Median 
Range 
SD 
SEM 
9.81 
10 
7.2-11.5 
0.97 
0.15 
9.59 
11.3 
7.7-11.3 
0.97 
0.15 
0.069 
2 Phosphate 
mg/dl 
Mean 
Median 
Range 
SD 
SEM 
3.67 
3.4 
2.5-5.9 
0.75 
0.12 
3.61 
3.5 
2-5.8 
0.88 
0.14 
0.99 
 
While comparing the SGPT before and after, there was significant reduction was 
observed.( p Value -0.01)  
7a.28.Renal function test(RFT): 
                ***p Value <0.001 is considered as significant. 
While comparing Urea level before and after, there was significant reduction was 
observed. ( p Value -0.0003)  
 
 
6 Uric acid 
mg/dl 
Mean 
Median 
Range 
SD 
SEM 
 
.24 
4.05 
2.7-7 
1.13 
0.18 
4.24 
4.2 
1.9-
6.9 
1.05 
 
 
 
 
 
0.98 
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7a.29.Anti CCP,RAF,CRP 
Table 7a.29.Anti CCP,RAF,CRP 
S.No Variables Measurements Before n=40 After n=40 p Value 
1 
Anti CCPSS 
mg/dL 
Mean 
Median 
Range 
SD 
SEM 
360.6 
187.8 
29.8-500 
172.1 
31.95 
344.1 
376.8 
9.21-500 
167.3 
31.07 
0.33 
2 CRP mg/dL 
Mean 
Median 
Range 
SD 
SEM 
16.42 
11.85 
1-65.3 
15.24 
2.69 
13.83 
11 
1.1-55.9 
13.18 
2.33 
0.080 
3 RAF mg/dL 
Mean 
Median 
Range 
SD 
SEM 
171.7 
107.3 
3.6-562.1 
158.2 
27.96 
153.1 
91.4 
4.1-636.6 
155.1 
27.42 
*0.032 
 
*p value <0.05 is considered as significant. 
While comparing RAF before and after treatment, there was significant reduction was 
observed. (p value 0.032) 
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Figure 7a.29.1 Anti CCP 
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Figure 7a.29.2 Rheumatoid factor : 
 
  
Figure 7a.29.3 C - Reactive Protein 
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8. DISCUSSION 
Siddhar Yugi Munivar, in his Yugi Vaithiya Chinthamani, classified   the Vatha 
diseases  into 80 types;
1
 one such disease is Uthira Vatha Suronitham. Uthira Vatha  
Suronitham is a systemic illness caused by the derangement of vatham which manifests as 
pain, swelling, tenderness and limitation of movements in major and minor joints, low 
grade fever, tiredness, and mental depression. The above mentioned signs and symptoms 
of Uthiravatha Suronitham may be correlated to rheumatoid arthritis  in modern science.  
         As mentioned by Yugi Munivar
4
 in his verses on  the aetiology of vatha disease, the 
socio-economic (starvation and doing hard work like lifting heavy weights), 
psychological (disrespecting elders and neglecting parents and teachers and defying 
Vedic scriptures), environmental (seasonal changes), and lifestyle factors (consumption 
of bitter astringent, rancid and salty food, alcohol, day time sleep and night-time 
overwork) causes immunological modification thereby leading to infection, which is 
highly correlated to the aetiology of RA as said in modern science. 
  Nandhi mezhugu is a cost- effective and time-tested Siddha herbo-mineral 
formulation and is well-known for its unique action against Uthira Vatha Suronitham 
(Rheumatoid Arthritis) as evidenced by several decades of its use in clinical practice. For 
global acceptance, scientific validation of Nandhi Mezhugu,
53,54,55
 by safety and efficacy 
studies is the need of the hour. 
          The required raw drugs for the preparation of Nandhi Mezhugu were procured from 
the ―The Indian Medical Practitioner‘s Co-operative Society, Pharmacy and Stores‖ 
(IMPCOPS), Chennai-41.The metals and mineral raw drugs were identified and 
authenticated by Smt.R.Shakila, RO chemistry in Siddha Central research Institute, 
Arumbakkam, Chennai-106. The Herbal raw drugs were identified and authenticated by 
Dr.Sasikala Ethirajalu, RO-Scientist II (Pharmacognosy) in Siddha Central research 
Institute, Arumbakkam, Chennai-106.The ingredients were purified as per the techniques 
stated in the Siddha literature
99
. The raw drugs were purified at The Indian Medical 
Practitioner‘s Cooperative Pharmacy. The medicine Nandhi Mezhugu was prepared at 
The Indian Medical Practitioner‘s Cooperative Pharmacy (IMPCOPS) as per the SOP 
mentioned in Siddha Vaidhiya Thirattu.The drug was subjected to physico-chemical 
analysis as per AYUSH Guidelines,
60,61
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      The organoleptic characters such as colour, odour, taste, and consistency were 
recorded. All the results of physio-chemical parameters were as follows: the loss on 
drying was observed to be 19.156% and fat content 20.683%. It was understood that the 
high value of loss on drying may be due to the fat content. The total ash was calculated as 
6.607% which indicated the content of total inorganics. The water soluble ash value of 
2.95 % showed the content of water soluble inorganic salts like sodium chloride, etc. The 
acid insoluble ash value was calculated as 0.93%. The water soluble and alcohol soluble 
extractives which were estimated to be 39.056 % and 23.558 % respectively indicated the 
presence of high polar secondary metabolites like glycosides, sugars, tannins, saponins, 
alkaloids, etc.  The calculated acid value, saponification value and iodine value were 
indicative of purity of the ghee used for the preparation and showing the number of 
milligrams of free acids and saponifiable   unsaturated acid in the drug. Though the 
reducing sugar (3.69 %) and total sugar (7.54%) values were expected to promote the 
growth of organisms, the drug did not become rancid due to its acidic nature (low pH 
value of 3.35). As  a result, the shelf life of the drug would be increased. The 
phytochemical analysis
62
 of extract of Nandhi Mezhugu revealed the presence of 
secondary metabolites, viz., Steroid, Triterpene, Flavonoid, Alkaloids, Phenol, Tannin, 
Saponin, Coumarin, Glycoside and Quinone which improve the therapeutic efficacy of the 
drug. 
  
         The qualitative inorganic
63
 analysis of the drug, which was carried out as per the 
methods mentioned in standard practical guide, revealed the presence of mercury, 
magnesium, aluminium, calcium, sodium, potassium, copper, zinc, iron, cobalt, chloride, 
carbonate, nitrate, sulphate, sulphide,  acetate, silicate and arsenate which are all 
biologically important radicles. Calcium controls nerve impulse transmission, muscle 
action and prevents convulsive muscular contraction.
100
 Magnesium plays a role in the 
stability of all polyphosphate compounds in the cells, 
101 
including those associated with 
the synthesis of DNA and RNA. It prevents osteoporosis and muscle spasms. Potassium 
prevents stroke, osteoporosis, hypertension, and renal stone. Copper maintains 
102
the 
strength of connective tissues throughout the body and plays a role in production of 
haemoglobin. Copper also scavenges free radicals and may reduce or help prevent some 
of the damage. Iron is used for oxygen transport in the blood through haemoglobin. 
Aluminium is involved in the action of enzymes such as succinic dehydrogenase which is 
involved in porphyrin synthesis. Acetate is the most common building block for 
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biosynthesis of fatty acids. Sulphate and sulphides prevent inflammation. 
103
Quantitative 
assays for Calcium, Magnesium, Potassium, Aluminium, Copper, Iron and Zinc, were 
observed in ICP-OES using standards.
104
 Sulphur (as SO2) was estimated by following 
AOAC 990.28 method and Chloride (as NaCl) was calculated by following AOAC 
950.52 method. Quantitative assay results of Nandhi Mezhugu revealed the presence of 
calcium, may due to the added ingredient Nandukkal (Crab’s fossil),in the drug; presence 
of potassium and aluminium may be due to  the added ingredients padikaram (Common 
Alum- Aluminum Potassium sulphate), Kuthiraipal padanam (Potassium Aluminium 
Silicate) and  Vediuppu.(Potassium nitrate); occurrence of copper was due to  the 
presence of  Mayil thutham(copper sulphate), and ponnimilai(copper pyrite); occurrence 
of iron and zinc was due to the presence of palm jiggery and pal thutham (zinc sulphate) 
respectively. Occurrence of Sulphur and chloride was due to presence of lingam(Mercuric 
sulphide), Thalagam (Arsenic trisulphide), Gowri padanam (Arsenic pentasulphide), 
Gandhagam(Sulphur), Padigaram(Aluminum Potassium sulphate), Rasa Chendooram 
(Red sulphide of mercury), Mayil thutham (copper sulphate), palthutham (zinc sulphate) 
and pooram((Mercurous chloride), Kariuppu (Sodium chloride) respectively. 
Quantitative results of heavy metal analysis revealed that the content of lead and 
cadmium were within the admissible limit. While the content of arsenic and mercury were 
high due to the presence of the ingredients  Rasam (mercury), Lingam (Mercuric 
sulphide), Pooram (Mercurous chloride), Thalagam(Arsenic trisulphide), Manosilai 
(Arsenic disulphide), Vellai padanams (Arsenic trioxide), gowri padanam(Arsenic penta 
sulphide), Kalmatham (Hydrous cobalt arsenate) and Rasa chenduram/sinduram (Red 
sulphide of mercury). WHO has mentioned the limits of heavy metals only for herbal raw 
material and food substances not for the  traditional mineral formulations. The products 
used in the traditional Indian Medical Systems are that they are mostly used in compound 
forms and are multi-component mixtures including minerals in some of the formulations 
and that substantial information is available regarding their prior human use vouchsafing 
safety and efficacy of these formulations. Therefore, an approach different from that for 
evaluation of synthetic drugs is required. It needs to be emphasized that since the 
substance to be tested is already in use in Indian systems of medicine or has been 
described in their texts, the need for testing its toxicity in animals has been considerably 
reduced--- says the Ethical guidelines for biomedical research on human 
subjects,ICMR,2006. In the microbial study, the drug was found free from E. coli, 
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Salmonella spp., Staphlococcus aureus and Enterobacteriacea. The total bacterial count 
and the total fungal count were within the permissible limits.  
Various pesticide residues of organo-chlorine and organo-phosphorous viz., alpha 
BHC,  beta BHC, gamma BHC(Lindane), delta BHC, Aldrin, Dieldrin, trans Chlordane, 
CIS-Chlordane, Endrin, Endrinaldehyde, Endrinketone, Endosulfan-I, Endosulfan-II, 
Endosulfansulfate, Heptachlor, Heptachlorepoxide, Dicofol, Chlorthalonil, 
Hexachlorobenzene, o,p"DDT, P,P"DDT, o,p"DDD, p,p"DDD, o,p"DDE, P,P"DDE, 4-
Bromo,2-Chlorophenol, Acephate, Chlorfenvinphos, Chlorpyrifos, Chlorpyrifos methyl, 
Diazinon, Dichlorvos, Dimethoate, Ethion, Etrimfos, Fenitrothion, Iprobenphos   , 
Malathion, Methamidophos, Monocrotophos, Omethoate, Oxydemeton-methyl, Parathion 
ethyl, Parathion methyl, Phorate, Phosalone, Phosphamidon, Profenophos, Quinalphos, 
Triazophos, Phorate sulphone  Phorate sulphoxide were checked by following AOAC 
2007.01 methods were found to be below limit of quantification (BLQ). The limit of 
quantification(LOQ) for the above mentioned pesticidal residue  is 0.01 ppm. All the 
tested organochlorine pesticides, organophosphorus pesticides were found to be lower 
than the limit of quantification, ie., 0.01 ppm and hence the drug Nandhi mezhugu is 
found to be safe as an internal medicine . 
Aflatoxins such as B1, B2, G1and G2 were checked using AOAC 2008.02 methods. All 
the four aflatoxins were not present in the drug.  
The TLC photo-documentation of hexane extract of Nandi Mezhugu under UV 254 
nm showed 5 visible spots at Rf value 0.25, 0.30, 0.38, 0.50 and 0.71 (all green); under 
UV 366 nm showed three visible spots at Rf value 0.30 (blue), 0.38 (fluorescent blue) and 
0.71 (pale blue). After derivatization with vanillin-sulphuric acid, showed 8 spots at 0.20, 
0.25, 0.30, 0.35 (all purple), 0.38 (brown), 0.46, 0.57 and 0.71 (all purple). 
The HPTLC finger print profile of hexane extract at UV 254 nm showed 12 peaks 
in which the peak at Rf 0.84 was the major peak with an area of 54.90 % followed by a 
peak at Rf 0.29 with an area of 11.66 %. All other peaks are minor with an individual area 
less than 10 %. 
The HPTLC finger print profile of hexane extract at UV 366 nm showed 8 peaks 
in which the peak at Rf 0.85 was the major peak with an area of 39.57 % followed by a 
peak at Rf 0.29 (19.43 %), 0.09 (13.40 %) and 0.37 (11.59 %). All other peaks are minor 
with an individual area less than 10 %. 
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The HPTLC finger print profile of hexane extract at 575 nm showed 10 peaks in 
which the peak at Rf  0.73 was the major peak with an area of 59.17 % followed by a peak 
at Rf 0.59 (14.35 %), 0.22 (8.02 %) and 0.47 (6.25 %). All other peaks are minor with an 
individual area less than 10 %. 
The HPTLC finger print profile of chloroform extract at UV 254 nm showed 9 
peaks in which the peak at Rf 0.12 was the major peak with an area of 56.90 %. All other 
peaks are minor appearing at Rf 0.17, 0.29, 0.56, 0.61, 0.73, 0.78, 0.85 and 0.89 with an 
individual area less than 10 %. 
The HPTLC finger print profile of chloroform extract at UV 366 nm showed 9 
peaks in which the peak at Rf 0.77 was the major peak with an area of 53.15 % followed 
by a peak at Rf 0.84 (23.00 %). Other peaks appeared at Rf 0.13, 0.28, 0.33, 0.38, 0.47, 
0.57 and 0.61 with an individual area contribution of less than 10 %. 
The HPTLC finger print profile of chloroform extract at 575 nm showed 10 peaks 
in which the peak at Rf 0.12 was the major peak with an area of 36.74 % followed by a 
peak at Rf  0.72 (12.76%), 0.36 (9.84%), 0.51 (8.16%), 0.91 (7.33%), 0.29 (6.82%) and all 
other peaks are minor with an individual area less than 5 %. 
The HPTLC finger print profile of ethanol extract at UV 254 nm showed 9 peaks 
in which the peak at Rf 0.19 was the major peak with an area of 41.80 % followed by a 
peak at Rf  0.65 (15.14%), 0.32 (14.32%), 0.54 (11.93%), 0.99 (8.20%)  and all other 
peaks are minor with an individual area less than 5 %. 
The HPTLC finger print profile of ethanol extract at UV 366 nm showed 9 peaks 
in which the peak at Rf 0.65 was the major peak with an area of 32.83 % followed by a 
peak at Rf  0.37 (22.64%), 0.31 (13.26%), 0.99 (8.06%), 0.58 (6.89%), 0.28 (6.57%)  and 
other peaks at Rf  0.52, 0.22 and 0.09 are minor with an individual area less than 5 %. 
The HPTLC finger print profile of ethanol extract at 525 nm showed 9 peaks in 
which the peaks at Rf 0.62 (18.86%), 0.67(17.52 %), 0.19 (14.40 %), 0.49 (14.32%), 0.55 
(13.55 %) and 0.30 (8.89 %) were the major peaks. The other peaks at Rf  0.73 (2.92 %) 
and 0.96 (3.38 %) were minor. The peak at Rf 0.01 was not µconsidered as it is very close 
to the spotting position. 
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 The HPTLC finger print profile of hexane extract, chloroform extract, ethanol 
extract       showed several peaks since it is a poly-herbo-mineral formulation it is difficult 
to read the individual peaks and it is done to assure the quality of the study drug. 
Any changes due to various concentrations of extract (eg 5,10,15 µl) can be 
inferred from 3D chromatogram of the extract at UV254,UV366 and UV 575.  
In continuation of the standardisation of study drug, the safety of the study drug 
had  been studied as per OECD guidelines 423,407,408 (acute, sub-acute sub-chronic 
toxicity studies).  As per OECD test guideline 423, acute oral toxicity study was 
performed on Nandhi Mezhugu in 3 dose levels. It was observed that there were no 
mortality and toxicity signs up to 2000 mg/kg. NM can be classified under category-5 
since the LD50 
69
 value was greater than 2000 mg/kg in accordance with Globally 
Harmonized System of Classification and Labelling of chemicals 
70
 and this provided us a 
direct relevance for protecting human and animal health. Therefore, it can be concluded 
that Nandhi Mezhugu when administered at single dose was non-toxic and can be used 
safely as oral formulation. 
The 28-day repeated dose oral toxicity study was performed as per OECD test 
guideline 407 in both male and female wistar albino rats. The NM administered  twice 
daily with Palm Jaggery solution as vehicle for 28 days of treatment duration as per 
Siddha literature, where 7 days test drug  administration was followed by 7 days drug 
holiday. Few parameters such as feed consumption, haematology and serum biochemical 
parameters showed a statistical significance in low and mid doses, which can be 
considered as incidental effect as there was no dose dependent relationship and the values 
were within the normal range for the rats used in the experimental studies. There were no 
treatment related abnormalities in liver, renal function and other biochemical parameters, 
suggesting that NM was non-toxic up to the high dose tested. Histopathological studies 
provided supportive evidence for biochemical and haematological observations. The 
organ weights were found to be non-significant between the control and NM treated rats 
in both 28 days and 90 days toxicity studies. No abnormality was recorded with respect to 
gross or histopathological examinations of all organs examined. Since there were no signs 
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of toxicity with respect to haematology, clinical chemistry, organ weight, gross and 
histopathological examinations noted in NM Recovery group, it can be inferred that NM 
did not produce delayed onset of toxicity in both 28 days and 90 days toxicity studies. 
Based on these results, the No Observed Adverse Effect Level (NOAEL) of “NM” was 
greater than 110 mg/kg/day. ICP-OES – detection of heavy metal traces in animal tissue 
samples(Brain, Liver, Kidney)in Sub-chronic toxicity studies (High dose group)of Nandhi 
Mezhugu reported the absence of traces of heavy metal such as lead, cadmium, mercury, 
arsenic. 
In Siddhar’s science of longevity, kayakarpa drugs (Kayam=body; 
Karpam=Rejuvenation) play a key role, in the prevention of degeneration and promotion 
of longevity 
105
. Semicarpus anacardium L.f.(Serankottai) 
106,107,108,109
, the chief 
ingredient and other  herbal ingredients namely Zingiber officinalis Rosc.(chukka)
110
, 
Elettaria cardamiomum (L.)Maton(Ellam) 
111
, Cuminum cyminum L.(jeerakam)
112
, 
Withania somifera (L.)Dunal (ammukkura)
113
, Trachyspermum ammi 
(L.)Spargue(Kurosani omam) 
114
, Plumbago zeylanica L.(sithiramoolam) 
115
, are the 
rejuvenating herbs (Kayakarpa mooligaigal) contain polyphenols, flavonoids and 
steroidal compounds 
116
 which protect the vital organs such as liver, kidney etc. from 
oxidative stress. Pirssonite (Pooneeru –Fuller’s earth) 51 one of the mineral ingredients of 
Nandhi Mezhugu has been categorized under rejuvenator of mineral origin (muppu=super 
salt). Even though the purified mercurial and arsenical compounds were added in a very 
small quantity in the preparation of NM, it is interesting to note that the above mentioned 
kayakarpa ingredients are well known potent detoxifying agent of mercury and arsenic as 
per the Siddha literature e.g. curcumin powder used for purification of mercury contribute 
to maintain the healthy status of liver and kidney 
117
. The purified arsenical and mercurial 
ingredients were further finely processed by the ingredients such as Indigofera tinctoria L. 
(avuri), Anacyclus pyrethrum(L.) Lag.(akkiragaram), Zingiber officinale Rosc.,Piper 
nigrum L.,Piper longum L. ,( thirikadugu- chukka,milagu, thippili)  ,Elettaria 
cardamomum(L.)Maton (elam,,Premna),  herbacea   Roxb.(siruthekku),Myristica 
fragrans Houtt. (jathikkai),Plumbago zeylanicaL. (chithiramoolam), pooneeru(Fuller’s 
earth),  kariuppu (Sodium chloride) ,(padikaram –Alum)Aluminium Potassium Sulphate 
and honey which possessed detoxifying properties
 105
. They also enriched the potential of 
the NM and yielded a qualitatively safe Siddha herbo-metallic mineral formulation NM 
,established through the screening of biochemical and haematological parameters in 
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rodents as per the above safety studies (acute, sub-acute, sub-chronic toxicity studies). 
The toxic effects of mercury were neutralized in the presence of sulphur which was one 
of the ingredients in NM 
118
. From other safety studies on herbo-metalo-mineral 
formulations
118,119
, It was evident that if the preparation of such formulations were carried 
out as per Standard Operating Procedures (They undergo thorough extensive purification 
and preparation methods which involve crushing, boiling, and repeated incinerations in 
earthen pots at specified temperatures to make the minerals ready for human 
consumption) mentioned in classical literature, they will not produce any toxic effects. In 
the prepared NM, the essential elements such as Na, K, Ca, Mg, Cu, Fe and Zn had also 
been found in µg/g amounts and trace amounts of arsenic and mercury seemed to remain 
chelated with organic ligands derived from medicinal herbs by alchemic processes 
making these elements biologically assimilable. If the Siddha herbo-metallic-mineral 
formulations containing biologically produced nanoparticles are taken along with palm 
jiggery, honey, ghee and milk they become easily assimilable and their harmful effects 
are removed enhancing their biocompatibility. It is well established that several metals 
play a vital role in the biochemical processes as well as in the cure of many diseases. It is 
believed that widely used heavy metals such as Hg and As in traditional systems of 
medicine act as a catalyser, which stimulates catalytic activity by their presence in 
the intestines without ever reaching the bloodstream. It is probably this property 
that renders many of the highly toxic metals into the nontoxic form. It is believed 
that the toxic effects of these medicines are neutralized by the medium of 
honey/ghee/milk and provide a natural and effective alternative to synthetic allopathic 
drugs 
118
. 
Acetic acid induced writhing method was preferred to evaluate  the analgesic 
efficacy of the Nandhi Mezhugu(NM) in mice. It was inferred that, in high dose group 
(NM  50mg + PJ solution)  there was delayed onset of writhing  and the number of 
writhings were also reduced. The effect was highly dose dependent. The high dose group 
showed significant analgesic activity when compared to standard drug. 
Acute anti-inflammatory activity was studied by Carrageenan induced paw 
odema method, the paw volume was  reduced significantly in high dose group(NM) 
900mg/kg b.w with that of standard (Diclofenac sodium 25mg/kg b.w). Percentage 
of inhibition in high dose group was comparatively high when compared to that of 
the standard. Chronic anti-inflammatory activity was studied by Cotton pellet 
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granuloma method: There were no biologically significant changes observed in body 
weight (g) and body weight gain (%) in all group animals. All the animals were 
found to be normal in their health condition during the entire experiment. 
Haematology parameters were well within the normal range .  Dose dependent 
inhibition of granuloma tissue formation was observed in dexamethasone treated 
group animals and Nandhi Mezhugu treated group animals when compared with the 
control group animals. Based on the results of the cotton pellet granuloma study, 
there was a significant decrease in the final weight of cotton pellet (right groin and 
left groin of animals) at G3, G4 and G5 (NM-50,150,500mg/Kg b.w respectively) 
when compared to G1(Vehicle control group--palm jaggery solution) group in both 
male and female animals. However, in the reference standard of treated group (G2- 
Dexamethasone sodium @ 0.5 mg/kg) an increase in the weight of cotton pellet was 
observed in comparison to control group (G1).  
In Freund’s Complete adjuvant (FCA) Arthritis  study, the arthritis was established 
in the G1(vehicle control group-palm jaggery solution) group animals and also across 
other groups(G2-reference drug Indomethacin-0.3mg/kg b.w, G3,G4,G5-NM-
50,150,500mg/kg b.w respectively) before the initiation of the treatment. The sum of 
arthritis indices noticed were 3.0, 2.0, 2.6, 2.0 and 2.0 in control( G1)standard( G2), low 
dose(G3),mid dose( G4) and high dose (G5) respectively. The total percentage change in 
inhibition of arthritis was 51.36% in high dose group with respect to control (0% 
inhibition). When compared with standard (56.60%), the test drug NM showed significant 
inhibition. Histologically, there was a moderate degree of arthritis induction at G1 group. 
There was mild degree of improvement in the arthritis condition at G2 when compared to 
the G1 group. There was a marginal degree of reduction in the arthritis score in G3, G4 
and G5 groups 
In vascular permeability study, the intra-peritoneal injection of 0.6% acetic acid 
induced increased permeability of vascular system resulting in dilation of the blood 
vessels of all the animals across all groups in both sexes. This was evidenced by the 
presence of Evans blue dye in peritoneal fluid. Administration of the test item (NM-
50,150,500mg/kg b.w to G2,G3,G4 respectively) caused a significant decrease in vascular 
permeability in G2, G3 and G4 in males and in G3 and G4 in females when compared to 
G1 group (palm jaggery solution). 
 In in-vitro cytotoxicity assay in a LPS induced inflammation in the RAW 264.7–Mouse 
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macrophage cell line study .Nandhi Mezhugu showed cytotoxicity at 500 µg/ml and 
above, which is too high concentration to correlate to the in vivo studies. The 
concentrations less than 250 µg/ml were considered for the cyto-protective cell line assay 
where the expression of the inflammatory biochemical markers such as COX-2 and TNF-
alpha were studied. Nandhi Mezhugu at 100 µg/ml showed a decrease in inflammatory 
markers to the extent of 14% and 10% of COX-2 and TNF-alpha respectively. This result 
suggests that the Nandhi Mezhugu preparation can be used as an alternative treatment for 
the inflammatory conditions. 
 
 In in-vivo –Rat Paw oedema bio-assay, there was a dose dependent decrease in the 
inflammation was observed. The highest dose studied in this bio-assay was 500 mg/kg 
which is almost equivalent to the standard drug indomethacin. The pro-inflammatory and 
anti-inflammatory gene expression studies were performed in the rat paw treated with 
Nandhi Mezhugu. A slight increase in the gene expression of Beta-galacturonidase, Acid 
phosphatase, and Cathepsin-D at 11,19, and 6% respectively which is biologically non-
significant, whereas there was a decrease in C-reactive protein and Interferon-gamma 
gene expression at 57 and 27% respectively considered due to anti-inflammatory effect of 
Nandhi Mezhugu. An increase in TNF-alpha which is a pro-inflammatory marker which 
is expected to reduce with the treatment; however the increase in the level could not be 
explained. Further studies are required to understand the pathway of anti-inflammatory 
effect of Nandhi mezhugu. 
 An open labelled, non-randomized, clinical study (without control) on 40 cases of 
Uthiravatha suronitham or Rheumatoid arthritis was conducted, to determine the safety 
and therapeutic efficacy of Nandhi melugu (NM), in out-patient and in-patient 
departments of Maruthuvam, Ayothidoss Pandithar hospital, National Institute of Siddha, 
Tambaram S anatorium,Chennai-47.   The study drug NM was given for 60 days (7 days 
drug dosing followed by 7 days drug holiday). Out- patients were asked to visit  OPD 
once in 2 weeks  and in-patients were taken care of every day by daily visits. Clinical 
assessment and prognosis were recorded during their visits. Clinical laboratory 
investigations were carried out before and after treatment. A total of 66.6% (40/60) 
patients were followed as per the study protocol and completed 60 days of treatment with 
NM. 5 patients refused to sign consent form and 15 patients did not come for regular 
follow-up and blood investigations. There  were (4/40) 10% male and (36/40) 90% 
female patients. At the baseline 100% of both male and female patients were tested high 
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positive for Anti CCP, RAF and  high ESR ,raised CRP level. After 60 days of treatment, 
the haematology report showed a significant reduction in the high value of ESR( ****p 
value -0.0001).While comparing the RAF before and after treatment, there was significant 
reduction observed  (*p value-0.032).   
           The observations regarding siddha parameters and demographic details were seen 
as follows. 
Gender distribution –The incidence of the disease  was far higher in female ( 90%)  
than in  male(10%) . 
Age incidence-among the 40 patients under study is as follows: 35% of patients belonged 
to the age between 31 and 40 , 35% of patients  between  41 and 50 , 17.5% of  patients 
between 20 and 30 and 12.5% of cases between 51and 60 .  
Thinai (Land distribution)- among the 40 patients under study---- 70% of patients 
hailed from Neithal (Coastal belt), 15%  from Marutham (plains), 7.5%  from Mullai 
(Forest range) and 7.5%  from Kurinji (Hilly terrain). 
Kaalam-wise age distribution (according to Siddha science)) – most of the 
patients i.e. (70%)  under study belonged to Pitha kaalam  of 34-66 years ,only 30%  
of patients to Vatha kaalam of 1-33 years . 
Paruvakalangal (Seasonal incidence) – Out of 40 patients, 2.5% of patients were 
treated during Pinpani kaalam (February 15- April 14), 60% of patients during  
Ilavaenil kalam (April 15- June 14), 32.5% patients during Muthuvaenil kaalam 
(June15-August 14) and 5% of patients during Kaar kaalam (August 15-October 
14). 
Food habits---97.5% of patients were non-vegetarian and 2.5% of patients were 
vegetarian. 
 Thegi (Body constitution) --30% of cases had Vatha pitha thegam, 22.5% of 
cases had Vatha thegam, 17.5% of cases had Vatha kabha thegam, 12.5% of cases had 
Pitha thegam, 10% of patients had Kabha thegam and 7.5% of cases had Kabha vaatha 
thegam.  
Socio economic status - 50% of cases were middle class , 22.5%  upper middle class, 
22.5% lower middle class and 5% of cases were Poor . 
Occupational status - 60% of cases were housewives,7.5% of cases were  field workers of 
intellectual job category, 7.5% of cases were Teachers and 25% of patients were  field 
workers of physical exertion category.  
293 
 
Gunam (Character) -- 85% of cases had Rajo gunam (courage, honesty, perseverance), 
12.5% of patients had Sathuva gunam (patience, self-control, humility), and 2.5% of 
patients had Thamo- gunam(excessive sleep, laziness, anger). 
Duration of illnesss - 7.5% of patients had been suffering from symptoms for more than 
10 years, 10% of patients for more than 5 years, 55% of patients for more than 1 year, 
12.5% of patients for 7 to 12 months and 15 % for 2 weeks to 6 months. 
Aimporigal (Five sense organs) --- The condition of Aimporigal with reference to five 
sense organs were studied in all the patients.  
Vai (mouth) -- 45% of patients had any one of the following  signs and symptoms like 
coated or  pallor or sore or dryness of the tongue  before treatment and  only 12.5% of 
patients  had any one of the above signs and symptoms after the treatment.  
Mei (Skin) -- In 15% of patients, dryness or pallor of the skin was observed  before and 
after the treatment.  
Kann (Eye) -- 27.5% of patients had any one of  the following conditions like pale 
conjunctivae or redness of the eye or squint before treatment and in 22.45% of patients  
had pale conjunctivae , squint after treatment.The patients showed improvement from 
redness of eye condition.  
Aimpulangal (Five senses) -- The condition of Aimpulangal with reference to five senses  
were studied in all the patients. 
 Sparism(Mei kuri (Touch sense) -Physical signs): It was affected and it was perceived 
through palpation i.e thoduvali-tenderness, veppam-local heat, neru neruthal - crepitation. 
 All the 100% of patients had tenderness in the affected joints before treatment and only 
25% of them had it even after treatment. 
Similarly before treatment, presence of local heat over the affected joints was perceived 
in all the 100% of patients and only 7.5% of patients had it even after treatment. 
 30% of patients had crepitation in the affected joints both before and after treatment.. 
Rasam(Taste sense) -- 37.5 % of patients had any one of the following symptoms 
i.e.Suvai inmai-Tastelessness, or Vai kasatthal- bitter taste or Vai pulithal-sour taste or 
Naa erichal-burning sensation  of the tongue  before treatment  and became normal after  
the treatment.  
Kann-(Visual sense) 7.5% of patients had defective vision due to myopia(kitta paarvai- 
near vision)  before and after the treatment. 
.Kanmenthiriyangal (the organs of action): The condition of kanmenthiriyangal with 
reference to five organs of action were studied in all the patients. 97.5 % of patients had 
294 
 
swollen joints and muscle spasm of the upper limb (kai) before treatment and only 17.5% 
of patients had the symptoms  after treatment. 
100% of patients had swollen joints and muscle spasm of lower limb (kal) before 
treatment and in only 17.5% of patients the symptoms continued even after treatment.  
Kanmavidayam (Motor actions) -- The condition of  kanmavidayam with reference to five 
motor actions were studied in all the patients. 
77.5% of patients had difficulty in kamanam (actions of lower limbs) i.e., abduction, 
adduction, flexion, extension, standing, walking, running, etc. before treatment and in 
only 17.5% of patients, the symptoms persisted even after the treatment.  
95 % of patients, had difficulty in Thaanam (actions of upper limb)  abduction,                               
adduction, flexion, extension, rotation, gripping, fisting, etc., before treatment and in only        
17.5 % of patients, the symptoms persisted even after the treatment. .  
Visargam-- (Defecation) was affected in 12.5% of patients who had constipation before 
treatment and were completely relieved of constipation after the treatment (0%) 
Kosangal (Sheaths or Coverings of Aathma (soul): The conditions of kosangal with 
reference to five kosams were studied in all the patients. 
Annamayakosam -- (Sheath of food- it is the body constituted by the 7 physical 
constituents. This food of sheath helps in the digestion of food which is separated into 
essence and excrement and nourishes the 7 physical constituents.  
Praanamayakosam (Sheath of breath/praanan- it is the body constituted by the 
combination of Praanan and Kanmenthiriyam. This helps to take in the vital air from 
outside and spreads it all over the body, collects the vayu (i.e.CO2) produced as a result of 
metabolic function from all over the body and expels it from the body).  
Manomaya kosam (Sheath of mind-it is the body constituted by the Manam (mind) and 
Gnanenthiriyam. The heart is said to be the seat of the mind. The heart, with the help of 
the vascular system, circulates the blood throughout the body. So the mind is said to have 
control or influence over the cardio-vascular system (N.B: According to some yogis, the 
mind has no specific seat and it pervades all the tissues.)  
Vignanamaya kosam (Sheath of knowledge- it is the body constituted by the Buddhi and 
Gnanenthiriyam. Seated in the brain, knowledge, with the support of Kanmenthiriyam 
and Gnanenthiriyam, rules over the other kosams).  
Aanandhamayakosam (Sheath of bliss-it is constituted by the Praana vayu and Suzhuthi 
(a sleep like state). It indicates the maintaining of a blissful state with the application of 
knowledge. 
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Annamayakosam was affected (Anorexia) in 45% of patients before treatment and no 
patients (0%) had the symptom after the treatment.
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 Praanamayakosam was affected (Dyspnoea due to moderate iron deficiency anaemia) in 
10% of patients  before  and after treatment. 
Manomayakosam was affected (Stress) in 100% of patients before treatment and 32.5% 
of patients had not been relieved from stress even after the treatment. 
Vignanamayakosam was affected (Depression due to disease process) in 100% of patients 
before treatment and the depression  continued in 32.5% of patients even after the 
treatment. 
Aanandhamayakosam was affected (Sleep disturbances) in 45% of patients before 
treatment and 20% of patients had sleep disturbances even  after  the treatment . 
Note: Kosam- It implies coverings of the aathma which experiences the different levels of 
consciousness ranging from the gross physical body to subtle levels of mind which 
includes emotional and spiritual aspects. It is the experience leading from individual 
consciousness to cosmic consciousness. 
Uyirthatukkal–Vatham--The condition of Vaatham with reference to ten vayus were 
studied in all the patients. 
 The Praanan helps in inspiration, expiration and digestion, Abaanan 
helps in the act of urination, defecation, discharge of semen during sexual act, Udhaanan 
is responsible for the reflexes like cough, sneeze, hiccup and vomiting, Viyaanan 
performs movements of both movable and immovable parts of the body, Samaanan 
controls all the other vayus, balances the six tastes, water and foodstuffs during the 
process of digestion and reaches them to their sites of action, Naagan acts as an 
instrument for Anthakaranam (Manam, Puthi, Sitham, Agankaaram) and is responsible 
for one’s intelligence. It activates the brain to learn all kinds of arts and to sing good 
songs), Koorman  emanates from manam (mind), acts on the eye and  produces blinking 
and good vision. It responsible for the act of yawning and closing of the mouth, 
Kirukaran acts on the tongue to produce salivary secretion and on the nose to produce 
nasal (mucous) secretion. It produces much hunger. Devathathan emanates in the form 
of circle and it  produces laziness and tiredness on waking up from bed.  
(Before treatment -BT/   After treatment-AT). 
 Praanan was affected (Dyspnoea on exertion) BT-10% and AT-10% 
due to moderate iron deficiency anaemia (Hb level 8-9.5 gm/dl). 
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Abaanan was affected (Constipation) BT-12.5% and  AT-0%. 
 Samaanan was affected (anorexia, controlling other vaayus like praanan, abaanan, 
vyanan,  koorman, kirukaran, devathaththan) in 100% of patients in before treatment and 
only 25%.of patients had derangement of samaanan. in after treatment. 
         Vyaanan was affected (Tenderness and Restricted movements of the 
minor and major joints of upper and lower limbs) BT-100% and AT- 25%. 
Koorman was affected (defective vision) BT- 7.5% and AT-7.5%. 
Kirukaran was affected (Anorexia and dryness of the tongue) BT-50% and AT-0%. 
Devathathan was affected (Tiredness ) BT-37.5% and AT-15%. 
Uyirthatukkal–Pitham or Azhal :The condition of pitham with reference to five pithams 
were studied in all the patients. 
 
Anal pitham -- located in the digestive organ, helps in the process of digestion; Ranjaka 
pitham -- has the characteristic of increasing the blood volume. Located in the stomach 
and intestine, it gives the juice, which is separated from the digested food, the typical red 
colour; Saathaka pitham -- has the characteristic of performing or executing an act; 
Praasakam -- located on the skin, it gives lustre to the skin; Alosakam -- has the 
characteristic of enabling the eyes to perceive the objects. 
Anal pitham was affected (Anorexia) BT-45% and AT-0% 
Ranjaka pitham was affected (Anemia) BT-52.5% and AT-50% 
Saathaka pitham was affected (difficult to perform routine works) BT-100% and AT-30% 
Praasakapitham was affected (loss of luster and dryness of skin) BT-40% and AT-40% 
Alosakapitham was affected (Myopia, squint) BT-7.5% and AT-7.5%. 
Uyirthatukkal–Kabam or Iyyam:The condition of kabam with reference to five kabams 
were studied in all the patients. 
Avalambagam -- It supports the other 4 Kabams);  Kilethagam -- located in the stomach, 
it wets the food and water ingested and renders them soft; Pothagam -- located in the 
tongue, it perceives the sense of taste of foods and liquids taken in by mouth; Tharpakam 
-- located in the head, it cools the eyes; Santhikam -- located in the joints, it gives 
lubrication and helps in extension, flexion and rotation. 
Avalambagam was affected (It supports other kabams-Tharpagam, Santhikam, etc) BT-
100% and AT-100% 
Kilethagam was affected (Anorexia) BT-45% and AT-0% 
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Pothagam was affected (Tastelessness , Bittertaste sense) BT-32.5% and AT-0% 
Tharpagam was affected (Burning sensation of eyes) BT-7.50% and AT-0% 
Santhikam was affected (Tenderness and restricted movement) BT-40% and AT-40%. 
The condition of seven udalthathukkal were studied in all the patients. 
In Seven Udal thathus, Saaram wsa affected leading to lethargic and depressed 
conditions. Senneer was affected leading to nervousness, dryness of skin, diminution of 
bodily luster. Oon was affected (muscle spasm), resulting in difficulty to perform routine 
duties. Kozhuppu was the main thathu affected leading to crepitations (due to diminution 
of the pulpy semifluid material) and difficulty in movements of the joints.. Enbu thathu 
was affected, leading to restricted movements of the joints and joint stiffness. Moolai 
thathu (bone marrow) was affected, leading to Anaemia. 
Saaram, Senneer, Oon, Kozhuppu, Enbu  was affected in 40 cases and Moolai was 
affected in 21 cases. 
 EnvagaiThervu (eight fold esxamination): 
 NaadiNadai (Pulse Play): among  40 cases, 80% of cases had Vatha pitha naadi, 20% of 
cases had Pithavatha naadi. 
 Sparism(Mei kuri -Physical signs):Thoduvali (Tenderness)- among 40 cases, 70% cases 
had tenderness till 29
th
 day of treatment and after further 14 days treatment, only 25% of 
cases had tenderness. 
  Veppam (Warmth)-among 40 cases, initially 100% of cases had veppam, 72.5% of cases 
had veppam (warmth) at 29
th
 day of treatment and after further 14 days of treatment only 
7.5% of cases had veppam. 
             Neruneruthal (Crepitation)- from Day1–Day60 only 30% of cases had 
Neruneruthal(Crepitation). 
 Naa (Tongue):among 40 patients 22.5% of patients had Maa padinthiruthal (coated 
tongue), 20% of patients had Suvai inmai(tastelessness), 12.5% of patients had Naa 
Vaeluppu( Pallor tongue), 10% of patients had Naa Kaippu( Bitter taste), 7.5% of patients 
had Naa Varatchi(Dryness of tongue), 7.5% of patients had Karu naakku(Pigmented 
tougue), 2.5% of patients had Naa pun.   
 Niram(Complexion)- among 40 cases 27.5% of cases had Vathaniram, 55 % of cases had 
Pithaniram and 17.5% of cases had Kabhaniram. 
 Mozhi- among 40 cases, 65% cases had samaoli (medium pitched voice), 12.5% cases 
had ennathoni (low pitched voice) and 22.5% cases had uratthaoli (high pitched voice). 
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 Vizhi (Eyes)- among 40 cases, 65% of cases had normal eyes, 20% of cases had Imai 
inaipaadala vaeluppu( pale conjunctivae), 7% cases had Kann eritchal (burning of eyes), 
5% of cases had Kittap parvai (myopia) and 3% of cases had Paarvai kuraipaadu 
(diminished vision). 
 Malam (Stools)-  among 40 cases, 100% cases had Yellow (Manjal) coloured stools 
throughout the treatment period, 12.5 % cases had constipation in first 3 visits and 
became normal in further course of treatment. 
 among 40 cases, 87.5 % cases had normal bowel habits and became 100% normal at the   
end of the treatment. 
 Neerkuri  (Urine-Physical characteristics): Colour of the urine-  among 40 cases, 40% 
cases had pale yellow coloured urine, 20% cases had colourless urine, 7.5 % cases had 
straw coloured urine, 20% cases had yellow coloured urine , 10% cases had dark yellow 
coloured urine and 2.5% cases had amber coloured urine   before treatment. 52.5% cases 
had pale yellow coloured urine, 27.5% cases had colourless urine, 7.5 % cases had straw 
coloured urine, 7.5% cases had yellow coloured urine and 5% cases had dark yellow 
coloured urine  after treatment 
Smell of the urine- among 40 cases, 100% of cases had normal odour(ammonical odour)  
before and    after treatment. 
Volume (Alavu) of urine-among 40cases, 100% of cases had normal volume of urine  
before and after treatment. 
Turbidity (Nurai) of urine- among 40cases, 100% of cases had clear urine ,  before and 
after treatment.   
Deposits (Enjal) in urine: among 40cases, 100% of cases reported normal   before and 
after treatment.   
Neikkuri (Oil on Urine sign): before treatment-Spreading pattern 
 Among 40cases, 95% of cases had slow spreading pattern  before treatment and 5% of 
cases had fast spreading pattern. 
Shape 
 5% of cases had Snake pattern, 22.5% of cases had Pearl shaped, 2.5% of case had 
Mountain shaped, 30% of cases had Sieve pattern, 27.5% cases had Ring shaped, 2.5% of 
cases had Trigon shape, 2.5% of case had half-moon shaped, 2.5% case had  irregular 
shaped, 2.5% case had oval shaped and 2.5% case had coin shaped and 0%  of cases had 
Drumstick pattern. 
 After treatmentSpreading pattern 
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 90% cases had slow spreading, 10% cases had fast spreading. 
Shape-2.5% of case had Snake pattern, 27.5% of cases had Pearl shaped, 0% of cases had 
Mountain shaped, 10% of cases had Sieve pattern, 42.5% cases had Ring shaped, 0% of 
cases had Trigone shaped, 0% cases had half-moon shaped, 7.5% cases had irregular 
shaped, 2.5% cases had oval shaped and 2.5% cases had coin shaped and 2.5% of cases 
had Drumstick pattern. 
Physical functions assessment was carried out before and after treatment in all the 
patients with respect to the clinical features : (i) arthritis of more than 3 joints--at the 
baseline period, 100 % of patients had pain and inflammation in more than three joints. 
At the end of treatment with NM i.e., 60
th
 day (7 days dosing followed by 7 days drug 
holiday) only 15% of patients had the pain and inflammation in more than three joints. 
(ii) Arthritis of hand joints --at the baseline period, 100 % of patients had pain and 
inflammation of hand joints. During the treatment period, in all the patients, pain and 
inflammation of hand joints were reduced gradually. Only 12.5% of patients had pain and 
inflammation of hand joints at the end of NM treatment. 
(iii) Morning stiffness> 1 hr -- at the baseline period, 100 % of patients had morning 
stiffness in the joints. During the treatment with NM for 60 days, only 17.5%.of patients 
had  the morning stiffness at the end of the treatment..  
(iv) Symmetrical arthritis--at the baseline period, 97.5 % of patients had involvement of 
arthritis in the symmetrical joints. During the treatment with NM for 60 days, the 
involvement of arthritis in symmetrical joints was reduced into 30% of patients at 43
rd 
day. Only 17.5% of patients had symmetrical joints involvement after the end of 60 days 
treatment. 
(v) Restricted movements--at the baseline period, 100 % of patients had restricted 
movements of the joints. During the treatment with NM for 6o days, only 27.5% of 
patients had restricted movements in the joints at 43
rd 
day of treatment and at the end of 
the treatment period, only 17.5% of patients had restricted movements. 
(vi) Spindled appearance of fingers -- at the baseline period, 20 patients had spindled 
appearance of fingers. No change was observed in all the 20 patients even after the 
treatment period of 60 days.  
(vii)Low grade fever-- at the baseline period, 90 % of patients had intermittent low grade 
fever. After 60 days of treatment with NM, none of the patients had reported of having 
low grade fever. 
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               (viii)  Tenderness--at the baseline period, 100 % of patients had tenderness in 
the joints. At the end of 60 days treatment with NM, only 25% of the patients had 
tenderness in the joints.  
 
(ix) Muscle spasm--at the baseline period, 100 % of patients had muscle spasm in the 
affected joints. During the treatment with NM for 60 days,only17.5% of patients  had 
muscle spasm in the affected joints.  
(x) Local heat-- at the baseline period, 100 % of patients had local heat. During the 
treatment with NM for 60 days, only 7.5%.of patients had local heat over the affected 
joints. 
 ( xi ) Joint stiffness--at the baseline period, 100 % of patients had joint stiffness. During 
60 days of treatment with NM ,only 25% of patient had stiffness of the joints at 43
rd 
day 
and
.
 at the end of 60
th
 day ,only17.5% of patients had  joint stiffness 
 (xii)  MHAQ:(Modified health assessment questionnaire (MHAQ) score 
 MHAQ score less than 0.3 is considered normal. 
The mean MHAQ score was recorded after treatment(0.406) and compared with the score 
of before treatment(1.753) for 40 patients. The mean score was significantly reduced from 
the base line after treatment with NM 500 mg/kg, orally with Palm Jaggery, twice daily 
for 60 days( 7 days drug dosing followed by 7 days drug holiday). In this study the mean 
of MHAQ after treatment for 40 patients was 0.406. So it was inferred that after 
treatment, the patients were improved in their disability index. 
          (xiii) Disease Activity - EULAR Score 
The mean EULAR score was recorded after treatment and compared with the score of 
before treatment for 40 patients.The mean score was reduced from 8.125 to 4.775 after 
treatment with NM 500 mg/kg, orally with Palm Jaggery, twice daily for 60 days( 7 days 
drug dosing followed by 7 days drug holiday).. 
(xiv) pain score status of forty patients was assessed by universal pain assessment 
scale.sIn after treatment, out of four patients who had worst pain, reported moderate pain 
(3 patients) and mild pain (1 patient) 
Out of thirty four patients, who had severe pain, twenty eight patients reported no pain 
and six patients reported mild pain.   
Out of two patients, who had moderate pain, reported no pain.  
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              (xv) Restricted Movement Assessment Scale:      (Ref:BearingPoint, Atos 
Healthcare &amp; DSP Copyright EBM Rheumatoid Arthritis Version 5.0 final) 
Grade I   - Able to perform normal duties. 
Grade II - Moderate Restriction- Self-care is possible. 
Grade III – Marked restriction – Limited self-care/ some assistance required. 
Grade IV – Confined to bed or wheel chair. 
As per the restricted movement assessment scale,in before treatment,four patients (10%) 
were in GradeII(moderate restriction-self care is possible), thirty two patients(80%) were 
in Grade III(marked restriction-limitted self care-some assistance required) and four 
patients(10%) were in GradeIV(confined to bed/wheel chair).  
After treatment thirty three patients (82.5%,) were found to perform normal 
duties(GradeI) ,six patients(15%) were able to care themselves(GradeII) and one 
patient(2.5%) needed some assistance(Grade III) 
 Haematological parameters: After 60 days of treatment ,the haematology report showed 
a significant reduction in the high value of ESR( ****p value - 0.0001). While comparing 
the serum RAF before and after treatment ,there was significant reduction was observed  
(*p value-0.032).   
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9. SUMMARY 
The study drug Nandhi mezhugu(NM) was tested for preclinical and clinical study, The 
findings of the drug were given as follows. 
  The raw drugs for NM were purified and the medicine NM was prepared at IMPCOPS as 
per the SOP mentioned in Siddha Vaidhiya Thirattu. 
 The physico-chemical analysis of the drug revealed that the drug possessed  high value 
for loss on drying , total ash indicated the presence of inorganic substances and the water 
soluble ash value  showed the  presence  of water soluble inorganic salts like sodium 
chloride. The water soluble and alcohol soluble extractives indicated the presence of high 
polar secondary metabolites like glycosides, sugars, tannins, saponins and alkaloids.  The 
calculated acid value, saponification value and iodine value were indicative of purity of 
the ghee used for the preparation and showed the number of milligrams of free acids and 
saponifiable   unsaturated acid in the drug. The shelf life of the drug is increased. 
  The phyto-chemical analysis of the extract of Nandhi mezhugu revealed the presence of 
secondary metabolites, viz., Steroid, Triterpene, Flavonoid, Alkaloids, Phenol, Tannin, 
Saponin, Coumarin, Glycoside, Quinone, which improve the therapeutic efficacy of the 
drug. 
   The qualitative inorganic analysis of the drug showed the presence of mercury, 
magnesium, aluminium, calcium, sodium, potassium, copper, zinc, iron, cobalt, chloride, 
carbonate, nitrate, sulphate, sulphide, acetate, silicate and arsenate which are biologically 
important radicles. 
   Quantitative results of heavy metal analysis revealed that the contents of lead and 
cadmium were within the admissible limits, whereas the contents of arsenic and mercury 
were high due to the presence of the ingredients  Rasam (mercury), Lingam (Mercuric 
sulphide), Pooram (Mercurous chloride), Thalagam (Arsenic trisulphide), Manosilai 
(Arsenic disulphide), Vellai padanams (Arsenic trioxide), gowri padanam(Arsenic penta 
sulphide), Kalmatham (Hydrous cobalt arsenate) and Rasa chenduram/sinduram (Red 
sulphide of mercury).  
 Quantitative assays showed the presence of Calcium, Magnesium, Potassium, 
Aluminium, Copper, Iron and Zinc . Sulphur (as SO2) and Chloride (as NaCl).  
 In the microbial study, the drug was found free from E. coli, Salmonella spp., 
Staphlococcus aureus and Enterobacteriacea.  
 All the four aflatoxins were not detected in the drug.  
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 Various pesticide residues were lower than the limit of quantification. 
 The TLC photo-documentation and the HPTLC finger print profile of hexane extract, 
chloroform extract, ethanol extract of Nandhi Mezhugu showed several peaks. Though it 
is difficult to read the individual peaks, it is done to assure the quality of the study drug. 
 The 28-days and 90 days repeated doses oral toxicity studies in Wistar albino rat inferred 
that NM did not produce delayed onset of toxicity in both 28 days and 90 days toxicity 
studies. Based on these results, the No Observed Adverse Effect Level (NOAEL) of 
“NM” was greater than 110 mg/kg/day. 
  ICP-OES – detection of heavy metal traces in animal tissue samples (Brain, Liver, 
Kidney) in Sub-chronic toxicity studies (High dose group) of Nandhi Mezhugu reported 
the absence of traces of heavy metals such as lead, cadmium, mercury and arsenic. 
 Acetic acid induced writhing method was preferred to evaluate the analgesic effect of NM 
in mice. It was inferred that, in high dose group (NM 50mg + PJ solution) there was 
delayed onset of writhing  and the number of writhings were also reduced. The effect was 
highly dose dependent. The high dose group showed significant analgesic activity when 
compared to standard drug. 
 
 Acute anti-inflammatory activity was studied by Carrageenan induced paw odema 
method, the paw volume was reduced significantly in high dose group (NM) 900mg/kg 
b.w with that of standard (Diclofenac sodium 25mg/kg b.w). Percentage of inhibition in 
high dose group was high when compared to that of the standard.  
 
 Chronic anti-inflammatory activity was studied and inferred that dose dependent 
inhibition of granuloma tissue formation. 
 In Freund’s Complete adjuvant (FCA) Arthritis  study, the arthritis was established in the 
G1(vehicle control group-palm jaggery solution) group animals and also across other 
groups (G2-reference drug Indomethacin-0.3mg/kg b.w, G3,G4,G5-NM- 
50,150,500mg/kg b.w respectively) before the initiation of the treatment. The total 
percentage change in inhibition of arthritis was 51.36% in high dose group with respect to 
control (0% inhibition). When compared with standard (56.60%), the test drug NM 
showed significant inhibition. Histologically, there was a moderate degree of arthritis 
induction at G1 group. There was mild degree of improvement in the arthritis condition at 
G2 when compared to the G1 group. There was a marginal degree of reduction in the 
arthritis score in G3, G4 and G5 groups. 
 In vascular permeability study, the intra-peritoneal injection of 0.6% acetic acid induced 
increase in permeability of vascular system resulting in dilation of the blood vessels of all 
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the animals across all groups in both sexes. This was evidenced by the presence of Evans 
blue dye in peritoneal fluid. Administration of the test item (NM-50,150,500mg/kg b.w to 
G2, G3, G4 respectively) caused a significant decrease in vascular permeability in G2, G3 
and G4 in males and in G3 and G4 in females when compared to G1 group (palm jaggery 
solution). 
 In in-vitro cytotoxicity assay   a LPS induced inflammation in the RAW 264.7–Mouse 
macrophage cell line study. Nandhi Mezhugu showed cytotoxicity at 500 µg/ml and 
above, which is too high a concentration to correlate to the in-vivo studies. The 
concentrations less than 250 µg/ml were considered for the cyto-protective cell line assay 
where the expression of the inflammatory biochemical markers such as COX-2 and TNF-
alpha were studied. Nandhi Mezhugu at 100 µg/ml showed a decrease in inflammatory 
markers to the extent of 14% and 10% of COX-2 and TNF-alpha respectively. This result 
suggests that the Nandhi Mezhugu preparation can be used as an alternative treatment for 
the inflammatory conditions. 
 In in-vivo –Rat Paw oedema bio-assay, a dose dependent decrease in the inflammation 
was observed. The highest dose studied in this bio-assay was 500 mg/kg which is almost 
equivalent to the standard drug indomethacin. The pro-inflammatory and anti-
inflammatory gene expression studies were performed in the rat paw treated with Nandhi 
Mezhugu. A slight increase in the gene expression of Beta-galacturonidase, Acid 
phosphatase, and Cathepsin-D at 11%, 19%, and 6% respectively is biologically non-
significant, whereas a decrease in C-reactive protein and Interferon-gamma gene 
expression at 57% and 27% respectively is considered due to anti-inflammatory effect of 
Nandhi Mezhugu. An increase in TNF-alpha, which is a pro-inflammatory marker, is 
expected to reduce with the treatment; however the increase in the level could not be 
explained. Further studies are required to understand the pathway of anti-inflammatory 
effect of Nandhi mezhugu. 
 An open labelled, non-randomized, clinical study (without control) on 40 cases of 
Uthiravatha suronitham or Rheumatoid arthritis was conducted, to determine the safety 
and therapeutic efficacy of Nandhi melugu (NM), in out-patient and in-patient 
departments of Maruthuvam, Ayothidoss Pandithar hospital, National Institute of Siddha, 
Tambaram Sanatorium, Chennai-47.   The study drug NM was given for 60 days (7 days 
drug dosing followed by 7 days drug holiday). Out- patients were asked to visit  OPD 
once in 2 weeks  and in-patients were taken care of every day by daily visits. Clinical 
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assessment and prognosis were recorded during their visits. Clinical laboratory 
investigations were carried out before and after treatment. A total of 66.6% (40/60) 
patients were followed as per the study protocol and completed 60 days of treatment with 
NM. 5 patients refused to sign consent form and 15 patients did not come for regular 
follow-up and blood investigations. There were (4/40) 10% male and (36/40) 90% female 
patients. At the baseline 100% of both male and female patients were tested high positive 
for Anti CCP, RAF and high ESR and raised CRP level. After 60 days of treatment, the 
haematology report showed a significant reduction in the high value of ESR (****p value 
-0.0001). While comparing the RAF before and after treatment, there was significant 
reduction observed (*p value-0.032).   
The observations were made and tabulated with regard to the following features: 
 Gender distribution(Sex distribution) 
 Age distribution 
 Kaalam distribution (Vaatha, Pitha, Kaba kaalam) 
 Food habits  
 Socio-economic status 
 Occupational status   
 Distribution of thinai(Land) 
 Paruvakaalam (Seasons) 
 Aimporigal 
 Aimpulangal 
 Kanmenthirium 
 Kanmavidayam 
 Kosangal 
 Seven udal thathukkal 
 Distribution of mukkutram 
o Deranged vatham 
o Deranged pitham 
o Deranged kabam 
 Envagai thervugal 
 Neerkkuri, Neikkuri 
 Clinical features 
 Clinical signs 
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 Clinical symptoms 
 Pain score 
 Grade for restricted movements 
 MHAQ 
 EULAR Score 
 Haematological parameters 
 Biochemical parameters 
 LFT 
 RFT 
 Hb, ESR 
 Anti CCP, RA, CRP 
 MHAQ:(Modified health assessment questionnaire (MHAQ) score 
MHAQ score less than 0.3 is considered normal.The mean MHAQ score was recorded 
after treatment (0.406) and compared with the score before treatment (1.753) for 40 
patients. The mean score was significantly reduced from the base line after treatment with 
NM 500 mg/kg, orally with Palm Jaggery, twice daily for 60 days (7 days drug dosing 
followed by 7 days drug holiday). In this study the mean of MHAQ after treatment for 40 
patients was 0.406. So it was inferred that after treatment, the patients were improved in 
their disability index. 
   Disease Activity - EULAR Score 
The mean EULAR score was recorded after treatment and compared with the 
score before treatment for 40 patients.The mean score was reduced from 8.125 to 4.775 
after treatment with NM 500 mg/kg, orally with Palm Jaggery, twice daily for 60 days (7 
days drug dosing followed by 7 days drug holiday).. 
 He Pain score status of forty patients was assessed by universal pain 
assessment scale. Out of 4 patients who had worst pain, 3 patients reported 
moderate pain and 1 patient mild pain after treatment. 
                Out of 34 patients, who had severe pain, 28 patients reported no pain and 6           
                patients reported mild pain.   
               2 patients, who had moderate pain, reported no pain.  
 Restricted Movement Assessment Scale:      (Ref: BearingPoint, Atos 
Healthcare &amp; DSP Copyright EBM Rheumatoid Arthritis Version 5.0 
final) 
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Grade I   - Able to perform normal duties. 
Grade II - Moderate Restriction- Self-care is possible. 
Grade III – Marked restriction – Limited self-care/ some assistance required. 
Grade IV – Confined to bed or wheel chair. 
As per the restricted movement assessment scale, before treatment, 4 patients 
(10%) were in GradeII (moderate restriction-self care is possible), 32 patients (80%) were 
in Grade III (marked restriction-limitted self care-some assistance required) and 4 patients 
(10%) were in GradeIV (confined to bed/wheel chair).  
After treatment 33 patients (82.5%,) were found to perform normal duties (Grade I), 6 
patients (15%) were able to care for themselves (GradeII) and only one patient (2.5%) 
needed some assistance (Grade III). 
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10. CONCLUSION 
 
The raw ingredients of the study drug, Nandhi Mezhugu (NM), were purchased  
and prepared at the Indian Medical Practitioner‘s Cooperative Pharmacy (IMPCOPS)  
society, as per standard operating procedure mentioned in the text Siddha Vaithiya 
Thirattu and standardised as per Ayush guidelines. The safety studies - acute, sub-acute, 
sub-chronic  of NM,  done as per OECD guidelines.Acute toxicity findings showed no 
mortality and toxicity signs up to 2000 mg/kg in acute oral toxicity study. NM can be 
classified under category-5, since the LD50  value was greater than 2000 mg/kg in 
accordance with Globally Harmonized System of Classification and Labelling of 
chemicals (GHS 2015] and this provided us a direct relevance for protecting human and 
animal health. NM did not produce delayed onset of toxicity in both 28 days and 90 days 
repeated oral toxicity studies. Based on these results, No Observed Adverse Effect Level 
(NOAEL) of ―NM‖ was greater than 110 mg/kg/day. ICP-OES –study for detection of 
heavy metal traces in animal tissue samples (Brain, Liver, Kidney) in Sub-chronic 
toxicity studies (High dose group) of NM reported the absence of traces of heavy metals 
such as lead, cadmium, mercury and arsenic. 
NM showed significant analgesic and anti-inflammatory (acute and chronic) and 
anti- arthritic activities in animal models. In vascular permeability study, NM caused a 
significant decrease in vascular permeability. In in-vitro cytotoxicity assay, in a LPS 
induced inflammation in the RAW 264.7–Mouse macrophage cell line study, NM showed 
cytotoxicity at 500 µg/ml and above. NM at 100 µg/ml showed a decrease in 
inflammatory markers to the extent of 14% and 10% of COX-2 and TNF-alpha 
respectively. This result suggests that the Nandhi Mezhugu preparation can be used as an 
alternative treatment for the inflammatory conditions. The pro-inflammatory and anti-
inflammatory gene expression studies performed in the rat paw treated with Nandhi 
Mezhugu, showed a decrease in C-reactive protein and Interferon-gamma gene 
expression  which is considered due to anti-inflammatory effect of Nandhi Mezhugu. 
An open labelled, non-randomized, clinical study (without control) was conducted in 
40 cases of Uthiravatha suronitham (or Rheumatoid arthritis), to determine the safety and 
therapeutic efficacy of Nandhi mezhugu (NM).   The study drug NM was given for 60 
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days (7 days drug dosing followed by 7 days drug holiday). At the baseline, 100% of both 
male and female patients were tested high positive for Anti CCP, RAF and high ESR, and 
raised CRP level. After 60 days of treatment, the haematology report showed a significant 
reduction in the high value of ESR (****p value -0.0001). While comparing the RAF 
before and after treatment, a significant reduction was observed (*p value-0.032). The 
quantitative outcome of MHAQ score, Universal pain assessment scale score, Restricted 
movement assessment scale score and EULAR score showed significant reduction after 
treatment and proved the therapeutic efficacy of NM for the treatment of RA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
310 
 
 
10. RECOMMENDATIONS 
 
In further, unexplained areas of gene expression and cell line studies of NM in 
anti –inflammatory, anti-rheumatoid pathways will also be studied. 
Due to time constraint this study drug was given for a period of 60days (as per 
literature 7days drug dosing followed by 7days drug holiday/patient). In future by 
recording the impact of NM in serum Anti CCP titre value, by extending the duration of 
treatment up to 6 months with large human sample size. 
Based on the above study findings, this research will be continued by doing a 
double blind randomized controlled clinical trial  to improve the quality of life in RA 
patients, then Nandhi Mezhugu as an anti-rheumatoid drug, will be a evidence based 
medicine for global recognization . 
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   PRECLINICAL AND CLINICAL EVALUATION OF SAFETY AND 
EFFICACY OF SIDDHA HERBOMINERAL FORMULATION  
NANDHI MEZHUGU IN THE TREATMENT OF 
 UTHIRA VATHA SURONITHAM (RHEUMATOID ARTHRITIS) 
        
  CASE RECORD FORM 
 
 
                                                               FORM I 
 SCREENING AND SELECTION PROFORMA   
  
1. O.P.No / I.P No ------------ 
2. S. No -------- 
3. Name --------------------------------------------- 
4. Age/sex ------------          
5. Occupation / Income ---------------------------------------   
6. Address: 
 
 
     
7. Contact No / E-mail ----------------------------------------------------- 
  
8. Selection Criteria 
 
Eligibility 
Age Eligible for Study :   18 Years to 60 Years 
Genders Eligible for Study :   Both 
Accepts Healthy Volunteers :   No 
 
 
 
 
 
 
 
 Inclusion criteria: 
 
Major                                                                                                          
                                                                                                                     Yes          No 
 
 Onset of arthritis after the age of 16 years 
 
 Positive for rheumatoid factor (RF) 
 
 Anti CCP                                                            
 
 Either an erythrocyte sedimentation rate (ESR) 
 Of greater than 30 mm/hr OR C-reactive protein  
Level greater than 1.0 mg/dl (normal less than 0.4) 
 
 Diagnosis of  Uthira Vadha Suronitham,         
As defined by fulfilling at least more than  
Two articular involvements  
 
 
Minor 
 
 
 Patients giving informed consent 
 (Signed or oral witnessed, according  
To local regulations) before any  
Protocol specific procedures. 
 
 .Morning stiffness 
 
 Willing to intake  study medication 
 
 Willing to follow diet restriction 
 
 
 
 
 
 
 
 
Exclusion Criteria 
 Diabetes Mellitus 
 Hypertension 
 Hypo & Hyperthyroidism 
 Cardiac disease 
 Renal disease 
 Liver disorders 
 Neurological disorders 
 Pregnancy and lactation 
 History of alcohol or substance abuse 
 Active infection, or chronic or persistent infection that might worsen with 
immunosuppressive treatment 
 Patients who have already participated in a new drug study in the past 3 
months. 
  
  Subject withdrawal criteria 
 
 Subject seeking any other treatment without informing the 
Investigator. 
 Clinical failure after 1 month of treatment as worsening or no 
amelioration of   signs and symptoms. 
 
 Request of the subject. 
 
 Repeated protocol criteria violation and non-compliance with its     
specification. 
 
 Subject is failed to come for follow up. 
 
 Serious adverse events/ reactions/ Inter current illness where 
continuation of study possess serious risk to the subject. 
 
 Subject who develop signs and symptoms of Hyper sensitivity. 
 
 Subject who become pregnant during the study period.  
 
 
 
 
 
Date:                                  Signature 
  FORM II 
CLINICAL ASSESSMENT FORM 
By 
Dr. T.Lakshmi kantham, MD(s) 
              Investigator’s signature and stamp 
                                                                                                Date:  
 
A. DEMOGRAPHIC DATA: 
 Age/Sex                                  :                  
  Weight                                   :                    kg 
 Height                                     :                    cm 
 BMI                                        : 
Address & Contact No            : 
 
B. CASE HISTORY: 
Presenting Complaints: 
 
 
Relevant past History 
 
 
Personal History: 
 
 
Concurrent illness and medications: 
 
C. GENERAL EXAMINATION: 
1. Temperature   :  
2. Heart rate               : 
3. Pulse rate              : 
4. Respiratory rate  : 
5. Blood pressure              : 
      6.   Pallor    :  
      7.   Icterus    :  
      8. Cyanosis              :  
      9. Clubbing   : 
10. Pedal oedema   : 
     11. Lymphadenopathy  :  
EXAMINATION OF VITAL ORGANS 
 CVS     
 RS 
 GIT 
 Genito urinary 
 CNS 
 
 
 
 
 
 
 
 
THE ACR/EULAR 2010 CLASSIFICATION CRITERIA FOR RA: 
To be applied to patients: (1) who have ≥ 1 joint with definite synovitis, excluding the DIP 
joints, first MTP joints, and first CMC joints, and (2) in whom the synovitis cannot be 
explained by another disease. 
Criteria Score 
A. Joint involvement:  
1 large joint 0 
2- 10 large joints
a 
1 
1-3 small joints( With or without involvement of large joints) 2 
4-10 small joints
b
( With or without involvement of large joints) 3 
            >10 joints(at least 1 small joints) 5 
B. Serology(at least 1 test result is needed for classification): 
Negative RF and negative anti-CCP antibodies 
0 
Low-positive RF or low-positive anti-CCP antibodies
c 
2 
High-positive RF or high-positive anti-CCP antibodies
d 
3 
C. Acute phase reactants: 
Normal CRP level and normal ESR 
0 
Abnormal CRP level or abnormal ESR 1 
D. Duration of symptoms: 
<6 weeks 
0 
≥6 weeks  1 
ACR, American College for Rheumatology; EULAR, European League Against 
Rheumatism; RA, rheumatoid arthritis; DIP, distal interphalangeal; MTP, 
metatarsophalangeal; CMC, Carpometacarpal; MCP, metacrpophalangeal; PIP, proximal 
interphalangeal; RF, Rheumatoid factor; anti-CCP, anti-cyclic citrullinated protein; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate. 
a
Large joints= shoulder, elbow, hips, knees, ankles. 
b
Small joints= MCPs, PIPs, Second-fifth MTPs, thumb IPs, wrists. 
c
Low-positive is ≤ 3 times the upper limit of normal 
d
High-positive is > 3 times the upper limit of normal 
 5. IMPORIGAL (SENSORY ORGANS):          
                  
6.IMPULANGAL (SENSES) 
 
 
 
 
 
 
 
 
 
7.KANMENDRIYANGAL (MOTOR ORGANS) : 
        
SIDDHA SYSTEM OF EXAMINATION 
1. THEGI (BODY CONSTITUTION): 
 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
 
 
3. KAALAM: 
 
4. GUNAM: 
 
 
 Day1 
 
Day15 Day29 Day43 Day60 
Mei (Skin)      
Vai (Tongue)      
Kann (Eye)      
Mooku (Nose)      
Sevi (Ear)      
 Day1 
 
Day15 Day29 Day43 Day60 
Sparisam      
Rasam      
Roobam      
kandham      
saptham      
 Day1 
 
Day15 Day29 Day43 Day60 
Kai       
Kaal       
Vai         
Eruvai       
Karuvai       
8.KANMAVIDAYANGAL  
 
 
9.  KOSANGAL (SHEATH):                
 
 
10. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 
 Day1 
 
Day15 Day29 Day43 Day60 
Saaram      
Senneer       
Oon      
Kozhuppu      
Enbu      
Moolai      
Sukkilam / Suronitham      
 
11. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
 
A) VALI 
 
 
 Day1 
 
Day15 Day29 Day43 Day60 
Praanan      
Abaanan      
 Day1 
 
Day15 Day29 Day43 Day60 
Kamanam      
Thaanam       
Vasanam       
Visarkam       
Anandham      
 Day1 
 
Day15 Day29 Day43 Day60 
Annamaya kosam      
Pranamaya kosam       
Manomaya kosam       
Vignanamaya kosam       
Ananthamaya kosam      
Samaanan      
Udhaanan      
Viyaanan      
Naagan      
Koorman      
Kirukaran      
Devathathan      
Dhananjeyan   
   
 
 
B) AZHAL 
 
 
Day1 
 
Day15 Day29 Day43 Day60 
Analakam   
   
Ranjakam    
   
Saathakam    
   
Prasakam    
   
Aalosakam   
   
 
 
 
 
C) IYYAM 
 
 
 
Day1 
 
Day15 Day29 Day43 Day60 
Avalambagam   
   
Kilethagam   
   
Pothagam   
   
Tharpagam   
   
Santhigam   
   
   
 
 
12. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
 
 
Day1 
 
Day15 Day29 Day43 Day60 
NAADI      
 
   II.     SPARISAM: [PALPATION] 
 
 
 
Day1 
 
Day15 Day29 Day43 Day60 
Thoduvali      
Veppam      
Creptation      
 
 
III. NAA: [TONGUE] 
 
 
Day1 
 
Day15 Day29 Day43 Day60 
NAA      
 
IV.NIRAM: [COMPLEXION]   
 
    
 
V.MOZHI: [VOICE] 
 
 
 
VI.VIZHI: [EYES] 
 VIZHI 
Day1 
 
Day15 Day29 Day43 Day60 
      
 
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 
 Day1 
 
Day15 Day29 Day43 Day60 
Niram      
Irugal      
Ilagal      
Others      
 
VIII. MOOTHIRAM [URINE EXAMINATION]  
  
NEERKKURI: 
 
Neerkkuri 
Day1 
 
Day15 Day29 Day43 Day60 
Niram      
Manam      
Edai      
Nurai      
Enjal      
 
 
NEIKKURI:  
 
Neikkuri Day1 
 
Day15 Day29 Day43 Day60 
 Spreading 
pattern 
 
  
   
Shape   
   
 
 
 
 PRECLINICAL AND CLINICAL EVALUATION OF SAFETY AND 
EFFICACY OF SIDDHA HERBOMINERAL FORMULATION  
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                            CLINICAL ASSESSMENT FORM 
 
 
 
 
CLINICAL EXAMINATION  
 
INSPECTION    
 Day1 
 
Day15 Day29 Day43 Day60 
Tenderness      
Muscle spasm      
Local heat      
Local Lymphadenopathy      
Pitting oedema      
Joint stiffness      
Nodules      
 
 
S.NO 
 
 
CLINICAL  FEATURES 
Day1 
 
Day15 Day29 Day43 Day60 
1. Arthritis of more than 3 joints    
 
  
2. Arthritis of hand joints     
 
 
3 Morning stiffness > 1 hr      
4. Symmetrical arthritis      
5. Restricted movements      
6. Spindled appearance of fingers      
7. Anorexia      
8. Low grade fever      
9. Subcutaneous nodules in specific 
places 
     
 CLINICAL SYMPTOMS: 
 
 
 
 
UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
                  
 
 
                     The National Initiative on Pain Control™ (NIPC™) 
 
 
 
 
 
  
 Day 1 Day 15 Day 29 Day 43 
Day 60 
Pain Onset:     
 
Early 
morning  
Stiffness 
 
 
   
 
Nature of 
pain 
 
 
   
 
 Stiffness     
 
Tenderness 
 
 
   
 
Restriction: 
 
 
   
 
  
Day1 Day15 Day29 Day43 Day60 
 0   :   No Pain  
 
 
   
 
1-3 :   Mild 
pain 
 
 
 
   
 
4-6:  Moderate 
pain 
 
 
 
   
 
7-10 :   Severe 
pain 
  
   
                    The National Initiative on Pain Control™ (NIPC™) 
 
RESTRICTED MOVEMENT ASSESSMENT SCALE:                
GRADATION OF MOVEMENTS 
Grade 1 – Able to perform normal duties 
Grade II – Moderate Restriction – Self care is possible 
Grade III – Marked restriction – Limited self care/some assistance required. 
Grade IV – Confined to bed or wheel chair 
 
  
Day1 
 
Day15 Day29 Day43 Day60 
    Grade 1    
 
 
   
   Grade 2    
 
 
   
   Grade 3     
 
 
   
   Grade 4   
   
 
BearingPoint, Atos Healthcare & DSP Copyright EBM Rheumatoid Arthritis Version 5.0 
FINAL 
 
 
MODIFIED HEALTH ASSESSMENT QUESTIONARRE 
 
Before treatment 
 
 
Source: Pincus T, Yazici Y, Bergman M. Development of a multi-dimensional health 
assessment questionnaire (MD-HAQ) for the infrastructure of standard clinical care. Clin 
Exp Rheumatol. 2005;23(Suppl 39):S19-S28. 
 
 
 
 
sAre you able to without 
ANY 
difficulty 
<0> 
with 
SOME 
difficulty 
<1> 
with 
MUCH 
difficulty 
<2> 
unable 
TO DO 
<3> 
Dress yourself, including tying 
shoelaces and doing buttons? 
    
Get in and out of bed? 
 
    
Lift a full cup or glass to your 
mouth? 
    
Walk outdoors on flat ground?     
Wash and dry your entire body?     
Bend down to pick up clothing from 
the floor? 
    
Turn regular faucets on and off?     
Get in and out of a bus, car, train, or 
airplane? 
    
Sub-total     
Total  
After treatment 
 
Are you able to without 
ANY 
difficulty 
<0> 
with 
SOME 
difficulty 
<1> 
with 
MUCH 
difficulty 
<2> 
unable 
TO DO 
<3> 
Dress yourself, including tying 
shoelaces and doing buttons? 
    
Get in and out of bed?     
Lift a full cup or glass to your 
mouth? 
    
Walk outdoors on flat ground?     
Wash and dry your entire body?     
Bend down to pick up clothing from 
the floor? 
    
Turn regular faucets on and off? 
 
    
Get in and out of a bus, car, train, or 
airplane? 
    
Sub-total     
Total  
 
How to score the MHAQ 
1.Ask the patient to complete the entire questionnaire by circling the appropriate 
responses while in the waiting room prior to his/her visit. 
2.Add the totals from each of the four columns to get the patient’s MHAQ score. 
3.Divide this score  by 8 and result should fall between 0.0 and 3.0. the higher the score, 
the greater the overall disability. MHAQ scores <0.3 are considered normal, although 
the average MHAQ in the general population increases with the age. 
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FORM-III 
                                                 LABORATORY INVESTIGATIONS 
1. O.P No: ________   Reg.No________   Serial No________ 
 
2. Name: ________________ 
 
3. Age :   _______ years 
 
4. Sex:          
 
5. Date of assessment: ____________________ 
 
 
BLOOD INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TMT (WITH 
DATE) 
AFTER TMT 
(WITH DATE) 
 
HB( gm/dl) 
M:12-15 
W:11.5-14 
  
 
T.WBC (cells/cu.mm) 
4000-
11000 
  
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-40   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 T.RBC(million cells/cu.mm) 
 
M:4.0-5.5 
  W:3.5-
4.5 
 
 
 
 
 
  ESR(mm/hour) ½ hr. M:6-12 
W:7-18 
  
  1 hr.   
Blood Investigations 
Normal 
Values 
Before 
TMT(WITH 
DATE) 
After TMT 
(WITH DATE) 
Blood 
glucose 
(mg/dl) 
Fasting    70-110   
PP    80-140   
Random    80-120   
RFT 
(mg/dl) 
Blood urea    16-50   
 
Serum creatinine 
   0.6-1.2   
 Serum uric acid    4-5.8   
LFT 
(mg/dl) 
Total bilirubin    0.2-1.2   
Direct bilirubin    0.1-1.2   
Indirect bilirubin    0.2-0.7   
SGOT     0-40   
SGPT     0-35   
Alkaline 
phosphatase 
   80-290   
Urine Albumin Nil   
 Sugar Nil   
 Deposits 
Epi cells 
1-2 
cells/hpf 
Pus cells 
1-2 
cells/hpf 
  
Motion  Ova  Nil   
 Cyst  Nil   
 Occult blood Nil   
 
 
 
 
 
 
 
 
 
 
 
SPECIFIC EXAMINATION 
       
                     
 
 
 
 BEFORE TMT AFTER TMT 
1.CRP   
 
 
   
2.RAFactor 
  
 
 
3.Anti CCP   
 
 
RADIOLOGICAL EXAMINATION: 
X-Ray –Of the affected joints  
                     ECG 
 
 
 Date:       Signature of the Doctor 
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FORM-IV 
CONSENT FORM FOR PARTICIPATION IN A 
CLINICAL TRIAL 
I ……………………………….exercising my free power of choice, hereby give my 
consent to be included as a subject in the clinical trial of a  drug namely Nandhi mezhugu 
for the treatment of  Uthira vatha suronitham(Rheumatoid arthritis).  I understand that I may 
be treated with this drug for the disease. I am suffering from Uthiravatha suronitham 
(Rheumatoid arthritis). which has been informed to my satisfaction by the attending 
physician and the purpose of the clinical trial, the nature of drug treatment and follow up 
including the laboratory investigations to monitor and safeguard my body functions. I have 
received, read, and understood the contents of the Information sheet, Dietary and General 
Advice Sheet. 
 I am also aware of my right to opt out of the trial at any time during the course of the 
trial without having to give the reasons for doing so. At the same time, I am also aware of my 
termination from the trial on the condition of my failure to co-operate with the investigators 
for the already explained conditions to me. 
Date………….                                                        Thumb impression /Signature of the patient 
       
Date……           Signature: 
                                                                               
Date:                                                              Name of the patient: 
Station:                                                       Signature of the Principal Investigator 
 
   
II-        
(CONSENT FROM - PHASE – II-Tamil Version) 
                                       
........................................................... .  
       ப  
   ¢        
      . 
 
                
    .  
,     
,     
  .    
        
  .    
    
   .  
, ,      
    . 
                                   
Date:         
 
Thumb Impression /Signature of Patient 
Date: 
 
Name of Patient: 
 
   Signature of Principal Investigator 
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FORM-V 
                                WITHDRAWAL FORM    
Name :                       OPD/IPD No: 
     
Age:                                                      Reg. No: 
 
Date of trial commencement: 
Date of withdrawal from trial: 
Reason(s) for withdrawal 
1. Long absence at reporting:                                Yes/No 
2. Irregular treatment:                                            Yes/No 
3. Shift of locality:                                                 Yes/No 
4. Complication/Adverse reactions if any:             Yes/No 
5. Poor patient compliance:                                    Yes/No 
 
Date:                                                                                            Signature of the Principal Investigator 
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FORM-VI 
ADVERSE REACTION FORM/PHARMACO VIGILANCE FORM 
Serial No: 
Name :                       OPD/IPD No:      
Age/Gender :                                              Reg.No: 
 
Date of trial commencement: 
Date of Adverse Reaction occur: 
Date of withdrawal from trial: 
Description of Adverse reaction: 
 
 
 
Date:                                                                                            Signature of the Principal Investigator 
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 Form-VII 
DRUG COMPLIANCE FORM 
     
   
Darkened space indicates intake of drug 
Coloured space   intake of drug 
 
Signature of the Principal Investigator 
 
 
 
 
 
 
 
S.no   Date 
 
  Drug issued  Not consumed 
Day1    
Day8    
Day15    
Day22    
Day29    
Day36    
Day43    
Day50    
Day57and58    
PRECLINICAL AND CLINICAL EVALUATION OF SAFETY AND          
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                                                          FORM-VIII 
             (PATIENT INFORMATION SHEET) 
                             
 
Rheumatoid Arthritis 
. 
 
. 
 
. 
 
. 
 
. 
: 
1.  500 2
. 
2. 7
. 
: 
1. 
. 
2. 
. 
3. 
 
. 
4. 
.  
5. 
. 
6. . 
7. 
. 
8. 
.  
9. 
. 
10. 
.  
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FORM-IX           
     DIETARY & GENERAL ADVICE 
                  
: 
: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
: 
 
 
 
 
 
 
 
: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
,  
 
 
 
 
 
 
 
 
 
. 
 
. 
 
 
 
: 
 
 
 
 
 
 
 
 etc 
 
-
 
 
 
 
, 
 
 
 
 
 
 
 
 
 
, 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



 18.12.2013 
 Certificate  
 
Certified that the market samples procured from “Indian Medical Practitioner’s Co-
operative Pharmacy & Stores, Chennai - 41 and submitted by Dr. T. Lakshmikantham, 
M.D(S), Lecturer / Research Scholar, Department of Maruthuvam, National Institute of 
Siddha, Tambaram Sanatorium, Chennai – 47 are identified / authenticated as below: 
1.  Pooram  Mercurous chloride  
2.  Kalnar Seemai  Magnesium calcium silicate  
3.  Ganthagam   Sulphur  
4.  Gowripashanam  Arsenic pentasulphide  
5.  Kuthiraipal pashanam Potassium Aluminium Silicate 
6.  Vellaipashanam  Arsenic trioxide  
7.  Padikaram  Aluminium Potassium Sulphate  
8.  Thalagam   Arsenic trisulphide  
9.  Lingam  Mercuric sulphide  
10.  Rasa sindooram  Rasa sindooram (Prepared Medicine)  
11.  Rasa Chendooram (Raw material)  Red Sulphide of mercury 
12.  Ponnimilai  Copper pyrite  
13.  Pooneeru   Fuller’s earth  
14.  Manosilai  Arsenic disulphide  
15.  Palthutham  Zinc sulphate  
16.  Mayilthutham  Copper sulphate  
17.       Kalmatham Hydrous Cobalt Arsenate  
18.  Pachai karpooram  Borenol  
19.  Nandukkal  Crab’s fossil  
20.  Kariuppu Sodium Chloride 
21.  Vediuppu Potassium nitrate 
  
 
           
                R. Shakila 
    Research Officer (Chemistry) 
                      (Dr. S. Jega Jothi Pandian)     
              Research Officer (Scientist 2) - I/c 
 
22.  Karchunnam Lime stone 
23.  Korosanam Gall stone of bull 
24.  Kaadi neer Acetic acid 
25.  Rasam Mercury 
26.  Ten  Apies mellifica - Honey 
27.  Ney Bos indicus - Ghee 
28.  Pasumpaal Bos indicus - Cow’s milk 
29.  Pasu nir Bos indicus - Cow’s Urine 
30.  Pasu saanam Bos indicus - Cow’s dung 
31.  Mor  Bos indicus - Butter Milk 
 18.12.2013 
 CERTIFICATE 
 
Certified that the market samples supplied by the Indian Medical Practitioner’s 
Cooperative Pharmacy & Stores, Chennai - 41 and submitted by   Dr. J. Lakshmikantham, 
M.D(S), Lecturer/Research Scholar, Department of Maruthuvam, National Institute of Siddha, 
Tambaram Sanatorium, Chennai–47 are identified / authenticated as below: 
1.  Akkirakaram Anacyclus pyrethrum (L.) Lag.  (Root) 
2.  Nattu Amukkara Withania somnifera (L.) Dunal (Root) 
3.  Ativitayam Aconitum heterophyllum Wall. ex Royle (Root) 
4.  Avuri elai Indigofera tinctoria L. (Leaf)  
5.  Catamancil Nardostachys jatamansi (D. Don) DC.  
Syn. N. grandiflora DC. (Rhizome) 
6.  Catikkai Myristica fragrans Houtt. (Kernel) 
7.  Catipattiri Myristica fragrans Houtt. (Aril) 
8.  Cerankottai Semecarpus anacardium L.f.   (Fruit) 
9.  Chevviyam Piper nigrum L. (Root) 
10.  Chukku Zingiber officinale Rosc.  (Rhizome) 
11.  Cirakam Cuminum cyminum L. (Fruit) 
12.  Cirutekku Premna herbacea Roxb. ( Root) 
13.  Cittarathai Alpinia officinarum Hance (Rhizome ) 
14.  Elarisi Elettaria cardamomum (L.) Maton (Seed) 
15.  Elumicham pazham Citrus aurantifolia (Christm.) Swingle (Fruit) 
16.  Etti vittu Strychnos nux-vomica L.  (Seed) 
17.  Ilavankam Syzygium aromaticum (L.) Merr. & L.M. Perry 
Syn. Eugenia caryophyllata Thunb. (Flower bud) 
18.  Kacakaca vitai Papaver somniferum L. (Seed) 
19.  Kattu milaku Piper attenuatum Buch. –Ham. ex. Miq. – (Fruit) 
20.  Katukkai Terminalia chebula Retz. ( Fruit) 
21.  Kodiveli ver Plumbago zeylanica L. – (Root) 
22.  Kopparai tenkai Cocos nucifera L. ( Dried kernel) 
23.  Kovai elai Coccinia grandis (L.) Voigt  (Leaf) 
Syn. C. indica W. & A. 
24.  Kurocani omam Trachyspermum ammi (L.) Sprague (Seed )  
25.  Milaku Piper nigrum L.  (Fruit) 
26.  Nellikkai Phyllanthus emblica L.  
Syn. Emblica officinalis Gaertn. (Fruit) 
27.  Nervalam Croton tiglium L. (Seed) 
28.  Pagal elai Momordica charantia L. (Leaf) 
29.  Perumcirakam Foeniculum vulgare Mill. (Fruit) 
30.  Sirukeerai Amaranthus tricolor L. 
Syn. A. tricolor var. tristis (L.) Thell. (Whole plant ) 
31.  Talica pattiri Taxus wallichiana Zucc.  
Syn. T. baccata L. (Leaf) 
32.  Tanrikkai Terminalia bellirica (Gaertn.) Roxb. (Fruit ) 
33.  Tippili Piper longum L. ( Fruit) 
34.  Tippilik kattai Piper longum L. (Stem) 
35.  Vaividankam Embelia ribes Burm.f. (Fruit) 
36.  Vellaip puntu Allium sativum L. ( Bulb) 
37.  Vetrilai Piper betle L. (Leaf) 
 
                                
                  (R.Shakila )                                                               (Dr. S. Jega Jothi Pandian) 
      Research Officer (Chemistry)                                         Research Officer (Scientist 2)-I/c  
 
LIVEON BIOLABS PRIVATE LIMITED Protocol No. : LBPL-IAEC 110-06/15Item & Species : 1 test item & Rat
CERTIFICATE
THIS IS TO CERTIFY THAT THE PROJECT TITLED “ANTI-ARTHRITIC EFFICACY 
EVALUATION OF TEST ITEM AGAINST ADJUVANT INDUCED ARTHRITIS IN RATS ’’HAS 
BEEN APPROVED BY THE lAEC.
Name of Chairman/Member Secretary lAEC:
Dr. K. Y. MATHUR, M.V.Sc 
Managing Director and Head 
Laboratory Services 
Liveon Biolabs Private Limited 
Antharasanahalli, Tumkur,
Karnataka, INDIA
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1. INTRODUCTION 
 
Rheumatoid Arthritis is a chronic disease which will 
affect the normal person to live a normal healthy life, due 
to its worst complications.[1] RA affects nearly 1% of 
population worldwide due to its debilitating nature, in 
advance stages; the disease burden is considerable in 
economics and health expenditure terms. In developed 
countries 0.5-1% of adults are affected. Incidence of new 
cases ranges from 5-50 per 100,000 adults in developed 
countries.[2] Bone loss is one of the most harmful effects 
induced by chronic inflammation as well as the 
medication taken to rheumatoid arthritis, such as 
glucocorticoids. It is therefore important that, we gain 
the better understanding of, which medications used to 
treat patients with chronic inflammation are less likely to 
impact negatively on bone health. One study has shown 
that continuous treatment with prednisone at 10 mg /day 
during 90 days or more increase the risk of vertebral 
fractures 17- folds and hip fractures 7- folds. At this 
juncture the intervention with the siddha system of 
medicine gives relief from the chronic inflammation and 
to retain the bone density.[3] Since the treatment for RA 
is a long term one, the siddha medications are completely 
secure and safe without any adverse effects, unlike 
NSAIDs which is the medication used for temporary 
pain relief worldwide but after long term use they can be 
very dangerous, can damage liver, kidney and may led to 
fatalities. Siddha system of medicine does not cause any 
harmful effects and is very effective in limiting the pain 
but also improves mobility of the joints to achieve better 
and healthy life. 
 
Siddha is more than a system of physical medicine, 
because it removes distress and diseases. In Siddha 
system, Siddhars classified the diseases on the basis of 
affected vital humors(Vali, azhal, Iyam), organs (eye and 
ear disease etc), kosam(systems like Gastro intestinal 
system, Respiratory system etc) in to 4448[4]. The saint 
Yugi classified different types of neuro musculo skeletal 
diseases under 80 types of Vatha diseases in his text 
YugiVaithiyacinthamani.[5] UthiraVathasuronitham is 
one among them. The signs and symptoms of 
UthiraVathasuronitham may be correlated with that of 
Rheumatoid Arthritis in modern science. This is the first 
system to emphasis health as the perfect state of 
Physical, Psychological, Social and Spiritual component 
of human being which was mainly needed for RA which 
is mainly caused by stress .Worldwide so many 
Rheumatology medical associations have been formed to 
find a new treatment and management strategies for 
RA.[1] This paper deals with single herb therapy and poly 
Siddha herbo-mineral formulations that have been 
mentioned in siddha literature and have been clinically 
well established. 
 
wjpmr, 2016,2(6), 211-214.  SJIF Impact Factor: 3.535 
 
 
Review Article 
ISSN 2455-3301 
WJPMR 
 
 
 
WORLD JOURNAL OF PHARMACEUTICAL 
AND MEDICAL RESEARCH 
www.wjpmr.com 
 
ABSTRACT 
 
The Siddha system is a treasure trove of several medicines for innumerable diseases that need to be scientifically 
validated. The saint Yugi classified different types of neuro musculo skeletal diseases under 80 types of Vatha 
diseases in his text YugiVaithiyacinthamani. UthiraVathasuronitham is one among them. The signs and symptoms 
of UthiraVathasuronitham may be correlated with that of Rheumatoid Arthritis in modern science. This paper 
deals with single herb therapy and poly Siddha herbo-mineral formulations that have been mentioned in siddha 
literature and have been clinically well established. This paper establishes the effectiveness of Siddha system of 
medicine as the best choice for the treatment of RA. This will create awareness among the Rheumatology 
associations and researchers worldwide. 
 
KEYWORDS: Siddha Medicine, Rheumatoid Arthritis, Vatha diseases, Herbs, Herbo-mineral formulations. 
 
www.wjpmr.com  
 
Lakshmi et al.                                                                       World Journal of Pharmaceutical and Medical Research  
212 
2. RHEUMATOID ARTHRITIS DISEASE IN 
SIDDHA SYSTEM OF MEDICINE 
 
Vatham was generated below the Abdomen and spread 
all over the body and responsible for the movements of 
the body. Saint Yugi in Yugi VaidhiyaChinthamani 
classified Vatha diseases(neuro muscular skeletal 
diseases) as  80 types. VathaSuronitham is the condition 
dealt under vatha disease .Yugi classified 
VathaSuronitham in to seven types[5] 
 Vathasuronitham 
 UthiraVathasuronitham 
 SithuVathasuronitham 
 VaigithaVathasuronitham 
 PaithiyaVathasuronitham 
 SlethumaVathasuronitham 
 UtharaVathasuronithamira 
 
Uthira Vatha suronitham is one type of Vatha 
suronitham . This disease is caused by imbalance of 
humors that is elevated vatham and pitham. 
Clinical Features of UthiraVathasuronitham[5] 
“Vaigithamaaikkanaikkaalumuzhangalthaanu 
Markadanthsandthupuravadiyumveengich 
Saeigithamaanjsiruviralgalmigavumnondhu 
Sinthaithadumaariyaesalippundaagum 
Paigithamaampaithiyaththilvathamminjip 
Baaramaaiurpaviththuazhalundaagum 
Uyikithamaaiasanamathuthaanumvaenda 
Uthiravathasuronithathinunaarchchiyaamae”-Song No-
319 
- YugiVaithiyaChinthamani 
 
 
 
Table 1: Correlation of Uthiravathasuronitham and Rheumatoid arthritis.
[1][6] 
 
S.No Symptoms for UthiraVathasuronitham Symptoms for Rheumatoid Arthritis 
1. 
“Vaigithamaaik kanaikkaalu muzhangal thaanu 
Markadanth sandthu puravadiyum veengich 
Swelling of Ankle, Knee, and smaller joints of the 
Hand. Flexion of distal inter- phalangeal joints and 
Extension of Proximal inter phalangeal joints 
looks like Apes Hand-Swan neck Deformity. 
2. Saeigithamaanj siruviralgal migavum nondhu 
Pain and tenderness of minor joints especially 
phalanges. 
3. Sinthai thadumaariyae salip pundaagum Depression and Apathetic mood. 
4. 
Paigithamaam paithiyaththil vatham minjip 
Baaramaaiurpaviththu 
Signs of Inflammation (Elevation of Pitham) pain 
and restricted movements of the joints (Elevation 
of vatham). 
5. Azhalundaagum Fever 
6. Uyikithamaai asanamathu thaanum vaenda Loss of appetite 
 
3. SIDDHA MEDICINES FOR RHEUMATOID 
ARTHRITIS. 
Herbo-Mineral Formulations for RA: In Siddha 
system there are several herbo mineral formulations 
mentioned for Vatha Disease. Some major formulations 
are given in the following Table.2 
 
 
 
Table 2: Herbo mineral formulations for RA. 
 
S.No Name of the Formulations Reference text Page no /Song no 
1.  AadathodaiManappagu Siddha Vaidhiya Thirattu [7] P.no:257 
2.  AttathiChooranam Thanjai Vaidhiyarajachinthamani [8] Part1 P.no:21-22 
3.  AyaChendooram AgathiyarParipooranam-400 [9] S.no:261-264 
4.  AyaveeraChendooram Gunapaadam Part 2 and 3 [10] P.no:58 
5.  ElathiChooranam Agathiyar Vaithiya Rathinasurukkam [11] S.no:149-150 
6.  GandhagaParpam Anubhogavaithiyanavaneetha [12] Part 6 P.no:28 
7.  GandhagaRasayanam Pulipaani-500 [13] S.no:324-330 
8.  GundhirigaThylam Hospital Pharmacoepia [14] P.no:133 
9.  KaalamegaNaarayanaChendooram Vaidiyasaarasangiragam [15] P.no:496-497 
10.  KorosanaiMathirai Agathiyar Vaithiya Rathinasurukkam[11] S.no:149-150 
11.  KoushigarKulambu Siddha vaidhiya Thirattu [7] P.no:204-213 
12.  LaguvisamushitiThylam Therayar Thyla Vargasurukkam [16] S.no:79 P.no:101 
13.  LingaChendooram Gunapaadam  Part 2 and 3 [10] P.no:159 
14.  LingaPathangam Therayar Karisal 300  [17] S.no:2 P.no:8 
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15.  MahavallathiLeghiyam Boogar Vaithiyam 700 [18] S no:175-187 
16.  MahaveeraMezhugu Siddha VaithiyaThirattu [7] P.no:203-204 
17.  MayanaThylam Therayar Thyla Vargasurukkam [16] S.no:79 P.No:130 
18.  MehanaathaKuligai Siddha Vaithiya Thirattu [7] P.no:41 
19.  MerugulliThylam Therayar Thyla Vargasurukkam [16] P.no:75 
20.  MoosambraPattru Siddha Vaithiya Thirattu [7] P.no:305 
21.  MuthuChippiParpam Siddha Vaithiya Thirattu [7] P.no:128 
22.  MuthuParpam Therayar Maha Karisal [19] P.no:132-134 S.no:50 
23.  NandhiMezhugu Siddha Vaithiya Thirattu [7] P.no:183-187 
24.  NavauppuMezhugu Siddha Vaithiya Thirattu [7] P.no:193-194 
25.  PachaikarpooraMathirai Siddha VaithiyaThirattu [7] P.no:30-31 
26.  PanchasoothaMezhugu Yugi Karisal-151 [19] S.no:16-24 
27.  ParangipattaiRasayanam AgathiyarVaithiyaRathinasurukkam [11] S.no:114-118 
28.  PoorakKattu Gunapaadam Part 2 and 3 [10] P.no:163 
29.  Rasa Mezhugu Agathiyar Paripooranam-400 [9] S.no:126-129 
30.  SeenthilChooranam Agathiyar Paripooranam-400 [9] S.no:324-325 
31.  SivanarAmirtham Siddha VaithiyaThirattu [7] P.no:165-166 
32.  ThalagaParpam Agathiyar Paripooranam-400 [9] S.no:195-201 
33.  ThalisathiChooranam Siddha VaithiyaThirattu [7] P.no:228-229 
34.  ThalisathiVadagam TherayarPaadalThirattu [21] P.no:28 
35.  ThangaParpam Gunapaadam Part 2 and 3 [10] P.no:109-110 
36.  ThettrankottaiLeghiyam Agathiyar Paripooranam-400 [9] S.no:281-282 
37.  UlogamandooraChendooram TherayarYamagaVenbha [22] P.no:150 
38.  VaathakesariThylam TherayarThylaVargasurukkam[16] S.no:9, P.No:48 
39.  VathaRakshanan AgathiyarVaithiyaRathinasurukkam[11] S no:36-38 
40.  VelliChendooram Gunapaadam Part 2 and 3[10] P.no:129-130 
41.  VelvangaChunnam Gunapaadam Part 2 and 3[10] P.no:122 
42.  ViresanaPoobathi BalaVaagadam[23] P.no:79-80 
 
4. ANTI-VATHA HERBS 
Drugs which are prevent the Vatha Diseases in the body 
mentioned in Gunapadam Part I Mooligaivaguppu.[24] 
Some important herbs which prevent Vatha diseases are 
mentioned in Table 3. 
 
Table 3: Herbs Prevent Vatha Diseases. 
 
S.No Herbs Botanical Name Part Used 
1. Aamanakku Ricinus communis, Linn. Leaves,roots 
2. Aanaipuli Adansonia digitata, Linn. Leaves 
3. Kadambu Anthocephalus  cadamba Roxb Seed 
4. Chinni Acalypha fruticosa, Forsk Root 
5. Kattaamanakku Jatropha curcus, Linn. Leaves,root 
6. Chevvamanakku Ricinus tanarius, Linn. Leaves,root 
7. Thakkolam Illicium veram, Hook.f. Seed 
8. PirappanKizhangu Calamus rotang Linn. Rhizome 
9. Mizhagu Piper nigram Linn. Seed 
10. Musuttai Rivea ornate (Roxb)W.& A WholePlant 
11. Merugu Alocasia indica, Schott. Rhizome 
12. Maikonrai Poinciana pulcherrima, Linn. Flower,Bark 
13. VathaNaarayanan Delonix elata, (L) Gamble Leaves 
14. Vizhuthi Cadaba trifoliate (Roxb)W.& A. Leaves and Fruit 
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5. CONCLUSION 
 
For the painless better future of RA patients, Siddha 
system of medicine has opened a venue in the treatment 
with promising Siddha formulations and Single herb 
therapy consisting of kayakalpa drugs (Rejuvenators) 
there by promoting  the health status of RA without any 
untoward adverse effects and ensure long life without 
any complication and disability.  It is interesting to note 
that the siddha medicines are made from easily available 
sources such as plant, animal, marine, metal and mineral 
kingdoms. Siddha medicines are easily available, cost 
effective and efficacious. It is apt to adhere the siddha 
system of medicine for the long term treatment of RA. 
These medicines necessitate so many studies to evaluate 
the safety and efficacy. This paper establishes the 
effectiveness of Siddha system of medicine as the best 
choice for the treatment of RA. This will create 
awareness among the Rheumatology associations and 
researchers worldwide. 
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1.  INTRODUCTION:
Recent years have witnessed that,  there is an exponential growth
and demand in traditional medicine due to the new global trend of
“Return to Nature”. It has been estimated that eighty percent of the
world population are using herbal and complementary medicines for
their primary healthcare needs, which provides a new sphere of growth
for traditional medicine[1].
The Siddha system of medicine is being time tested and still cater to
the health needs of the society. For Global acceptance, this system
of  medicine  has  to  undergo  scientific  validation  through  quality
control measures of the medicinal raw drugs as well as  standard
operating procedures for preparing Siddha medicines. Nandi mezhugu
is one such drug which is to be standardized. It is enlisted in Siddha
Formulary of India, Part I. it is prescribed for various ailments[2][3].
Nandhi  Melugu  was  subjected  to  the  following  analysis  such  as
physico  chemical,  heavy  metals,  pesticide  residue,  aflatoxin,
qualitative phytochemical, qualitative inorganic analysis, TLC photo
documentation and HPTLC finger print profile as per WHO[4] and
AYUSH Guidelines[5] .
2.  MATERIALS AND METHODS
2.1. Collection and Authentication of  Raw Drugs
All the ingredients of Nandi Mezhugu were purchased from Indian
Medical Practitioners Co-operative Pharmacy and Stores Limited
Sales (IMPCOPS), Chennai-600041. The metals and mineral raw drugs
were identified and authenticated in the chemistry lab; the herbal raw
drugs were identified and authenticated by Dr.Sasikala Ethirajalu
Research Officer-Scientist  II (Pharmacognosy)  in Siddha Central
research Institute, Arumbakkam, Chennai-106.
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ABSTRACT
Background: Standardisation is essential for scientific validation of any poly herbo mineral formulation. Nandhi mezhugu is a classical
Siddha herbo mineral formulation has indication for many diseases such as all  types of arthritis, male and female reproductive tract
disorders, different types of cancers eg ovarian cancer, testicular cancer, cancer penis, cancer cervix, oral and cheek cancers, fistula,
hydrocele, chronic ulcers, skin diseases eg eczema, leucoderma, diabetic carbuncle, chronic ulcers, Hanson’s disease etc. Aim: The aim of
this study was to standardise Nandi mezhugu. Materials and Methods: The drug was prepared as per the procedure mentioned in Siddha
Literature and then subjected to the following analysis such as physico chemical, heavy metals, pesticide residue, aflatoxin, qualitative
phytochemical, qualitative inorganic analysis, TLC photo documentation and HPTLC finger print profile. Results and conclusion: The drug
was free of microbial contamination and aflatoxins and pesticide residues. Hence the drug was safe for consumption.
KEYWORDS: Serankottai, Etti kottai, Rasa chendooram, Nervalam, Nandukkal, Pooneeru.
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2.2 . Preparation of the drug Nandhi Mezhugu
Ingredients:
Table 1: Ingredients of Nandhi mezhugu
Sl.No. Ingredients Source Quantity
1.         Purified Marking Nut (Serankottai) *  Semecarpus anacardium L.f.   (Fruit) 1Kg
2.        Purified Nux Vomica (Ettikkottai) seeds ** Strychnos nux-vomica L.  (Seed) 315 gms
3.         Ghee (Nei) Bos indicus – Ghee 1400 gms
4.         Common Alum (Padikaram) * Aluminium Potassium Sulphate 1120 gms
5.      Palm Jaggery (Panai Vellam) Borassus  flabellifer L.(Palm Jaggery) 2240 gms
6.   Honey (Then) Apies mellifica – Honey 1400 gms
7.    Ponnimilai parpam * Calx of Copper pyrites 53 gms
8.    Kalnar Parpam   * Calx of Magnesium calcium silicate 53 gms
9.     Kalmatha Parpam*** Calx of Hydrous Cobalt Arsenate 53 gms
10.  Nandukkal Parpam * Calx of Crab’s fossil 53 gms
11.  Pachai karpooram* Borneol 53 gms
12.  Kungumap poo** Crocus sativus  L. (Style & Stigma) 53 gms
13.      Gorochan (Korochanam)* Gall stone of bull 53 gms
14.  Prepared Rasa sindooram Rasa sindooram 140 gms
15.   Chukku*** Zingiber officinale Rosc.  (Rhizome) 35 gms
16.   Milaku** Piper nigrum L.  (Fruit) 35 gms
17.  Tippili*** Piper longum L. ( Fruit) 35 gms
18.  Elarisi** Elettaria cardamomum (L.) Maton (Seed) 35 gms
19.   Beetle killer roots (Siruthekku)** Premna herbacea Roxb. ( Root) 35 gms
20.   Yew leaves (Thalisa Pathiri) ** Taxus wallichiana Zucc. 35 gms
Syn. T. baccata L. (Leaf)
21.  Henbane niger (Kurosani Omam) ** Trachyspermum ammi (L.) Sprague (Seed ) 35 gms
22.  Vaividankam** Embelia ribes Burm.f. (Fruit) 35 gms
23.  Athividayam ( Atis) ** Aconitum heterophyllum Wall. ex Royle (Root) 35 gms
24.  Jathikkai (Nutmeg)** Myristica fragrans Houtt. (Kernel) 35 gms
25.  Jathipattri(Mace)** Myristica fragrans Houtt. (Aril) 35 gms
26.  Karunjeeragam*** Nigella sativa L.(Seed) 35 gms
27.  Cirakam*** Cuminum cyminum L. (Fruit) 35 gms
28. Ilavankam** Syzygium aromaticum (L.) Merr. & L.M. Perry 35 gms
Syn. Eugenia caryophyllata Thunb. (Flower bud)
29.   Chevviyam** Piper nigrum L. (Root) 35 gms
30. Kattu milaku** Piper attenuatum Buch. –Ham. ex Miq. – (Fruit) 35 gms
31. Kodiveli ver** Plumbago zeylanica L. – (Root) 35 gms
32.  Tippilik kattai** Piper longum L. (Stem) 35 gms
33.  Kacakaca Papaver somniferum L. (Seed) 35 gms
34.  Perumcirakam** Foeniculum vulgare Mill. (Fruit) 35 gms
35.   Nervalam* Croton tiglium L. (Seed) 35 gms
36.   Cittarathai** Alpinia officinarum Hance (Rhizome ) 35 gms
37.  Catamancil** Nardostachys jatamansi (D. Don) DC. 35 gms
Syn. N. grandiflora DC. (Rhizome)
38. Akkirakaram** Anacyclus pyrethrum (L.) Lag.  (Root) 35 gms
39.  Nattu Amukkara** Withania somnifera (L.) Dunal (Root) 35 gms
40. Rasa Chendooram Red Sulphide of mercury 25gms
(Raw material) *
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Drugs were purified as per the Siddha literatures * Siddha Materia
Medica, **Sikitcha  Rathina  Deepam, ***Sarakku  Suththi
Muraigal[6],[7],[8].
Preparation:
(a) Fry items 1 & 2 in 3 ingredients .Ground 1 & 2 into a fine paste.
(b) Ground 4, 14-39 in to fine powder separately.
(c) Ground 40-52 in to a paste with juice of drug no 53 for 6 hours and
were made cakes and dried. Covered the cakes with the paste of drug
no 53 and subjected to calcination process, then the product was
taken and powdered.
(d) Syrup of palm jaggery was prepared and the ingredients (a),(b)
and (c) and the calxes were added, after that ghee and honey were
added. To this mixture powders of 11, 12, 13 were added, thoroughly
mixed and stored in Air tight Container.[2],[3]
2.3. Organoleptic properties
The organoleptic characters such as colour, odour, taste, consistency
were observed.
2.4. Physico Chemical Parameters:
Loss on drying at 105°C, total ash, water soluble ash, acid-insoluble
ash, water soluble extractive, alcohol soluble extractive, rancidity,
acid value,  saponification value, iodine value, pH, total solid, fat
content  ,  reducing sugar,  total  sugar  were carried out  as per  the
procedures mentioned in standard references (WHO, Protocol for
testing)[4][5][9]
2.5 Assays:
Quantitative assays for Calcium, Magnesium, Potassium, Aluminium,
Copper, Iron and Zinc, were observed in ICP-OES using standards.
Sulphur (as SO
2
) was estimated by following AOAC 990.28 method
and Chloride (as NaCl) was calculated by following AOAC 950.52
method.
2.6 . Qualitative Phytochemical Analysis:
Various  tests  for  different  types  of  secondary  metabolites,  viz.,
Steroids, terpinoids, alkaloids, flavanoids, etc were carried out as
per the  procedures quoted in standard  organic  book. (Ref
Harborne)[10]
2.7.  Qualitative Inorganic Analysis:
Qualitative test for various cations and anions were carried out as
per the methods mentioned in standard practical guide. (Ref : Feigl)[11]
2.8 .  Heavy metal Analysis:
 Tests for heavy metals, viz., lead, cadmium, arsenic and mercury
were carried out in  ICP-OES instrument (Perkin Elmer Optima 3000
DV).
2.9. Microbial contamination:
Tests  for  total  bacterial  /fungal  counts E. coli, Salmonella spp.,
Staphylococcus aureus and Entero bacteriacea were done. [9]
2.10. Pesticide residues:
Various  pesticide  residues  of  organo  chlorine  and  organo
phosphorous  viz.,  alphaBHC,  betaBHC, gam  BHC(Lindane),
deltaBHC, Aldrin, Dieldrin, trans Chlordane, cis Chlordane, Endrin,
Endrinaldehyde, Endrinketone, Endosulfan-I, Endosulfan-II,
Endosulfansulfate, Heptachlor, Heptachlorepoxide, Dicofol,
Chlorthalonil, Hexachlorobenzene, o,p''DDT, P,P''DDT, o,p''DDD,
p,p''DDD, o,p''DDE, P,P''DDE, 4-Bromo,2-Chlorophenol, Acephate,
Chlorfenvinphos, Chlorpyrifos, Chlorpyrifos  methyl, Diazinon,
Dichlorvos, Dimethoate, Ethion, Etrimfos, Fenitrothion, Iprobenphos,
Malathion , Methamidophos, Monocrotophos, Omethoate,
Oxydemeton-methyl, Parathion ethyl, Parathion methyl, Phorate,
41. Pooneeru * Fuller’s earth 25gms
42.  Mayilthutham* Copper sulphate 25gms
43.   Palthutham ** Zinc sulphate 25gms
44.   Rasam*** Mercury 25gms
45.  Pooram* Mercurous chloride 25gms
46.   Lingam* Mercuric sulphide 25gms
47.   Manosilai* Arsenic monosulphide 25gms
48.  Ganthagam* Sulphur 25gms
49.   Thalagam* Arsenic trisulphide 25gms
50.   Kuthiraipal pashanam*** Potassium Aluminium Silicate 25gms
51. Vellaipashanam * Arsenic trioxide 25gms
52.   Gowripashanam * Arsenic pentasulphide 25gms
53.  Avuri elai Indigofera tinctoria L. (Leaf) Q.S
Sl.No. Ingredients Source Quantity
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Phosalone, Phosphamidon, Profenophos, Quinalphos, Triazophos,
Phorate sulphone , Phorate sulphoxide were checked by following
AOAC 2007.01 methods.
2.11 . Tests for Aflatoxins:
Aflatoxins such as B1,B2,G1and G2 were checked using AOAC 2008.02
methods.
2.12 TLC Photodocumentation[12]/HPTLC Finger print profiling[13]
Sample preparation
Four gm of the drug was extracted successively by hexane, chloroform
and ethanol using  Soxhlet apparatus. The extracts were filtered freed
from solvents and made up to 10 ml in standard flasks using the
respective  solvents.
TLC plate
Aluminium plate precoated with silica gel 60F
254
 of 0.2 mm thickness
(Merck) was used for the TLC/HPTLC analysis.
Developing chamber
Camag’s twin trough chamber was used for the development.
Solvent system
Many solvent  systems were  tried  for  a  better  separation  and  the
same was achieved in Toluene : Ethyl acetate (10 : 0.5, v/v) for hexane
extract; Toluene : Ethyl acetate (5:1.5, v/v) for chloroform extract  and
ethanol extract.
Derivatization reagent
For derivatization vanillin-sulphuric acid reagent was used (1 gram
vanillin dissolved in a mixture of ethanol and sulphuric acid  with the
composition 95 ml : 5 ml).
Instrument
Linomat 5 automatic applicator, CAMAG’s visualizer, CAMAG’s
scanner  030618  attached  with  WINCATS  software  were  the
instruments used for photo documentation and HPTLC finger printing.
CAMAG’s plate heater was used for derivatization.
Procedure
5 µl, 10 µl and 15 µl of the hexane, chloroform and ethanol extracts
were applied on three different plates  as 10 mm bands with 8 mm
distance in between and developed up to 8 cm in the above mentioned
solvent  systems. The air dried developed plates were  visualized
under UV 254 and 366 nm for documenting TLC chromatograms. The
plates  were  scanned in UV 254 nm (all extracts) & 366 nm (hexane
and chloroform) and the finger print profiles were recorded. Then the
plates were dipped in vanillin-sulphuric acid reagent and heated in
an oven at 105ÚC until the development of colored spots. TLC photo
documentation in white light after derivatization were recorded and
finger print profiles at 575 nm (hexane and chloroform) were also
recorded.
3.  RESULTS  AND  DISCUSSION:
3.1. Organoleptic properties
Colour: Dark brown colour; Odour: Resinous odour; Taste: Metallic
taste; Consistency: Semisolid.
3.2. Physicochemical Properties
All  the  results  of  physico  chemical  parameters  are  presented  in
table 2. The loss on drying was observed as 19.156% and fat content
was observed as 20.683%. It is understood that the high value of
loss on drying due to the fat content. The total ash was calculated as
6.607% which indicates the content of total inorganics. The water
soluble  ash  value  of  2.95  %  shows  the  content  of  water  soluble
inorganic salts like sodium chloride, etc. The acid insoluble ash value
was calculated  as 0.93%. The  water  soluble and  alcohol  soluble
extractives were estimated as 39.056 % and 23.558 % respectively
indicating  the presence of  high  polar  secondary metabolites  like
glycosides, sugars, tannins, saponins, alkaloids, etc.  The calculated
acid value, saponification value and iodine value were indicative of
purity of the ghee used for the preparation and showing the number
of  milligrams of  free  acids and  saponifiable acid and number of
unsaturation in the drug. Though the reducing sugar (3.69 %) and
total sugar (7.54%) values are indicative of promoting the growth of
organisms, the drug was free from rancidity and the pH value (10 %
solution) of 3.35 indicates the acidic nature of the drug. Hence the
susceptibility of microbial growth due to presence of sugar may be
decreased  by  the  acidity and  the  shelf  life  of  the  drug  would  be
increased.
Table  2. Physicochemical results of Nandhi mezhugu
Sl.No Parameter Mean (n=2)
2 Loss on Drying at 105° C 19.16%
3 Total Ash 6.61%
4 Water soluble ash 2.95%
5 Acid-insoluble ash 0.93%
6 Water soluble extractive 39.06%
7 Alcohol soluble extractive 23.56%
8 Rancidity Nil
9 Acid value 10.592
10 Saponification value 262.62
11 Iodine value 16.864
12 Ph 3.35
13 Total solid 80.84%
14 Fat content 20.68%
15 Reducing Sugar 3.69%
16 Total Sugar 7.54%
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3.3. Qualitative Phytochemical Analysis
The  extract of  Nandi mezhugu was subjected  to  various
phytochemical tests as per the standard procedure (Ref. Harborne
book). All the tested secondary metabolites were present in the drug
which would improve the therapeutic efficacy of the drug.
3.4. Qualitative Inorganic Analysis
The qualitative inorganic analysis of the drug revealed the presence
of  mercury, magnesium, aluminium, calcium, sodium, potassium,
copper,  zinc,  iron,  cobalt,  chloride,  carbonate,  nitrate,  sulphate,
sulphide,  arsenate,  acetate,  silicate  and  arsenate  which  are  all
biologically important radicles.
3.5. Heavy metal analysis
The content of lead and cadmium are within the admissible limit of
WHO standards. While the content of arsenic and mercury are high
due to the reasons they are added in the drug in the form of rasam,
lingam,  pooram,  thalagam,  manosilai,  vellai  pashanam,  gowri
pashanam, kalmatham and rasa chenduram/sinduram. But they are
not present in the elemental form and hence non toxic. In continuation
of the standardisation of trail drug  we had studied the safety of the
trail  drug  as per  OECD  guidelines(acute,  sub-acute  sub-chronic
toxicity studies) showed non-toxic effect in rodents(unpublished).
The result ( table 3 ) from the safety study provided was encouraging
and opened a venue in the management of auto immune disease like
Rheumatoid arthritis that needs long term treatment with Nandhi
mezhugu. Physico-chemical forms of heavy metals in the indigenous
medicine is totally different from the known Physico-chemical forms
of that metal.[14]
3.6 . Microbial contamination
In  the  microbial  study,  the  drug  was  found  free  from  E. coli,
Salmonella spp., Staphlococcus aureus and Enterobacteriacea. The
results are shown in the table 4. The total bacterial count and the
total  fungal  count  were  within  the  permissible  limits  of  WHO
standards. Hence the drug is safe for consumption.
3.7 Pesticide residue
All  the  tested  organochlorine  pesticides  organophosphorus
pesticides were found to be lower than the limit of quantification, ie.,
0.01 ppm and hence safe as internal medicine.
3.8 Assays
Presence of calcium was detected which may due to added nandukkal
in the drug; presence of potassium and aluminium may be due to
padikaram, kuthiraipal padanam, vediuppu. Occurrence of copper is
due to  mayilthutham, ponnimilai; presence of iron and zinc is due to
added of palm jaggery, palthutham  respectively. Sulphur and chloride
occurrence  is due  to  added of lingam,  thalagam, gowripasanam,
gandhagam, padigaram, rasa chendooram, mayilthutham, palthutham
and pooram, kariuppu respectively (table 5 ).
Table 4. Microbial contamination results of Nandhi mezhugu
Table 3. Heavy metals present in Nandhi mezhugu
3.9 . Test for Aflatoxins (B1,B2,G1,G2)
All the four aflatoxin were not detected in the drug. As the total
fungal count was within the permissible limit, txins were not promoted
in the drug and is free from these aflatoxins.
3.10.  TLC/HPTLC
The TLC photodocumentation of hexane extract of Nandi mezhugu
under UV 254 nm showed 5 visible spots at R
f
 value 0.25, 0.30, 0.38,
0.50 and 0.71 (all green); under UV 366 nm showed three visible
spots at R
f
 value 0.30 (blue), 0.38 (fluorescent blue) and 0.71 (pale
Table  5.  Assays results of Nandhi mezhugu
Heavy metal Quantity (in ppm) WHO limit
(in ppm)
Lead (as Pb) 2.95 10
 Arsenic (as As) 7233.42 3
Cadmium (as Cd) 0.01 0.3
Mercury (as Hg) 9336.61 1
S. No Parameter Value WHO Limit
(CFU/g)
1.                 E. coli Absent 1 0
2.                 Salmonella spp. Absent None
3.                 Staphylococcus aureus Absent Absent
4.                 Enterobacteriacea Absent 103
5.                 Total  Bacterial  count 2  x  103 105
6.                 Total  Fungal  count Less  than  10 103
Calcium (as Ca) 3165.72 mg/kg
Magnesium(as  Mg) 358.72 mg/kg
Potassium  (as  K) 1950.25 mg/kg
Aluminum  (as Al) 4943.37 mg/kg
Copper  (as  Cu) 501.35 mg/kg
Iron  (as  Fe) 497.3 mg/kg
Zinc  (as  Zn) 26.29 mg/kg
Sulphur  (as SO
2
) BLQ mg/kg
(LOQ  :  10.0)
Chloride  (as  NaCl) 0.03 g/100g
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Fig. 5. HPTLC finger print profile of hexane extract of Nandi
mezhugu at 366 nm
UV 254 nm UV 366 nm White light after dipping
in vanillin-sulphuric acid
Fig.1.TLC photo documentation of hexane extract of Nandi mezhugu
Solvent system - Toluene : Ethyl acetate (10:0.5, v/v)
Table 6. TLC results of Nandhi mezhugu
Fig. 2. HPTLC finger print profile of hexane extract of Nandi
mezhugu at 254  nm
Fig. 3. R
f
 value of peaks
 
with percentage peak area of HPTLC finger
print profile of  hexane extract of Nandi mezhugu at 254 nm
The HPTLC finger print profile of hexane extract at UV 254 nm showed
12 peaks in which the peak at R
f
 0.84 was the major peak with an area
of 54.90 % followed by a peak at R
f
 0.29 with an area of 11.66 %. All
other peaks are minor with an individual area less than 10 %.
Fig. 4. 3D chromatogram of hexane extract of Nandi mezhugu at
254 nm
blue). After derivatization with vanillin-sulphuric acid, showed 8 spots
at 0.20, 0.25, 0.30, 0.35 (all purple), 0.38 (brown), 0.46, 0.57 and 0.71 (all
purple) (table 6, fig 1 and 2-10).
Under UV Under UV White light
254 nm 366 nm after derivatization
R
f            
Colour R
f        
Colour R
f                
Colour
-                              -        -                     0.2          Purple
0.25  All green - - 0.25 Purple
0.3                         0.3     Blue 0.3           Purple
0.38 - - 0.35 Purple
- 0.38 Fluorescent 0.38 Brown
           blue
0.5 - - 0.46 Purple
- - - 0.57 Purple
0.71 0.71 Pale blue 0.71 Purple
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Fig. 6. R
f
 value of peaks
 
with percentage peak area of HPTLC finger
print profile of hexane extract of Nandi mezhugu at 366 nm.
The HPTLC finger print profile of hexane extract at UV 366 nm showed
8 peaks in which the peak at R
f
 0.85 was the major peak with an area
of 39.57 % followed by a peak at R
f
 0.29 (19.43 %), 0.09 (13.40 %) and
0.37 (11.59 %). All other peaks are minor with an individual area less
than 10 %.
Fig. 7. 3D chromatogram of hexane extract of Nandi mezhugu at
366 nm
Fig. 8. HPTLC finger print profile of hexane extract of Nandi
mezhugu at 575 nm
Fig. 9. R
f
 value of peaks
 
with percentage peak area of HPTLC finger
print profile of hexane extract of Nandi mezhugu at 575 nm
The HPTLC finger print profile of hexane extract at 575 nm showed 10
peaks in which the peak at R
f
  0.73 was the major peak with an area of
59.17 % followed by a peak at R
f
 0.59 (14.35 %), 0.22 (8.02 %) and 0.47
(6.25 %). All other peaks are minor with an individual area less than
10 %.
Fig. 10. 3D chromatogram of hexane extract of Nandi mezhugu at
575 nm
4. CONCLUSION:
Based  on  the  above  results,  it  is  known  that  the  drug  Nandhi
mezhugu has  validated the traditional claim. The result from the
physico chemical  and safety study  is  encouraging and pave  the
way in  the management of auto immune disease like Rheumatoid
arthritis .
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